10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________________________________________

 FORM 10-Q

_______________________________________________

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 29, 2019

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 001-36353

_______________________________________________

Perrigo Company plc

(Exact name of registrant as specified in its charter)

_______________________________________________

Ireland	Not Applicable
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74

+353 1 7094000

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive offices)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary shares	PRGO	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐	Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.							☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 ☐  Yes  ☒ No

As of August 2, 2019, there were 136,054,652 ordinary shares outstanding.

PERRIGO COMPANY PLC

FORM 10-Q

INDEX

		PAGE NUMBER
Cautionary Note Regarding Forward-Looking Statements		1
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Statements of Operations		2
Condensed Consolidated Statements of Comprehensive Income		3
Condensed Consolidated Balance Sheets		4
Condensed Consolidated Statements of Shareholders' Equity		5
Condensed Consolidated Statements of Cash Flows		6
Notes to the Condensed Consolidated Financial Statements
1	Summary of Significant Accounting Policies	7
2	Revenue Recognition	9
3	Acquisitions	10
4	Goodwill and Intangible Assets	10
5	Inventories	11
6	Fair Value Measurements	11
7	Investments	14
8	Assets Held For Sale	15
9	Derivative Instruments and Hedging Activities	15
10	Leases	20
11	Indebtedness	23
12	Earnings per Share and Shareholders' Equity	24
13	Accumulated Other Comprehensive Income (Loss)	25
14	Income Taxes	25
15	Contingencies	27
16	Restructuring Charges	35
17	Segment Information	36
18	Subsequent Events	36
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		37
Item 3. Quantitative and Qualitative Disclosures About Market Risk		51
Item 4. Controls and Procedures		51
PART II. OTHER INFORMATION
Item 1. Legal Proceedings		52
Item 1A. Risk Factors		52
Item 6. Exhibits		54
SIGNATURES		55

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this report are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” "forecast," “predict,” “potential” or the negative of those terms or other comparable terminology.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the Notice of Assessment ("NoA") issued by the Irish Office of the Revenue Commissioners (“Irish Revenue”) and the Notice of Proposed Adjustment ("NOPA") issued by the U.S. Internal Revenue Service and the impact that an adverse result in such proceedings would have on operating results, cash flows and liquidity; potential third-party claims and litigation, including litigation relating to our restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NoA and the NOPA; potential impacts of ongoing or future government investigations and regulatory initiatives; the impact of tax reform legislation and healthcare policy; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions and the success of such transactions, and our ability to realize the desired benefits thereof; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts, and strategic and other initiatives. Statements regarding the separation of the RX business, including the expected benefits, anticipated timing, form of any such separation and whether the separation ultimately occurs, are all subject to various risks and uncertainties, including future financial and operating results, our ability to separate the business, the effect of existing interdependencies with our manufacturing and shared service operations, and the tax consequences of the planned separation to us or our shareholders. Furthermore, we may incur additional tax liabilities in respect of 2016 and prior years or be found to have breached certain provisions of Irish company law in connection with our restatement of our previously-filed financial statements, which may result in additional expenses and penalties. These and other important factors, including those discussed in our form 10-K for the year-ended December 31, 2018, this report under “Risk Factors” and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this report are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

TRADEMARKS, TRADE NAMES AND SERVICE MARKS

This report contains trademarks, trade names and service marks that are the property of Perrigo Company plc, as well as, for informational purposes, trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, certain trademarks, trade names, and service marks referred to in this report appear without the ^®, ™ and ^SM symbols, but those references are not intended to indicate that we or the applicable owner, as the case may be, will not assert, to the fullest extent under applicable law, our or their rights to such trademarks, trade names, and service marks.

1

Perrigo Company plc - Item 1

PART I.     FINANCIAL INFORMATION

ITEM 1.        FINANCIAL STATEMENTS (UNAUDITED)

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share amounts)

(unaudited)

 

	Three Months Ended						Six Months Ended
	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Net sales	$	1,149.0		$	1,186.4		$	2,323.5		$	2,403.4
Cost of sales	718.2			715.4			1,443.9			1,439.7
Gross profit	430.8			471.0			879.6			963.7
Operating expenses
Distribution	23.7			23.8			47.1			48.5
Research and development	43.9			91.9			84.0			130.3
Selling	140.1			155.2			288.7			316.5
Administration	127.2			96.8			252.3			204.5
Impairment charges	27.8			1.7			31.9			1.7
Restructuring	12.2			3.7			21.5			5.2
Other operating expense (income)	0.9			3.2			(3.2		)	6.1
Total operating expenses	375.8			376.3			722.3			712.8
Operating income	55.0			94.7			157.3			250.9
Change in financial assets	(5.5		)	(0.6		)	(15.9		)	9.0
Interest expense, net	31.2			32.1			59.8			63.5
Other (income) expense, net	2.3			7.9			5.5			12.1
Loss on extinguishment of debt	—			—			—			0.5
Income before income taxes	27.0			55.3			107.9			165.8
Income tax expense	18.0			19.1			35.0			48.8
Net income	$	9.0		$	36.2		$	72.9		$	117.0
Earnings per share
Basic	$	0.07		$	0.26		$	0.54		$	0.84
Diluted	$	0.07		$	0.26		$	0.54		$	0.84
Weighted-average shares outstanding
Basic	136.0			138.1			136.0			139.5
Diluted	136.5			138.7			136.3			140.0

See accompanying Notes to the Condensed Consolidated Financial Statements.

2

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in millions)

(unaudited)

	Three Months Ended					Six Months Ended
	June 29, 2019		June 30, 2018			June 29, 2019			June 30, 2018
Net income	$	9.0	$	36.2		$	72.9		$	117.0
Other comprehensive income (loss):
Foreign currency translation adjustments	27.8		(165.6		)	11.0			(92.6		)
Change in fair value of derivative financial instruments, net of tax	2.7		(3.5		)	4.4			(4.1		)
Change in post-retirement and pension liability, net of tax	—		(0.2		)	(0.5		)	(0.4		)
Other comprehensive income (loss), net of tax	30.5		(169.3		)	14.9			(97.1		)
Comprehensive income (loss)	$	39.5	$	(133.1	)	$	87.8		$	19.9

See accompanying Notes to the Condensed Consolidated Financial Statements.

3

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except per share amounts)

(unaudited)

	June 29, 2019			December 31, 2018
Assets
Cash and cash equivalents	$	1,055.7		$	551.1
Accounts receivable, net of allowance for doubtful accounts of $6.3 and $6.4, respectively	1,117.1			1,073.1
Inventories	940.5			878.0
Prepaid expenses and other current assets	322.1			400.0
Total current assets	3,435.4			2,902.2
Property, plant and equipment, net	824.3			829.1
Operating lease assets	135.4			—
Goodwill and indefinite-lived intangible assets	3,967.8			4,029.1
Definite-lived intangible assets, net	2,675.2			2,858.9
Deferred income taxes	6.8			1.2
Other non-current assets	383.8			362.9
Total non-current assets	7,993.3			8,081.2
Total assets	$	11,428.7		$	10,983.4
Liabilities and Shareholders’ Equity
Accounts payable	$	513.7		$	474.9
Payroll and related taxes	126.3			132.1
Accrued customer programs	385.2			442.4
Accrued liabilities	262.7			201.3
Accrued income taxes	104.1			96.5
Current indebtedness	398.8			190.2
Total current liabilities	1,790.8			1,537.4
Long-term debt, less current portion	3,084.4			3,052.2
Deferred income taxes	280.2			282.3
Other non-current liabilities	546.9			443.4
Total non-current liabilities	3,911.5			3,777.9
Total liabilities	5,702.3			5,315.3
Commitments and contingencies - Refer to Note 15
Shareholders’ equity
Controlling interests:
Preferred shares, $0.0001 par value per share, 10 shares authorized	—			—
Ordinary shares, €0.001 par value per share, 10,000 shares authorized	7,395.5			7,421.7
Accumulated other comprehensive income	99.5			84.6
Retained earnings (accumulated deficit)	(1,768.8		)	(1,838.3		)
Total controlling interest	5,726.2			5,668.0
Noncontrolling interest	0.2			0.1
Total shareholders’ equity	5,726.4			5,668.1
Total liabilities and shareholders' equity	$	11,428.7		$	10,983.4
Supplemental Disclosures of Balance Sheet Information
Preferred shares, issued and outstanding	—			—
Ordinary shares, issued and outstanding	136.0			135.9

See accompanying Notes to the Condensed Consolidated Financial Statements.

4

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in millions, except per share amounts)

(unaudited)

	Ordinary Shares Issued					Accumulated Other Comprehensive Income			Retained Earnings (Accumulated Deficit)			Total
	Shares		Amount
Balance at December 31, 2017	140.8		$	7,892.9		$	253.1		$	(1,975.5	)	$	6,170.5
Adoption of new accounting standards	—		—			(1.0		)	6.3			5.3
Net income	—		—			—			80.8			80.8
Other comprehensive income	—		—			72.2			—			72.2
Stock options exercised	—		0.2			—			—			0.2
Restricted stock plan	0.2		—			—			—			—
Compensation for stock options	—		2.7			—			—			2.7
Compensation for restricted stock	—		10.0			—			—			10.0
Cash dividends, $0.19 per share	—		(26.7		)	—			—			(26.7		)
Shares withheld for payment of employees' withholding tax liability	—		(1.5		)	—			—			(1.5		)
Repurchases of ordinary shares	(1.3	)	(108.1		)	—			—			(108.1		)
Balance at March 31, 2018	139.7		$	7,769.5		$	324.3		$	(1,888.4	)	$	6,205.4
Net income	—		—			—			36.2			36.2
Other comprehensive income	—		—			(169.3		)	—			(169.3		)
Stock options exercised	—		0.1			—			—			0.1
Restricted stock plan	0.1		—			—			—			—
Compensation for stock options	—		2.7			—			—			2.7
Compensation for restricted stock	—		6.9			—			—			6.9
Cash dividends, $0.19 per share	—		(26.1		)	—			—			(26.1		)
Shares withheld for payment of employees' withholding tax liability	(0.1	)	(1.9		)	—			—			(1.9		)
Repurchases of ordinary shares	(2.0	)	(156.9		)	—			—			(156.9		)
Balance at June 30, 2018	137.7		$	7,594.3		$	155.0		$	(1,852.2	)	$	5,897.1

	Ordinary Shares Issued					Accumulated Other Comprehensive Income			Retained Earnings (Accumulated Deficit)			Total
	Shares		Amount
Balance at December 31, 2018	135.9		$	7,421.7		$	84.6		$	(1,838.3	)	$	5,668.0
Adoption of new accounting standards	—		—			—			(3.4		)	(3.4		)
Net income	—		—			—			63.9			63.9
Other comprehensive loss	—		—			(15.6		)	—			(15.6		)
Restricted stock plan	0.2		—			—			—			—
Compensation for stock options	—		1.8			—			—			1.8
Compensation for restricted stock	—		14.2			—			—			14.2
Cash dividends, $0.19 per share	—		(25.9		)	—			—			(25.9		)
Shares withheld for payment of employees' withholding tax liability	(0.1	)	(2.4		)	—			—			(2.4		)
Balance at March 30, 2019	136.0		$	7,409.4		$	69.0		$	(1,777.8	)	$	5,700.6
Net income	—		—			—			9.0			9.0
Other comprehensive income	—		—			30.5			—			30.5
Stock options exercised	—		0.3			—			—			0.3
Compensation for stock options	—		1.3			—			—			1.3
Compensation for restricted stock	—		14.2			—			—			14.2
Cash dividends, $0.21 per share	—		(28.9		)	—			—			(28.9		)
Shares withheld for payment of employees' withholding tax liability	—		(0.8		)	—			—			(0.8		)
Balance at June 29, 2019	136.0		$	7,395.5		$	99.5		$	(1,768.8	)	$	5,726.2

See accompanying Notes to the Condensed Consolidated Financial Statements.

5

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(unaudited)

	Six Months Ended
	June 29, 2019			June 30, 2018
Cash Flows From (For) Operating Activities
Net income	$	72.9		$	117.0
Adjustments to derive cash flows:
Depreciation and amortization	191.5			217.8
Share-based compensation	28.0			22.3
Impairment charges	31.9			1.7
Change in financial assets	(15.9		)	9.0
Loss on extinguishment of debt	—			0.5
Restructuring charges	21.5			5.2
Deferred income taxes	9.2			(14.2		)
Amortization of debt premium	(3.0		)	(3.7		)
Other non-cash adjustments, net	26.4			5.1
Subtotal	362.5			360.7
Increase (decrease) in cash due to:
Accounts receivable	(55.3		)	(24.3		)
Inventories	(78.3		)	(99.3		)
Accounts payable	41.2			89.2
Payroll and related taxes	(23.0		)	(48.4		)
Accrued customer programs	(52.8		)	33.9
Accrued liabilities	(19.2		)	(30.4		)
Accrued income taxes	(36.7		)	(20.8		)
Other, net	19.9			(5.9		)
Subtotal	(204.2		)	(106.0		)
Net cash from (for) operating activities	158.3			254.7
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	1.7			10.3
Purchase of investment securities	—			(7.5		)
Royalty Pharma contingent milestone payment	250.0			—
Asset acquisitions	(35.0		)	—
Additions to property, plant and equipment	(54.7		)	(33.3		)
Net proceeds from sale of business and other assets	—			1.3
Net cash from (for) investing activities	162.0			(29.2		)
Cash Flows From (For) Financing Activities
Issuances of long-term debt	—			431.0
Payments on long-term debt	(158.9		)	(457.3		)
Borrowings (repayments) of revolving credit agreements and other financing, net	397.5			(8.2		)
Deferred financing fees	—			(2.4		)
Issuance of ordinary shares	0.3			—
Repurchase of ordinary shares	—			(265.0		)
Cash dividends	(54.8		)	(52.8		)
Other financing, net	(5.9		)	(7.5		)
Net cash from (for) financing activities	178.2			(362.2		)
Effect of exchange rate changes on cash and cash equivalents	6.1			(15.5		)
Net increase (decrease) in cash and cash equivalents	504.6			(152.2		)
Cash and cash equivalents, beginning of period	551.1			678.7
Cash and cash equivalents, end of period	$	1,055.7		$	526.5

See accompanying Notes to the Condensed Consolidated Financial Statements.

6

Perrigo Company plc - Item 1

Note 1

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

The Company

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

We are dedicated to making lives better by bringing “Quality, Affordable Self-Care Products™” that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. We are also a leading producer of generic prescription pharmaceutical topical products such as creams, lotions, gels, and nasal sprays.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Segment Reporting Change

               During the three months ended March 30, 2019, we changed the composition of our operating and reporting segments. We moved our Israeli diagnostic business from the Consumer Self-Care International segment to the Prescription Pharmaceuticals segment and we made certain adjustments to our allocations between segments. These changes were made to reflect changes in the way in which management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in Note 2 and Note 17.

Our new reporting and operating segments are as follows:

• Consumer Self-Care Americas ("CSCA"), formerly Consumer Healthcare Americas, comprises our consumer self-care business (OTC, contract manufacturing, infant formula and animal health categories) in the U.S., Mexico and Canada.

• Consumer Self-Care International ("CSCI"), formerly Consumer Healthcare International, comprises our branded consumer self-care business primarily in Europe, our consumer-focused business in the United Kingdom and Australia, and our liquid licensed products business in the United Kingdom.

• Prescription Pharmaceuticals ("RX") comprises our Prescription Pharmaceuticals business in the U.S. and our diagnostic business in Israel, which was previously in our CSCI segment.

7

Perrigo Company plc - Item 1

Note 1

Recent Accounting Standard Pronouncements

Below are recent Accounting Standard Updates ("ASU") that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Recently Issued Accounting Standards Not Yet Adopted
Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
ASU 2018-15: Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract	This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.	January 1, 2020	We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.
ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement	This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.	January 1, 2020	We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.
ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ASU 2018-19: Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments ASU 2019-05: Financial Instruments-Credit Losses: Targeted Transition Relief	This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.	January 1, 2020	We are in the process of completing our evaluation. Upon adoption, we are not expecting a material impact on the financial statements.
ASU 2018-18: Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606	This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.	January 1, 2020	We are in the process of completing our evaluation. Upon adoption, we are not expecting a material impact on the financial statements.
ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans	This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans.	December 31, 2020	We are currently evaluating the implications of adoption on our Consolidated Financial Statements.

8

Perrigo Company plc - Item 1

Note 2

NOTE 2 – REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations⁽¹⁾ (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
U.S.	$	768.6	$	772.3	$	1,537.4	$	1,558.7
Europe(2)	315.8		344.3		656.7		706.2
All other countries(3)	64.6		69.8		129.4		138.5
	$	1,149.0	$	1,186.4	$	2,323.5	$	2,403.4

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $6.9 million and $12.1 million for the three and six months ended June 29, 2019, respectively, and $5.0 million and $10.4 million for the three and six months ended June 30, 2018, respectively.

(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

The following is a summary of our net sales by category (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
CSCA(1)
Cough/cold/allergy/sinus	$	120.9	$	109.3	$	253.5	$	250.8
Gastrointestinal	106.2		103.0		206.5		195.2
Infant nutritionals	85.5		109.2		181.5		212.6
Analgesics	88.2		92.2		177.0		185.9
Smoking cessation	77.0		71.2		143.8		137.1
Animal health	22.4		31.9		42.0		58.2
Vitamins, minerals and dietary supplements	3.9		4.3		7.3		7.3
Other CSCA(2)	78.0		75.8		152.3		151.4
Total CSCA	582.1		596.9		1,163.9		1,198.5
CSCI
Cough/cold/allergy/sinus	74.1		84.7		169.8		183.4
Lifestyle	81.2		86.1		162.7		175.8
Personal care and derma-therapeutics	69.2		79.7		135.2		155.3
Natural health and vitamins, minerals and dietary supplements	25.6		27.9		55.4		61.1
Anti-parasites	26.0		30.4		52.7		58.5
Other CSCI(3)	51.4		49.1		102.5		101.6
Total CSCI	327.5		357.9		678.3		735.7
Total RX	239.4		231.6		481.3		469.2
Total net sales	$	1,149.0	$	1,186.4	$	2,323.5	$	2,403.4

(1)    Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

9

Perrigo Company plc - Item 1

Note 2

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $65.8 million and $133.1 million for the three and six months ended June 29, 2019, respectively, and $77.1 million and $146.5 million for the three and six months ended June 30, 2018, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	June 29, 2019		December 31, 2018
Short-term contract assets	Prepaid expenses and other current assets	$	16.6	$	25.5

NOTE 3 – ACQUISITIONS

Acquisitions Completed During the Six Months Ended June 29, 2019

Generic Product Acquisition

On May 17, 2019, we purchased the Abbreviated New Drug Application ("ANDA") for a generic product used to relieve pain from osteoarthritis, for $15.7 million in cash, which we capitalized as a developed product technology intangible asset. We plan to launch the product during the third quarter of 2019 and begin amortizing it over a 20-year useful life. Operating results attributable to the product are included within our RX segment.

Budesonide Nasal Spray and Triamcinolone Nasal Spray

On April 1, 2019, we purchased product ANDAs and other records and registrations of Budesonide Nasal Spray, a generic equivalent of Rhinocort Allergy^®, and Triamcinolone Nasal Spray, a generic equivalent of Nasacort Allergy^®, from Barr Laboratories, Inc. ("Barr"), a subsidiary of Teva Pharmaceuticals, for $14.0 million in cash. We previously developed and marketed the products in collaboration with Barr under a development, marketing and commercialization agreement that originated in August 2003. Under this prior agreement, we paid Barr a percentage of net income from products sold by Perrigo in the U.S. By purchasing the assets from Barr and terminating the original development, marketing and commercialization agreement, we are now entitled to 100% of the income from sales of the product. Operating results attributable to these products are included within our CSCA segment. The intangible assets acquired are classified as developed product technology with a 10-year useful life.

Acquisitions Completed During the Year Ended December 31, 2018

Nasonex-branded products

On May 29, 2018, we entered into a license agreement with Merck Sharp & Dohme Corp. ("Merck"), which allows us to develop and commercialize an OTC version of Nasonex-branded products containing the compound, mometasone furoate monohydrate. The acquisition was accounted for as an asset acquisition based on our assessment that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset to be used for R&D. In accordance with Accounting Standards Codification Topic 730 Research and Development, the non-refundable upfront license fee of $50.0 million was recorded in R&D expense in our CHCA segment because the intangible research and development asset acquired has no alternative use. The agreement requires us to make contingent payments if we obtain regulatory approval and achieve certain sales milestones. We will also be obligated to make royalty payments on potential future sales. The contingent consideration will be included in the measurement of the cost of the asset when the contingency is resolved and the consideration is paid or becomes payable. Consideration paid after U.S. Food and Drug Administration approval will be capitalized and amortized to cost of goods sold over the economic life of each product.

NOTE 4 – GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):

	December 31, 2018		Transfer to assets held-for-sale			Currency Translation Adjustments			June 29, 2019
CSCA(1)	$	1,713.7	$	(42.2	)	$	2.1		$	1,673.6
CSCI(2)	1,151.3		—			(9.2		)	1,142.1
RX	1,114.8		—			4.8			1,119.6
Total goodwill	$	3,979.8	$	(42.2	)	$	(2.3	)	$	3,935.3

(1) We had accumulated impairments of $24.5 million and $161.2 million as of June 30, 2018 and June 29, 2019, respectively.

(2) We had accumulated impairments of $868.4 million as of June 30, 2018 and June 29, 2019.

  During the three months ended June 29, 2019, our RX U.S. reporting unit had an indication of potential impairment which was driven by a combination of industry and market factors and uncertainty related to the timing

10

Perrigo Company plc - Item 1

Note 4

and associated cash flows of the projected ProAir launch. Goodwill remaining in this reporting unit was $1,119.6 million as of June 29, 2019. We prepared an impairment test as of June 29, 2019 and determined that the fair value of the RX U.S. reporting unit continued to exceed net book value by approximately 10%. The excess was lower than our annual impairment test as of October 1, 2018, in which fair value exceeded carrying value by more than 25%. While no impairment was recorded as of June 29, 2019, future developments such as deterioration in business performance or market multiples could reduce the fair value of this reporting unit and lead to impairment in a future period. 

In conjunction with the test performed during the three months ended June 29, 2019, we early adopted ASU 2017-04 which removes the Step 2 requirement in instances when the carrying value of a reporting unit exceeds its fair value. Prospectively, if a reporting unit’s carrying value exceeds its fair value, we will record an impairment charge in the amount of the difference, limited to the amount of goodwill attributed to that reporting unit.

Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):

	June 29, 2019				December 31, 2018
	Gross		Accumulated Amortization		Gross		Accumulated Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands	$	18.0	$	—	$	18.1	$	—
In-process research and development	14.5		—		31.2		—
Total indefinite-lived intangibles	$	32.5	$	—	$	49.3	$	—
Definite-lived intangibles:
Distribution and license agreements and supply agreements	$	173.7	$	105.2	$	178.6	$	99.0
Developed product technology, formulations, and product rights	1,321.0		706.1		1,318.8		654.6
Customer relationships and distribution networks	1,558.5		613.9		1,586.6		566.5
Trademarks, trade names, and brands	1,266.0		219.5		1,282.4		188.5
Non-compete agreements	8.3		7.6		12.9		11.8
Total definite-lived intangibles	$	4,327.5	$	1,652.3	$	4,379.3	$	1,520.4
Total intangible assets	$	4,360.0	$	1,652.3	$	4,428.6	$	1,520.4

We recorded amortization expense of $73.6 million and $149.0 million for the three and six months ended June 29, 2019, respectively, and $85.3 million and $172.4 million for the three and six months ended June 30, 2018, respectively.

During the three months ended June 29, 2019, we identified impairment indicators for a certain definite-lived asset related to changes in pricing and competition in the market, which lowered the projected cash flows we expect to generate from the asset. We determined the asset was impaired by $27.8 million in our RX segment.

We recorded an impairment charge of $4.1 million on an in process R&D asset in the CSCA segment during the three months ended March 30, 2019 due to changes in projected development and regulatory timelines.

NOTE 5 – INVENTORIES

Major components of inventory were as follows (in millions):

 

	June 29, 2019		December 31, 2018
Finished goods	$	501.2	$	444.9
Work in process	192.8		197.5
Raw materials	246.5		235.6
Total inventories	$	940.5	$	878.0

NOTE 6 – FAIR VALUE MEASUREMENTS

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):

	June 29, 2019						December 31, 2018
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Measured at fair value on a recurring basis:
Assets:
Investment securities	$	2.8	$	—	$	—	$	9.4	$	—	$	—
Foreign currency forward contracts	—		4.0		—		—		3.8		—
Funds associated with Israeli severance liability	—		14.0		—		—		13.0		—
Royalty Pharma contingent milestone payments	—		—		89.1		—		—		323.2
Total assets	$	2.8	$	18.0	$	89.1	$	9.4	$	16.8	$	323.2
Liabilities:
Foreign currency forward contracts	$	—	$	3.6	$	—	$	—	$	9.2	$	—
Contingent consideration	—		—		12.1		—		—		15.3
Total liabilities	$	—	$	3.6	$	12.1	$	—	$	9.2	$	15.3
Measured at fair value on a non-recurring basis:
Assets:
Goodwill(1)	$	—	$	—	$	—	$	—	$	—	$	42.2
Indefinite-lived intangible assets(2)	—		—		—		—		—		10.5
Definite-lived intangible assets(3)	—		—		—		—		—		22.4
Total assets	$	—	$	—	$	—	$	—	$	—	$	75.1

(1) As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million.

(2) As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million.

(3) As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million.

There were no transfers among Level 1, 2, and 3 during the three and six months ended June 29, 2019 or the year ended December 31, 2018.

11

Perrigo Company plc - Item 1

Note 6

Royalty Pharma Contingent Milestone Payments

The table below summarizes the change in fair value of the Royalty Pharma contingent milestone payments (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019			June 30, 2018
Beginning balance	$	83.6	$	124.9	$	323.2		$	134.5
Payments received	—		—		(250.0		)	—
Change in fair value	5.5		0.6		15.9			(9.0		)
Ending balance	$	89.1	$	125.5	$	89.1		$	125.5

We value our contingent milestone payments from Royalty Pharma using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri^® that are received by Royalty Pharma until the contingent milestones are resolved. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. The table below represents the volatility and rate of return:

	Three Months Ended
	June 29, 2019		June 30, 2018
Volatility	30.0	%	30.0	%
Rate of return	7.99	%	8.09	%

The fair value of the Royalty Pharma contingent milestone payment increased by $5.5 million and $15.9 million during the three and six months ended June 29, 2019, respectively. These adjustments were driven by higher projected global net sales of Tysabri^® and the estimated probability of achieving the earn-out. The fair value of the Royalty Pharma contingent milestone payments increased by $0.6 million during the three months ended June 30, 2018. This increase included a $2.9 million decrease in the fair value of the 2018 contingent milestone payment, more than offset by a $3.5 million increase in the fair value of the 2020 contingent milestone payment. During the six months ended June 30, 2018, the fair value of the Royalty Pharma contingent milestone payments decreased $9.0 million. The net changes in the fair value of the contingent milestone payments were due to the fluctuation of the projected global net sales of Tysabri^®_, which were impacted by competition, namely the launch of Ocrevus^® in the U.S. and European markets.

In order for us to receive the 2020 milestone payment of $400.0 million, Royalty Pharma contingent payments for Tysabri^® sales in 2020 must exceed $351.0 million. In 2018, the Royalty Pharma contingent payments for Tysabri^® were $337.5 million, which exceeded the threshold. If Royalty Pharma contingent payments for Tysabri^® sales do not meet the prescribed threshold in 2020, we will write off the $89.1 million asset as an expense. If the prescribed threshold is exceeded, we will increase the asset to $400.0 million and recognize income of $310.9 million in Change in financial assets on the Condensed Consolidated Statements of Operations.

12

Perrigo Company plc - Item 1

Note 6

Contingent Consideration

The table below summarizes the change in fair value of contingent consideration (in millions):

	Three Months Ended						Six Months Ended
	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Beginning balance	$	12.4		$	18.1		$	15.3		$	22.0
Changes in value	0.9			(1.8		)	(2.0		)	(1.4		)
Currency translation adjustments	—			(0.1		)	—			—
Settlements and other adjustments	(1.2		)	—			(1.2		)	(4.4		)
Ending balance	$	12.1		$	16.2		$	12.1		$	16.2

Goodwill and Intangible Assets

Animal Health

When determining the fair value of our animal health reporting unit for the year ended December 31, 2018, we utilized a combination of comparable company market and discounted cash flow techniques. In our comparable company market approach, we considered observable market information and transactions for companies that we deemed to be of a comparable nature, scope, and size of animal health (Level 2 inputs). Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products, plus gross margin, advertising and promotion, and other operating expenses based on the growth plans (Level 3 inputs). In our discounted cash flow analysis, we utilized projected sales growth rate and discount rate assumptions of 2.5% and 9.8%, respectively. The discount rate correlates with the required investment return and risk that we believe market participants would apply to the projected growth rate. In addition, we burdened projected free cash flows with the capital spending deemed necessary to support the cash flows and applied the jurisdictional tax rate of 22.8%. We weighted indications of fair value resulting from the market approach and present value techniques, considering the reasonableness of the range of measurements and the point within the range that we determined was most representative of fair market conditions.

When assessing our animal health indefinite-lived intangible asset for the year ended December 31, 2018, we utilized a multi-period excess earnings method ("MPEEM") to determine the fair value of the intangible asset. Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products. We utilized long-term growth rate and discount rate assumptions of (0.3)% and 9.8%, respectively, and we applied a jurisdictional tax rate of 22.8%.

When assessing our animal health definite-lived assets for impairment for the year ended December 31, 2018, we utilized a combination of MPEEM and relief from royalty methods to determine the fair values of definite-lived assets within the asset group. The projected financial information, inputs, and assumptions utilized were consistent with those utilized in the goodwill discounted cash flow analysis described above.

Generic product

When measuring the impairment of a certain definite-lived asset during the three months ended June 29, 2019, we utilized a discounted cash flow technique to estimate the fair value of the asset. Significant valuation inputs and assumptions relate to our projected future cash flows, including the total market size, our estimated market share, and our average selling price.

13

Perrigo Company plc - Item 1

Note 6

Fixed Rate Long-term Debt    

Our fixed rate long-term debt consisted of the following (in millions):

	June 29, 2019				December 31, 2018
	Level 1		Level 2		Level 1		Level 2
Public Bonds
Carrying Value (excluding discount)	$	2,600.0			$	2,600.0
Fair value	$	2,533.0			$	2,316.6
Retail bond and private placement note
Carrying value (excluding premium)			$	153.5			$	292.5
Fair value			$	167.8			$	307.9

The fair values of our public bonds for all periods were based on quoted market prices. The fair value of our private placement note for all periods was based on interest rates offered for borrowings of a similar nature and remaining maturities. The fair value of our retail bond for the year ended December 31, 2018 was based on interest rates offered for borrowings of a similar nature and remaining maturities. On May 23, 2019, we repaid the retail bond in full (refer to Note 11).

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt, revolving credit agreements, and variable rate long-term debt, approximate their fair value.

NOTE 7 – INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):

Measurement Category	Balance Sheet Location	June 29, 2019		December 31, 2018
Fair value method	Prepaid expenses and other current assets	$	2.8	$	9.4
Fair value method(1)	Other non-current assets	$	2.8	$	4.4
Equity method	Other non-current assets	$	16.8	$	15.1

(1) Measured at fair value using the Net Asset Value practical expedient.

The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):

		Three Months Ended						Six Months Ended
Measurement Category	Income Statement Location	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Fair value method	Other (income) expense, net	$	1.8		$	6.3		$	7.9		$	10.6
Equity method	Other (income) expense, net	$	(1.0	)	$	(0.9	)	$	(1.7	)	$	(0.7	)

During the three months ended June 30, 2018, Perrigo Asia Holding Company Limited increased its investment in Zibo Xinhua - Perrigo Pharmaceutical Company Limited by $7.5 million.

14

Perrigo Company plc - Item 1

Note 8

NOTE 8 – ASSETS HELD FOR SALE

We classify assets as "held for sale" when, among other factors, management approves and commits to a formal plan of sale with the expectation the sale will be completed within one year. The net assets of the business held for sale are then recorded at the lower of their current carrying value and the fair market value, less costs to sell.

During the three months ended June 29, 2019, management committed to a plan to sell our animal health business; as a result, such assets were classified as held-for-sale. On July 8, 2019, we completed the sale of our animal health business (refer to Note 18). The assets associated with our animal health business were reported in our CSCA segment.

The assets held-for-sale were reported within Prepaid expenses and other current assets and liabilities held-for-sale were reported in Accrued liabilities. The amounts consisted of the following (in millions):

	June 29, 2019
Assets held for sale
Current assets	$	29.3
Property, plant and equipment, net	10.8
Goodwill and indefinite-lived intangible assets	42.2
Definite-lived intangible assets, net	36.4
Other assets	25.7
Total assets held for sale	$	144.4
Liabilities held for sale
Current liabilities	$	11.3
Other liabilities	38.3
Total liabilities held for sale	$	49.6

NOTE 9 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

On January 1, 2019, we adopted Accounting Standards Update No. 2017-12 Targeted Improvements to Accounting for Hedge Activities ("ASU 2017-12") using a modified retrospective approach. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three and six months ended June 30, 2018 below conform to the disclosure requirements prior to the adoption of ASU 2017-12.

Prior to the adoption of ASU 2017-12, we were required to separately measure and reflect the amount by which the hedging instrument did not offset the changes in the fair value or cash flows of hedged items, which was referred to as the ineffective amount. We assessed hedge effectiveness on a quarterly basis and recorded the gain or loss related to the ineffective portion of derivative instruments, if any, in Other (income) expense, net on the Condensed Consolidated Statements of Operations. Pursuant to the provisions of ASU 2017-12, we are no longer required to separately measure and recognize hedge ineffectiveness. Therefore, we no longer recognize hedge ineffectiveness separately on our Condensed Consolidated Statements of Income, but instead recognize the entire change in the fair value of:

• Cash flow hedges included in the assessment of hedge effectiveness in OCI. The amounts recorded in OCI will subsequently be reclassified to earnings in the same line item on the Condensed Consolidated Statements of Operations as impacted by the hedged item when the hedged item affects earnings; and

• Fair value hedges included in the assessment of hedge effectiveness in the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item.

Prior to the adoption of ASU 2017-12, we excluded option premiums and forward points (excluded components) from our assessment of hedge effectiveness for our foreign exchange cash flow hedges. We

15

Perrigo Company plc - Item 1

Note 9

recognized all changes in fair value of the excluded components in Other (income) expense, net, on the Condensed Consolidated Statements of Operations. The amendments in ASU 2017-12 continue to allow those components to be excluded from the assessment of hedge effectiveness and add cross-currency basis spread as an allowable excluded component. The provisions of ASU 2017-12 allow a policy election to either continue to recognize changes in the fair value of the excluded components currently in earnings or to recognize the initial value of the excluded component using an amortization approach. We have elected to recognize the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. The cumulative effect adjustment between Accumulated Other Comprehensive Income ("AOCI") and Retained earnings (accumulated deficit) from applying this policy on existing hedges at the date of adoption was immaterial.

We record derivative instruments on the balance sheet on a gross basis as either an asset or liability measured at fair value (refer to Note 6). Additionally, changes in a derivative's fair value, which are measured at the end of each period, are recognized in earnings unless a derivative can be designated in a qualifying hedging relationship.

Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. We have elected to recognize the fair value of the excluded component in OCI and amortize on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. All of our designated derivatives are assessed for hedge effectiveness quarterly. All of our designated derivatives were classified as cash flow hedges as of June 29, 2019 and December 31, 2018.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.

We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "Aa3" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of our forward currency exchange contracts is 18 months.

We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.

All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.

16

Perrigo Company plc - Item 1

Note 9

Interest Rate Swaps

Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense. There were no active designated or non-designated interest rate swaps as of June 29, 2019 and December 31, 2018.

Foreign Currency Derivatives

Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows (in millions):

	Notional Amount
	June 29, 2019		December 31, 2018
Israeli Shekel (ILS)	$	340.6	$	232.6
British Pound (GBP)	111.0		90.2
European Euro (EUR)	108.0		134.2
Swedish (SEK)	42.2		38.7
Danish Krone (DKK)	58.2		56.5
United States Dollar (USD)	46.2		39.3
Canadian Dollar (CAD)	41.9		31.7
Polish Zloty (PLZ)	33.5		18.2
Chinese Yuan (CNY)	20.0		—
Norwegian Krone (NOK)	6.8		6.2
Romanian New Leu (RON)	5.9		4.4
Mexican Peso (MPX)	4.2		25.9
Other	12.6		8.7
Total	$	831.1	$	686.6

Effects of Derivatives on the Financial Statements

The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects.

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):

		Asset Derivatives
		Fair Value
	Balance Sheet Location	June 29, 2019		December 31, 2018
Designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	1.0	$	2.0
Non-designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	3.0	$	1.8

17

Perrigo Company plc - Item 1

Note 9

		Liability Derivatives
		Fair Value
	Balance Sheet Location	June 29, 2019		December 31, 2018
Designated derivatives:
Foreign currency forward contracts	Accrued liabilities	$	2.6	$	6.4
Non-designated derivatives:
Foreign currency forward contracts	Accrued liabilities	$	1.0	$	2.8

The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments in AOCI (in millions):

	Three Months Ended
	June 29, 2019
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings			Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements			Interest expense, net	$	(0.4	)	Interest expense, net	$	—
Foreign currency forward contracts	$	1.1	Net sales	0.1			Net sales	0.1
			Cost of sales	(0.2		)	Cost of sales	(1.1		)
				$	(0.5	)		$	(1.0	)

	Six Months Ended
	June 29, 2019
Instrument	Amount of Gain/(Loss) Recorded in OCI(1)		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings			Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements			Interest expense, net	$	(1.0	)	Interest expense, net	$	—
Foreign currency forward contracts	$	—	Net sales	0.3			Net sales	—
			Cost of sales	(1.4		)	Cost of sales	(2.2		)
				$	(2.1	)		$	(2.2	)

(1) Net loss of $1.6 million is expected to be reclassified out of AOCI into earnings during the next 12 months.

18

Perrigo Company plc - Item 1

Note 9

	Three Months Ended
	June 30, 2018
	Effective Portion
Instrument	Amount of Gain/(Loss) Recorded in OCI			Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements				Interest expense, net	$	(0.4	)
Foreign currency forward contracts	$	(4.3	)	Net sales	—
				Cost of sales	1.6
				Interest expense, net	(1.1		)
				Other (income) expense, net	(0.1		)
					$	—

	Six Months Ended
	June 30, 2018
	Effective Portion
Instrument	Amount of Gain/(Loss) Recorded in OCI			Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements				Interest expense, net	$	(0.9	)
Foreign currency forward contracts	$	(4.3	)	Net sales	—
				Cost of sales	3.9
				Interest expense, net	(2.0		)
				Other (income) expense, net	(0.5		)
					$	0.5

The amounts of gain/(loss) recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):

		Three Months Ended					Six Months Ended
Non-Designated Derivatives	Income Statement Location	June 29, 2019			June 30, 2018		June 29, 2019			June 30, 2018
Foreign currency forward contracts	Other (income) expense, net	$	(4.3	)	$	11.8	$	(13.1	)	$	8.6
	Interest expense, net	1.4			0.2		1.8			(0.7		)
Total		$	(2.9	)	$	12.0	$	(11.3	)	$	7.9

The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Condensed Consolidated Statements of Operations in Other (income) expense, net for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar-translated amounts of each Income Statement account in current and/or future periods.

19

Perrigo Company plc - Item 1

Note 9

The classification and amount of gain/(loss) recognized in earnings on fair value and cash flow hedging relationships are as follows (in millions):

	Three Months Ended
	June 29, 2019
	Net Sales		Cost of Sales			Interest Expense, net			Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,149.0	$	718.2		$	31.2		$	2.3
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	0.1	$	(0.2	)	$	—		$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	0.1	$	(1.1	)	$	—		$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—		$	(0.4	)	$	—

	Six Months Ended
	June 29, 2019
	Net Sales		Cost of Sales			Interest Expense, net			Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	2,323.5	$	1,443.9		$	59.8		$	5.5
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	0.3	$	(1.4	)	$	—		$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	(2.2	)	$	—		$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—		$	(1.0	)	$	—

NOTE 10 – LEASES

We adopted ASU 2016-02, Leases, as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification.

Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately $166.5 million and $164.0 million, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.

20

Perrigo Company plc - Item 1

Note 10

We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.

We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.

Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The balance sheet location of our lease assets and liabilities were as follows (in millions):

Assets	Balance Sheet Location	June 29, 2019
Operating	Operating lease assets	$	135.4
Finance	Other non-current assets	17.1
Total		$	152.5

Liabilities	Balance Sheet Location	June 29, 2019
Current
Operating	Accrued liabilities	$	32.9
Finance	Current indebtedness	1.9
Non-Current
Operating	Other non-current liabilities	107.4
Finance	Long-term debt, less current portion	11.8
Total		$	154.0

21

Perrigo Company plc - Item 1

Note 10

The below table shows our lease assets and liabilities by reporting segment (in millions):

	Assets				Liabilities
	Operating		Financing		Operating		Financing
	June 29, 2019		June 29, 2019		June 29, 2019		June 29, 2019
CSCA	$	22.7	$	8.9	$	22.9	$	8.4
CSCI	42.0		6.1		42.9		3.2
RX	37.5		0.3		38.9		0.3
Unallocated	33.2		1.8		35.6		1.8
Total	$	135.4	$	17.1	$	140.3	$	13.7

Lease expense was as follows (in millions):

	Three Months Ended		Six Months Ended
	June 29, 2019		June 29, 2019
Operating leases(a)	$	11.2	$	23.2
Finance leases
Amortization	$	0.7	$	1.3
Interest	0.1		0.2
Total finance leases	$	0.8	$	1.5

(a) Includes short-term leases and variable lease costs, which are immaterial.

Total operating lease expense for the three and six months ended June 30, 2018 was $14.2 million and $26.1 million, respectively.

The annual future maturities of our leases as of June 29, 2019 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2019	$	19.4	$	1.2	$	20.6
2020	34.6		2.3		36.9
2021	24.9		3.6		28.5
2022	18.3		1.2		19.5
2023	14.0		1.0		15.0
After 2023	51.7		7.8		59.5
Total lease payments	162.9		17.1		180.0
Less: Interest	22.6		3.4		26.0
Present value of lease liabilities	$	140.3	$	13.7	$	154.0

`

Our weighted average lease terms and discount rates are as follows:

	June 29, 2019
Weighted-average remaining lease term (in years)
Operating leases	6.59
Finance leases	9.43
Weighted-average discount rate
Operating leases	4.19	%
Finance leases	4.35	%

22

Perrigo Company plc - Item 1

Note 10

Our lease cash flow classifications are as follows (in millions):

	Six Months Ended
	June 29, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	23.0
Operating cash flows for finance leases	$	0.2
Financing cash flows for finance leases	$	1.4
Leased assets obtained in exchange for new finance lease liabilities	$	7.8
Leased assets obtained in exchange for new operating lease liabilities	$	12.8

NOTE 11 – INDEBTEDNESS

Total borrowings outstanding are summarized as follows (in millions):

			June 29, 2019			December 31, 2018
Revolving Credit Agreement
	2018 Revolver due March 8, 2023		$	325.0		$	—
Term loan
	2018 Term loan due March 8, 2020(1)		323.4			351.3
Notes and Bonds
	Coupon	Due
	5.000%	May 23, 2019	—			137.6
	3.500%	March 15, 2021	280.4			280.4
	3.500%	December 15, 2021	309.6			309.6
	5.105%	July 28, 2023(1)	153.5			154.9
	4.000%	November 15, 2023	215.6			215.6
	3.900%	December 15, 2024	700.0			700.0
	4.375%	March 15, 2026	700.0			700.0
	5.300%	November 15, 2043	90.5			90.5
	4.900%	December 15, 2044	303.9			303.9
	Total notes and bonds		2,753.5			2,892.5
Other financing			87.2			2.8
Unamortized premium (discount), net			8.9			12.2
Deferred financing fees			(14.8		)	(16.4		)
Total borrowings outstanding			3,483.2			3,242.4
	Current indebtedness		(398.8		)	(190.2		)
Total long-term debt less current portion			$	3,084.4		$	3,052.2

(1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

We are in compliance with all covenants under our debt agreements as of June 29, 2019.

Revolving Credit Agreements

On March 8, 2018, we terminated the revolving credit agreement entered into on December 5, 2014 and entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2018 Revolver"). During the three months ended June 29, 2019, in anticipation of the Ranir Global Holdings, LLC (“Ranir”) acquisition (refer to Note 18), we borrowed $375.0 million under this facility. There were $325.0 million of borrowings outstanding under the 2018 Revolver as of June 29, 2019. There were no borrowings outstanding under the 2018 Revolver as of December 31, 2018.

Term Loans

On December 5, 2014, Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ($614.3 million) tranche, maturing on December 5, 2019. On March 8, 2018, we refinanced the €350.0 million outstanding under the term loan with the proceeds of a new €350.0 million ($431.0 million) term loan, maturing on March 8, 2020 (the "2018 Term Loan"). In addition, as a result of the refinancing during the three months ended March 31, 2018, we recorded a loss of $0.5 million, consisting of the write-off of deferred financing fees in Loss on extinguishment of debt on the Condensed Consolidated Statements of Operations. During the six months ended June 29, 2019, we made $24.7 million in scheduled principal payments on the 2018 Term Loan.

23

Perrigo Company plc - Item 1

Note 11

Notes and Bonds

In connection with the Omega acquisition, on March 30, 2015, we assumed a 5.000% retail bond due in 2019 in the amount of €120.0 million ($130.7 million). On May 23, 2019 we repaid the bond in full.

Other Financing

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". The balance outstanding under the facilities was $73.9 million at June 29, 2019. There were no borrowings outstanding under the facilities as of December 31, 2018.

We have financing leases that are reported in the above table under "Other financing" (refer to Note 10).

NOTE 12 – EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
Numerator:
Net income	$	9.0	$	36.2	$	72.9	$	117.0
Denominator:
Weighted average shares outstanding for basic EPS	136.0		138.1		136.0		139.5
Dilutive effect of share-based awards	0.5		0.6		0.3		0.5
Weighted average shares outstanding for diluted EPS	136.5		138.7		136.3		140.0
Anti-dilutive share-based awards excluded from computation of diluted EPS	1.7		1.7		1.8		0.9

Shareholders' Equity

Share Repurchases

Following the expiration of our 2015 share repurchase plan authorization, in October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program. We did not repurchase any shares during the three and six months ended June 29, 2019. During the three and six months ended June 30, 2018, we repurchased 2.0 million and 3.3 million ordinary shares

24

Perrigo Company plc - Item 1

Note 12

at an average repurchase price of $79.42 and $80.42 per share, for a total of $156.9 million and $265.0 million, respectively.

NOTE 13 – ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):

	Fair Value of Derivative Financial Instruments, net of tax			Foreign Currency Translation Adjustments		Post-Retirement and Pension Liability Adjustments, net of tax			Total AOCI
Balance at December 31, 2018	$	(15.5	)	$	104.5	$	(4.4	)	$	84.6
OCI before reclassifications	0.2			11.0		—			11.2
Amounts reclassified from AOCI	4.2			—		(0.5		)	3.7
Other comprehensive loss	$	4.4		$	11.0	$	(0.5	)	$	14.9
Balance at June 29, 2019	$	(11.1	)	$	115.5	$	(4.9	)	$	99.5

NOTE 14 – INCOME TAXES

The effective tax rates were as follows:

Three Months Ended				Six Months Ended
June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
66.6	%	34.5	%	32.5	%	29.4	%

The effective tax rate for the three months ended June 29, 2019 increased compared to the prior year period due primarily to changes in the jurisdictional mix of pre-tax book income and a $27.8 million reduction in pre-tax income due to an impairment charge related to a definite-lived intangible asset.

The effective tax rate for the six months ended June 29, 2019 increased compared to the prior year period due primarily to changes in the jurisdictional mix of pre-tax book income.

On October 31, 2018, we received an audit finding letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the years ended December 31, 2012 and December 31, 2013. The audit finding letter relates to the tax treatment of the 2013 sale of the Tysabri^® intellectual property and other assets related to Tysabri^® to Biogen Idec from Elan Pharma. The consideration paid by Biogen to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Irish Revenue issued a Notice of Amended Assessment (“NoA”) on November 29, 2018 which assesses an Irish corporation tax liability against Elan Pharma in the amount of €1,636 million, not including interest or any applicable penalties. We disagree with this assessment and believe that the NoA is without merit and incorrect as a matter of law. We filed an appeal of the NoA on December 27, 2018 and will pursue all available administrative and judicial avenues as may be necessary or appropriate. As part of this strategy to pursue all available administrative and judicial avenues, Elan Pharma was, on February 25, 2019, granted leave by the Irish High Court to seek judicial review of the issuance of the NoA by Irish Revenue. The judicial review filing is based on our belief that Elan Pharma's legitimate expectations as a taxpayer have been breached, not on the merits of the NoA itself. The High Court has scheduled a hearing in this judicial review proceeding in April 2020, and we would expect a decision in this matter in the second half of 2020. If we are ultimately successful in the judicial review proceedings the NoA will be invalidated and Irish Revenue will not be able to re-issue the NoA. The proceedings before the Tax Appeals Commission have been stayed until a decision on the judicial review application has been made.

On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $163.6 million of Federal income tax, penalties, and interest assessed and collected by the IRS, plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the

25

Perrigo Company plc - Item 1

Note 14

United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of $37.2 million for the 2009 tax year, $61.5 million for the 2010 tax year, $40.2 million for the 2011 tax year, and $24.7 million for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017. The cumulative deferred charge as recorded on the balance sheet is $29.7 million lower than the amounts reflected above due to overpayments credited to succeeding years, such that the actual refund the company is seeking to receive will be reduced by that amount. In addition, we recently conceded a royalty due to Perrigo U.S. on all omeprazole sales that equates to a 24% of our refund claims and any omeprazole adjustments that may be asserted by the IRS for future years.

On July 11, 2017, we received a draft Notice of Proposed Adjustment (“NOPA”) associated with transfer pricing positions for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Athena was the originator of the patents associated with Tysabri^® prior to the acquisition of Athena by Elan in 1996. The draft NOPA asserted that when Elan took over the future funding of Athena’s in-process R&D in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. In response to the draft NOPA, we provided the IRS with substantial additional documentation supporting our position. On April 26, 2019, we received a revised NOPA from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA. The revised NOPA proposes a payment of $843.0 million, which represents additional tax and a 40.0% penalty. This amount excludes consideration of offsetting tax attributes and potentially material interest. We strongly disagree with the IRS position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation.

On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Perrigo acquired Elan in December 2013. This proposed adjustment relates to the deductibility of litigation costs. We disagree with the IRS’s position asserted in the notice of proposed adjustment and intend to contest it.

We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Ireland and other jurisdictions in Europe. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015 (which covers the period of the Elan transaction). The Israel Tax Authority's audit of our fiscal years ended June 29, 2013 and June 28, 2014 concluded with no material impact to the financial statements and the Israel Tax Authority is now auditing our fiscal years ended December 31, 2015, December 31, 2016 and December 31, 2017.

26

Perrigo Company plc - Item 1

Note 15

NOTE 15 – CONTINGENCIES

In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of June 29, 2019, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to, individually or in the aggregate, have a material adverse effect on our financial condition, results of operations, or cash flows. 

Price-Fixing Lawsuits

We have been named as a co-defendant with certain other generic pharmaceutical manufacturers in a number of class actions alleging that we and other manufacturers of the same product engaged in anti-competitive behavior to fix or raise the prices of certain drugs and/or allocate customers starting, in some instances, as early as June 2013. The class actions were filed on behalf of putative classes of (a) direct purchasers, (b) end payors, and (c) indirect resellers. The products in question are Clobetasol gel, Desonide, and Econazole. The same class plaintiffs have filed complaints naming us as a co-defendant, along with 27 other manufacturers, alleging an overarching conspiracy to fix or raise the prices of 15 generic prescription pharmaceutical products starting in 2011. Perrigo manufactures only two of the products at issue, Nystatin cream and Nystatin ointment.

We have also been named a co-defendant along with 35 other manufacturers in a complaint filed by three supermarket chains alleging that defendants conspired to fix prices of 31 generic prescription pharmaceutical products starting in 2013. The only allegations specific to us relate to Clobetasol, Desonide, Econazole, Nystatin cream, and Nystatin ointment.

On August 3, 2018, a large managed care organization filed a complaint against us alleging price-fixing and customer allocation concerning 17 different products among 27 manufacturers including Perrigo. The only allegations specific to us concern Clobetasol gel, Desonide, Econazole, Nystatin cream, and Nystatin ointment.

Most recently, on January 16, 2019, a similar suit was brought by a health insurance carrier in the U.S. District Court for the District of Minnesota alleging a conspiracy to fix prices of 30 products among 30 defendants. The only allegations specific to us concern Clobetasol gel, Desonide, Econazole, Nystatin cream, and Nystatin ointment.

Certain complaints listed above were amended in December 2017, January 2018, and April 2019. All of the above complaints have been consolidated for pretrial proceedings, along with complaints filed against other companies alleging price fixing with respect to more than two dozen other drugs, as part of a case captioned In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724 in the U.S. District Court for the Eastern District of Pennsylvania.

Pursuant to the court’s schedule staging various cases in phases, we moved to dismiss the complaints relating to Clobetasol and Econazole. The court issued a decision denying the motions in part in October 2018 and issued a second decision in February 2019 dismissing various state law claims, but allowing other state law claims to proceed. We filed answers to the Clobetasol gel complaints on December 31, 2018. We filed answers to the Desonide and Econazole complaints on March 15, 2019.

Motions to dismiss certain other complaints listed above were filed on February 21, 2019. Plaintiffs’ oppositions were due on May 2, 2019 and defendants’ replies were filed on June 13, 2019. Certain deposition discovery is allowed to proceed as of the court’s July 15, 2019 order in all cases and documentary discovery is also proceeding. At this stage, we cannot reasonably predict the outcome of the liability, if any, associated with these claims.

27

Perrigo Company plc - Item 1

Note 15

Securities Litigation

In the United States (cases related to events in 2015-2017)

On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (Roofers’ Pension Fund v. Papa, et al.). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (Wilson v. Papa, et al.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated the Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.

On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. In the amended complaint, the lead plaintiffs seek to represent three classes of shareholders - shareholders who purchased shares during the period April 21, 2015 through May 3, 2017 on the U.S. exchanges; shareholders who purchased shares during the same period on the Tel Aviv exchange; and shareholders who owned shares on November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (the final day of the Mylan tender offer) regardless of whether the shareholders tendered their shares. The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company and at Omega, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri^® royalty stream. The amended complaint does not include an estimate of damages. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions to dismiss in part and denying the motions to dismiss in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims arising from the Tysabri^® accounting issue described above and claims alleging incorrect disclosure of organic growth described above. The defendants who were not dismissed are Perrigo Company plc, Joe Papa, and Judy Brown. The claims (described above) that were not dismissed relate to the integration issues regarding the Omega acquisition and the alleged price fixing activities with respect to six generic prescription pharmaceuticals. The defendants who remain in the case (the Company, Mr. Papa, and Ms. Brown) have filed answers denying liability, and the discovery stage of litigation has begun. We intend to defend the lawsuit vigorously.

On November 1, 2017, Carmignac Gestion, S.A., filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Carmignac Gestion, S.A. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through April 2016. Plaintiff contends that the defendants provided

28

Perrigo Company plc - Item 1

Note 15

inadequate disclosure throughout the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. On July 31, 2019, the court granted the motion to dismiss in part and denied it in part. The case is now in the discovery phase. We intend to defend the lawsuit vigorously.

On January 16, 2018, Manning & Napier Advisors, LLC filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Manning & Napier Advisors, LLC v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5) and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. On July 31, 2019, the court granted the motion to dismiss in part and denied it in part. The case is now in the discovery phase. We intend to defend the lawsuit vigorously.

On January 26, 2018, two different plaintiff groups (the Mason Capital group and the Pentwater group) each filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (Roofers’ Pension Fund case). The same law firm represents these two plaintiff groups, and the two complaints are substantially similar. These two cases are not securities class actions. One case is styled Mason Capital L.P., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The other case is styled Pentwater Equity Opportunities Master Fund Ltd., et al.  v. Perrigo Company plc, et al., and also was filed in the U.S. District Court for the District of New Jersey. Both cases are assigned to the same federal judge that is hearing the class action case and the other individual cases described above (Carmignac and Manning & Napier). Each complaint asserts claims under Securities Exchange Act sections 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the factual allegations in these two cases overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above and the allegations in the Carmignac case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to these cases conferred about how these cases should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in these cases. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuits vigorously.

29

Perrigo Company plc - Item 1

Note 15

On February 13, 2018, a group of plaintiff investors affiliated with Harel Insurance Investments & Financial Services, Ltd. filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (Roofers’ Pension Fund case). This lawsuit is not a securities class action. The new complaint is substantially similar to the amended complaint in the Roofers' Pension Fund case. The relevant period in the new complaint stretches from February 2014 to May 2, 2017. The complaint adds as defendants two individuals who served on our Board prior to 2016. The case is styled Harel Insurance Company, Ltd., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action cases and the four other individual cases described above (Carmignac, Manning & Napier, Mason Capital, and Pentwater). The Harel Insurance Company complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule 10b‑5) and section 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. The complaint also asserts claims based on Israeli securities laws. In general, the plaintiffs' allegations describe events during the period from February 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset from February 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above and the allegations in the four opt out cases also described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously.

On February 16, 2018, First Manhattan Company filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled First Manhattan Co. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the five other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. This lawsuit was filed by the same law firm that filed the Manning & Napier Advisors case and the Carmignac case described above and generally makes the same factual assertions as in the Manning & Napier Advisors case. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. On April 20, 2018, the plaintiff filed an amended complaint that did not materially change the factual allegations of the original complaint. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants filed a motion to dismiss addressing the additional allegations in this case. On July 31, 2019, the court granted the motion to dismiss in part and denied it in part. The case is now in the discovery phase. We intend to defend the lawsuit vigorously.

On April 20, 2018, a group of plaintiff investors affiliated with TIAA-CREF filed a lawsuit against us and the same individuals who are the defendants in the Harel Insurance case complaint. This lawsuit is not a securities class action. The law firm representing the plaintiffs in the Harel Insurance case also represents the TIAA-CREF plaintiff entities in this case, and the new complaint is substantially similar to the Harel Insurance complaint. The relevant period in the new complaint is August 14, 2014 to May 2, 2017 inclusive. The case is styled TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action case and the six other individual cases described above (Carmignac, Manning & Napier, Mason Capital, Pentwater, Harel Insurance,

30

Perrigo Company plc - Item 1

Note 15

and First Manhattan). The TIAA-CREF Investment Management complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule l0b-5), section 14(e) (related to tender offer disclosures) against all defendants as well as section 20(a) control person liability against the individual defendants. In general, plaintiffs' allegations describe events during the period from August 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset from August 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously.

On October 29, 2018, Nationwide Mutual Funds and Nationwide Variable Insurance Trust (both on behalf of several fund series) filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the seven other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the First Manhattan case, the Manning & Napier Advisors case, and the Carmignac case described above and generally makes the same factual assertions as in the Manning & Napier case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. The defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. On July 31, 2019, the court granted the motion to dismiss in part and denied it in part. The case is now in the discovery phase. We intend to defend the lawsuit vigorously.

On November 15, 2018, a group of plaintiff investors affiliated with Westchester Capital Funds filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the Mason Capital L.P. case and the Pentwater Equity Opportunities Master Fund Ltd. case (described above) represents the affiliates of the Westchester Funds in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the Mason Capital and in the Pentwater cases described above. The case is styled WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al., and is filed in the U.S. District Court for the District of New Jersey. The WCM case is assigned to the same federal judge that is hearing the Roofer’s Fund class action case and the eight other individual cases described above. The complaint asserts claims under Securities Exchange Act sections 10(b) (and SEC Rule 10b‑5) and 14(e) against all defendants as well as 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 as well us up through May 3, 2017. Plaintiffs identify disclosures concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case. The defendants (the Company, Mr.

31

Perrigo Company plc - Item 1

Note 15

Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.

On November 15, 2018, a group of plaintiff investors affiliated with Hudson Bay Capital Management LP filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the Mason Capital L.P., the Pentwater Equity Opportunities Master Fund Ltd., and the WCM cases (described above) represents the affiliates of Hudson Bay Capital Management in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the Mason Capital, in the Pentwater, and in the WCM cases described above. The case is styled Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al., and is filed in the U.S. District Court for the District of New Jersey. The Hudson Bay Fund case is assigned to the same federal judge that is hearing the Roofer’s Fund class action case and the nine other individual cases described above. The complaint asserts claims under Securities Exchange Act section 14(e) against all defendants and section 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.

On January 31, 2019, Schwab Capital Trust and a variety of other Schwab entities filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Schwab Capital Trust, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the ten other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the Carmignac case, the Manning & Napier case, the First Manhattan case, and the Nationwide Mutual Funds case described above and generally makes the same factual assertions as in the Nationwide Mutual Funds case. The complaint does not include factual allegations that the court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The plaintiff does not provide an estimate of damages. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending in the Carmignac, Manning & Napier, First Manhattan, and Nationwide Mutual cases described above. On July 31, 2019, the court granted in part and denied in part the motion to dismiss in the Carmignac and related cases; therefore this case has now also moved into the discovery phase. We intend to defend the lawsuit vigorously.

On February 6, 2019, OZ Master Fund, Ltd. and a related entity filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the eleven other opt out cases described above. The complaint asserts claims under Securities Exchange Act sections 10(b) (and SEC Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of

32

Perrigo Company plc - Item 1

Note 15

Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The plaintiff does not provide an estimate of damages. The parties agreed that the court's rulings in July 2018 in the Roofer's case (discussed above) and in July 2019 in the Carmignac and other cases (discussed above) will apply to this case as well.The parties agreed to a proposed schedule, which the court approved in July 2019, by which the plaintiffs are participating in the discovery proceedings in the Roofer's Pension Fund case described above and the various individual cases also described above. We intend to defend the lawsuit vigorously.

On February 14, 2019, Highfields Capital I LP and related entities filed a securities lawsuit against the Company and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Highfields Capital I LP, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of Massachusetts. The complaint asserts claims under Securities Exchange Act sections 14(e) and 18 against all defendants, as well as 20(a) control person liability against the individual defendants. The complaint also asserts Massachusetts state law claims under Massachusetts Unfair Business Methods Law (chapter 93A § 11), and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged improper accounting for the Tysabri^® asset. Some of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above and with allegations in one or more of the opt out cases described above. Plaintiffs do not provide a clear calculation of how they estimated damages and seek treble damages, punitive damages, and attorney's fees. On May 7, 2019, defendants filed a motion to transfer this case to the U.S. District Court for the District of New Jersey so that the proceedings in this case can be coordinated with the other cases (discussed above) pending in that court. The transfer motion has been fully briefed. We intend to defend the lawsuit vigorously.

On February 22, 2019, Aberdeen Canada Funds -- Global Equity Funds (and 30 other entities, some unrelated to Aberdeen) filed a securities lawsuit against the Company and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Aberdeen Canada Funds -- Global Equity Fund, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the twelve other opt-out cases pending in that Court. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5) against all defendants and 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged undisclosed pricing pressure for generic prescription pharmaceuticals, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the Carmignac case, the Manning & Napier case, the First Manhattan case, the Nationwide Mutual Funds case, and the Schwab Capital Trust case described above, and generally makes the same factual assertions as in the Nationwide Mutual Funds case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending the Carmignac, Manning & Napier, First Manhattan, and Nationwide Mutual Funds cases described above. The plaintiff does not provide an estimate of damages. On July 31, 2019, the court granted in part and denied in part the motion to dismiss in the Carmignac and related cases; therefore this case has now also moved into the discovery phase. We intend to defend the lawsuit vigorously.

33

Perrigo Company plc - Item 1

Note 15

In Israel (cases related to events in 2015-2017)

Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are potentially subject to securities litigation in Israel. Three cases were filed; one was voluntarily dismissed in each of 2017 and 2018 and one was stayed in 2018. We are consulting Israeli counsel about our response to these allegations and we intend to defend this case vigorously.

On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. The lead plaintiff seeks to represent a class of shareholders who purchased Perrigo stock on the Tel Aviv exchange during the period April 24, 2015 through May 3, 2017 and also a claim for those that owned shares on the final day of the Mylan tender offer (November 13, 2015). The amended complaint names as defendants the Company, Ernst & Young LLP (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri^® royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of 2.7 billion NIS (approximately $760.0 million at 1 NIS = 0.28 cents). After the other two cases filed in Israel were voluntarily dismissed, the plaintiff in this case agreed to stay this case pending the outcome of the Roofers’ Pension Fund case in the U.S. (described above). The Israeli court approved the stay, and this case is now stayed. We intend to defend the lawsuit vigorously.

In the United States (cases related to Irish Tax events)

On January 3, 2019, a shareholder filed a complaint against the Company, our CEO Murray Kessler, and our former CFO Ronald Winowiecki in the U.S. District Court for the Southern District of New York (Masih v. Perrigo Company, et al.). Plaintiff purports to represent a class of shareholders for the period November 8, 2018 through December 20, 2018, inclusive. The complaint alleges violations of Securities Exchange Act section 10(b) (and Rule 10b‑5) against all defendants and section 20(a) control person liability against the individual defendants. In general the allegations contend that the Company, in its Form 10‑Q filed November 8, 2018, disclosed information about an October 31, 2018 audit finding letter received from Irish tax authorities but failed to disclose enough material information about that letter until December 20, 2018, when we filed a current report on Form 8‑K about Irish tax matters. The plaintiff does not provide an estimate of class damages. The Court selected lead plaintiffs and changed the name of the case to In re Perrigo Company plc Sec. Litig. The lead plaintiffs filed an amended complaint on April 12, 2019, which named the same defendants, asserted the same class period, and invoked the same Exchange Act sections. The amended complaint generally repeated the allegations of the original complaint with a few additional details and adds that the defendants also failed to timely disclose the Irish tax authorities’ Notice of Amended Assessment received on November 29, 2018. Defendants filed a motion to dismiss on May 3, 2019. On May 31, 2019, the plaintiffs filed a second amended complaint, which asserted a longer class period (March 1, 2018 through December 20, 2018) and added one additional individual defendant, former CEO Uwe Roehrhoff. In general, the second amended complaint contends that Perrigo’s disclosures about the Irish tax audit were inadequate beginning with Perrigo’s 10-K filed on March 1, 2018 through December 20, 2018 and repeats many of the allegations of the April 2019 amended complaint. The second amended complaint alleges violations of Securities Exchange Act section 10(b) (and SEC Rule 10b-5) against all defendants and section 20(a) control person liability against the three individual defendants. All defendants filed a joint motion to dismiss, and the plaintiffs filed an opposition. The defendants' reply is due in mid-August 2019. At some time thereafter the court will decide the motion. We intend to defend the lawsuit vigorously.

34

Perrigo Company plc - Item 1

Note 15

In Israel (cases related to Irish Tax events)

On December 31, 2018, a shareholder filed an action against the Company, our CEO Murray Kessler, and our former CFO Ronald Winowiecki in Tel Aviv District Court (Baton v. Perrigo Company plc, et. al.). The case is a securities class action brought in Israel making similar factual allegations for the same period as those asserted in the In re Perrigo Company plc Sec. Litig case in New York federal court. This case alleges that persons who invested through the Tel Aviv stock exchange can assert claims under Israeli securities law that will follow the liability principles of Sections 10(b) and 20(a) of the U.S. Securities Exchange Act. The plaintiff does not provide an estimate of class damages. We filed a request for a stay, the plaintiff agreed in part, and the court approved a stay and required the parties to update the court about the U.S. proceedings by September 1, 2019. We intend to defend the lawsuit vigorously.

Claim Arising from the Omega Acquisition

On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV (together the "Sellers") in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo has asserted a counterclaim for monetary damages contending that we breached a warranty in the SPA and breached the duty of good faith in performing the SPA. Alychlo has recently filed papers seeking permission to introduce an additional counterclaim theory of recovery related to the Irish tax issue recently disclosed by the Company such that if the position of the Irish tax authorities prevails, Alychlo would have a further basis for its counterclaim against Perrigo. The proposed additional counterclaim theory does not appear to increase any damages sought. In June 2019, the Tribunal denied permission for Alychlo to introduce the additional counterclaim and dismissed certain aspects of the original Alychlo counterclaim. There can be no assurance that our Claim will be successful, and the Sellers deny liability for the Claim. To the extent that aspects of Alychlo’s counterclaim survived the Tribunal’s ruling in June 2019, we deny that Alychlo is entitled to any relief (including monetary relief). The arbitration proceedings are confidential as required by the SPA and the rules of the CEPANI.

Other Matters

Our Board of Directors received a shareholder demand letter dated October 30, 2018 relating to the allegations in the securities cases and price fixing lawsuits described above. The letter demands that the Board of Directors initiate an action against certain current and former executives and Board members to recover damages allegedly caused to the Company. In response, the Company reminded the shareholder that any derivative claim can only proceed in accordance with Irish law, the law that governs the Company’s internal affairs. The shareholder has responded that he intends to file a lawsuit asserting derivative claims but has not yet filed a lawsuit.

NOTE 16 – RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, and asset impairments. The following reflects our restructuring activity (in millions):

	Three Months Ended						Six Months Ended
	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Beginning balance	$	20.5		$	12.4		$	24.0		$	21.4
Additional charges	12.2			3.7			18.1			5.2
Payments	(9.0		)	(3.1		)	(18.0		)	(13.8		)
Non-cash adjustments	0.3			(0.3		)	(0.1		)	(0.1		)
Ending balance	$	24.0		$	12.7		$	24.0		$	12.7

35

Perrigo Company plc - Item 1

Note 16

The charges incurred during the three and six months ended June 29, 2019 were primarily associated with the reorganization of our executive management team and other actions taken to streamline the organization. Of the amount recorded during the six months ended June 29, 2019, $9.8 million related to the CSCI segment due primarily to the sales force reorganization in France. The charges incurred during the six months ended June 30, 2018 were primarily associated with continued costs from actions we took to streamline our organization as announced on February 21, 2017, as well as additional lease exit costs. All charges are recorded in Restructuring expense on the Condensed Consolidated Financial Statements. The remaining $24.0 million liability for employee severance benefits is expected to be paid within the next year.

NOTE 17 – SEGMENT INFORMATION

Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company.

The below tables show select financial measures by reporting segment (in millions):

	Total Assets
	June 29, 2019		December 31, 2018
CSCA	$	4,041.9	$	3,571.7
CSCI	4,593.5		4,613.0
RX	2,793.3		2,798.7
Total	$	11,428.7	$	10,983.4

	Three Months Ended
	June 29, 2019							June 30, 2018
	Net Sales		Operating Income (Loss)			Intangible Asset Amortization		Net Sales		Operating Income (Loss)			Intangible Asset Amortization
CSCA	$	582.1	$	107.8		$	9.3	$	596.9	$	64.6		$	15.3
CSCI	327.5		(2.9		)	43.0		357.9		4.0			49.2
RX	239.4		14.7			21.3		231.6		53.6			20.8
Unallocated	—		(64.6		)	—		—		(27.5		)	—
Total	$	1,149.0	$	55.0		$	73.6	$	1,186.4	$	94.7		$	85.3

	Six Months Ended
	June 29, 2019							June 30, 2018
	Net Sales		Operating Income (Loss)			Intangible Asset Amortization		Net Sales		Operating Income (Loss)			Intangible Asset Amortization
CSCA	$	1,163.9	$	202.0		$	19.3	$	1,198.5	$	183.2		$	30.5
CSCI	678.3		5.1			87.1		735.7		16.3			100.3
RX	481.3		75.3			42.6		469.2		114.8			41.6
Unallocated	—		(125.1		)	—		—		(63.4		)	—
Total	$	2,323.5	$	157.3		$	149.0	$	2,403.4	$	250.9		$	172.4

NOTE 18 – SUBSEQUENT EVENTS

Animal health business

On July 8, 2019, we completed the sale of our animal health business to PetIQ for base consideration of$185.0 million, which we estimate will result in a pre-tax gain of $80.0 million to $90.0 million. The final purchase price and gain is subject to customary post-closing adjustments for changes to working capital compared to the target working capital on the closing date and is expected to be finalized by the fourth quarter of 2019.

Generic product acquisition

On July 2, 2019, we purchased the ANDA for a generic gel product used for the treatment of Hemophilus vaginitis for $49.0 million in cash, which we capitalized as a developed product technology intangible asset. We plan to launch the product during the three months ended September 28, 2019 and begin amortizing it over a 20-year useful life. Operating results attributable to the product will be included within our RX segment.

Ranir Global Holdings, LLC

36

Perrigo Company plc - Item 1

Note 18

On July 1, 2019, we acquired 100% of the outstanding equity interest in Ranir, a privately-held company, for total base consideration of $750.0 million in a debt-free, cash-free transaction. We funded the transaction with cash on hand and borrowings under the 2018 Revolver (refer to Note 11).

Ranir is headquartered in Grand Rapids, Michigan, and is a leading global supplier of private label and branded oral care products. This transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions. Ranir operations will be reported in our CSCA segment.

During the three and six months ended June 29, 2019, in connection with the acquisition, we incurred $2.2 million of general transaction costs (legal, banking and other professional fees). The amounts were recorded in Administration expenses and were not allocated to the CSCA segment.

We are in the process of gathering significant relevant information needed to complete the valuation for the assets acquired and liabilities assumed. As a result, the initial accounting for the acquisition accounting is incomplete. The provisional acquisition amounts recognized for assets acquired and liabilities assumed and the supplemental pro-forma information will be included in our quarterly Report on Form 10-Q for the third quarter of 2019.

ITEM 2.        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EXECUTIVE OVERVIEW

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements included in this Form 10-Q and our Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”). These historical financial statements may not be indicative of our future performance. This discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks referred to under “Risk Factors” in Item 1A of our 2018 Form 10-K and Part II. Item 1A of this Form 10-Q.

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

We are dedicated to making lives better by bringing “Quality, Affordable Self-Care Products™” that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. We are also a leading producer of generic prescription pharmaceutical topical products such as creams, lotions, gels, and nasal sprays.

Segment Reporting Change

               During the three months ended March 30, 2019, we changed the composition of our operating and reporting segments. We moved our Israeli diagnostic business from the Consumer Self-Care International segment to the Prescription Pharmaceuticals segment and we made certain adjustments to our allocations between

37

Perrigo Company plc - Item 2

Executive Overview

segments. These changes were made to reflect changes in the way in which management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in Item 1. Note 2 and Note 17. For results by segment, see "Segment Results" below.

Our new reporting and operating segments are as follows:

• Consumer Self-Care Americas ("CSCA"), formerly Consumer Healthcare Americas, comprises our consumer self-care business (OTC, contract manufacturing, infant formula and animal health categories) in the U.S., Mexico and Canada.

• Consumer Self-Care International ("CSCI"), formerly Consumer Healthcare International, comprises our branded consumer self-care business primarily in Europe, our consumer-focused business in the United Kingdom and Australia, and our liquid licensed products business in the United Kingdom.

• Prescription Pharmaceuticals ("RX") comprises our Prescription Pharmaceuticals business in the U.S. and our diagnostic business in Israel, which was previously in our CSCI segment.

Highlights

• On August 9, 2018, we announced a plan to separate our RX business, which, when completed, will enable us to focus on expanding our consumer-facing businesses. We have made significant progress related to the preparations for separation, which may include a possible sale, spin-off, merger or other form of separation. While we remain committed to transforming to a consumer-focused business, we cannot commit to a specific date for the separation. In connection with the proposed separation, we anticipate incurring significant preparation costs, excluding restructuring expenses and transaction costs, in the range of $45.0 million to $80.0 million depending on the final structure of the transaction.

• On July 1, 2019, we acquired 100% of the outstanding equity interest in Ranir Global Holdings, LLC (“Ranir”), a privately-held company, for total base consideration of $750.0 million in a debt-free, cash-free transaction, subject to post-closing adjustments for changes to working capital compared to the target working capital on the closing date. This transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions (refer to Item 1. Note 18).

RESULTS OF OPERATIONS

CONSOLIDATED

Recent Developments

Notice of Proposed Adjustment

On April 26, 2019, we received a revised Notice of Proposed Adjustment (“NOPA”) from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA that when Elan took over the future funding of Athena’s in-process Research & Development ("R&D") in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40.0% penalty. This amount excludes consideration of offsetting tax attributes and potentially material interest. We strongly disagree with the IRS income position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation. While we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is resolved unfavorably it could have a material adverse impact on our liquidity and capital resources (refer to Item 1. Note 14).

38

Perrigo Company plc - Item 2

Consolidated

Consolidated Results

Three Month Comparison

	Three Months Ended
(in millions)	June 29, 2019			June 30, 2018
Net sales	$	1,149.0		$	1,186.4
Gross profit	$	430.8		$	471.0
Gross profit %	37.5		%	39.7		%
Operating income	$	55.0		$	94.7
Operating income %	4.8		%	8.0		%

* Total net sales by geography is derived from the location of the entity that sells to a third party.

Operating income decreased $39.7 million, or 42%, over the prior year period due to:

• $37.4 million, or 3%, decrease in net sales over the prior year period due to:

• $51.9 million decrease in sales of existing products due primarily to pricing pressure and decreased sales volumes of certain products;

• $26.6 million decrease due to discontinued products; and

• $23.8 million decrease due primarily to unfavorable European Euro foreign currency translation; partially offset by

• $64.9 million increase due to new product sales.

• $40.2 million decrease in gross profit, or a 220 basis point decrease in gross profit as a percentage of net sales, due primarily to the net sales decreases discussed above.

• $0.5 million decrease in operating expenses due primarily to:

• $50.0 million decrease in R&D expense due to the absence of an upfront license fee payment to enter into a license agreement with Merck Sharp & Dohme Corp ("Merck") in the prior year period;

• $15.3 million decrease in selling expenses due primarily to the effect of European Euro favorable foreign currency translation; partially offset by

• $30.4 million increase in administrative expenses due primarily to increased legal and consulting fees;

• $27.8 million impairment charge related to a definite-lived intangible asset;

• $8.4 million increase in restructuring expense due primarily to the reorganization of our sales force in France.

39

Perrigo Company plc - Item 2

Consolidated

Six Month Comparison

	Six Months Ended
(in millions)	June 29, 2019			June 30, 2018
Net sales	$	2,323.5		$	2,403.4
Gross profit	$	879.6		$	963.7
Gross profit %	37.9		%	40.1		%
Operating income	$	157.3		$	250.9
Operating income %	6.8		%	10.4		%

* Total net sales by geography is derived from the location of the entity that sells to a third party.

Operating income decreased $93.6 million, or 37%, over the prior year period due to:

• $79.9 million, or 3%, decrease in net sales over the prior year period due to:

• $90.3 million decrease in sales of existing products due primarily to pricing pressure;

• $59.6 million decrease due primarily to unfavorable European Euro foreign currency translation; and

• $49.7 million decrease due to discontinued products; partially offset by

• $119.7 million increase due to new product sales.

• $84.1 million decrease in gross profit, or a 220 basis point decrease in gross profit as a percentage of net sales, due primarily to the decrease in net sales discussed above, increased commodity costs related to certain products and operating inefficiencies in the CSCA segment.

• $9.5 million increase in operating expenses due primarily to:

• $47.8 million increase in administrative expenses due primarily to increased legal and consulting fees;

• $31.9 million of impairment charges related to a definite-lived intangible asset and an in-process R&D asset; and

• $16.3 million increase in restructuring expense due primarily to the reorganization of our sales force in France; partially offset by

• $50.0 million decrease in R&D expense due to the absence of an upfront license fee payment to enter into a license agreement with Merck in the prior year period;

• $27.8 million decrease in selling expenses due primarily to the effect of European Euro favorable foreign currency translation; and

• $9.4 million decrease in acquisition and integration-related charges and contingent consideration adjustments.

40

Perrigo Company plc - Item 2

Consolidated

CONSUMER SELF-CARE AMERICAS

Recent Developments

• On July 8, 2019, we completed the sale of our animal health business to PetIQ for base consideration of$185.0 million, which we estimate will result in a pre-tax gain of $80.0 million to $90.0 million. The final purchase price and gain is subject to customary post-closing adjustments for changes to working capital compared to the target working capital on the closing date and is expected to be finalized by the fourth quarter of 2019 (refer to Item 1. Note 18).

• On July 1, 2019, we acquired 100% of the outstanding equity interest in Ranir, a privately-held company, for total base consideration of $750.0 million in a debt-free, cash-free transaction, subject to post-closing adjustments for changes to working capital compared to the target working capital on the closing date. This transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions (refer to Item 1. Note 18).

• On April 1, 2019, we purchased product Abbreviated New Drug Application ("ANDA"s) and other records and registrations of Budesonide Nasal Spray, a generic equivalent of Rhinocort Allergy^® and Triamcinolone Nasal Spray, a generic equivalent of Nasacort Allergy^®, from Barr Laboratories, Inc., a subsidiary of Teva Pharmaceuticals, for $14.0 million in cash (refer to Item 1. Note 3).

Segment Results

Three Month Comparison

	Three Months Ended
(in millions)	June 29, 2019			June 30, 2018
Net sales	$	582.1		$	596.9
Gross profit	$	196.8		$	202.5
Gross profit %	33.8		%	33.9		%
Operating income	$	107.8		$	64.6
Operating income %	18.5		%	10.8		%

Three Months Ended June 29, 2019 vs. Three Months Ended June 30, 2018

Operating income increased $43.2 million, or 67%, over the prior year period due to:

• $14.8 million, or 3%, decrease in net sales over the prior year period due primarily to:

• $11.8 million decrease in sales of existing products due primarily to:

▪ Pricing pressure across all categories; and

▪ Lower sales volume in our infant nutritionals and animal health categories; partially offset by

▪ Higher sales volume in our cough/cold/allergy/sinus, gastrointestinal, and smoking cessation categories; and

• $11.2 million decrease due to discontinued products; partially offset by

• $8.0 million increase due primarily to the launches of various new antacids and smoking cessation products.

• $5.7 million decrease in gross profit due primarily to the net sales decrease discussed above and certain operational inefficiencies.

• $48.9 million decrease in operating expenses due primarily to the absence of a $50.0 million upfront license fee payment to enter into a license agreement with Merck in the prior year period in R&D.

41

Perrigo Company plc - Item 2

CSCA

Six Month Comparison

	Six Months Ended
(in millions)	June 29, 2019			June 30, 2018
Net sales	$	1,163.9		$	1,198.5
Gross profit	$	380.8		$	408.4
Gross profit %	32.7		%	34.1		%
Operating income	$	202.0		$	183.2
Operating income %	17.4		%	15.3		%

Six Months Ended June 29, 2019 vs. Six Months Ended June 30, 2018

Operating income increased $18.8 million, or 10%, over the prior year period as a result of:

• $34.6 million, or 3%, decrease in net sales over the prior year period due primarily to:

• $27.2 million decrease in sales of existing products due primarily to:

▪ Pricing pressure across all categories; and

▪ Lower sales volume in our infant nutritionals and animal health categories; partially offset by

▪ Higher sales volume in our cough/cold/allergy/sinus, gastrointestinal, and smoking cessation categories; and

• $21.9 million decrease due to discontinued products; partially offset by

• $15.0 million increase due primarily to the launches of various new antacids, cough/cold/allergy/sinus, and smoking cessation products.

• $27.6 million decrease in gross profit, or a 140 basis point decrease in gross profit as a percentage of net sales, due primarily to the decrease in net sales discussed above, and increased commodity costs related to certain products in the cough/cold/allergy/sinus categories and operating inefficiencies related to infant formula production.

• $46.4 million decrease in operating expenses due primarily to the absence of a $50.0 million upfront license fee payment to enter into a license agreement with Merck in R&D in the prior year period.

CONSUMER SELF-CARE INTERNATIONAL

Recent Trends and Developments

• Management continues to implement its previously disclosed strategy for brand prioritization, sales force restructuring, and manufacturing insourcing, which is expected to reduce selling costs, improve operating margins and focus on higher value OTC products. As part of this strategy, we are making progress on the previously reported CSCI restructuring plan that we expect to improve our cost structure.

Segment Results

Three Month Comparison

	Three Months Ended
(in millions)	June 29, 2019			June 30, 2018
Net sales	$	327.5		$	357.9
Gross profit	$	155.4		$	173.2
Gross profit %	47.4		%	48.4		%
Operating income (loss)	$	(2.9	)	$	4.0
Operating income (loss) %	(0.9		)%	1.1		%

42

Perrigo Company plc - Item 2

CSCI

Three Months Ended June 29, 2019 vs. Three Months Ended June 30, 2018

Operating income decreased $6.9 million, or 173%, over the prior year period due to:

• $30.4 million, or 9%, decrease in net sales over the prior year period due to:

• $30.6 million decrease in sales of existing products due primarily to:

▪ Lower net sales in France due to the reorganization of our sales force, which disrupted sales effectiveness and customer outreach; and

▪ Lower net sales in the cough/cold/allergy/sinus and anti-parasites categories; partially offset by

▪ Higher net sales in the distribution business and in analgesic products ;

• $24.0 million decrease due to unfavorable European Euro foreign currency translation; and

• $6.0 million decrease due to discontinued products; partially offset by

• $30.2 million increase due primarily to the launches of XLS Forte 5 and ACO brands in the lifestyle and personal care and derma-therapeutic categories, respectively.

• $17.8 million decrease in gross profit due primarily to the net sales decrease discussed above.

• $10.9 million decrease in operating expenses due primarily to:

• $18.5 million decrease in selling and administrative expense due to the effect of European Euro favorable foreign currency translation; partially offset by

• $8.6 million increase in restructuring expense due primarily to the reorganization of our sales force in France.

Six Month Comparison

	Six Months Ended
(in millions)	June 29, 2019			June 30, 2018
Net sales	$	678.3		$	735.7
Gross profit	$	323.7		$	359.1
Gross profit %	47.7		%	48.8		%
Operating income	$	5.1		$	16.3
Operating income %	0.8		%	2.2		%

Six Months Ended June 29, 2019 vs. Six Months Ended June 30, 2018

Operating income decreased $11.2 million, or 69%, over the prior year period as a result of:

• $57.4 million, or 8%, decrease in net sales over the prior year period as a result of:

• $57.7 million decrease due to unfavorable European Euro foreign currency translation;

• $48.0 million decrease in sales of existing products due primarily to:

▪ Lower net sales in the personal care and derma-therapeutics and lifestyle categories; partially offset by

▪ Higher net sales in the distribution business; and

• $8.0 million decrease due to discontinued products; partially offset by

• $56.3 million increase due primarily to the launches of XLS Forte 5 and ACO brands in the lifestyle and personal care and derma-therapeutic categories, respectively.

• $35.4 million decrease in gross profit, due primarily to the net sales decrease discussed above.

• $24.2 million decrease in operating expenses due primarily to:

• $31.6 million decrease in selling and administrative expense due to the effect of European Euro favorable foreign currency translation; partially offset by

• $8.7 million increase in restructuring expense due primarily to the reorganization of our sales force in France.

43

Perrigo Company plc - Item 2

CSCI

PRESCRIPTION PHARMACEUTICALS

Recent Trends and Developments

• Although pricing pressure is beginning to moderate, we continue to experience a year-over-year reduction in pricing in our RX segment due to competitive pressures. Similar to the first quarter of 2019, we experienced a year-over-year decrease in pricing pressure in the second quarter and expect softness in pricing to continue to impact the segment for the foreseeable future.

• On May 17, 2019, we purchased the ANDA for a generic product used to relieve pain from osteoarthritis, for $15.7 million in cash, which we capitalized as a developed product technology intangible asset. We plan to launch the the product during the third quarter of 2019 (refer to Item 1. Note 3).

• During the three months ended June 29, 2019, we identified impairment indicators for a certain definite-lived asset related to changes in pricing and competition in the market, which lowered the projected cash flows we expect to generate from the asset. We determined the asset was impaired by $27.8 million. Competition and other industry and market factors may contribute to future impairment charges or indications of impairment in the segment (refer to Item 1. Note 4).

• On July 2, 2019, we purchased the ANDA for a generic gel product used for the treatment of Hemophilus vaginitis for $49.0 million in cash, which we capitalized as a developed product technology intangible asset. We plan to launch the product during the third quarter of 2019.

Segment Results

Three Month Comparison

	Three Months Ended
(in millions)	June 29, 2019			June 30, 2018
Net sales	$	239.4		$	231.6
Gross profit	$	78.6		$	95.3
Gross profit %	32.8		%	41.1		%
Operating income	$	14.7		$	53.6
Operating income %	6.1		%	23.1		%

Three Months Ended June 29, 2019 vs. Three Months Ended June 30, 2018

Operating income decreased $38.9 million, or 73%, over the prior year period due to:

• $7.8 million, or 3%, increase in net sales over the prior year period due primarily to:

• $26.7 million increase due to new product sales; partially offset by

• $9.4 million decrease in sales of existing products due primarily to pricing pressure and decreased sales volumes of certain existing products; and

• $9.4 million decrease due to discontinued products.

• $16.7 million decrease in gross profit, or a 830 basis point decrease in gross profit as a percentage of net sales, due primarily to pricing pressure and less favorable product mix.

• $22.2 million increase in operating expenses due primarily to an impairment charge related to a definite-lived intangible assets of $27.8 million; partially offset by the absence of $4.7 million of acquisition and integration-related charges and contingent consideration adjustments.

44

Perrigo Company plc - Item 2

RX

Six Month Comparison

	Six Months Ended
(in millions)	June 29, 2019			June 30, 2018
Net sales	$	481.3		$	469.2
Gross profit	$	175.1		$	196.2
Gross profit %	36.4		%	41.8		%
Operating income	$	75.3		$	114.8
Operating income %	15.7		%	24.5		%

Six Months Ended June 29, 2019 vs. Six Months Ended June 30, 2018

Operating income decreased $39.5 million, or 34%, over the prior year period as a result of:

• $12.1 million, or 3%, increase in net sales over the prior year period due to:

• $48.4 million increase due to new product sales; partially offset by

• $19.8 million decrease due to discontinued products;

• $15.1 million decrease in sales of existing products due to pricing pressure; partially offset by increased sales volumes of certain products; and

• $1.4 million decrease due to unfavorable Israeli Shekel foreign currency translation.

• $21.1 million decrease in gross profit, or 540 basis points decrease of gross profit as a percentage of net sales, due primarily to pricing pressure and less favorable product mix.

• $18.4 million increase in operating expenses due primarily to an impairment charge related to a definite-lived intangible asset of $27.8 million; partially offset by the absence of $8.7 million of acquisition and integration-related charges and contingent consideration adjustments.

Unallocated Expenses

Unallocated expenses are comprised of certain corporate services not allocated to our reporting segments and are recorded in Operating income on the Condensed Consolidated Statements of Operations. Unallocated expenses were as follows (in millions):

Three Months Ended				Six Months Ended
June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
$	64.6	$	27.5	$	125.1	$	63.4

The increase of $37.1 million in unallocated expenses during the three months ended June 29, 2019 compared to the prior year period was due to a $23.5 million increase in legal and consulting fees and a $4.0 million increase in share-based compensation expense driven primarily by the on-boarding of new executives.

The increase of $61.7 million in unallocated expenses during the six months ended June 29, 2019 compared to the prior year period was due to a $45.9 million increase in legal and consulting fees, a $7.4 million increase due to the reorganization of our executive management team, and an increase in share-based compensation expense of $3.2 million driven by the on-boarding of new executives.

45

Perrigo Company plc - Item 2

Unallocated, Interest, Other, and Taxes

Change in Financial Assets, Interest expense, net, and Other (income) expense, net (Consolidated)

	Three Months Ended						Six Months Ended
(in millions)	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Change in financial assets	$	(5.5	)	$	(0.6	)	$	(15.9	)	$	9.0
Interest expense, net	$	31.2		$	32.1		$	59.8		$	63.5
Other (income) expense, net	$	2.3		$	7.9		$	5.5		$	12.1

Change in Financial Assets

During the three and six months ended June 29, 2019, the fair value of the Royalty Pharma contingent milestone payments increased $5.5 million and $15.9 million, respectively. These increases were driven by higher projected global net sales of Tysabri^® and the estimated probability of achieving the earn-out. The fair value of the Royalty Pharma contingent milestone payments increased by $0.6 million during the three months ended June 30, 2018. This increase included a $2.9 million decrease in the fair value of the 2018 contingent milestone payment, more than offset by a $3.5 million increase in the fair value of the 2020 contingent milestone payment. During the six months ended June 30, 2018, the fair value of the Royalty Pharma contingent milestone payments decreased $9.0 million. The net changes in the fair value of the contingent milestone payments were due to the fluctuation of the projected global net sales of Tysabri^®_, which were impacted by competition, namely the launch of Ocrevus^® in the U.S. and European markets.

In order for us to receive the 2020 milestone payment of $400.0 million, Royalty Pharma contingent payments for Tysabri^® sales in 2020 must exceed $351.0 million. In 2018, the Royalty Pharma contingent payments for Tysabri^® were $337.5 million, which exceeded the threshold. If Royalty Pharma contingent payments for Tysabri^® sales do not meet the prescribed threshold in 2020, we will write off the $89.1 million asset as an expense. If the prescribed threshold is exceeded, we will increase the asset to $400.0 million and recognize income of $310.9 million in Change in financial assets on the Condensed Consolidated Statements of Operations (refer to Item 1. Note 6).

Interest Expense, Net

Interest expense, net was $31.2 million and $59.8 million during the three and six months ended June 29, 2019, respectively, compared to $32.1 million and $63.5 million for the three and six months ended June 30, 2018, respectively. The $0.9 million and $3.7 million decreases for the three and six months ended June 29, 2019, respectively, were due primarily to changes in our underlying hedge exposure (refer to Item 1. Note 9).

Other (Income) Expense, Net

Other (income) expense, net was $2.3 million expense for the three months ended June 29, 2019 compared to $7.9 million expense for the three months ended June 30, 2018. The $5.6 million decrease was due primarily to the absence of a $6.3 million loss on investment securities in the prior year period (refer to Item 1. Note 7); partially offset by $1.0 million of favorable changes in revaluation of monetary assets and liabilities held in foreign currencies.

Other (income) expense, net was $5.5 million expense during the six months ended June 29, 2019 compared to $12.1 million expense for the six months ended June 30, 2018. The $6.6 million change was due primarily to the decrease of $3.7 million in losses on investment securities (refer to Item 1. Note 7) and $1.9 million of favorable changes in revaluation of monetary assets and liabilities held in foreign currencies.

46

Perrigo Company plc - Item 2

Unallocated, Interest, Other, and Taxes

Income Taxes (Consolidated)

The effective tax rates were as follows:

Three Months Ended				Six Months Ended
June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
66.6	%	34.5	%	32.5	%	29.4	%

The effective tax rate for the three months ended June 29, 2019 increased compared to the prior year period due primarily to changes in the jurisdictional mix of pre-tax book income and a $27.8 million reduction in pre-tax income due to an impairment charge related to a definite-lived intangible asset.

The effective tax rate for the six months ended June 29, 2019 increased compared to the prior year period due primarily to changes in the jurisdictional mix of pre-tax book income (refer to Item 1. Note 14 for more information on income taxes).

FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES

We finance our operations with internally generated funds, supplemented by credit arrangements with third parties and capital market financing. We routinely monitor current and expected operational requirements and financial market conditions to evaluate other available financing sources including revolving bank credit and securities offerings. In determining our future capital requirements we regularly consider, among other factors, known trends and uncertainties, such as the Notice of Assessment ("NoA") and the Notice of Proposed Adjustment ("NOPA") and other contingencies. We note that no payment of the additional amounts assessed by Irish Revenue pursuant to the NoA or proposed by the IRS in the NOPA is currently required, and no such payment is expected to be required, unless and until a final determination of the matter is reached that is adverse to us, which could take several years in either case. Based on the foregoing, management believes that our operations and borrowing resources are sufficient to provide for our short-term and long-term capital requirements, as described below. However, we continue to evaluate the impact of the above factors on liquidity and may determine that modifications to our capital structure are appropriate if market conditions deteriorate, favorable capital market opportunities become available, or any change in conditions relating to the NoA, the NOPA or other contingencies has a material impact on our capital requirements.

Cash and Cash Equivalents

* Working capital represents current assets less current liabilities, excluding cash and cash equivalents, and current indebtedness.

Cash, cash equivalents, cash flows from operations, and borrowings available under our credit facilities are expected to be sufficient to finance our liquidity and capital expenditures in both the short and long term. Although our lenders have made commitments to make funds available to us in a timely fashion under our revolving credit agreements and overdraft facilities, if economic conditions worsen or new information becomes publicly available

47

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

impacting the institutions’ credit rating or capital ratios, these lenders may be unable or unwilling to lend money pursuant to our existing credit facilities. Should our outlook on liquidity requirements change substantially from current projections, we may seek additional sources of liquidity in the future.

Cash Generated by (Used in) Operating Activities

The $96.4 million decrease in operating cash inflow was due primarily to:

• Decreased net earnings after adjustments for items such as deferred income taxes, impairment charges, restructuring charges, changes in our financial assets, share-based compensation, amortization of debt premium, and depreciation and amortization;

• Changes in accrued customer programs due primarily to pricing dynamics in our RX segment, as well as timing of rebate and chargeback payments;

• Changes in accounts payable due primarily to the timing of payments, and mix of payment terms; and

• Changes in accounts receivable due primarily to timing of shipments and receipt of payments in our CSCA and RX segments; partially offset by

• Changes in payroll and related taxes due primarily to increase in employee-related expenses;

• Changes in inventory due primarily to the build-up of inventory levels to support customer demands; and

• Changes in accrued liabilities due primarily to the change in royalty and profit sharing accruals, and changes in legal, consulting and litigation accruals, partially offset by deferred revenue associated with BCH-Belgium distribution contracts and changes in our underlying hedge exposure.

48

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

Cash Generated by (Used in) Investing Activities

The $191.2 million increase in investing cash inflow was due primarily to:

• $250.0 million increase from the receipt of the Royalty Pharma contingent milestone payment;

• $7.5 million increase due to the absence of the investment in Zibo Xinhua - Perrigo Pharmaceutical Company Limited in the prior year period (refer to Item 1. Note 7); partially offset by

• $35.0 million decrease due primarily to the acquisition of an ANDA for a generic product used to relieve pain from osteoartheritis for $15.7 million, and Budesonide Nasal Spray and Triamcinolone Nasal Spray for $14.0 million (refer to Item 1. Note 3);

• $21.4 million increase in capital spending due primarily to increased tablet and infant formula capacity and quality/regulation projects; and

• $8.6 million decrease in proceeds from royalty rights.

Cash Generated by (Used in) Financing Activities

The $540.4 million decrease in financing cash outflow was due primarily to:

• $405.7 million increase in net borrowings of revolving credit agreements and other financing;

• $298.4 million net decrease in payments on long-term debt; and

• $265.0 million decrease in share repurchases; partially offset by

• $431.0 million decrease in issuances of long-term debt.

The declaration and payment of dividends, if any, is subject to the discretion of our Board of Directors and will depend on our earnings, financial condition, availability of distributable reserves, capital and surplus requirements, and other factors our Board of Directors may consider relevant.

49

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

In October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program.

Borrowings and Capital Resources

Revolving Credit Agreements

On March 8, 2018, we terminated the revolving credit agreement entered into in December 2014 and entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2018 Revolver"). There were $325.0 million of borrowings outstanding under the 2018 Revolver as of June 29, 2019. There were no borrowings outstanding under the 2018 Revolver as of December 31, 2018.

Term Loans and Notes

We had $2.8 billion outstanding under our notes and bonds as of both June 29, 2019 and December 31, 2018. We had $323.4 million and $351.3 million outstanding under our 2018 Term Loan as of June 29, 2019 and December 31, 2018, respectively.

On December 5, 2014, Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ($614.3 million) tranche, maturing December 5, 2019. On March 8, 2018, we refinanced the €350.0 million outstanding under the term loan with the proceeds of a new €350.0 million ($431.0 million) term loan, maturing March 8, 2020 (the "2018 Term Loan"). During the six months ended June 29, 2019, we made $24.7 million in scheduled principal payments on the 2018 Term Loan.

In connection with the Omega acquisition, on March 30, 2015, we assumed a 5.000% retail bond due 2019 in the amount of €120.0 million ($130.7 million). On May 23, 2019 we repaid the bond in full.

Overdraft Facilities

We have overdraft facilities available that we use to support our cash management operations. The balance outstanding under the facilities was $73.9 million at June 29, 2019. There were no borrowings outstanding under the facilities as of December 31, 2018.

Leases

We had $154.0 million of lease liabilities and $152.5 million of lease assets as of June 29, 2019.

Accounts Receivable Factoring

The total amount factored on a non-recourse basis and excluded from accounts receivable was $12.8 million and $24.3 million at June 29, 2019 and December 31, 2018, respectively.

50

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

We are in compliance with all covenants under our debt agreements as of June 29, 2019 (refer to Item 1. Note 10 and Note 11 for more information on all of the above lease activity and debt facilities, respectively).

Credit Ratings

Our credit ratings on June 29, 2019 were Baa3 (stable) and BBB- (stable) by Moody's Investors Service and Standard and Poor's Rating Services, respectively.

Credit rating agencies review their ratings periodically and, therefore, the credit rating assigned to us by each agency may be subject to revision at any time. Accordingly, we are not able to predict whether current credit ratings will remain as disclosed above. Factors that can affect our credit ratings include changes in operating performance, the economic environment, our financial position, and changes in business strategy. If changes in our credit ratings were to occur, they could impact, among other things, future borrowing costs, access to capital markets, and vendor financing terms.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, net sales or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and collaborate on potential products still in development and enter into R&D arrangements with third parties that often require milestone payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required upon the successful achievement of an important point in the development life cycle of the product. Because of the contingent nature of these payments, they are not included in the table of contractual obligations included in our 2018 Form 10-K and referred to below.

Contractual Obligations and Commitments

There were no material changes in contractual obligations as of June 29, 2019 from those provided in our 2018 Form 10-K.

Critical Accounting Policies

The determination of certain amounts in our financial statements requires the use of estimates. These estimates are based upon our historical experiences combined with management’s understanding of current facts and circumstances. Although the estimates are considered reasonable based on the currently available information, actual results could differ from the estimates we have used. There have been no material changes to the critical accounting policies disclosed in our 2018 Form 10-K other than the hedging policies that we updated upon adoption of ASU 2017-12 (refer to Item 1. Note 9) and our leasing polices that we updated upon adoption of ASU 2016-02 (refer to Item 1. Note 10).

ITEM 3.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our quantitative or qualitative disclosures found in Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," of our 2018 Form 10-K.

ITEM 4.        CONTROLS AND PROCEDURES

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act) as of June 29, 2019. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective in ensuring that all material information relating to us and our consolidated subsidiaries required to be included in our periodic SEC filings would be made known to them by others within those entities in a timely manner and that no changes are required at this time.

51

Perrigo Company plc - Item 4

Controls and Procedures

Evaluation of the Effectiveness of Internal Control over Financial Reporting

Our management assessed the effectiveness of our internal control over financial reporting as of June 29, 2019. The framework used in carrying out our evaluation was the 2013 Internal Control - Integrated Framework published by the Committee of Sponsoring Organizations ("COSO") of the Treadway Commission. In evaluating our information technology controls, we also used components of the framework contained in the Control Objectives for Information and related Technology, which was developed by the Information Systems Audit and Control Association’s IT Governance Institute, as a complement to the COSO internal control framework. Management has concluded that our internal control over financial reporting was effective as of June 29, 2019. The results of management’s assessment have been reviewed with our Audit Committee.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended June 29, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.     OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

Refer to Part I, Item 1. Note 15 of the Notes to the Condensed Consolidated Financial Statements.

ITEM 1A.    RISK FACTORS

Our Annual Report on Form 10-K for the year ended December 31, 2018 includes a detailed discussion of our risk factors. At the time of this filing, there have been no material changes to the risk factors that were included in the Form 10-K, other than as described below.

Management transition creates uncertainties, and any difficulties we experience in managing such transitions may negatively impact our business.

Over the last several years, we have experienced a number of changes in our executive leadership. Most recently, on March 20, 2019, we announced the appointment of Raymond P. Silcock as Chief Financial Officer and principal accounting officer. Mr. Silcock’s appointment followed the resignation of Ronald L. Winowiecki, who had held those roles since his appointment in February 2017. Changes in executive management create uncertainty. Moreover, changes in our company as a result of management transition could have a disruptive impact on our ability to implement, or result in changes to, our strategy and could negatively impact our business, financial condition and results of operations.

The resolution of uncertain tax positions could be unfavorable, which could have an adverse effect on our business.

Although we believe that our tax estimates are reasonable and that our tax filings are prepared in accordance with all applicable tax laws, the final determination with respect to any tax audit or any related litigation could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results or cash flows in the periods for which that determination is made and in future periods after the determination. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties or interest assessments.

We are currently involved in several audits and adjustment-related disputes, including litigation, with the IRS. These include litigation regarding our 2009, 2010, 2011, 2012, and 2013 tax years, as well as proposed audit adjustments related to litigation costs related to Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the 2011, 2012 and 2013 tax years.

In addition, on October 31, 2018, we received an audit finding letter from Irish Revenue for the years under audit 2012-2013. The audit finding letter relates to the tax treatment of the 2013 sale of the Tysabri^® intellectual

52

Perrigo Company plc - Item 1A

Risk Factors

property and other assets related to Tysabri^® to Biogen Idec from Elan Pharma. The consideration paid by Biogen to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Irish Revenue issued a Notice of Assessment ("NoA") on November 29, 2018, which assesses an Irish corporation tax liability against Elan Pharma in the amount of €1,636.0 million, not including interest or any applicable penalties. We disagree with this assessment and believe that the NoA is without merit and incorrect as a matter of law. We filed an appeal of the NoA on December 27, 2018 and will pursue all available administrative and judicial avenues as may be necessary or appropriate. As part of this strategy to pursue all available administrative and judicial avenues, Elan Pharma was, on February 25, 2019, granted leave by the Irish High Court to seek judicial review of the issuance of the NoA. The judicial review filing is based on our belief that Elan Pharma's legitimate expectations as a taxpayer have been breached, not on the merits of the NoA itself. The High Court has scheduled a hearing in this judicial review proceeding in April 2020, and we would expect a decision in this matter in the second half of 2020. If Perrigo is ultimately successful in the judicial review proceedings, the NoA will be invalidated and Irish Revenue will not be able to re-issue the NoA. The proceedings before the Tax Appeals Commission have been stayed until a decision on the judicial review application has been made, which could take up to, or more than, a year. No payment of any amount related to this assessment is required to be made, if at all, until all applicable proceedings have been completed, which could take a number of years. However, while we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is ultimately resolved unfavorably it would have a material adverse impact on us, including on liquidity and capital resources.

On April 26, 2019, we received a revised Notice of Proposed Adjustment (“NOPA”) from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA that when Elan took over the future funding of Athena’s in-process R&D in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40.0% penalty. This amount excludes consideration of offsetting tax attributes and potentially material interest. We strongly disagree with the IRS income position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation. While we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is resolved unfavorably it could have a material adverse impact on our liquidity and capital resources.

In addition, going forward, uncertainty regarding the future outcome of tax disputes such as the NoA or NOPA may have an adverse impact on our financial condition and strategy, including our plan to separate our RX business.

At this time, we cannot predict the outcome of any audit or related litigation. Unfavorable developments in or resolutions of matters such as those discussed above could, individually or in the aggregate, have a material impact on our Condensed Consolidated Financial Statements in future periods (refer to Item 1, Note 14 for further information related to uncertain tax positions and ongoing tax audits and Item 1. Note 15 for further information related to legal proceedings).

53

Perrigo Company plc - Item 6

Exhibits

ITEM 6.    EXHIBITS

Exhibit Number	Description
3.1	Certificate of Incorporation of Perrigo Company plc (formerly known as Perrigo Company Limited) (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed on December 19, 2013).
3.2	Memorandum and Articles of Association of Perrigo Company plc, as amended and restated (incorporated by reference from Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on August 10, 2017).
10.1	Perrigo Company plc 2019 Long-Term Incentive Plan (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 30, 2019).
10.2	Waiver and Release Agreement by and between Perrigo Company plc and Ronald Winowiecki effective as of April 17, 2019 (incorporated by reference from Exhibit 10.9 to the Company’s Quarterly Report on Form 10-Q filed on May 9, 2019).
10.3	Stock Purchase Agreement and Agreement and Plan of Merger by and among Perrigo Oral Health Care Holdings, Inc., Perrigo Ireland 6 DAC, Big Mouth Merger Sub, LLC, Ranir Global Holdings, LLC, Camden Partners III SPV, L.P., RGH SELLER REP, LLC and Perrigo Company plc, effective as of May 8, 2019 (filed herewith).
10.4	Supplemental Waiver and Release Agreement by and between Perrigo Company plc and Ronald Winowiecki effective as of July 1, 2019 (filed herewith).
31.1	Rule 13a-14(a) Certification by Murray S. Kessler, Chief Executive Officer (filed herewith).
31.2	Rule 13a-14(a) Certification by Raymond P. Silcock, Chief Financial Officer (filed herewith).
32	Certification Pursuant to 18 United States Code 1350 and Rule 13a-14(b) of the Securities Exchange Act of 1934 (furnished herewith).
101. INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Date File, formatted in Inline XBRL (contained in Exhibit 101).

54

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		PERRIGO COMPANY PLC
		(Registrant)
Date:	August 8, 2019	/s/ Murray S. Kessler
		Murray S. Kessler
		Chief Executive Officer and President
		(Principal Executive Officer)
Date:	August 8, 2019	/s/ Raymond P. Silcock
		Raymond P. Silcock
		Chief Financial Officer
		(Principal Accounting and Financial Officer)

55

EX-10.3

Exhibit 10.3

EXECUTION VERSION

STOCK PURCHASE AGREEMENT
AND
AGREEMENT AND PLAN OF MERGER
BY AND AMONG
PERRIGO ORAL HEALTH CARE HOLDINGS, INC.,
PERRIGO IRELAND 6 DAC,
BIG MOUTH MERGER SUB, LLC,
RANIR GLOBAL HOLDINGS, LLC,
CAMDEN PARTNERS III SPV, L.P.
RGH SELLER REP, LLC, IN ITS CAPACITY AS THE REPRESENTATIVE
AND
PERRIGO COMPANY PLC, IN ITS CAPACITY AS THE GUARANTOR
MAY 8, 2019

ARTICLE I    THE BLOCKER PURCHASE    2

1.01    Sale of Blocker Shares    2

1.02    Consideration    2

1.03    Closing    2

ARTICLE II    THE MERGER    2

2.01    Merger    2

2.02    Effective Time; Closing    2

2.03    Effect of the Merger    2

2.04    Certificate of Formation    2

2.05    Limited Liability Company Agreement    3

2.06    Managers and Officers    3

2.07    Conversion of Company Units    3

2.08    Unitholders Payments; Letters of Transmittal    4

2.09    Required Withholding    4

ARTICLE III    CLOSING, TRANSACTION CONSIDERATION

ADJUSTMENT    6

3.01    The Closing    6

3.02    Closing Transactions    6

3.03    Estimated Closing Cash Payment Adjustment    8

3.04    Cooperation    10

3.05    Representative's Determination of the Amounts Owed to Blocker

Seller and the Designated Unitholders ARTICLE IV REPRESENTATIONS AND WARRANTIES OF US BUYER, IRISH BUYER AND MERGER SUB		11 11
4.01	Status	11
4.02	Power and Authority	11
4.03	Enforceability	11
4.04	No Violations; Consents and Approvals	11
4.05	Brokers	12
4.06	Financing	12
4.07	Investment Representation	12
4.08	Litigation	12
4.09	No Additional Representations or Warranties	12
ARTICLE V	REPRESENTATIONS AND WARRANTIES OF BLOCKER
SELLER	12
5.01	Status	12
5.02	Power and Authority	12
5.03	Enforceability	13
5.04	No Violations; Consents and Approvals	13
5.05	Capitalization; Ownership	13
5.06	Investments	13
5.07	Tax Matters	13
5.08	Holding Company	14

5.09	Litigation	15
5.10	No Brokers	15
5.11	No Additional Representations or Warranties	15
ARTICLE VI	REPRESENTATIONS AND WARRANTIES OF THE
COMPANY	15
6.01	Corporate Status	15
6.02	Power and Authority	15
6.03	Enforceability	15
6.04	Capitalization; Ownership	16
6.05	No Violation; Consents and Approvals	16

6.06	Financial Statements; No Undisclosed Liabilities	16
6.07	Absence of Certain Developments	17
6.08	Litigation	18
6.09	Environmental Matters	18
6.10	Title to Properties	18

6.11	Compliance with Laws	19
6.12	Labor and Employment Matters	20
6.13	Employee Benefit Plans	21
6.14	Tax Matters	23
6.15	Insurance	25
6.16	Licenses and Permits	25
6.17	Affiliated Transactions	25
6.18	Material Contracts	25
6.19	Intellectual Property	27
6.20	Key Customers and Suppliers	28
6.21	Regulatory Matters	29
6.22	Condition and Sufficiency of Assets	30
6.23	Inventory	31
6.24	No Brokers	31
6.25	Cyber-security and Data Privacy.	31
6.26	Accounts Receivable	32
6.27	Closing Cash Payment	32
6.28	Dissenters' Rights	32
6.29	No Additional Representations or Warranties	32
ARTICLE VII	PRE-CLOSING COVENANTS	32
7.01	Efforts	32
7.02	Regulatory Filings	33
7.03	Conduct of the Business	34
7.04	Access to Information	35
7.05	Exclusivity	36
7.06	Confidentiality Agreement	36
7.07	Notice of Certain Events	36
7.08	Intellectual Property	37
7.09	Payoff Letters	37
7.10	401(k) Plan Termination	37

ii

7.11    Section 280G Approval    37

7.12    Specified Award Agreements    38

7.13    Third Party Consents    38

7.14    Other Items    38

ARTICLE VIII    POST-CLOSING COVENANTS    38

8.01    Further Assurances    38

8.02    Director and Officer Liability and Indemnification    38

8.03    R&W Policy    39

8.04    Access to Books and Records    39

8.05    Transfer Taxes    39

8.06    Employee Matters    39

8.07    Release    40

8.08    Insurance Receivables    41

ARTICLE IX    TAX COVENANTS    41

9.01    Tax Return Filing    41

9.02    Pre-Closing Tax Matters    43

9.03    Tax Proceedings    43

9.04    Cooperation    43

9.05    No Code Section 338 or Section 336 Election    44

9.06    Straddle Period    44

9.07    Closing of Tax Period    44

9.08    Allocation of the Closing Cash Payment    45

9.09    Tax Treatment of Payments    45

9.10    Merger Tax Liability    45

ARTICLE X    CONDITIONS TO THE OBLIGATIONS OF BUYER AND

MERGER SUB    45

10.01    Accuracy of Representations and Warranties    45

10.02    Compliance with Covenants    45

10.03    No Adverse Proceeding    45

10.04    Termination of HSR Waiting Period    46

10.05    German Merger Control Clearance    46

10.06    No Material Adverse Effect    46

10.07    Dissenting Interests    46

10.08    Unitholder Consent    46

10.09    Closing Deliverables    46

ARTICLE XI    CONDITIONS TO THE OBLIGATIONS OF THE COMPANY

AND BLOCKER SELLER    46

11.01    Accuracy of Representations and Warranties    46

11.02    Compliance with Covenants    46

11.03    No Adverse Proceeding.    46

11.04    Termination of HSR Waiting Period    46

11.05    German Merger Control Clearance    47

11.06    Closing Deliverables    47

iii

ARTICLE XII    DEFINITIONS    47

12.01    Defined Terms    47

12.02    Other Definitional Provisions.    60

ARTICLE XIII    TERMINATION    61

13.01    Termination    61

13.02    Effect of Termination    62

ARTICLE XIV    GENERAL PROVISIONS    62

14.01    Survival    62

14.02    Notices    62

14.03    Entire Agreement    64

14.04    Expenses    64

14.05    Amendment; Waiver    64

14.06    Binding Effect; Assignment    64

14.07    Counterparts    64

14.08    Interpretation.    64

14.09    Schedules.    65

14.10    Governing Law; Interpretation    65

14.11    Forum Selection; Consent to Jurisdiction; Waiver of Jury Trial     65

14.12    Specific Performance    66

14.13    Arm's Length Negotiations; Drafting    66

14.14    Time    66

14.15    Made Available    66

14.16    Confidentiality; Public Announcements    66

14.17    Designation of the Representative    67

14.18    Company Representation    69

14.19    Acknowledgements    69

14.20    Guaranty    70

EXHIBITS

Exhibit A    Unitholder Consent

Exhibit B    Form of Certificate of Merger

Exhibit C    Form of Paying Agent Agreement

Exhibit D    Form of Letter of Transmittal

Exhibit E-1    Form of FIRPTA Certificate

Exhibit E-2    Form of Blocker FIRPTA Certificate

Exhibit F    Form of Company FIRPTA Certificate

Exhibit G    [Intentionally omitted]

iv

Exhibit H    Allocation Schedule

Exhibit I    Form of Escrow Agreement

Exhibit J    Working Capital

v

STOCK PURCHASE AGREEMENT AND AGREEMENT AND PLAN OF MERGER

This STOCK PURCHASE AGREEMENT AND AGREEMENT AND PLAN OF MERGER, entered into as of May 8, 2019 (this "Agreement"), is by and among Perrigo Oral Health Care Holdings, Inc., a Delaware corporation ("US Buyer"), Perrigo Ireland 6 DAC, an Irish designated activity company ("Irish Buyer" and, together with US Buyer, "Buyer"), Big Mouth Merger Sub, LLC, a Delaware limited liability company ("Merger Sub"), Ranir Global Holdings, LLC, a Delaware limited liability company (the "Company"), Camden Partners III SPV, L.P., a Delaware limited partnership ("Blocker Seller"), RGH SELLER REP, LLC, a Delaware limited liability company ("RGHSR"), solely in its capacity as the Representative (as hereinafter defined), and, solely for purposes of Section 14.20, Perrigo Company Plc (the "Guarantor"). Capitalized terms shall have the meanings ascribed to them in Section 12.01 of this Agreement. Buyer, Merger Sub, the Company, Blocker Seller and RGHSR are referred to herein collectively as the "Parties" and individually as a "Party."

RECITALS

WHEREAS, Blocker Seller is the record and beneficial owner of 100% of the issued and outstanding shares of capital stock (the "Blocker Shares") of CP Kayak Holdings, Inc., a Delaware corporation ("Blocker");

WHEREAS, Blocker is the record and beneficial owner of 27,058.82 Common Units and 1,485.32 Incentive Units (collectively, the "Blocker Company Units");

WHEREAS, Blocker Seller desires to sell to US Buyer, and US Buyer desires to purchase from Blocker Seller, 100% of the Blocker Shares, on the terms and subject to the conditions set forth in this Agreement (the "Blocker Purchase");

WHEREAS, immediately following the closing of the Blocker Purchase, Buyer, Merger Sub and the Company desire to merge Merger Sub with and into the Company, with the Company as the surviving limited liability company, on the terms and subject to the conditions set forth in this Agreement (the "Merger");

WHEREAS, the boards of manager (or the equivalent governing body) of US Buyer, Irish Buyer, Merger Sub and the Company have each approved the Merger and deemed it advisable and in the best interests of their respective equityholders and have directed that this Agreement be submitted to their respective equityholders for adoption;

WHEREAS, US Buyer and Irish Buyer, acting as the sole equityholders of Merger Sub, have approved this Agreement and the Transactions; and

WHEREAS, the Unitholders holding, in the aggregate, not less than the minimum number of votes required to approve the Merger in accordance with the Delaware Limited Liability Company Act (the "DLLCA") and the Operating Agreement have approved this Agreement and the Transactions pursuant to a written consent, a copy of which is attached hereto as Exhibit A (the "Unitholder Consent").

AGREEMENT

NOW, THEREFORE, in consideration of the mutual representations, warranties, agreements and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

ARTICLE I

THE BLOCKER PURCHASE

1.01    Sale of Blocker Shares. Subject to and upon the terms and conditions of this Agreement, immediately prior to the Effective Time, Blocker Seller shall sell to US Buyer, and US Buyer shall purchase from Blocker Seller, all right, title and interest in and to the Blocker Shares, free and clear of all Liens.

1.02 Consideration. In consideration for the Blocker Shares, US Buyer shall pay Blocker Seller (collectively, the "Blocker Purchase Price"):

(a)    an aggregate amount of cash equal to the amount set forth on the Estimated Closing Statement under the heading "Blocker Closing Payment", as determined in accordance with Section 3.03(a)(the "Blocker Closing Payment"); plus

(b)    whether paid directly or through the release of the applicable withheld amounts, an aggregate amount of cash equal to the portion (as determined by the Representative based on the Distribution Principles) of any Future Distribution Amount attributable to the Blocker Company Units.

1.03 Closing. The closing of the Blocker Purchase shall take place on the Closing Date immediately prior to the Effective Time (the "Blocker Closing"); provided that, in the event the Merger does not become effective, the Blocker Closing shall be deemed void and to not have occurred.

ARTICLE II
THE MERGER

2.01 Merger. Subject to and upon the terms and conditions of this Agreement and the DLLCA, at the Effective Time, Merger Sub shall be merged with and into the Company, whereupon the separate existence of Merger Sub shall cease and the Company shall continue as the surviving limited liability company. The Company, as the surviving limited liability company in the Merger, is hereinafter sometimes referred to as the "Surviving Company."

2.02 Effective Time; Closing. At the Closing, the Company, Buyer and Merger Sub shall cause a certificate of merger in the form of Exhibit B attached hereto (the "Certificate of Merger") to be executed, acknowledged and filed with the Secretary of State of the State of Delaware, and shall make all other filings or recordings required by the DLLCA to effectuate the Merger. The Merger shall become effective at such time as the Certificate of Merger is duly filed with the Secretary of State of the State of Delaware or at such later date as Buyer and the Company shall agree and shall specify in the Certificate of Merger in accordance with the DLLCA (the "Effective Time").

2.03 Effect of the Merger. At the Effective Time, the effect of the Merger shall be as provided in this Agreement and the applicable provisions of DLLCA. Without limiting the generality of the foregoing, from and after the Effective Time, all of the assets, property, rights, privileges, powers and franchises of the Company and Merger Sub shall vest in the Surviving Company, and all debts, Liabilities and duties of the Company and Merger Sub shall become the debts, Liabilities and duties of the Surviving Company.

2.04 Certificate of Formation. The certificate of formation of Merger Sub in effect at the Effective Time shall be the certificate of formation of the Surviving Company until amended in accordance with applicable Law.

2

2.05 Limited Liability Company Agreement. The limited liability company agreement of Merger Sub in effect at the Effective Time shall be the limited liability company agreement of the Surviving Company until amended in accordance with applicable Law; provided that such limited liability company agreement shall maintain the same economics and ownership of the Blocker Company Units owned by Blocker as was maintained by the limited liability company agreement of the Surviving Company immediately before the Effective Time.

2.06 Managers and Officers. From and after the Effective Time, until successors are duly elected or appointed in accordance with the terms of the operating agreement of the Surviving Company and applicable Law, the managers and officers of Merger Sub at the Effective Time shall be the managers and officers, as applicable, of the Surviving Company.

2.07 Conversion of Company Units. On the terms and subject to the conditions of this Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the Parties or any of the Unitholders, the following shall occur:

(a)    Common Units and Vested Incentive Units. Each Common Unit and each Vested Incentive Unit outstanding immediately prior to the Effective Time (other than Common Units and Vested Incentive Units to be canceled pursuant to Section 2.07(b), if any, and Blocker Company Units) shall be canceled and extinguished and shall be converted into the right to receive an amount in cash, without interest, equal to:

(i)    a portion of the Estimated Closing Cash Payment as set forth on the Estimated Closing Statement under the heading "Designated Unitholders Payment" as determined in accordance with Section 3.03(a), plus

(ii)    the portion (as determined by the Representative based on the Distribution Principles) of any Future Distribution Amount attributable to such Common Unit or Vested Incentive Unit.

(b)    Unvested Incentive Units. Each Incentive Unit outstanding immediately prior to the Effective Time that is not a Vested Incentive Unit shall be canceled and extinguished and no cash or other consideration shall be paid with respect thereto.

(c)    Cancellation of Treasury Units. Each Common Unit or Incentive Unit held immediately prior to the Effective Time by the Company in treasury, if any, or held by Buyer or any of its subsidiaries (excluding the Blocker Company Units) shall be canceled and no cash or other consideration shall be paid with respect thereto.

(d)    Blocker Company Units. Each Blocker Company Unit shall be converted into and exchanged for one validly issued Common Unit or one validly issued Incentive Unit, as applicable, of the Surviving Company, in each case, with the same economics as the Blocker Company Units owned by Blocker immediately prior to the Effective Time (which Common Units and Incentive Units of the Surviving Company shall, for the avoidance of doubt, continue to be held by Blocker) and there shall be no payments made to US Buyer or Blocker in respect of the Blocker Company Units pursuant to this Section 2.07.

(e)    Merger Sub Units. The limited liability company interests of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and exchanged for validly issued Common Units and Incentive Units of the Surviving Company with the same economics as the Common Units and Vested Incentive Units outstanding immediately prior to the Effective Time (other than the Blocker Company Units owned by Blocker).

3

(f)    Books and Records. All consideration paid to the Designated Unitholders in accordance with the terms of this Agreement shall be deemed to have been exchanged and paid in full satisfaction of all rights pertaining to the Common Units and Incentive Units (other than the Blocker Company Units) outstanding as of immediately prior to the Effective Time and the books of the Company shall be closed and there shall be no further registration of transfers on the transfer books of the Company with respect to the equity interests that were issued and outstanding immediately prior to the Effective Time. From and after the Effective Time, any holder of Common Units and Incentive Units (other than the Blocker Company Units) as of immediately prior to the Effective Time shall cease to have any rights as an equity holder of the Company (or, for the avoidance of doubt, the Surviving Company), except as specifically provided in this Agreement or by applicable Law.

2.08 Unitholders Payments; Letters of Transmittal.

(a)    Prior to the Closing, the Company, Irish Buyer and US Buyer shall enter into a paying agent agreement, in the form attached to this Agreement as Exhibit C, with Acquiom Financial LLC (the "Paying Agent" and such agreement, the "Paying Agent Agreement"). The Paying Agent shall act as paying agent in effecting payments to Designated Unitholders and the exchange of cash for Common Units and Incentive Units (other than the Blocker Company Units).

(b)    Within fifteen Business Days following the date of this Agreement, to the extent not delivered prior to the date of this Agreement, the Company shall, or shall instruct the Paying Agent to, deliver to each Designated Unitholder a letter of transmittal, in the form of Exhibit D attached hereto (the "Letter of Transmittal").

(c)    If a Designated Unitholder delivers its duly completed and validly executed Letter of Transmittal to the Paying Agent prior to the Closing, then at the Closing the Company shall instruct the Paying Agent to deliver to such Designated Unitholder the portion of the Estimated Closing Cash Payment payable to such Designated Unitholder pursuant to Section 2.07(a)(i). If a Designated Unitholder delivers its duly completed and validly executed Letter of Transmittal to the Paying Agent after the Closing, then promptly thereafter, the Company shall instruct the Paying Agent to deliver to such Designated Unitholder the portion of the Estimated Closing Cash Payment payable to such Designated Unitholder pursuant to Section 2.07(a)(i), and any Future Distribution Amount held by the Paying Agent that such Designated Unitholder is entitled to receive pursuant to Section 2.07(a)(ii) at that time, if any. From and after the Closing, each Common Unit and Incentive Unit (other than the Blocker Company Units and any Common Units or Incentive Units cancelled pursuant to Section 2.07(b) or Section 2.07(c)) shall represent solely the right to receive the portion of the Transaction Consideration into which the Common Units and Incentive Units shall have been converted pursuant to Section 2.07, without interest.

(d)    Any portion of the consideration paid to the Paying Agent by Irish Buyer pursuant to Section 3.02(b) that remains unclaimed by the Designated Unitholders twelve months after the Effective Time shall be returned to Irish Buyer, upon demand, and any such Designated Unitholder who has not delivered its duly completed and validly executed Letter of Transmittal to the Paying Agent on or prior to such date shall thereafter look only to Irish Buyer for payment of such consideration; provided that, notwithstanding the foregoing, Irish Buyer shall not be liable to any Designated Unitholder for any amounts paid to a public official pursuant to applicable abandoned property, escheat or similar Laws. Any amounts remaining unclaimed by the Designated Unitholders five years after the Effective Time (or if earlier, immediately prior to such time when the amounts would otherwise escheat to or become property of any Governmental Authority) shall become, to the extent permitted by applicable Law, the property of Irish Buyer free and clear of any claims or interest of any Person previously entitled thereto.

2.09 Required Withholding.

4

(a)    Each of Buyer, the Escrow Agent, the Paying Agent and the Surviving Company (and any other Person that has any withholding obligation with respect to any payment made pursuant to this Agreement or any other agreements referenced herein) shall be entitled to deduct and withhold from any consideration payable or otherwise deliverable pursuant to this Agreement or any other agreements referenced herein such amounts as may be required to be deducted or withheld therefrom under the Code, or under any provision of state, local or foreign Tax Law; provided that, except with respect to payments in the nature of compensation to be made to employees or former employees of any of the Group Companies, if Buyer, the Escrow Agent, the Paying Agent or the Surviving Company determines that an amount is required to be deducted and withheld, Buyer shall use commercially reasonable efforts to provide the payee, at least three Business Days prior to the date the applicable payment is scheduled to be made, (i) with written notice of the intent to deduct and withhold, which shall include a copy of the calculation of the amount to be deducted and withheld and (ii) a reasonable opportunity to provide forms or other evidence that would exempt such amounts from withholding (or reduce such withholding); provided, further, that such notice obligation shall not be applicable with respect to any payment to a Person who does not deliver (i) IRS Form W-9 or applicable IRS Form W-8, and (ii) (A) in the case of Blocker Seller, the certificate described in Section 3.02(e)(iii) or (B) subject to Section 2.09(b), in the case of a Person other than Blocker Seller, a statement that such Person is not a "foreign person" for purposes of Sections 1445 and 1446(f) of the Code in the form of Exhibit E-1 attached to this Agreement. To the extent such amounts are so deducted or withheld and remitted to the proper Taxing Authority, the amount of such consideration shall be treated for all purposes under this Agreement as having been paid to the Person to whom such consideration would otherwise have been paid.

(b)    The Representative, the Company and Buyer shall cooperate with each other, as and to the extent reasonably requested by any of the foregoing, in connection with the computation and verification of any amounts required to be withheld, including any "amount realized" with respect to the Transactions, and as determined under Code Section 1446(f), by causing the Company to provide to Buyer prior to the Closing Date a certification as described in Section 7.03 of IRS Notice 2018-29 or other information to determine any amount included in amounts realized pursuant to Treasury Regulation Section 1.752-1(h)).

(c)    Notwithstanding any other provision of this Agreement, each Designated Unitholder shall, in such Person's applicable Letter of Transmittal, if the Reimbursement Conditions are satisfied, agree to pay to Buyer the excess of: (A)(x) the amount of any withholding taxes required to be withheld by the Company with respect to such Designated Unitholder under Section 1446(a) of the Code with respect to the portion of the U.S. federal income tax period of the Company that begins before the Closing Date (excluding, in each case, any interest and penalties with respect to such matters and any amount that is actually withheld from such Designated Unitholder's pro rata portion of the Estimated Closing Cash Payment or any Future Distribution Amount), but only to the extent that such amount actually paid by the Company constitutes an advance payment of, or an offset to, a Tax liability imposed on such Designated Unitholder; or (y) the amount of any U.S. state non-resident withholding taxes required to be paid by the Company with respect to such Designated Unitholder as a result of a Pass-Through Income Tax Return prepared pursuant to and in accordance with the procedures of Section 9.01 or the resolution of the applicable PT-Tax Proceeding pursuant to and in accordance with the procedures set forth in Section 9.03(excluding, in each case, any penalties and interest with respect to such matter and any amount that is actually withheld from such Designated Unitholder's pro rata portion of the Estimated Closing Cash Payment or any Future Distribution Amount), but only to the extent that such amount actually paid by the Company constitutes an advance payment of, or an offset to, a Tax liability imposed on such Designated Unitholder; over, in the case of both clause (A)(x) and clause (A)(y), (B) the amount of any proceeds or other third-party recovery (including pursuant to the R&W Policy) to which Buyer or any of its Affiliates (including the Company and its Subsidiaries) are entitled with respect to any such Taxes. The Letter of Transmittal shall also provide that if Buyer or any of its Affiliates (including the Company and its Subsidiaries) receives a refund of any amount for which Buyer has received a payment from a Designated Unitholder, Buyer shall promptly remit such refund to the Designated Unitholder.

5

ARTICLE III

CLOSING, TRANSACTION CONSIDERATION ADJUSTMENT

3.01    The Closing. The closing of the Transactions (the "Closing") shall take place at the offices

of Kirkland & Ellis LLP located at 300 North LaSalle, Chicago IL 60654 (a) at 9:00 a.m. prevailing Eastern Time on the later of (i) June 10, 2019 and (ii) the second Business Day following satisfaction or waiver of all of the closing conditions set forth in ARTICLE X and ARTICLE XI hereof (other than those conditions which by their nature are to be satisfied at the Closing, but subject to the satisfaction or, if permissible, waiver of such conditions at the Closing), or (b) on such other date and at such other time as are mutually agreed in writing by Buyer and the Company. The date on which the Closing actually occurs is referred to herein as the "Closing Date."

3.02    Closing Transactions. At the Closing:

(a)    the Company, Buyer and Merger Sub shall cause the Certificate of Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware;

(b)    Buyer (or the applicable Buyer as designated below) shall deliver:

(i)    US Buyer shall deliver to Blocker Seller, the Blocker Closing Payment;

(ii)    to the Paying Agent, the Estimated Closing Cash Payment, less the Blocker Closing Payment;

(iii)    to the Escrow Agent, the Adjustment Escrow Amount, to be held for the purpose of funding any payments required pursuant to Section 3.03(b)(v), and to be administered under the terms of the Escrow Agreement; and

(iv)    to the Representative:

(A)    the Representative Holdback, pursuant to Section 14.17(c);

(B)    a certificate, dated as of the Closing Date and signed by an officer of Buyer, stating that the conditions specified in Sections 11.01 and 11.02 with

respect to Buyer and Merger Sub have been satisfied; and

(C)    the Escrow Agreement, duly executed by Irish Buyer, US Buyer and the Escrow Agent;

(c)    Buyer shall pay, on behalf of the Group Companies, the outstanding balance of any Funded Debt listed on the Estimated Closing Statement, pursuant to payoff letters, which payoff letters shall be in form and substance reasonably satisfactory to Buyer, from the holders of all such Funded Debt (the "Payoff Letters");

(d)    Buyer shall pay, on behalf of the Group Companies and Blocker, all Transaction Expenses, in each case, in the amounts and to the Persons identified on the Estimated Closing Statement;

(e)    Blocker Seller shall deliver to US Buyer:

6

(i)    the certificates representing the Blocker Shares, together with a duly

executed stock power;

(ii)    a certificate, dated as of the Closing Date and signed by an officer of Blocker Seller, stating that the conditions specified in Sections 10.01 and 10.02 with respect to Blocker and Blocker Seller have been satisfied;

(iii)    a certificate from Blocker Seller stating that such entity is not a "foreign person" in the form of Exhibit E-2 attached hereto and an IRS Form W-9;

(iv)    a copy of Blocker's Certificate of Incorporation, certified by the Secretary of State of the State of Delaware, and a certificate of good standing of Blocker from the Secretary of State of the State of Delaware dated within five days of the Closing Date;

(v)    a certificate, dated as of the Closing Date and signed by an officer of Blocker certifying that attached thereto are true and complete copies of (A) all resolutions or written consents duly adopted by Blocker's directors and stockholders authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents, and the consummation of the Transactions, and (B) Blocker's by-laws; and

(vi)    written resignations, effective as of the Effective Time, for each director and officer of Blocker;

(f)    the Company shall deliver to Buyer:

(i)    a certificate, dated as of the Closing Date and signed by an officer of the Company, stating that the conditions specified in Sections 10.01, 10.02 and 10.06 with respect to the Company have been satisfied;

(ii)    a certificate from the Company in accordance with Treasury Regulation Section 1.1445-11T(b) in the form of Exhibit F attached hereto;

(iii)    written resignations, effective as of the Effective Time, for each manager and officer of the Group Companies;

(iv)    a certificate, dated as of the Closing Date and signed by an officer of the Company certifying that attached thereto are true and complete copies of (A) all resolutions or written consents duly adopted by the Company's respective managers and Unitholders authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents, and the consummation of the Transactions, and (B) the Company's operating agreement, including copies of all amendments thereto;

(v)    a copy of the Company's Certificate of Formation, certified by the Secretary of State of the State of Delaware and a certificate of good standing of the Company from the Secretary of State of the State of Delaware dated within five days of the Closing Date;

(vi)    the Payoff Letters, duly executed by the applicable lenders;

(vii) invoices issued by each intended beneficiary of the Transaction Expenses described in clause (i) of the definition of "Transaction Expenses" that set forth (A) the outstanding balance

7

of such Transaction Expense as of the Closing Date, and (B) the wire transfer instructions for the payment of such Transaction Expenses to such Person;

(viii) the Paying Agent Agreement, duly executed by the Company and the

Paying Agent; and

(ix)    evidence that the Contracts set forth on Schedule 3.02(f)(ix) have been terminated as of no later than the Closing; and

(g)    the Representative shall deliver to Buyer the Escrow Agreement, duly executed by the Representative and the Escrow Agent.

3.03 Estimated Closing Cash Payment Adjustment.

(a)    Estimated Closing Cash Payment.

(i)    Not less than three Business Days prior to the Closing Date, the Representative shall deliver to Buyer a statement (the "Estimated Closing Statement") that sets forth (including, in each case, reasonable supporting documentation and detail as to how each was determined) (A) the Company's good faith estimate of the Cash Amount, the outstanding amount of all Funded Debt as of the Adjustment Time, the Transaction Expenses, the Tax Liability Amount, the Blocker Tax Liability Amount, the Working Capital (and the Working Capital Surplus or Working Capital Deficit, if any, implied thereby), (B) the Closing Cash Payment resulting therefrom (the "Estimated Closing Cash Payment"), (C) the Representative's determination, based on the Distribution Principles, of the portion of the Estimated Closing Cash Payment payable to Blocker Seller and (D) the Representative's determination, based on the Distribution Principles, of the portion of the Estimated Closing Cash Payment payable to each Designated Unitholder.

(ii)    Notwithstanding any other provision of this Agreement, Buyer and its representatives may make inquiries of or provide comments to the Company regarding questions or comments concerning, or disagreements with, the Estimated Closing Statement or arising in the course of Buyer's review thereof. If Buyer shall object to any of the information set forth on the Estimated Closing Statement, then Buyer and the Company shall negotiate in good faith concerning Buyer's proposed adjustments to the Estimated Closing Statement, if any, but in the absence of an agreement between Buyer and the Company with respect to such proposed adjustments, the Estimated Closing Statement as prepared by the Company shall control. In no event shall the Closing be delayed as a result of this Section 3.03(a)(ii).

(b)    Final Calculations.

(i)    Within ninety days after the Closing Date, Buyer shall prepare and deliver to the Representative a statement that sets forth (including, in each case, reasonable supporting documentation and detail as to how each was determined) (A) the Cash Amount, the outstanding amount of all Funded Debt as of the Adjustment Time, the Transaction Expenses, the Tax Liability Amount, the Blocker Tax Liability Amount and the Working Capital (and the Working Capital Surplus or Working Capital Deficit, if any, implied thereby) and (B) the Closing Cash Payment resulting therefrom (the "Closing Statement"). If the Representative has any objections to the Closing Statement, the Representative shall deliver to Buyer a written statement (an "Objection Statement") setting forth its objections (the "Objection Disputes") to the Closing Statement, which Objection Statement shall set forth in reasonable detail each such disagreement and the amount thereof. Any amount(s) set forth on the Closing Statement not included in a timely delivered Objection Statement as the subject of an Objection Dispute shall be treated as final, binding and non-appealable by the Parties. If an Objection Statement is not delivered to

8

Buyer within 45 days after receipt of the Closing Statement by the Representative, then the Closing Statement as originally received by the Representative shall be the final Closing Statement, and accordingly, final, binding and non-appealable by the Parties. If an Objection Statement is timely delivered, then Buyer and the Representative shall negotiate in good faith to resolve any Objection Disputes. If such negotiations result in a written resolution executed by Buyer and the Representative as to any Objection Dispute, such written resolution shall be final, binding and non-appealable by the Parties.

(ii)    If Buyer and the Representative cannot reach a final resolution on all of the Objection Disputes within 30 days after the delivery of the Objection Statement, the Representative and Buyer shall submit each unresolved Objection Dispute to KPMG US LLP (the "Firm") to resolve such Objection Disputes. If KPMG US LLP refuses or is otherwise unable to act as the Firm, then Buyer and the Representative shall cooperate in good faith to appoint a nationally recognized independent accounting or valuation firm mutually agreeable to Buyer and the Representative, in which event "Firm" shall mean such firm. The Firm shall be requested to render a written determination of the unresolved Objection Disputes (acting as an expert and not as an arbitrator) within forty-five days following its retention, which determination must be in writing and must set forth, in reasonable detail, the basis therefor and must be based solely on (A) the definitions and other applicable provisions of this Agreement, (B) a single written presentation (which presentation shall be limited to the unresolved Objection Disputes) submitted by each of Buyer and the Representative to the Firm within fifteen days after its retention (which the Firm shall forward to the other Party) and (C) one written response submitted by each of Buyer and the Representative to the Firm within fifteen days after receipt of each presentation (which the Firm shall forward to the other Party) and not on independent review. Buyer and the Representative will instruct the Firm not to assign a value to any item in dispute greater than the greatest value for such item assigned by Buyer, on the one hand, or the Representative, on the other hand, or less than the smallest value for such item assigned by Buyer, on the one hand, or the Representative, on the other hand. The Firm's determination of such Objection Disputes shall be final and binding upon the Parties and not subject to review by a court or other tribunal. The terms of appointment and engagement of the Firm shall be as reasonably agreed upon between Buyer and the Representative, and any associated engagement fees shall initially be allocated 50% to Buyer and 50% to the Representative; provided that such fees, costs and expenses of the Firm will ultimately be allocated between Buyer, on the one hand, and the Representative, on the other hand, in the same proportion that the aggregate amount of the disputed items so submitted to the Firm that is unsuccessfully disputed by such Party (as finally determined by the Firm) bears to the total amount of disputed items submitted. For example, if the Representative submits an adjustment of $1,000 for a specific item in the Objection Statement, and if Buyer contests only $500 of the amount claimed by the Representative, and if the Firm ultimately resolves the dispute by awarding the Representative $300 of the $500 contested, then the fees, costs and expenses of the Firm will be allocated 60% (i.e., 300/500) to Buyer and 40% (i.e., 200/500) to the Representative. Except as provided in this Section 3.03(b)(ii), all other costs and expenses incurred by the Parties in connection with resolving any dispute hereunder before the Firm shall be borne by the Party incurring such costs and expense. The process set forth in this Section 3.03(b) shall be the exclusive remedy of the Parties for any disputes related to items required to be reflected on the Closing Statement or included in the calculation of Working Capital, the Cash Amount, the Tax Liability Amount, the Blocker Tax Liability Amount, the outstanding amount of all Funded Debt as of the Adjustment Time or the Transaction Expenses.

(iii)    The Closing Statement (as adjusted by the agreement of the Representative and Buyer and/or the determination of the Firm, as applicable) shall be deemed the final Closing Statement for the purposes of this Section 3.03(b) and, accordingly, shall be final, binding and non-appealable by the Parties.

(iv)    If the Closing Cash Payment based on the final Closing Statement as finally determined pursuant to this Section 3.03(b) is greater than the Estimated Closing Cash Payment, (x)

9

Buyer shall promptly (but in any event within five Business Days after the final Closing Statement is determined pursuant to this Section 3.03(b)) pay (A) to Blocker Seller, an amount equal to the applicable portion (as determined by the Representative based on the Distribution Principles) of such difference allocable to Blocker Seller (the "Blocker Adjustment Payment") and (B) to the Paying Agent, (I) the amount of such difference, less (II) the Blocker Adjustment Payment (which amount the Company shall instruct the Paying Agent to distribute to the Designated Unitholders based upon each such Designated Unitholder's applicable portion thereof (as determined by the Representative based on the Distribution Principles), except as otherwise determined by the Representative in accordance with Section 14.17), in each case, by wire transfer of immediately available funds to the account designated by Blocker Seller or the Paying Agent, as applicable, and (y) Buyer and the Representative shall promptly (but in any event within five Business Days after the final Closing Statement is finally determined pursuant to this Section 3.03(b))deliver to the Escrow Agent a joint written instruction instructing the Escrow Agent to release the Adjustment Escrow Fund (A) to Blocker Seller, in an amount equal to the applicable portion (as determined by the Representative based on the Distribution Principles) of the Adjustment Escrow Fund allocable to Blocker Seller and (B) to the Paying Agent, the remaining portion of the Adjustment Escrow Fund (which amount the Company shall instruct the Paying Agent to distribute to the Designated Unitholders based upon each such Designated Unitholder's applicable portion (as determined by the Representative based on the Distribution Principles) thereof, except as otherwise determined by the Representative in accordance with Section 14.17), in each case, by wire transfer of immediately available funds to such accounts designated by Blocker Seller or the Representative, as applicable.

(v)    If the Closing Cash Payment based on the final Closing Statement

determined pursuant to this Section 3.03(b) is less than the Estimated Closing Cash Payment, Buyer and the Representative shall promptly (but in any event within five Business Days after the final Closing Statement is finally determined pursuant to this Section 3.03(b)) deliver to the Escrow Agent a joint written instruction instructing the Escrow Agent to release the Adjustment Escrow Fund (x) to Buyer, in an amount equal to the lesser of (A) the amount by which the Estimated Closing Cash Payment is greater than the Closing Cash Payment based on the final Closing Statement determined pursuant to this Section 3.03(b)(the "Seller Purchase Price Adjustment Payment"), and (B) the Adjustment Escrow Fund, (y) to Blocker Seller, in an amount equal to the applicable portion (as determined by the Representative based on the Distribution Principles) of the remaining Adjustment Escrow Fund (if any, after payment pursuant to clause (x)), and (z) to the Paying Agent, the remaining portion of the Adjustment Escrow Fund (if any, after payment pursuant to clauses (x) and (y)) (which amount the Company shall instruct the Paying Agent to distribute to the Designated Unitholders based upon each such Designated Unitholder's applicable portion (as determined by the Representative based on the Distribution Principles) thereof, except as otherwise determined by the Representative in accordance with Section 14.17), in each case, by wire transfer of immediately available funds to such accounts designated by Buyer, Blocker Seller or the Representative, as applicable. If the Seller Purchase Price Adjustment Payment exceeds the Adjustment Escrow Fund, the Representative shall promptly inform the Blocker Seller and the Designated Unitholders of such excess, including the Blocker Seller's and each Designated Unitholder's respective payment obligation. Notwithstanding anything contained in this Agreement, Blocker Seller and the Designated Unitholders, severally and not jointly in accordance with their respective Unitholder Percentage, shall promptly (but in any event within ten Business Days after the final Closing Statement is finally determined pursuant to this Section 3.03(b)) pay Buyer the amount by which the Seller Purchase Price Adjustment Payment exceeds the Adjustment Escrow Fund.

3.04 Cooperation. During the period of time from and after the Representative's receipt of the Closing Statement through the determination of the final Closing Statement in accordance with Section 3.03(b), Buyer shall, and shall cause Blocker, the Surviving Company, its Subsidiaries and their respective officers, employees, consultants, accountants and agents to (a) reasonably cooperate with the Representative and its accountants and other representatives in connection with their review of the Closing

10

Statement (including by providing the Representative with reasonable access during business hours and under reasonable circumstances to the employees of the Surviving Company and its Subsidiaries who are knowledgeable about the information contained in, and the preparation of, the Closing Statement) and (b) provide reasonable access during business hours and under reasonable circumstances to any books, records and other information reasonably requested by the Representative and its accountants or other representatives, in each case, to the extent relevant to the Representative's review of the Closing Statement and determination of the Closing Cash Payment or any component thereof.

3.05 Representative's Determination of the Amounts Owed to Blocker Seller and the Designated Unitholders. Notwithstanding any other provision of this Agreement, the Parties agree that Buyer, Merger Sub and the Surviving Company shall be entitled to rely solely on the Representative's determination of the portion of the Closing Cash Payment or any Future Distribution Amount payable to Blocker Seller and each Designated Unitholder. Buyer, Merger Sub and the Surviving Company shall not be responsible for any such determinations.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF US BUYER, IRISH BUYER AND MERGER SUB

US Buyer, Irish Buyer and Merger Sub jointly and severally represent and warrant to the Company and Blocker Seller as follows, as of the date of this Agreement and as of the Closing:

4.01 Status. US Buyer is a corporation, duly organized, validly existing and in good standing

under the Laws of the State of Delaware. Irish Buyer is an Irish designated activity company, duly organized, validly existing and in good standing under the Laws of the Republic of Ireland. Merger Sub is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Delaware.

4.02 Power and Authority. Each of US Buyer, Irish Buyer and Merger Sub has all requisite power and authority to execute and deliver this Agreement and the other Transaction Documents to which it is a party, to perform its obligations pursuant to this Agreement and the other Transaction Documents to which it is a party and to consummate the Transactions. All acts or proceedings required to be taken by US Buyer, Irish Buyer or Merger Sub applicable to authorize the execution and delivery of this Agreement and the other Transaction Documents to which it is a party and the performance of US Buyer's, Irish Buyer's and Merger Sub's obligations pursuant to this Agreement and the other Transaction Documents to which it is a party have been properly taken.

4.03 Enforceability. This Agreement and the other Transaction Documents have been or will be duly authorized, executed and delivered by each of US Buyer, Irish Buyer and Merger Sub, as applicable, and assuming the due and valid authorization, execution and delivery of this Agreement and the other Transaction Documents by the other Parties and the other Transaction Documents to which they are a party, this Agreement and the other Transaction Documents constitute or will constitute the legal, valid and binding obligation of each of US Buyer, Irish Buyer and Merger Sub, as applicable, enforceable against each in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting or relating to creditors' rights generally and general equitable principles (the "Bankruptcy and Equity Exceptions").

4.04 No Violations; Consents and Approvals. The execution, delivery and performance of this Agreement and the other Transaction Documents by US Buyer, Irish Buyer and Merger Sub, and the consummation of the Transactions will not (i) violate any provision of the organizational documents of any of US Buyer, Irish Buyer or Merger Sub, (ii) violate any material Law applicable to, binding upon or enforceable against any of US Buyer, Irish Buyer or Merger Sub, (iii) result in any material breach of, or

11

constitute a material default (or an event which would, with the passage of time or the giving of notice or both, constitute a material default) under, or give rise to a right of payment under or the right to terminate any Contract to which any of US Buyer, Irish Buyer or Merger Sub is a party or bound, (iv) result in the creation or imposition of any Lien upon any of the material property or material assets of any of US Buyer, Irish Buyer or Merger Sub or (v) except as set forth on Schedule 4.04, require the consent or approval of any Governmental Authority or any other Person, other than (A) the filing of a certificate of merger with respect to the Merger with the Secretary of State of the State of Delaware and appropriate documents with the relevant authorities of other states in which the Company is qualified to do business and (B) compliance with any applicable requirements of the Hart-Scott-Rodino Act and the German Anti-Trust Law.

4.05 Brokers. Except for the fee payable to Centerview Partners LLC, none of US Buyer, Irish Buyer or Merger Sub has incurred any obligation for any finder's or broker's or agent's fees or commissions or similar compensation in connection with the Transactions for which Blocker Seller or any Unitholder may be liable.

4.06 Financing. At the time the Closing is required to occur pursuant to Section 3.01, each of US Buyer and Irish Buyer will have immediately available funds sufficient to consummate its respective portion of the Transactions, including the payment of the Transaction Consideration and all fees and expenses payable by US Buyer, Irish Buyer or Merger Sub in connection with the Transactions. Neither of US Buyer's or Irish Buyer's obligation to consummate the Transactions is subject to any condition or contingency with respect to any financing or funding by any third party.

4.07 Investment Representation. US Buyer is acquiring Blocker and US Buyer and the Irish Buyer are acquiring the Company for its own account with the present intention of holding the securities of Blocker and the Company, as applicable, for investment purposes and not with a view to or for sale in connection with any public distribution of such securities in violation of any federal or state securities Laws. Each of US Buyer, Irish Buyer and Merger Sub is an "accredited investor" as defined in Regulation D promulgated by the Securities and Exchange Commission under the Securities Act.

4.08 Litigation. There are no Proceedings pending or, to Buyer's knowledge, expressly threatened against US Buyer, Irish Buyer or Merger Sub, at law or in equity, before or by any Governmental Authority that would reasonably be expected to affect the legality, validity or enforceability of this Agreement or the consummation of the Transactions.

4.09 No Additional Representations or Warranties. Except for the representations and warranties contained in this ARTICLE IV, none of US Buyer, Irish Buyer or Merger Sub or any other Person on behalf of US Buyer, Irish Buyer or Merger Sub, makes any other express or implied representation or warranty with respect to any of US Buyer, Irish Buyer or Merger Sub.

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF BLOCKER SELLER

Blocker Seller hereby represents and warrants to Buyer and Merger Sub as follows, as of the date of this Agreement and as of the Closing:

5.01 Status. Blocker is a corporation, duly organized, validly existing and in good standing

under the Laws of the State of Delaware. Blocker Seller is a limited partnership duly organized, validly existing and in good standing under the Laws of the State of Delaware.

5.02 Power and Authority. Blocker Seller has all requisite power and authority to execute and deliver this Agreement and the other Transaction Documents to which it is a party, to perform its obligations

12

pursuant to this Agreement and the other Transaction Documents and to consummate the Transactions. All acts or proceedings required to be taken by Blocker Seller applicable to authorize the execution and delivery of this Agreement and the other Transaction Documents to which it is a party and the performance of Blocker Seller's obligations pursuant to this Agreement and the other Transaction Documents have been properly taken.

5.03 Enforceability. This Agreement and the other Transaction Documents have been or will be duly authorized, executed and delivered by Blocker Seller and, assuming the due and valid authorization, execution and delivery of this Agreement and the other Transaction Documents by the other parties to the this Agreement and the other Transaction Documents to which they are a party, this Agreement and the other Transaction Documents constitute or will constitute the legal, valid and binding obligation of Blocker Seller, enforceable against Blocker Seller in accordance with its terms, except as the same may be limited by the Bankruptcy and Equity Exceptions.

5.04 No Violations; Consents and Approvals. The execution, delivery and performance of this Agreement and the other Transaction Documents by Blocker Seller, and the consummation of the Transactions will not (i) violate any provision of the organizational documents of either Blocker Seller or Blocker, (ii) violate any material Law applicable to, binding upon or enforceable against either Blocker Seller or Blocker, (iii) result in any material breach of, or constitute a material default (or an event which would, with the passage of time or the giving of notice or both, constitute a material default) under, or give rise to a right of payment under or the right to terminate any Contract to which either Blocker Seller or Blocker is a party or bound, (iv) result in the creation or imposition of any Lien upon the Blocker Shares or any of the material property or material assets of Blocker or (v) require the consent or approval of any Governmental Authority or any other Person, other than compliance with any applicable requirements of the Hart-Scott-Rodino Act and the German Anti-Trust Law.

5.05 Capitalization; Ownership. All Blocker Shares are held of record and beneficially by Blocker Seller and are free and clear of all Liens. Blocker Seller has good and valid title to the Blocker Shares. The Blocker Shares constitute 100% of the total issued and outstanding ownership interests of Blocker. The Blocker Shares are duly authorized, validly issued, fully-paid and non-assessable. The Blocker Shares were issued in compliance with applicable Laws. The Blocker Shares were not issued in violation of the organizational documents of Blocker or any other agreement, arrangement or commitment to which Blocker Seller or Blocker is a party and are not subject to or in violation of any preemptive or similar rights of any Person. There are no outstanding rights, options, warrants, convertible securities, subscription rights, conversion rights, exchange rights or other arrangements, commitments or agreements that require Blocker to issue or sell any of its equity interests (or securities convertible into or exchangeable for its equity interests). Other than the organizational documents of Blocker, there are no voting trusts, proxies or other agreements or understandings in effect with respect to the voting or transfer of any of the Blocker Shares. Upon consummation of the Transactions, Buyer shall own all of the Blocker Shares, free and clear of all Liens.

5.06 Investments. Blocker owns no equity interests in any Person, other than the Blocker Company Units.

5.07 Tax Matters.

(a)    Blocker has filed all material Tax Returns that are required to be filed by it (taking into account any extensions of time to file that have been duly perfected). All material Taxes of Blocker that are due and payable (whether or not shown or required to be shown as owing by Blocker) have been fully and timely paid, and all such Tax Returns are true and correct in all material respects.

13

(b)    All material Taxes that Blocker is obligated to withhold and pay over from amounts owing to any employee, creditor or third party have been properly withheld and fully paid over to the extent due and payable, and Blocker has complied in all material respects with all applicable requirements with respect to all Forms W-2 and 1099 required with respect thereto, and such forms have been properly completed and timely filed.

(c)    Blocker is not a party to, and is not otherwise bound to, any Tax allocation, Tax sharing, Tax indemnity, Tax reimbursement agreement or arrangement (other than (i) any customary agreements with customers, vendors, lenders, lessors or the like entered into in the Ordinary Course and not primarily related to Taxes and (ii) any agreements with respect to property Taxes payable with respect to properties leased). Blocker has no Liability for Taxes of any other Person (x) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local or foreign Law) or (y) as a transferee or successor, by contract or otherwise.

(d)    Blocker has not been the subject of any audit or other examination of Taxes by the Taxing Authorities of any Governmental Authority with respect to any open Tax years and, to Blocker Seller's knowledge, no such audit or other examination is contemplated or pending. Blocker has not received in writing from any Governmental Authority with respect to Taxes (including jurisdictions where Blocker has not filed Tax Returns) any (i) notice indicating an intent to open an audit or other review, (ii) request for information related to Tax matters, or (iii) notice of deficiency or proposed adjustment for any amount of Tax proposed, asserted, or assessed by any Taxing Authority against Blocker, in each case, which remains outstanding or unresolved.

(e)    Blocker has not waived in writing any statute of limitations in respect of Taxes payable by it, which waiver is currently in effect.

(f)    There are no Liens for Taxes (other than Permitted Liens) upon any of the assets of Blocker.

(g)    Subject to a successful 280G Approval, Blocker is not party to any agreement that would require any of the Group Companies to make any payment in connection with the Closing that would constitute an "excess parachute payment" for purposes of Sections 280G and 4999 of the Code.

(h)    Blocker will not be required to include any item of income in, or exclude an item of deduction from, taxable income for any taxable period (or portion thereof) beginning after the Closing Date as a result of any Tax Accrual Amounts.

(i)    Blocker is not subject to Tax in any jurisdiction other than its place of incorporation or formation by virtue of having a permanent establishment (within the meaning of an applicable Tax treaty) or other fixed place of business in such jurisdiction.

(j)    Blocker has not distributed stock of another Person, and has not had its stock distributed by another Person, within the last two years, in a transaction that was governed by Section 355 or Section 361 of the Code.

5.08 Holding Company. Except as set forth on Schedule 5.08, Blocker has no operations or assets, and does not engage in, and has never engaged in, any business activities, other than (i) its ownership of the Blocker Company Units, (ii) activities in connection with this Agreement and the Transactions and (iii) engaging in transactions related to its capital stock (including the issuance of the Blocker Shares to Blocker Seller), in each case, including any activities related or incidental thereto. Blocker (i) has no, and has never had any, employees and (ii) does not own or lease, and has never owned or leased, any real

14

property or personal property. Blocker does not have any Liabilities other than in connection with the ownership, directly or indirectly, of the Group Companies.

5.09 Litigation. There are no Proceedings pending or, to Blocker Seller's knowledge, threatened against Blocker Seller or Blocker, at law or in equity, before or by any Governmental Authority which would reasonably be expected to affect the legality, validity or enforceability of this Agreement or the consummation of the Transactions.

5.10 No Brokers. Blocker Seller has not incurred any obligation for any finder's or broker's or agent's fees or commissions or similar compensation in connection with the Transactions.

5.11 No Additional Representations or Warranties. Except for the representations and warranties contained in this ARTICLE V, neither Blocker, nor Blocker Seller nor any other Person on behalf of Blocker or Blocker Seller makes any other express or implied representation or warranty with respect to Blocker and Blocker Seller or with respect to any other information provided to Buyer or its Affiliates.

ARTICLE VI

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company hereby represents and warrants to Buyer and Merger Sub as follows, as of the date of this Agreement and as of the Closing:

6.01 Corporate Status. The Company is a limited liability company duly organized, validly

existing and in good standing under the Laws of the State of Delaware. Each of the Subsidiaries of the Company as set forth on Schedule 6.01 is duly organized, validly existing and in good standing (or its local equivalent) under the Laws of the jurisdiction of its formation. Each of the Group Companies has all requisite power and authority to own or lease its properties and assets (including, as applicable, Company Intellectual Property) and to carry on its business as is now being conducted. Schedule 6.01 sets forth each jurisdiction in which each Group Company (a) was formed or incorporated and (b) is licensed or qualified to do business. Each Group Company is legally qualified to transact business as a foreign company in all jurisdictions where the nature of its properties and the conduct of its business as now conducted require such qualification, except where the failure to be so qualified would not have a Material Adverse Effect.

6.02 Power and Authority. The Company has all requisite power and authority to execute and deliver this Agreement and the other Transaction Documents to which it is a party, to perform its obligations pursuant to this Agreement and the other Transaction Documents and to consummate the Transactions. All acts or proceedings required to be taken by the Company to authorize the execution and delivery of this Agreement and the other Transaction Documents to which it is a party and the performance of the Company's obligations pursuant to this Agreement and the other Transaction Documents have been properly taken.

6.03 Enforceability. This Agreement and the other Transaction Documents have been or will be duly authorized, executed and delivered by the Company and, assuming the due and valid authorization, execution and delivery of this Agreement and the other Transaction Documents by the other Parties and the other Transaction Documents to which they are a party, this Agreement and the other Transaction Documents constitute or will constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as the same may be limited by the Bankruptcy and Equity Exceptions.

15

6.04 Capitalization; Ownership. Schedule 6.04(a) sets forth, for each Group Company, the number of issued and outstanding equity securities of such Group Company and the holders of record of the outstanding equity securities of such Group Company as of the close of business on the date of this Agreement, all of which are owned by such Persons free and clear of all Liens (other than Liens that will be removed at, or prior to, Closing). All of the issued and outstanding equity securities of each Group Company are duly authorized, validly issued, fully paid and non-assessable, and were issued in compliance with all applicable Laws. Except as set forth on Schedule 6.04(b), there are no outstanding options, warrants, convertible securities, subscription rights, conversion rights, exchange rights or other arrangements, commitments or agreements that require any Group Company to issue or sell any of its equity securities (or securities convertible into or exchangeable for shares of its equity securities). Except as set forth on Schedule 6.04(c), none of the Group Companies owns, holds or has the right to acquire any stock, partnership interest, joint venture interest or other equity securities in any other Person (other than another Group Company), and there are no voting trusts, proxies or other agreements or understandings in effect with respect to the voting or transfer of any of the equity securities of any of the Group Companies.

6.05 No Violation; Consents and Approvals. Except as set forth on Schedule 6.05, the execution, delivery and performance of this Agreement and the other Transaction Documents by the Company, and the consummation of the Transactions will not (i) violate any provision of the organizational documents of any Group Company, (ii) violate any material Law applicable to, binding upon or enforceable against any of the Group Companies, (iii) result in any material breach of, or constitute a material default (or an event which would, with the passage of time or the giving of notice or both, constitute a material default) under, or give rise to a right of payment under or the right to terminate any Material Contract, (iv) result in the creation or imposition of any Lien upon any of the material property or material assets of any Group Company or (v) require the consent or approval of any Governmental Authority or any other Person, other than compliance with any applicable requirements of the Hart-Scott-Rodino Act and the German Anti-Trust Law.

6.06    Financial Statements; No Undisclosed Liabilities.

(a)    Attached to Schedule 6.06(a) are complete copies of (i) the audited consolidated balance sheet of the Group Companies as of December 31, 2017 and the related audited consolidated statements of income and cash flows for the fiscal year ended December 31, 2017, (ii) the audited consolidated balance sheet of the Group Companies as of December 31, 2018 (the "Latest Balance Sheet")and the related audited statements of income and cash flows for the fiscal year ended December 31, 2018 (the "Year-End Financial Statements") and (iii) the unaudited consolidated balance sheet of the Group Companies as of March 31, 2019 ( the "Interim Financial Statements" and collectively with the Year-End Financial Statements, the "Financial Statements"). Except as set forth on Schedule 6.06(a), the Financial Statements are based on the books and records of the Group Companies and fairly present, in all material respects, the financial position and results of operations of the Group Companies, as of the dates and for the periods referred to therein and have been prepared in accordance with GAAP applied on a consistent basis throughout the period involved (subject, in the case of the Interim Financial Statements, to audit adjustments to non-cash items at year-end, which adjustments include goodwill and deferred Taxes, and the lack of footnote disclosures and other presentation items, none of which such adjustments, notes or presentation items would be material individually or in the aggregate).

(b)    Except as set forth on Schedule 6.06(b), the Group Companies do not have any liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise ("Liabilities"), except (i) Liabilities to the extent specifically accrued on or adequately reserved against in the Latest Balance Sheet or specifically disclosed in the notes to the other Financial Statements, (ii) Liabilities that have arisen since the date of the Latest Balance Sheet in the Ordinary Course (none of which is a liability

16

resulting from breach of contract of warranty, tort, infringement or misappropriation) or (iii) Liabilities to be included in the computation of Funded Debt as of the Adjustment Time, Transaction Expenses, the Tax Liability Amount or Working Capital.

6.07 Absence of Certain Developments. Since the date of the Latest Balance Sheet through the date of this Agreement:

(a)    the business of the Group Companies has been conducted in all material respects in the Ordinary Course;

(b)    there has not occurred any Material Adverse Effect; and

(c)    except as set forth on Schedule 6.07, none of the Group Companies has:

(i)    issued, delivered, reissued or sold, disposed of or pledged, split, combined or reclassified any of its equity securities or granted any options, warrants or other rights to purchase or obtain (including upon conversion, exchange or exercise) any of its equity securities;

(ii)    created, incurred, assumed or guaranteed any Funded Debt, other than (x) in the Ordinary Course, (y) pursuant to the Company's existing credit facilities, or (z) arrangements solely among or between the Group Companies;

(iii)    sold or transferred any material portion of its assets or property (tangible or intangible);

(iv)    leased, mortgaged, pledged or otherwise subjected to any Lien (other than Permitted Liens) any material portion of its assets or property (tangible or intangible);

(v)    acquired (whether by merger, acquisition of stock or assets, or otherwise) any business, line of business or any material portion of another Person's assets or property (tangible or intangible);

(vi)    made or authorized any change to the organizational documents of any of the Group Companies;

(vii) made an election to change the status of any of the Group Companies (as a corporation, partnership or disregarded entity) for federal, state or local Tax purposes;

(viii) suffered any damage, destruction or loss, regardless of whether covered by insurance, with respect to the property and assets of the Group Companies having a replacement cost of more than $500,000;

(ix)    established, terminated or materially amended any Plan or granted any equity incentive unit awards thereunder;

(x)    hired or terminated the employment (other than for cause) of any employee whose annual rate of base salary is in excess of $200,000;

(xi)    (A) increased the compensation payable or to become payable to any of the Group Companies' employees whose annual rate of base salary is in excess of $250,000, except to the extent otherwise required by the Plans, (B) granted any severance or termination pay, or (C) funded,

17

accelerated the vesting and/or payment of, or increased the benefits payable or otherwise available under, any Plan;

(xii) adopted a plan of merger (other than this Agreement), liquidation, dissolution, consolidation or other reorganization or filed a petition in bankruptcy under any provisions of federal or state bankruptcy Law, or the international equivalent of such bankruptcy Law, or consented to the filing of any bankruptcy petition against it under any similar Law;

(xiii) made a material change in its accounting or Tax reporting methods,

principles or policies;

(xiv) abandoned or allowed a lapse of any material Registered Intellectual Property of the Group Companies; or

(xv) committed to do any of the foregoing.

6.08 Litigation. Except as set forth on Schedule 6.08, as of the date of this Agreement, there are no Proceedings pending or, to the Company's Knowledge, threatened against any of the Group Companies or otherwise affecting their respective properties or assets, at law or in equity, before or by any Governmental Authority. As of the date of this Agreement, none of the Group Companies is subject to any outstanding judgment, order or decree of any Governmental Authority.

6.09 Environmental Matters. Except as set forth on Schedule 6.09: (a) the Group Companies are, and since January 1, 2016 have been, in compliance in all material respects with all applicable Environmental Laws and Environmental Permits; (b) none of the Group Companies has received since January 1, 2016, (or prior to that date if Liabilities remain outstanding) any written notice of a violation of Environmental Laws or any Liability arising under Environmental Laws, relating to the Group Companies or their facilities, the subject of which is unresolved or with respect to which any material Liabilities or obligations remain outstanding; (c) there is no material Proceeding pending or, to the Company's Knowledge, threatened against any of the Group Companies pursuant to or relating to Environmental Laws or Environmental Permits; (d) no Releases of Hazardous Materials have occurred, and no Person has been exposed to any Hazardous Materials, at, from, in, to, on, or under any Site, and no Hazardous Materials are present in the environment on, about or migrating to or from any Site, in each case that has given rise to, or would give rise to, any material Liability to any of the Group Companies; (e) the Group Companies hold all material Environmental Permits; (f) none of the Group Companies, no predecessor of any of the Group Companies, nor any entity previously owned by any of the Group Companies, has transported or arranged for the treatment, storage, handling, disposal, or transportation of any Hazardous Material to any off-Site location which has resulted in, or would result in, material Liability to any of the Group Companies; (g) there are no polychlorinated biphenyl containing equipment, underground storage tanks, or asbestos containing material at the Owned Real Property, or to the Company's Knowledge, at the Leased Real Property; (h) there are no Phase I or Phase II environmental assessments in the possession of any Group Company with respect to any Site which have not been made available to Buyer; (i) none of the Group Companies is subject to any outstanding judgment, decree or order of any Governmental Authority under any Environmental Laws; and (j) none of the Group Companies has, either expressly or by operation of Law, assumed responsibility for or agreed to indemnify or hold harmless any Person for any material Liability or obligation of the Group Companies or any other Person arising under or relating to Environmental Laws, including any material obligation for investigation, corrective or remedial action.

6.10    Title to Properties.

18

(a)    The Group Companies have valid title to, or a valid leasehold interest in (or other right to use), all of the tangible personal property shown to be owned by the Group Companies on the Latest Balance Sheet, free and clear of all Liens (other than Permitted Liens), except for assets disposed of in the Ordinary Course since the date of the Latest Balance Sheet.

(b)    The real property leased by the Group Companies pursuant to the leases described on Schedule 6.10(b) (the "Leased Real Property") constitutes all of the real property leased by the Group Companies. Except as set forth on Schedule 6.10(b), the Group Companies hold a good and valid leasehold interest in (or a valid right to use, occupy or access) all of the Leased Real Property. Each of the leases described on Schedule 6.10(b) is a valid and binding agreement of the applicable Group Company and is in full force and effect, subject to proper authorization and execution of such lease by the other party and the application of any Bankruptcy and Equity Exceptions. The Company has made available to Buyer true and correct copies of each lease described on Schedule 6.10(b), including all amendments, extensions, renewals, guaranties and other agreements with respect thereto. None of the Group Companies is in default in any material respect under any lease described on Schedule 6.10(b). The Group Companies' possession and quiet enjoyment of the Leased Real Property is not currently being disturbed. None of the Group Companies has subleased, licensed or otherwise granted any Person the right to use or occupy any of the Leased Real Property or any portion thereof. Except as set forth on Schedule 6.10(b)(i), none of the Group Companies has collaterally assigned or granted any security interest in any Leased Real Property or any interest therein.

(c)    The real property at the addresses listed on Schedule 6.10(c) (which also includes the Group Company that is the owner of such real property) constitutes all of the real property owned by the Group Companies (the "Owned Real Property"). Except as set forth on Schedule 6.10(c), with respect to each parcel of Owned Real Property:

(i)    the applicable Group Company owns good marketable title to such Owned Real Property, free and clear of all Liens, other than Permitted Liens;

(ii)    there are no leases, subleases, licenses, concessions or other agreements granting to any Person the right of use or occupancy of any portion of such Owned Real Property;

(iii)    copies of all material deeds, title reports and surveys for the Owned Real Property have been made available to Buyer to the extent that such documents are within the possession or control of the Group Companies;

(iv)    there are no outstanding options or rights of first refusal to purchase such Owned Real Property or any portion of, or any interest in, such Owned Real Property;

(v)    each parcel of Owned Real Property and all of the material improvements and fixtures thereon are in material compliance with all Laws based on the current use of such Owned Real Property and are in good operating condition, subject to ordinary wear and tear and repairs and maintenance being carried out in the Ordinary Course; and

(vi)    there are no pending or, to the Company's Knowledge, threatened condemnation proceedings that would reasonably be expected to preclude or impair the use of such parcel of Owned Real Property for the current use.

6.11 Compliance with Laws.

19

(a)    The Group Companies are, and since January 1, 2016 have been, in compliance in all material respects with all applicable Laws. Since January 1, 2016, (i) none of the Group Companies has been cited or fined or had any Proceeding initiated for any failure to comply with any Laws that has not been cured, and (ii) to the Company's Knowledge, no investigation by any Governmental Authority with respect to any of the Group Companies is pending or threatened.

(b)    Since January 1, 2016, each of the Group Companies and each of their respective directors, managers, officers, employees, agents and other Persons acting on their behalf: (i) have complied in all material respects with Anti-Corruption Laws; and (ii) have not unlawfully offered, promised or made payments of money or anything of value, whether directly or indirectly, to any Government Official to (A) influence any official act or decision of a Government Official, (B) induce a Government Official to do or omit to do any act in violation of a lawful duty, (C) secure any improper business advantage or (D) obtain or retain business for, or otherwise direct business to, any of the Group Companies.

6.12 Labor and Employment Matters.

(a)    None of the Group Companies (i) is, or has been since January 1, 2016, a party to or bound by any collective bargaining agreement, or other Contract or arrangement with a labor union, works council, trade union or other organization or body representing any of its employees or (ii) is or since January 1, 2016 has been a member of any multi-employers bargaining association or organization. As of the date of this Agreement, to the Company's Knowledge, there is currently no organized effort by any labor union to organize any employees of the Group Companies into one or more collective bargaining units. Since January 1, 2016, none of the Group Companies has experienced any strike or grievance, slowdown, work stoppage, lockout, picketing, concerted refusal to work overtime, handbilling, demonstrations, leafletting, jurisdictional dispute, or similar material labor dispute. Since January 1, 2016, none of the Group Companies has been subject to any pending unfair labor practice charge or complaint, or other material collective bargaining dispute before the National Labor Relations Board or any other labor relations tribunal or authority and none are pending or, to the Company's Knowledge, threatened as of the date of this Agreement. Since January 1, 2016, to the Company's Knowledge, the Group Companies have not been subject to any union or works council organizing efforts or election activity, including any demands for recognition or certification, attempts to bargain collectively, or filings for recognition with any applicable Governmental Authority. No employee of the Group Companies is represented by a union or other labor organization in connection with their employment with the Group Companies and, to the Company's Knowledge, there are no labor organizations seeking to represent any employees of the Group Companies. None of the Group Companies has committed any material unfair labor practice since January 1, 2016.

(b)    The Company is, and since January 1, 2016 has been, in compliance in all material respects with all applicable Laws regarding employment and employment practices, health and safety, immigration, terms and conditions of employment, and wage and hour, including: (i) Title VII of the Civil Rights Act of 1964; (ii) the Equal Pay Act of 1967; (iii) the Age Discrimination in Employment Act of 1967; (iv) the Americans with Disabilities Act; (v) the Family and Medical Leave Act; (vi) the Fair Credit Reporting Act; (vii) the Employee Retirement Income Security Act of 1974; (viii) the Fair Labor Standards Act and the related rules and regulations adopted by those federal agencies responsible for the administration of such laws; (ix) the WARN Act, and any similar state WARN Act Law, and the related rules and regulations adopted by those federal agencies responsible for the administration of such laws; (x) the Immigration Reform and Control Act of 1986 and all related regulations and all executive orders in effect regarding the employment in the U.S. of persons who are not citizens of the U.S.; (xx) the United States National Labor Relations Act; and (xxi) the Occupational Safety and Health Act and any other equivalent and applicable Laws to which a Group Company may be subject in any other jurisdiction in which any Group Company employs and engages individuals.

20

(c)    The Company has delivered to Buyer a schedule setting forth a true, correct and complete list, as of February 2019, of all employees of the Group Companies, by Position ID and including for each such employee, title or position, department and organizational unit, date of hire or rehire, status as part-time or full-time, location, base salary and leave status. The Company has made available to Buyer all employment agreements with employees in the United States to which any Group Company is a party (excluding offer letters for at-will employment) and a list of all employment contracts and individual independent contractor agreements that have been terminated in the past twelve months ending on the date of this Agreement pursuant to which any Group Company has outstanding obligations as of the date of this Agreement.

(d)    To the Company's Knowledge, no current employee of any of the Group Companies is in material violation of any term of any employment Contract or invention assignment, patent disclosure or restrictive covenant agreement to a former employer relating to the right of any such employee to be employed by any of the Group Companies due to the use of trade secrets or proprietary information of others.

(e)    Since January 1, 2016, there has not been any pending, or, to the Company's Knowledge, threatened, allegation of sexual harassment or sexual misconduct against any current or former supervisory employee of any Group Company. Since January 1, 2016 none of the Group Companies have entered into a settlement agreement related to allegations or threatened allegations of sexual harassment or sexual misconduct by any current or former employee or independent contractor of any Group Company.

(f)    Except as set forth on Schedule 6.12(f), there are no pending, and since January 1, 2016, there have been no, Proceedings brought by or on behalf of any applicant for employment, any current or former employee, consultant, independent contractor, leased employee, volunteer, temporary worker, Governmental Authority or any group or class of the foregoing, alleging violation of any applicable Laws relating to labor or employment, including unpaid compensation, including with respect to overtime amounts, misclassification, breach of any express or implied contract of employment, wrongful termination of employment, or any other discriminatory, wrongful, or tortious conduct in connection with the employment or service relationship.

(g)    Since January 1, 2016, no Group Company has received written notice of the intent of any Governmental Authority responsible for the enforcement of labor or employment laws to conduct an investigation of a Group Company and to the Company's Knowledge, no such action has been threatened.

(h)    For non US-employees and directors, no material complaint of sex, race, disability, age, sexual orientation or religion or religious belief discrimination has been raised by any current or former employee that is currently pending against any Group Company.

(i)    Except as would not result in a material liability to the Group Companies, since January 1, 2016, all Group Companies have paid or properly accrued all wages and compensation due to all employees, including all overtime pay, vacations or vacation pay, holidays or holiday pay, sick days or sick pay, and bonuses.

6.13 Employee Benefit Plans.

(a)    Schedule 6.13 sets forth a complete and correct list of each material Plan.

(b)    Each of the Plans that is intended to be qualified under Section 401(a) of the Code either has received a favorable determination letter from the Internal Revenue Service or is a prototype plan that has received a favorable opinion letter from the Internal Revenue Service. The Plans, and the provision

21

of compensation and benefits by the Group Companies under the Plans, have at all times since January 1, 2013 complied in all material respects in form and in operation with the requirements of the Code, ERISA and all applicable Laws. Each Plan has at all times since January 1, 2013 been operated in compliance in all material respects with its terms.

(c)    With respect to the Plans, all required contributions have been made or, if not yet due, have been properly accrued (to the extent required by GAAP to be accrued). All monies withheld from employee paychecks with respect to Plans have been transferred to the appropriate Plans in all material respects in a timely manner as required by applicable Laws. The Company has made available to Buyer with respect to each Plan true and correct copies of (as applicable) (i) the current Plan document, amendments and related trust agreements, (ii) Forms 5500 (to the extent applicable), including all attachments thereto, for the past three years, (iii) the latest financial statements for each Plan, (iv) a summary of the material terms of any unwritten Plans, (v) the most recent actuarial report, (vi) the most recent IRS determination or opinion letter, (vii) the most recent summary plan description and any summaries of material modifications and (viii) any other material documentation issued by Governmental Authorities and received by the Company in respect of any Plan.

(d)    None of the Group Companies maintains, participates in, sponsors, has any obligation to contribute to or has any Liability with respect to, nor has any of the Group Companies, since January 1, 2013, maintained, participated in, sponsored, had an obligation to contribute to, or had any Liability with respect to, any (i) defined benefit pension plan or any plan, program or arrangement subject to Title IV of ERISA or Section 412 of the Code or any other equivalent applicable Laws to which a Group Company is subject in any other jurisdiction outside of the United States, (ii) Multiemployer Plan (as defined in Section 4001(a)(3) of ERISA), (iii) "multiple employer plan" within the meaning of Section 4063 or 4064 of ERISA or (iv) "multiple employer welfare arrangement" within the meaning of Section 3(40) of ERISA. No Plan provides for post-employment health or life insurance benefits or coverage, or other similar retiree welfare benefits, to any Person (other than as required under Part 6 of Subtitle B of Title I of ERISA, Section 4980B of the Code, or any similar Laws).

(e)    Outside of the United States, the Group Companies do not have any unfunded pension Liabilities, seniority premiums, or termination indemnity, other than such Liabilities relating to such benefit or compensation plans, programs, policies, agreements or arrangements that are required by applicable Laws.

(f)    Since January 1, 2016, all required reports and descriptions with respect to each Plan (including Form 5500 Annual Reports, Summary Annual Reports, and Summary Plan Descriptions) have been filed or distributed in all material respects in compliance with the applicable requirements of ERISA, the Code and all other applicable Laws.

(g)    No Proceeding with respect to any Plan (other than routine claims for benefits) is pending or, to Company's Knowledge, threatened. Since January 1, 2016, none of the Group Companies has incurred any material Liability for excise, income or other Taxes or penalties with respect to any Plan.

(h)    Subject to entering into the amendments contemplated by Section 7.12, each Plan that constitutes a "nonqualified deferred compensation plan" (as defined in Section 409A(d)(1) of the Code) is, and since January 1, 2016 has been, established, administered and maintained in compliance in all material respects with the documentary and operational requirements of Section 409A of the Code and the regulations promulgated thereunder.

(i)    Each of the Group Companies and each Plan is and at all times since January 1, 2016 has been in compliance in all material respects with the Patient Protection and Affordable Care Act

22

and its companion bill, the Health Care and Education Reconciliation Act of 2010 (the "Health Care Law"),to the extent applicable. The operation of each Plan since January 1, 2016 has not resulted in the incurrence of any material penalty or Liability to any of the Group Companies pursuant to the Health Care Law.

(j)    Neither the execution and delivery of this Agreement nor the consummation of the Transactions (either alone or in combination with any other event) will (i) result in any payment, acceleration, forgiveness of indebtedness, vesting, increase in payments or benefits, or obligation to fund payments or benefits with respect to any current or former employee, independent contractor, manager or director of any of the Group Companies or (ii) give rise to the payment of any amount that would not be deductible by any of the Group Companies by reason of Section 280G of the Code or that would be subject to Tax under Section 4999 of the Code. None of the Group Companies have an obligation to indemnify, hold harmless or gross-up any individual with respect to any excise tax imposed under Section 4999 or Section 409A of the Code or any other equivalent applicable Laws to which a Group Company is subject in any other jurisdiction outside of the U.S. No Group Company (other than TotalCare International Corp (and its Subsidiary Ranir Changshu Oral Care Co. Ltd.), which have no "disqualified individuals" (as defined in Section 280G of the Code)), individually or grouped with one or more of the other Group Companies, constitutes a "corporation" for purposes of Section 280G of the Code.

6.14 Tax Matters.

(a)    The Group Companies have filed all material Tax Returns that are required to be filed by them (taking into account any extensions of time to file that have been duly perfected). All Taxes of the Group Companies that are due and payable (whether or not shown or required to be shown as owing by the Group Companies) have been fully and timely paid, and all such Tax Returns are true and correct in all material respects.

(b)    All material Taxes that any of the Group Companies is obligated to withhold and pay over from amounts owing to any employee, creditor or third party have been properly withheld and fully paid over to the extent due and payable, and the Group Companies have complied in all material respects with all applicable requirements with respect to all Forms W-2 and 1099 required with respect thereto, and such forms have been properly completed and timely filed.

(c)    None of the Group Companies is party to or is otherwise bound by, any Tax allocation, Tax sharing, Tax indemnity, Tax reimbursement agreement or arrangement (other than (a) customary agreements with customers, vendors, lenders, lessors or the like entered into in the Ordinary Course and not primarily related to Taxes and (b) any agreements with respect to property Taxes payable with respect to properties leased). None of the Group Companies has any Liability for Taxes of any other Person (i) under Treasury Regulations Section 1.1502-6 (or any similar provision of Law) or (ii) as a transferee or successor, by contract or otherwise.

(d)    Except as set forth on Schedule 6.14(d), none of the Group Companies has been the subject of any audit or other examination of Taxes by any Taxing Authority with respect to any open Tax years and, to the Company's Knowledge, no such audit or other examination is contemplated or pending. None of the Group Companies has received in writing from any Governmental Authority with respect to Taxes (including jurisdictions where none of the Group Companies have filed Tax Returns) any (i) notice indicating an intent to open an audit or other review, (ii) request for information related to Tax matters, or (iii) notice of deficiency or proposed adjustment for any amount of Tax proposed, asserted, or assessed by any Taxing Authority against any Group Company, in each case, which remains outstanding or unresolved.

23

(e)    None of the Group Companies has waived in writing any statute of limitations in respect of Taxes payable by any of them, which waiver is currently in effect.

(f)    There are no Liens for Taxes (other than Permitted Liens) upon any of the assets of the Company or any of the Group Companies.

(g)    The unpaid Taxes of the Group Companies (i) did not, as of the date of the latest Financial Statements, materially exceed the reserve for Tax Liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the latest Financial Statements (rather than in any notes thereto) and (ii) do not materially exceed that reserve as adjusted for the passage of time through the Closing Date in accordance with the past custom and practice of the Group Companies in filing their Tax Returns, in each case to the extent consistent with GAAP. Since the date of the latest Financial Statements, no Group Company has incurred any material Liability for Taxes from transactions outside of the Ordinary Course.

(h)    None of the Group Companies will be required to include any item of income in, or exclude an item of deduction from, taxable income for any taxable period (or portion thereof) beginning after the Closing Date as a result of any (i) change in or use of an improper method of accounting for a taxable period ending on or prior to the Closing Date, (ii) "closing agreement" as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or non-U.S. income Tax Law) executed prior to the Closing, (iii) intercompany transaction or excess loss amount described in the Treasury Regulations under Section 1502 of the Code (or any corresponding or similar provision of state, local or non-U.S. income Tax Law), (iv) installment sale or open transaction disposition made on or prior to the Closing Date, (v) election under Section 108(i) of the Code, (vi) prepaid amount received outside of the Ordinary Course or deferred revenue accrued on or prior to the Closing, (vii) ownership of "United States property" (as defined in Section 956(c) of the Code) on a date prior to the Closing Date by any Subsidiary of the Company that that is a "controlled foreign corporation" (within the meaning of Section 957(a) of the Code), (viii) Subsidiary of the Company that is a "controlled foreign corporation" (within the meaning of Section 957(a) of the Code) having "subpart F income" (within the meaning of Section 952(a) of the Code) or having "global intangible low-taxed income" (within the meaning of Section 951A of the Code), in each case, earned prior to the Closing, or (ix) application of Section 965 of the Code (including an election under Section 965(h) of the Code (or any similar provision of Law)) (collectively, (i) through (viii), the "Tax Accrual Amounts").

(i)    None of the Group Companies is subject to Tax in any country other than its country of incorporation or formation by virtue of having a permanent establishment (within the meaning of an applicable Tax treaty) or other fixed place of business in such jurisdiction.

(j)    Each Group Company has properly collected and remitted all material sales, use, valued added and similar Taxes with respect to sales or leases made or services provided to its customers and for all sales, leases or provision of services that are exempt from sales, use, valued added and similar Taxes and that were made without charging or remitting sales, use, valued added or similar Taxes, received and retained any appropriate Tax exemption certificates and other documentation qualifying such sale, lease or provision of services as exempt.

(k)    Except as set forth on Schedule 6.14(k), each of the Group Companies is, and has been since its formation, properly treated as either a "partnership" or "disregarded entity" for U.S. federal income tax purposes and no election has been made pursuant to Treasury Regulation Section 301.7701-3(c) to treat any of the Group Companies as an association taxable as a corporation. Schedule 6.14(k) sets forth each Subsidiary of the Company that is characterized as an association taxable as a corporation for U.S. federal Income Tax purposes (i) whether each such entity is a "controlled foreign corporation" within the

24

meaning of Section 957 of the Code or a "passive foreign investment company" within the meaning of Section 1297 of the Code and (ii) for U.S. federal Income Tax purposes, the tax year end of any such entity that is a "controlled foreign corporation" within the meaning of Section 957 of the Code.

(l)    No Group Company that is characterized as an association taxable as a corporation for U.S. federal Income Tax purposes has distributed stock of another Person, or has had its stock distributed by another Person, within the last two years, in a transaction that was governed by Section 355 or Section 361 of the Code.

(m)    The Company has in effect an election under Section 754 of the Code.

6.15    Insurance. Schedule 6.15 lists each insurance policy in effect as of the date of this

Agreement that is maintained by any of the Group Companies, including the name of the insurer, the policy number and the limits of coverage (the "Insurance Policies"). The Insurance Policies are in full force and effect. None of the Group Companies has received written notice of any cancellation or threat of cancellation of any of the Insurance Policies. All premiums due prior to Closing on the Insurance Policies have been paid prior to Closing in accordance with the payment terms of each such Insurance Policy. All of the Insurance Policies are (a) valid and binding in accordance with their terms and (b) have not been subject to any lapse in coverage. None of the Group Companies is in material breach or material default under any of the Insurance Policies. The Company has made available to Buyer loss runs for the current policy period for each of the Insurance Policies. Except as set forth on Schedule 6.15, there are no claims related to the business of the Group Companies pending under any such Insurance Policies as to which coverage has been questioned, denied or disputed or in respect of which any of the Group Companies received a reservation of rights letter that is currently outstanding. Except as set forth on Schedule 6.15,none of the Group Companies has any self-insurance or co-insurance programs.

6.16 Licenses and Permits. The Group Companies hold or have otherwise made or received all material franchises, grants, authorizations, licenses, permits, consents, certificates, exemptions, clearances, de novos, approvals, declarations, registrations, drug product listings, CE marks, filings and orders of or required by any Governmental Authority (collectively, the "Permits") to allow the Group Companies to (i) perform their design, development, manufacturing, processing, testing, packaging/repackaging, labeling/relabeling, storage, handling, distribution, supply, import, export, marketing, commercialization and sales activities, (ii) own, lease and operate their properties, and (iii) carry on their respective businesses as they are now being conducted. No violation, suspension, withdrawal, revocation, adverse modification, or cancellation of any of the Permits is pending, or, to the Company's Knowledge, threatened or under investigation. The Group Companies are, and since January 1, 2016 have been, in compliance in all material respects with the terms of all Permits. All of the Permits are in full force and effect and none of the Permits will be terminated or become terminable, in whole or in part, as a result of the Transactions. The Group Companies have paid or accrued all fees and charges with respect to such Permits in full, and met all filing, reporting, and maintenance obligations in all material respects and in a timely fashion.

6.17    Affiliated Transactions. Except as set forth on Schedule 6.17, no Related Party (a) is a party

to any agreement or transaction with any of the Group Companies, other than (i) customary employment arrangements in the Ordinary Course and (ii) the Plans, or (b) has any material interest or right in any material property or right, tangible or intangible, used by any of the Group Companies.

6.18    Material Contracts.

(a)    Schedule 6.18(a) sets forth a list of all Contracts in effect as of the date of this Agreement to which any of the Group Companies is a party or by which any of the Group Companies is

25

bound, meeting any of the descriptions set forth below (collectively referred to herein as the "MaterialContracts"):

(i)    all Contracts relating to any completed material business acquisition by any of the Group Companies since January 1, 2016;

(ii)    all employment or consulting Contracts with employees and independent contractors of the Group Companies providing for annual base cash compensation that exceeds $100,000 and all equity incentive unit Contracts with employees or independent contractors of any of the Group Companies;

(iii)    all Contracts with temporary staffing, employee leasing, or other professional placement firms;

(iv)    all Contracts for Funded Debt;

(v)    all Contracts under which any of the Group Companies is lessee of, or holds or operates, any personal property owned by any other Person, for which the annual rental exceeds $250,000 and that are not terminable by the applicable Group Company upon notice of sixty days or less;

(vi)    all Contracts under which a Group Company is lessor of, or permits any third party to hold or operate any personal property of any of the Group Companies, for which the annual rental payments exceed $250,000 and that are not terminable by the applicable Group Company upon notice of sixty days or less;

(vii) all Contracts that prohibit any of the Group Companies from freely engaging in business anywhere in the world (excluding non-disclosure, confidentiality and employee non-solicitation covenants entered into in the Ordinary Course);

(viii) all material software licenses other than Off-the-Shelf Licenses;

(ix)    all Contracts (A) that are material Inbound Licenses (other than Off-the-Shelf Licenses or software licenses scheduled under Section 6.18(a)(vii)) or material Outbound Licenses (other than non-exclusive licenses granted to customers or that are incidental to sale of products in the Ordinary Course) or (B) that relate to any consent-to-use, coexistence, forbearance to sue, settlement, distribution or development of Company-Owned Intellectual Property and that materially limit or restrict the ability of any of the Group Companies to use, exploit, assert, register, or enforce any Company-Owned Intellectual Property anywhere in the world;

(x)    all Contracts relating to joint ventures, partnerships, profit sharing or

similar arrangements;

(xi)    all Contracts with Key Suppliers and Key Customers;

(xii) all Contracts with any Governmental Authority to which any Group

Company is a party; and

(xiii) all agreements involving any resolution or settlement of any actual or threatened Proceeding and providing for payments by any Group Company after the date of this Agreement or imposing any ongoing requirements or restrictions on any of the Group Companies.

26

(b)    Except as set forth on Schedule 6.18(b), the Company has made available to Buyer a complete, true and correct copy of all written Material Contracts, together with all amendments and exhibits to such Material Contracts. None of the Group Companies nor, to the Company's Knowledge, any other party to any Material Contract is, in any material respect, in breach of, or in default under, any Material Contract. To the Company's Knowledge, no event or circumstance has occurred that, with notice or lapse of time or both, would constitute an event of default under any Material Contract or result in a termination of such Material Contract or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit under such Material Contract. Each Material Contract is a valid, binding and enforceable obligation of the applicable Group Company and, to the Company's Knowledge, each of the other parties thereto, except as enforceability may be limited by the Bankruptcy and Equity Exceptions, and is in full force and effect (other than any such Material Contract that expires in accordance with its terms). As of the date of this Agreement, no counterparty to any Material Contract has given notice to any of the Group Companies of its intention to cancel or otherwise terminate any such Material Contract.

6.19    Intellectual Property.

(a)    Schedule 6.19(a) contains a complete and accurate list of all Registered Company-Owned Intellectual Property, including the registration status, the accurate and up-to-date owner of record title, and, if different, the current legal owner. Excluding items the Group Companies have abandoned, allowed to lapse or failed to maintain in the Ordinary Course, all registrations and applications for registration or issuance of Registered Company-Owned Intellectual Property have been duly maintained (including the payment of maintenance, application, registration, renewal and/or other fees). Except as set forth on Schedule 6.19(a), no Registered Company-Owned Intellectual Property is involved in any interference, reissue, re-examination, opposition or cancellation proceeding, and no such proceeding has been threatened in writing since January 1, 2016. All Registered Company-Owned Intellectual Property (excluding any pending applications included therein) is valid, subsisting, and enforceable.

(b)    Except as set forth in Schedule 6.19(b), (i) one of the Group Companies owns (in a sole capacity) all Company-Owned Intellectual Property, free and clear of any Lien other than Permitted Liens, (ii) the Group Company shown as the owner of each item of Registered Company-Owned Intellectual Property on Schedule 6.19(a) owns all right, title and interest in, and is the record title owner of, such Registered Company-Owned Intellectual Property and (iii) the applicable Group Company owns and/or has the valid and enforceable right to use pursuant to a license, sublicense, agreement, or other permission all other Intellectual Property used in or necessary for the operation of the Group Companies' business as currently conducted. The Company Intellectual Property constitutes all material Intellectual Property used in or necessary for the operation of the businesses of the Group Companies as currently conducted. Except as set forth on Schedule 6.19(b), the Company Intellectual Property used or held for use by the Group Companies immediately prior to the Closing will be owned or available for use (as applicable) by the Group Companies on terms and conditions that are identical in all material respects immediately after the Closing.

(c)    Except as set forth on Schedule 6.19(c), neither the Company-Owned Intellectual Property, the use or exploitation of the Company-Owned Intellectual Property, nor the conduct of the business of the Group Companies has, since January 1, 2016 (or, solely with respect to patents held by any third Person, since January 1, 2013), infringed, misappropriated, or otherwise violated, or is infringing, misappropriating, or otherwise violating, any Intellectual Property of any Person. Except as set forth on Schedule 6.19(c), since January 1, 2016 (or, solely with respect to patents held by any third Person, since January 1, 2013), none of the Group Companies has received any written claim, demand or notice, and no action is pending or, to the Company's Knowledge, threatened against any of the Group Companies (x) alleging that any Group Company has infringed, misappropriated or otherwise violated any Intellectual Property rights of any Person or (y) challenging the validity, registrability, enforceability or ownership of, or the right of a Group Company to use, any Company Intellectual Property.

27

(d)    Except as set forth in Schedule 6.19(d), to the Company's Knowledge, no Person is infringing, misappropriating or otherwise violating any Registered Company-Owned Intellectual Property or any other Company-Owned Intellectual Property. None of the Group Companies has brought or threatened a claim in writing against or provided written notice to any Person (i) alleging that such Person is infringing, misappropriating or otherwise violating any Company-Owned Intellectual Property or (ii) challenging such Person's ownership or use, or the validity, registrability, or enforceability, of such Person's Intellectual Property.

(e)    Each of the Group Companies have taken commercially reasonable steps to maintain the proprietary nature of the Company-Owned Intellectual Property, and to protect the confidentiality of the confidential information and trade secrets included in the Company Intellectual Property, including (i) implementing and maintaining requirements that all employees and other Persons with access to confidential information of the Group Companies, or any third party (as applicable), be subject to confidentiality obligations and (ii) causing all current employees and consultants and contractors of any of the Group Companies that are involved in the development of Company-Owned Intellectual Property to enter into valid and binding written contracts with the applicable Group Company, sufficient to vest title in the applicable Group Company, of all Intellectual Property created by such employee or consultant/contractor within the scope of their employment or engagement by the Group Companies and to prevent the unauthorized use and disclosure of trade secrets and other confidential information owned, used or held for use by the Group Companies. No past or present employee, partner, director, stockholder, member, officer, consultant or Affiliate of any of the Group Companies has any rights to or ownership interest in any Company-Owned Intellectual Property.

(f)    All software used in the operation of the business of the Group Companies as presently conducted is properly licensed and is not a "bootleg" version or copy. All such software: (i) is in all material respects in working order and/or performs in material conformance with its documentation, is free from any material software defect and does not contain any self-help mechanism or unauthorized code; (ii) does not contain viruses, Trojan horses or other malicious code; and (iii) has not suffered any material error, breakdown, failure or security breach since January 1, 2016 that has caused material disruption or damage to the operation of the business of the Group Companies that has not been properly remedied in all material respects, or that was required to be reportable to any Governmental Authority or Person.

6.20 Key Customers and Suppliers.

(a)    Schedule 6.20(a) lists the top ten customers by dollar sales volume of the Group Companies (on a consolidated basis) for the twelve-month period ended December 31, 2018 (each, a "KeyCustomer"). None of the Key Customers has (i) terminated, or given written notice to any of the Group Companies of its intention to terminate, its relationship with any of the Group Companies, or (ii) given written notice to any of the Group Companies that it plans to reduce substantially the quantity of products or services that it purchases from any of the Group Companies. None of the Group Companies has any reason to believe that any of the Key Customers intends to (i) terminate its relationship with any of the Group Companies, or (ii) reduce substantially the quantity of products or services that it purchases from any of the Group Companies.

(b)    Schedule 6.20(b) lists the top ten suppliers by dollar sales volume of the Group Companies (on a consolidated basis) for the twelve-month period ended December 31, 2018 (each, a "KeySupplier"). None of the Key Suppliers has (i) terminated, or given written notice to any of the Group Companies of its intention to terminate, its relationship with any of the Group Companies, or (ii) given written notice to any of the Group Companies that it plans to reduce substantially the quantity of products or services that it provides to any of the Group Companies. None of the Group Companies has any reason to believe that any of the Key Suppliers intends to (i) terminate its relationship with any of the Group

28

Companies, or (ii) reduce substantially the quantity of products or services that it provides to any of the Group Companies.

6.21    Regulatory Matters.

(a)    The Group Companies have, since January 1, 2016, complied and are complying, in each case, in all material respects with all applicable Laws with respect to their respective businesses and the products designed, developed, manufactured, processed, tested, packaged/repackaged, labeled/relabeled, stored, handled, distributed, supplied, imported, exported, marketed, promoted, commercialized, or sold by or for any of the Group Companies (the "Company Products") including: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.); (ii) any applicable FDA investigational device exemption, device listing, premarket approval, 510(k) clearance, or de novo request and the equivalent EU CE-marking requirements; (iii) the Federal Trade Commission Act (15 U.S.C. §§ 41-58) and the equivalent EU and national EU member states competition Laws; (iv) the Poison Prevention Packaging Act (15 U.S.C. § 1471 et seq.) and the equivalent EU and national EU member states Laws; (v) the Medical Device Directive 93/42/EC; (vi) the Cosmetics Regulation (EC) 1223/2009; (vii) the Administrative Measures on Supervision of Manufacturing of Medical Devices promulgated by the China Food and Drug Administration on November 17, 2017; (viii) the Anti-Kickback Statute (42 U.S.C. § 1320a-7b), the Civil Monetary Penalty Statute (42 U.S.C. § 1320a-7a), the Foreign Corrupt Practices Act, the civil and criminal False Claims Acts (31 U.S.C. § 3729 et seq. and 18 U.S.C. § 287) and the equivalent EU and member states laws and codes including the Bribery Act 2010 and the EFPIA Disclosure Code as implemented by EU member state trade associations; (ix) any applicable state or local Laws relating to any of the foregoing; and (x) all other relevant Laws of jurisdictions within, and outside of, the United States. The Company Products are not, and since January 1, 2016 have not been, materially adulterated or misbranded, or prohibited from introduction into interstate commerce under applicable Law. Except as set forth on Schedule 6.21(a), all of the Company Products that are over-the-counter drug products are either being marketed pursuant to and in compliance in all material respects with a final over-the-counter drug monograph or the FDA's enforcement policies (or equivalent foreign policies) with respect to non-final over-the-counter drug monographs.

(b)    Except as set forth on Schedule 6.21(b), none of the Group Companies, nor, to the Company's Knowledge, any other Person, has, since January 1, 2016, received written notice of or been subject to, any adverse inspectional finding, data integrity review, investigation, penalty, fine, reprimand, sanction, assessment, request for corrective or remedial action, import alert, detention at port, warning letter, regulatory letter, cyber letter, untitled letter, FDA Form 483, or other compliance or enforcement notice, communication, correspondence, Proceeding, or action from or by the FDA or any other Governmental Authority (including any notified body) related to any Company Product.

(c)    Except as set forth on Schedule 6.21(c), since January 1, 2016, none of the Company Products have been subject to a recall, removal, market withdrawal, or any other field correction (collectively, a "Recall"), nor is any Company Product Recall currently under consideration by any of the Group Companies or, to the Company's Knowledge, any Governmental Authority, manufacturer, supplier, distributor, or customer of a Company Product. Each of the Company Products has been, since January 1, 2016, and is being designed, developed, manufactured, processed, tested, packaged/repackaged, labeled/relabeled, stored, handled, distributed, supplied, imported, exported, marketed, promoted, commercialized, or sold in compliance in all material respects with applicable Laws.

(d)    None of the Group Companies, nor any employee, nor, to the Company's knowledge, any agent of the Group Companies has, since January 1, 2016: (i) made an untrue statement of material fact or fraudulent statement to the FDA or any other Governmental Authority, or in any records or documentation prepared or maintained to comply with the applicable Laws, with respect to any Company

29

Product; (ii) failed to disclose a material fact required to be disclosed to any Governmental Authority; (iii) been investigated by the FDA, National Institutes of Health, Office of the Inspector General for the Department of Health and Human Services, Department of Justice, or other comparable Governmental Authority for data or healthcare program fraud; or (iv) otherwise committed an act, made a statement, or failed to make a statement that, would reasonably be expected to provide a basis for the FDA to invoke its policy respecting "Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities" Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) (the "FDA Ethics Policy"). None of the Group Companies, nor any employee, nor, to the Company's knowledge, any agent of the Group Companies is or, since January 1, 2016, has been the subject of any pending or, to the Company's Knowledge, threatened investigation, action, or Proceeding pursuant to the FDA Ethics Policy or otherwise resulting from any other untrue, fraudulent, or false statement or omission.

(e)    As required under Law or pursuant to a Permit, the Group Companies have since January 1, 2016, maintained, filed, or furnished to the applicable Governmental Authority or Person all material filings, documents, claims, reports, notices, and other submissions (collectively, "Reports"), required to be maintained, filed, or furnished on a timely basis, and, at the time of maintenance, filing, or furnishing, all such Reports were complete and accurate in all material respects, or were subsequently updated, changed, corrected, or modified.

(f)    None of the Group Companies, nor, to the Company's Knowledge, any employee or agent of the Group Companies (in such capacity) has, since January 1, 2016: (i) been debarred, suspended, excluded, deemed ineligible, or disqualified under any Law or, to the Company's Knowledge, threatened with the same, including under 21 U.S.C. § 335a, 42 U.S.C. § 1320a-7, 42 C.F.R. Part 1001, or with respect to federal procurement and non-procurement programs or with respect to any equivalent foreign Laws; (ii) been disqualified or restricted pursuant 21 C.F.R. Parts 58, 312, 511, or 812, or otherwise listed in the FDA's Disqualification Proceedings database; (iii) been assessed or, to the Company's Knowledge, threatened with assessment of civil money penalties pursuant to 21 U.S.C. § 335b, 21 C.F.R. Part 17, or 42 C.F.R. Part 1003 or with respect to any equivalent foreign Laws; or (iv) been otherwise subject to any Proceeding or received written notice from a Governmental Authority either threatening or pursuing (i)-(iii) above.

(g)    There are not presently pending, nor, to Company's Knowledge, threatened, any civil, criminal or administrative Proceedings, demands, claims, notices of violation, investigations or demand letters or other written allegation relating to any alleged hazard or alleged defect in design, manufacture, materials or workmanship, including any failure to warn or alleged breach of express or implied warranty or representation, relating to any Company Product, or alleging that any Company Product is otherwise unsafe or ineffective for its intended use or improperly promoted or advertised. None of the Group Companies has since January 1, 2016 made a modification to any Company Product because of warranty, product Liability, regulatory or other claims or communications concerning alleged hazards or defects in such product. None of the Group Companies has since January 1, 2016 received any complaint or notice of any adverse drug experiences, device malfunctions, or other adverse events related to a Company Product that would have, or would reasonably be expected to have, a Material Adverse Effect on the Group Companies.

6.22 Condition and Sufficiency of Assets. Except as set forth on Schedule 6.22, the buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles and other items of tangible personal property of the Group Companies are structurally sound, are in good operating condition and repair, and are adequate for the uses to which they are being put, and none of such buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles and other items of tangible personal property is in need of material maintenance or material repairs, except for routine maintenance and repairs being carried out in the Ordinary Course. The buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles

30

and other items of tangible personal property currently owned or leased by the Group Companies, together with all other properties and assets of the Group Companies, are sufficient in all material respects for the continued conduct of the businesses of the Group Companies immediately after the Closing in substantially the same manner as conducted immediately prior to the Closing and constitute all of the materials rights, property and assets reasonably necessary in all material respects to conduct the businesses of the Group Companies as currently conducted.

6.23 Inventory. All inventory of the Group Companies, whether or not reflected in the Latest Balance Sheet, consists of a quality and quantity usable and salable in the Ordinary Course consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. All such inventory is owned by the applicable Group Company, free and clear of all Liens, other than Permitted Liens, and no inventory is held by any third Person on a consignment basis. The quantities of the Group Companies' inventory (whether raw materials, work in process or finished goods), taken as a whole, are not excessive, but are reasonable in the present circumstances of the Group Companies.

6.24 No Brokers. Except for the fee payable to William Blair & Company, L.L.C., none of the Group Companies has incurred any obligation for any finder's or broker's or agent's fees or commissions or similar compensation in connection with the Transactions.

6.25 Cyber-security and Data Privacy.

(a)    Each of the Group Companies is in compliance in all material respects with all applicable Laws, contractual obligations and payment card industry regulations regarding the collection, use and protection of Personal Data, including any information relating to an identified or identifiable natural person, and in compliance with applicable data protection rules in all jurisdictions in which any Group Company does business. The Group Companies, in the ordinary conduct of their businesses, have performed audits of their information security controls, system and procedures.

(b)    Since January 1, 2016, the Group Companies have complied in all material respects with (i) all of their own privacy policies and (ii) all Contracts with vendors, suppliers, service providers, marketing affiliates, and other business partners of each Group Company's businesses, in each case in clauses (i) and (ii), that are applicable to the collection, protection, storage, processing, use and/or disclosure of Personal Data in connection with the Group Companies' businesses (such policies and Contracts, the "Privacy Agreements"). No complaint relating to an improper use or disclosure of, or a breach in the security of, any Personal Data has been made or, to the Company's Knowledge, threatened against any of the Group Companies. The Privacy Agreements do not require the delivery of any notice to or consent from any Person, or prohibit the unqualified transfer of Personal Data, in connection with the execution, delivery, or performance of this Agreement.

(c)    Each of the Group Companies' systems, networks, hardware, software, servers, on and off-premises data storage, electronic information resources, computer communications facilities, applications, data, databases, operating systems, platforms, computers or other equipment with which any of the foregoing interacts ("Group Companies' IT Systems") are operational and, with respect to the Group Companies' IT Systems owned by the Group Companies, do not contain any Cyber Threats.

(d)    The Group Companies' IT Systems that are owned, licensed or used by the Group Companies in connection with the Group Companies' businesses are sufficient in all material respects for the current operations of the Group Companies' businesses.

31

(e)    Except as set forth on Schedule 6.25, since January 1, 2016, there has been no (i) infiltration or security breach of the Group Companies' IT Systems that has impacted the confidentiality, integrity or availability of any Personal Data or other confidential data of any of the Group Companies, (ii) unauthorized disclosure of any proprietary information or Personal Data in the possession, custody or control of the Group Companies or (iii) claim, action, complaint or Proceeding asserted or threatened in writing against any Group Company alleging a violation of any Person's rights of publicity or privacy, personal information, data rights or otherwise regarding data privacy.

(f)    The Group Companies have taken reasonable measures and implemented reasonable security procedures, standards, systems, policies and technologies consistent with applicable industry standards to protect the Group Companies' IT Systems and the Personal Data in the possession of the Group Companies.

6.26 Accounts Receivable. The accounts receivable reflected on the Latest Balance Sheet and the accounts receivable arising after the date thereof (a) have arisen from bona fide transactions entered into by the Group Companies in the Ordinary Course and (b) subject to the Group Companies' bad debt reserve, constitute only valid, undisputed claims of the Group Companies, not subject to claims of set-off or other defenses or counterclaims, other than normal cash discounts accrued in the Ordinary Course. The reserve for bad debts shown on the Latest Balance Sheet or, with respect to accounts receivable arising after the date of the Latest Balance Sheet, on the accounting records of the Group Companies, has been determined in accordance with GAAP, consistently applied, subject to normal year-end adjustments and the absence of disclosures normally made in footnotes.

6.27 Closing Cash Payment. The portion of the Closing Cash Payment payable to Blocker Seller and each Designated Unitholder shall have been determined in accordance with the requirements of the Operating Agreement.

6.28    Dissenters' Rights. None of the Unitholders are entitled to appraisal right or dissenters'

rights pursuant to Section 18-210 of the DLLCA.

6.29 No Additional Representations or Warranties. Except for the representations and warranties contained in this ARTICLE VI, neither the Company nor any other Person on behalf of the Company makes any other express or implied representation or warranty with respect to any of the Group Companies or with respect to any other information provided to Buyer or its Affiliates.

ARTICLE VII

PRE-CLOSING COVENANTS

7.01    Efforts. Subject to the terms of this Agreement (including the limitations set forth in

Section 7.02 and this Section 7.01), the Company will, and will cause its Subsidiaries to, use their commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper or advisable to consummate and make effective, as promptly as practicable, the Transactions, including using commercially reasonable efforts to cause the conditions to Closing set forth in ARTICLE X to be satisfied; provided that, except as otherwise specifically set forth in this Agreement, the Group Companies will not be required to (a) expend any money to remedy any breach of any representation or warranty hereunder, (b) commence any litigation or arbitration proceeding, (c) waive or surrender any right or modify any agreement (including any Material Contract), (d) offer or grant any accommodation or concession (financial or otherwise) to any third party, (e) make any payment to third parties, (f) obtain any consent required for the consummation of the Transactions, (g) waive or forego any right, remedy or condition hereby, or (h) provide financing to Buyer or Merger Sub for the consummation of the Transactions.

32

7.02    Regulatory Filings.

(a)    General. Subject to Section 7.02(b), each of Buyer, Merger Sub and the Company shall, and each shall cause its Affiliates to, use their commercially reasonable efforts to, as promptly as practicable, and in any event within five Business Days after the date of this Agreement, make all necessary filings (or drafts if required by any applicable Governmental Authority), and thereafter make any other required submissions, with respect to this Agreement required under any applicable Law, including the Hart-Scott-Rodino Act, the German Anti-Trust Law and any other antitrust Laws applicable to the Transactions. Buyer, Merger Sub and the Company shall, and each shall cause its Affiliates to, cooperate with each other in connection with obtaining all such consents, approvals, authorizations, declarations, waivers, licenses, franchises, permits or orders and the making of all such filings. Buyer, Merger Sub and the Company shall, and Buyer shall cause its Affiliates to, promptly furnish to each other all information required for any application or other filing to be made by any Party in connection with the Transactions. Buyer will not, and will not permit its Affiliates to, consent or agree to any voluntary delay of the consummation of the Transactions without the prior written consent of the Company.

(b)    Antitrust Laws. Buyer, Merger Sub and the Company agree to make, and to cause their Affiliates to make, any necessary filings under the Hart-Scott-Rodino Act, the German Anti-Trust Law and any other applicable antitrust Laws as soon as practicable and no later than five Business Days after the date of this Agreement, which filings shall include a request for early termination of the applicable waiting period under the Hart-Scott-Rodino Act, the German Anti-Trust Law and any other antitrust Laws. Buyer, Merger Sub and the Company shall, and shall cause their Affiliates to, comply at the earliest practicable date with any request under the Hart-Scott-Rodino Act, the German Anti-Trust Law or, if applicable, such other antitrust Laws to provide information, documents or other materials requested by any Governmental Authority. Buyer, Merger Sub and the Company shall, and shall cause their Affiliates to, (i) use their commercially reasonable efforts to resolve as soon as practicable any objections asserted by any Governmental Authority with respect to this Agreement or the Transactions and (ii) take all actions necessary to obtain termination or expiration of the applicable waiting period and all requisite clearances and approvals under the Hart-Scott-Rodino Act, the German Anti-Trust Law and any other applicable antitrust Laws (collectively, the "Antitrust Conditions") as promptly as practicable; provided that neither Buyer, Merger Sub or the Company shall have any obligation to agree to any structural or conduct remedy or to litigate. Buyer shall, and shall cause its Affiliates to, coordinate and cooperate with the Company, and the Company shall, and shall cause its Affiliates to, coordinate and cooperate with Buyer, in each case, in connection with their efforts to satisfy the Antitrust Conditions, including (A) cooperating in all respects with the other Party in connection with any investigation or other inquiry, (B) keeping the other Party promptly informed of any material communication received by Buyer or any of its Affiliates, or Company or any of its Affiliates, from any Governmental Authority, including the Federal Trade Commission, the U.S. Department of Justice or any similar foreign Governmental Authority, regarding any of the Transactions, (C) providing the other Party and its advisors with a reasonable opportunity to (x) review the content of any communication, presentations, white papers or other written materials to be submitted to any Governmental Authority in advance of any such submission, (y) consult with the other Party prior to any meeting or conference with any Governmental Authority, and (z) to the extent permitted by such Governmental Authority, attend and participate in such meetings or conferences. Buyer shall, in all cases act in good faith and in consultation with the Company to (1) determine timing and strategy and control the final content of any substantive oral or written communications with any applicable Governmental Authority in connection with the Antitrust Conditions, and (2) lead all proceedings and coordinate all activities with respect to seeking any actions, consents, approvals or waivers of any Governmental Authority in connection with the Antitrust Conditions. Buyer and the Company shall be equally responsible for the payment of all filing fees under the Hart-Scott-Rodino Act, the German Anti-Trust Law and any other antitrust Laws.

33

(c)    Other Actions. Except as specifically required by this Agreement, Buyer and the Company shall not, and each shall cause its Affiliates not to, knowingly take any action, or knowingly refrain from taking any action, the effect of which would reasonably be expected to delay or impede the ability of the Parties to consummate the Transactions by the End Date. Without limiting the generality of the forgoing, Buyer shall not, and shall not permit any of its Affiliates to, acquire or agree to acquire (by merging or consolidating with, or by purchasing a substantial portion of the assets of or equity in, or in any other manner), any Person or line of business or portion thereof, or otherwise acquire or agree to acquire any assets, if the entry into a definitive agreement relating to, or the consummation of, such acquisition would reasonably be expected to (i) impose any delay in obtaining, or increase the risk of not obtaining, any authorizations, consents, orders, declarations or approvals of any Governmental Authority necessary to consummate the Transactions or the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Act, the German Anti-Trust Law or any other applicable antitrust Laws, (ii) increase the risk of any Governmental Authority entering an order prohibiting or delaying the consummation of the Transactions or (iii) delay the consummation of the Transactions.

7.03 Conduct of the Business. Blocker Seller shall cause Blocker to, and the Company shall, and shall cause the Group Companies to, during the period from the date of this Agreement to the Closing or the earlier termination of this Agreement (the "Interim Period"), except as required by applicable Law, as set forth on Schedule 7.03 or as otherwise contemplated by this Agreement, or as consented to in writing by Buyer, use commercially reasonable efforts to conduct their respective businesses in the Ordinary Course. Without limiting the generality of the foregoing, during the Interim Period, except as required by applicable Law, as set forth on Schedule 7.03, as otherwise contemplated by this Agreement, as consented to in writing by Buyer, or for the use of available cash to repay any Funded Debt and pay Transaction Expenses prior to the Adjustment Time, Blocker Seller shall cause Blocker not to, and the Company shall not, and shall cause each of its Subsidiaries not to, take any of the following actions:

(a)    Absence of Certain Developments. Take any action that would be required to be set forth on Schedule 6.07 if such action had been taken prior to the date of this Agreement;

(b)    Equity Interests. Make any changes (by combination, merger, consolidation, reorganization, liquidation, split, combination, reclassification, adjustment or otherwise) in the capital structure of the Group Companies or Blocker, or redeem, repurchase or otherwise acquire or offer to redeem, repurchase or otherwise acquire any securities of the Group Companies or Blocker or otherwise amend the terms of any equity securities of the Group Companies or Blocker;

(c)    Tax. Make or change any material Tax election, make any change in any Tax accounting method (except as required by Law or as a result of a change in Law), change any annual accounting period for Tax purposes, amend any Tax Return, enter into any closing agreement (as defined in Section 7121 of the Code or similar provisions of state or local law), surrender any right to claim a refund of Taxes, consent to any extension or waiver of the limitation period applicable to any Tax claim or assessment or settle any material claim for Taxes or file any Tax Return in a manner inconsistent with past practice;

(d)    Payables, Receivables and Inventory. Other than in the Ordinary Course, accelerate the payment, funding, right to payment or collection of accounts receivable, delay the payment of accounts payable, defer expenses or reduce inventory levels;

(e)    Material Contracts. Enter into any Contract that if in existence on the date of this Agreement would be a Material Contract, or amend, modify, terminate or supplement any Material Contract, in each case, other than the entry into, or amendment, modification, termination or supplement of, customer or supplier Contracts in the Ordinary Course;

34

(f)    Related Party Transactions. Enter into any transactions with any Related Party (other than as contemplated by this Agreement, pursuant to any Contract set forth on the Schedules and transactions among the Group Companies);

(g)    Distributions. Declare, pay or set aside any distribution or make any distribution with respect to any equity interests of any of the Group Companies or the equity interests of Blocker; provided that the foregoing shall not prohibit the distribution of cash prior to 11:59 P.M. on the day immediately preceding the Closing Date;

(h)    Loans. Loan or advance any money or other property or modify any existing loan to any present or former director, manager, officer or employee of any of the Group Companies or Blocker other than advances for travel and other normal business expenses to officers and employees of the Group Companies or Blocker in the Ordinary Course;

(i)    Capital Expenditures. Make, or agree to make, any commitment with respect to any capital expenditures that are (x) in the aggregate, in excess of $2,500,000 or (y) not contemplated by the Group Companies' capital expenditure budget provided to Buyer prior to the date of this Agreement;

(j)    New Lines of Business. Enter into any new line of business outside of the businesses being conducted by the Group Companies as of the date of this Agreement other than in connection with the integration of businesses acquired prior to the date of this Agreement;

(k)    Licenses. Other than in the Ordinary Course, grant any license or sublicense of, or assign or transfer any material rights under or with respect to, any Company-Owned Intellectual Property;

(l)    Insurance Policies. Obtain any insurance policy with respect to the Group Companies, Blocker or their respective business or assets, other than to replace any Insurance Policy on terms materially similar thereto; or

(m)    Related Actions. Agree to do any of the foregoing.
7.04 Access to Information.

(a)    From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, Blocker and the Company shall provide Buyer and Buyer's authorized agents and representatives reasonable access, at reasonable times and upon reasonable advance notice, to Blocker's and the Group Companies' officers, employees, properties, books and records; provided that (i) such access does not unreasonably interfere with the operation of the Group Companies' business, (ii) in no event shall Buyer be permitted to conduct or cause to be conducted any intrusive environmental investigation, testing, sampling or other intrusive assessment of the current or former operations, facilities or real property of any of the Group Companies without the prior written consent of the Company (which may be given or withheld in the Company's sole discretion), and (iii) Blocker and the Group Companies shall not be required to furnish to Buyer or any of Buyer's authorized agents or representatives or provide Buyer or any of Buyer's authorized agents or representatives with access to information if such access (x) would result in the waiver or forfeiture of any attorney-client privilege, work product doctrine or similar privilege, (y) would be in violation of applicable Laws or (z) would violate any contractual confidentiality obligation of such party; provided, further, that Blocker or the Group Companies, as applicable, must have used their commercially reasonable efforts to obtain a waiver of any such contractual confidentiality obligation prior to invoking the exception set forth in clause (z) above.

35

(b)    From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, the Group Companies shall promptly furnish to Buyer copies of any material written notices or other written communications received from any Governmental Authority pertaining to the Company Products. The Company shall, subject to applicable Laws, provide Buyer with a reasonable opportunity to provide reasonable input in connection with any written response that any Group Company may determine to provide to any such Governmental Authority in connection with any such notice or communication.

(c)    From the date hereof until the Closing Date or the earlier termination of this Agreement, Buyer and Merger Sub shall not, and shall cause their Affiliates not to, contact any officer, director, employee, customer, supplier, distributor, lessee, lessor, equityholder, lender, noteholder or other material business relation of the Company or its Subsidiaries with respect to the Company, its Subsidiaries, their businesses or the Transactions, in each case, without receiving the prior written consent of the Chief Executive Officer of Ranir LLC.

7.05    Exclusivity.

(a)    From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, the Company shall not, and shall direct its directors, officers, employees, investment bankers and other representatives not to, (a) solicit, initiate or knowingly encourage the initiation of any Acquisition Proposal or take any action that could reasonably be expected to lead to an Acquisition Proposal, (b) participate in any discussions or negotiations with any third party regarding, or furnish to any third party any information in connection with, or take any other action to facilitate any inquiry or the making of any proposal or indication of interest that constitutes, or may reasonably be expected to lead to, an Acquisition Proposal, (c) approve, endorse or recommend an Acquisition Proposal or (d) enter into any letter of intent or similar document or any Contract contemplating or otherwise relating to any Acquisition Proposal. The Company shall immediately cease and cause to be terminated, and shall cause their respective Affiliates and all of their and their Affiliates' representatives to immediately cease and cause to be terminated, all existing discussions or negotiations with any Persons conducted prior to the date of this Agreement with respect to, or that could lead to, any Acquisition Proposal.

(b)    In addition to the other obligations under this Section 7.05, the Company shall promptly (and in any event within one Business Day after receipt thereof by the Company or its representatives) advise Buyer orally and in writing of any Acquisition Proposal, any request for information with respect to any Acquisition Proposal, the material terms and conditions of such request, Acquisition Proposal or inquiry, and the identity of the Person making the same.

(c)    The Company agrees that the rights and remedies for noncompliance with this Section 7.05 shall include having such provision specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach shall cause irreparable injury to Buyer and that money damages would not provide an adequate remedy to Buyer.

7.06 Confidentiality Agreement. Buyer, for itself and on behalf of its Affiliates, employees and advisors, hereby agrees to be bound by and to comply with the confidentiality agreement, dated as of January 18, 2019, by and between Perrigo Company plc and Ranir LLC (the "Confidentiality Agreement"). Any information provided to Buyer and Buyer's authorized agents and representatives pursuant to Section 7.04(a) shall be governed by the Confidentiality Agreement.

7.07 Notice of Certain Events. From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, the Company shall use commercially reasonable efforts to promptly notify Buyer in writing of:

36

(a)    any fact, circumstance, event or action the existence, occurrence or taking of which (A) has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or (B) has resulted in, or could reasonably be expected to result in, the failure of any of the conditions set forth in ARTICLE XI to be satisfied;

(b)    any written notice or other written communication from any Person alleging that the consent of such Person is or may be required in connection with the Transactions;

(c)    any notice or other communication from any Governmental Authority outside of the Ordinary Course or in connection with the Transactions; and

(d)    any actions commenced or, to the Company's Knowledge, threatened against, relating to or involving or otherwise affecting the Company that relates to the consummation of the Transactions.

Buyer's receipt of information pursuant to this Section 7.07 shall not operate as a waiver or otherwise affect any representation, warranty or agreement given or made by the Company in this Agreement and shall not be deemed to amend or supplement the Disclosure Schedules.

7.08 Intellectual Property. From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, each of the Group Companies shall use commercially reasonable efforts to make all filings at the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in the United States necessary to release outstanding Liens on any U.S. Registered Company-Owned Intellectual Property that have been paid and released; provided, that neither actually making any such filings nor any such office or agency actually updating its records shall be a condition to the obligations of Buyer and Merger Sub to consummate the Closing.

7.09 Payoff Letters. The Company will use its commercially reasonable efforts to deliver to Buyer for its review and comment, at least five days prior to the Closing, drafts of the Payoff Letters to be delivered to Buyer at the Closing.

7.10 401(k) Plan Termination. The Company shall cause Ranir LLC to adopt a resolution terminating the Ranir LLC 401(k) Plan (the "401(k) Plan") effective as of the date immediately prior to the Closing Date. No later than one day prior to the Closing Date, the Company shall provide Buyer with evidence that such resolution has been adopted and that Ranir LLC has fully vested all account balances. The form and substance of such resolutions shall be provided to Buyer for reasonable review and comment no later than three Business Days prior to the Closing Date. From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, the Company shall use commercially reasonable efforts to cause Ranir LLC to amend the loan policy of the 401(k) Plan so that any loans under the 401(k) Plan do not become due upon termination of the 401(k) Plan, and, to the extent such policy is amended, the Company shall deliver a copy of such amendment to Buyer no later than one day prior to the Closing Date.

7.11    Section 280G Approval. Blocker Seller shall cause Blocker to (a) no later than five Business Days prior to the Closing Date, use commercially reasonable efforts to obtain from each "disqualified individual" (within the meaning of Section 280G(c) of the Code), with respect to Blocker that is eligible to receive any payment or benefits that would constitute a "parachute payment" (within the meaning of Section 280G(b)(2)(A) of the Code), a waiver of such disqualified individual's rights to some or all of such payments or benefits, including any arrangements entered into by Buyer or its Affiliates with any such "disqualified individual" the details of which are made available to Blocker Seller at least ten Business Days prior to the Closing Date (the "Waived 280G Benefits"), to the extent necessary, so that all shall not be deemed to be

37

"excess parachute payments" (within the meaning of Section 280G of the Code) and (b) no later than two Business Days prior to the Closing Date, with respect to each individual who agrees to the waiver described in clause (a), submit to a stockholder vote, in a manner intended to satisfy the requirements of Section 280G(b)(5) of the Code and any regulations promulgated thereunder, the right of any such "disqualified individual" to receive the Waived 280G Benefits. Blocker Seller shall cause Blocker to provide drafts of such waivers and approval materials to Buyer for its reasonable review and comment no later than two Business Days prior to soliciting such waivers and soliciting such approval. Prior to the Closing, if any waiver described in clause (a) above is actually obtained, Blocker Seller shall deliver to Buyer evidence reasonably acceptable to Buyer that a vote of the applicable stockholders was solicited and that either (i) the requisite number of votes of the applicable stockholders was obtained with respect to the Waived 280G Benefits (the "280G Approval") or (ii) the 280G Approval was not obtained.

7.12 Specified Award Agreements. From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, the Company shall use commercially reasonable efforts to amend the phantom equity unit agreements set forth on Schedule 7.12 (each, a "Specified Award Agreement") to provide that any payment under such Specified Award Agreement must be made no later than the 90th day following a "Separation from Service" or "Sale of the Company" and that the applicable service provider does not have a right to designate the taxable year of payment, in accordance with Treasury Regulation Section 1.409A-3(b) and Internal Revenue Service Notice 2010-6, Part VI.A.

7.13 Third Party Consents. From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, the Company shall use commercially reasonable efforts to obtain the third party consents set forth on Schedule 7.13; provided that (a) the Group Companies shall not be required to make any payment or grant any economic or non-economic concession to any Person in connection with such efforts, (b) the failure of the Company to obtain any such consent shall not excuse Buyer and the Merger Sub from any of their obligations hereunder and (c) actually obtaining any such consent shall not be a condition to the obligations of Buyer and Merger Sub to consummate the Closing.

7.14 Other Items. From the date of this Agreement until the Closing Date or the earlier termination of this Agreement, the Company shall comply with Schedule 7.14.

ARTICLE VIII

POST-CLOSING COVENANTS

8.01 Further Assurances. From and after the Closing, upon the reasonable request of any Party and at such Party's expense, any other Party shall execute, acknowledge and deliver, or cause to be executed, acknowledged and delivered, all such further documents and instruments and shall take, or cause to be taken, all such further actions as the requesting Party may reasonably deem necessary or desirable to evidence and effectuate the Transactions.

8.02 Director and Officer Liability and Indemnification.

(a) Buyer shall cause the Company, each of its Subsidiaries and Blocker to maintain

in effect for a period of not less than six years from the Closing provisions in their organizational documents concerning the indemnification (including advancement of expenses) and exculpation of the their former and current officers, directors, employees and agents that are no less favorable to such officers, directors, employees and agents than the corresponding provisions of their organizational documents as of the date of this Agreement.

38

(b)    Prior to the Closing, the Company shall purchase an extended reporting period endorsement under the Company's existing directors' and officers' liability, employment practices liability and fiduciary insurance coverages to provide coverage for a period of at least six years after the Closing Date (the "D&O Tail"). Buyer shall not, and shall cause the Surviving Company and its Subsidiaries not to, take any action that results in the cancellation or termination of, or amend or otherwise modify, the D&O Tail. The cost of the D&O Tail shall be borne by the Company.

8.03 R&W Policy. During the policy period of the R&W Policy, Buyer shall not, and shall not permit any of its Affiliates to, amend, modify or waive any provision of the R&W Policy in a manner that is adverse to Blocker Seller without the prior written consent of Blocker Seller or to any Designated Unitholder without the prior written consent of the Representative.

8.04 Access to Books and Records. From and after the Closing until the seventh anniversary of the Closing Date, Buyer shall, and shall cause Blocker, the Surviving Company and its Subsidiaries, (a) not to destroy, alter or otherwise dispose of any Tax books and records of Blocker, the Surviving Company and its Subsidiaries, or any portions thereof, relating to periods prior to the Closing Date without first giving reasonable prior written notice to the Representative and offering to surrender to the Representative (on behalf of the Unitholders and Blocker Seller) such books and records or such portions thereof and (b) to provide the Representative and its authorized representatives with reasonable access, during normal business hours and under reasonable circumstances, to the Tax books and records of Blocker, the Surviving Company and its Subsidiaries with respect to periods prior to the Closing Date.

8.05    Transfer Taxes.

(a)    Buyer shall pay, or cause to be paid, when due all stamp tax, stock transfer tax or other similar Tax imposed on Blocker, the Group Companies, Blocker Seller or one or more of the Unitholders as a result of the Transactions, including 100% of any indirect transfer tax imposed by China (collectively, "Transfer Taxes") and shall file, or cause to be filed, all Tax Returns with respect to such Transfer Taxes. Notwithstanding the foregoing, Buyer, on the one hand, and the Representative (on behalf of Blocker Seller and the Unitholders), solely through inclusion of any such amounts in Transaction Expenses, on the other hand, shall each bear 50% of any indirect transfer tax imposed by Germany or India. The Representative shall use commercially reasonable efforts to cooperate with Buyer in the filing of any Tax Returns with respect to the Transfer Taxes.

(b)    If requested by Buyer, the Representative (on behalf of Blocker Seller and the Designated Unitholders) shall, at the sole cost and expense of Buyer, cooperate with Buyer's making filings in China pursuant to Circular 7 with respect to the Transactions.

8.06 Employee Matters.

(a)    For a period of ninety days after the Closing Date, neither Buyer nor the Surviving Company shall, and neither Buyer nor the Surviving Company shall permit any of the Surviving Company's Subsidiaries to, terminate employees of the Group Companies, except in full compliance with all requirements of the WARN Act; provided that neither Buyer nor the Surviving Company's obligation shall apply if the Liability arising under the WARN Act is a result of actions taken by the Group Companies within 90 days prior to the Closing Date.

(b)    During the period beginning on the Closing Date and ending on December 31, 2019, Buyer must, and must cause, as applicable, its Affiliates and the Group Companies to:

39

(i)    provide each employee of the Group Companies ("ContinuingEmployees") with a base annual salary or wage rate that is no less than the base annual salary or wage rate that is in effect for such Continuing Employee as of the date of this Agreement;

(ii)    not make any changes to the cash component of the Ranir Bonus Plan as disclosed on Schedule 6.13(a), Item 26 (and not including, for the avoidance of doubt, the Deferred Bonus Plan thereof);

(iii)    maintain the Plans set forth on Schedule 6.13 that are identified as group benefit Plans (other than the Company's 401(k) Plan); and

(iv)    grant each Continuing Employee with credit for any and all service with the Group Companies (and any predecessor thereof) earned prior to the Closing Date for eligibility and vesting purposes, and for purposes of vacation and paid time off accrual and severance benefit determinations, under each benefit or compensation plan, program, agreement or arrangement that may be established or maintained by Buyer, the Surviving Company or any of its or their respective Affiliates on or after the Closing Date and in which the Continuing Employees may at any time participate (the "NewPlans").

(c)    Buyer shall, or shall cause the Group Companies to, (i) within thirty (30) days following the Closing Date, have in effect one or more defined contribution plans that include a qualified cash or deferred arrangement within the meaning of Section 401(k) of the Code (collectively, "Buyer's401(k) Plan") in which the Continuing Employees may participate effective as of the Closing Date, and (ii) cause Buyer's 401(k) Plan to allow each Continuing Employee to, within 90 days following the Closing Date, make a "direct rollover" to Buyer's 401(k) Plan of the account balances of such Continuing Employee (including promissory notes for any outstanding loans; provided that Buyer and the Company shall cooperate to (A) ensure that any third party administrator of the 401(k) Plan and the third party administrator of Buyer's 401(k) Plan exchange all necessary information and (B) take all such actions necessary to be able to administer the rollover of, such promissory notes) under the 401(k) Plan to Buyer's 401(k) Plan.

(d)    The provisions of this Section 8.06 are for the sole benefit of the Parties and nothing herein, expressed or implied, is intended or shall be construed to (i) constitute an amendment to or modification of any New Plan or any Plan or other compensation and benefits plans or arrangements maintained for or provided to any Person prior to or following the Closing or (ii) confer upon or give to any Person, other than the Parties and their respective permitted successors and assigns, any legal or equitable or other rights or remedies (including any third-party beneficiary rights) with respect to the matters provided for in this Section 8.06 under or by reason of any provision of this Agreement.

8.07    Release.

(a)    From and after the Closing, Blocker Seller generally, irrevocably, unconditionally and completely releases, acquits and forever discharges Buyer, its representatives and their respective Affiliates, and each of their respective related parties, and each of the successors and assigns of any of the foregoing (the "Buyer Parties"), from all past, present and future losses of every kind, nature, description or character, whether known or unknown, liquidated or unliquidated, that Blocker Seller has, owns or holds, or claims to have, own or hold, or may have, own or hold, in each case, arising from the beginning of time through the Closing relating to any matter involving the Blocker Shares, Blocker, any of the Group Companies or their respective businesses, including breach of any fiduciary duty relating to any pre-Closing actions or failures to act by any Buyer Party; provided that nothing in this Section 8.07(a) shall constitute a release or waiver of any rights provided under this Agreement.

40

(b)    From and after the Closing, each of the Company, for itself and the other Group Companies, and Blocker generally, irrevocably, unconditionally and completely releases, acquits and forever discharges Blocker Seller, its representatives and their respective Affiliates, and each of their respective related parties, and each of the successors and assigns of any of the foregoing (the "BlockerSeller Parties"), from all past, present and future losses of every kind, nature, description or character, whether known or unknown, liquidated or unliquidated, that any Group Company or Blocker has, owns or holds, or claims to have, own or hold, or may have, own or hold, in each case, arising from the beginning of time through the Closing relating to any matter involving the Blocker Shares, Blocker, any of the Group Companies or their respective businesses, including breach of any fiduciary duty relating to any pre-Closing actions or failures to act by any Blocker Seller Party; provided that nothing in this Section 8.07(b) shall constitute a release or waiver of any rights provided under this Agreement.

(c)    The Company hereby acknowledges, agrees to, affirms, and covenants to comply with, be bound by, and honor, the release of claims set forth in Section 9 of the Letters of Transmittal as if such release of claims were set forth fully in this Agreement and the applicable Unitholder was a third party beneficiary thereof.

8.08 Insurance Receivables. After the Closing Date, Blocker Seller and the Unitholders shall be entitled to all Insurance Receivables received by Buyer or any of its Affiliates, any of the Group Companies or Blocker. Buyer will pay over or cause to be paid over to the Representative (for further distribution to Blocker Seller and the Unitholders) any such Insurance Receivables promptly (but in all cases within five Business Days) after actual receipt of such Insurance Receivables. Buyer or any of its Affiliates will use commercially reasonable efforts to collect the Insurance Receivables.

ARTICLE IX

TAX COVENANTS

9.01    Tax Return Filing.

(a)    After the Closing, Buyer shall prepare or cause to be prepared all Pass-Through Income Tax Returns of the Group Companies for periods ending on or before the Closing Date and the due date of which (taking into account extensions of time to file) is after the Closing Date, but only to the extent not filed prior to the Closing Date (the "Pre-Closing Buyer Returns"). Buyer shall submit each such Pre-Closing Buyer Return, along with all workpapers, to the Representative at least 30 days prior to the due date (taking into account any extensions) for the Representative's review and approval, which approval shall not be unreasonably withheld, conditioned or delayed; provided that, if Buyer and the Representative are not able to resolve any comments of the Representative with respect to any such Pre-Closing Buyer Return, then such items of disagreement shall be promptly submitted to and resolved by the Firm in accordance with standards for preparation of such Tax Returns set forth in this ARTICLE IX, including Section 9.01(c); provided, further, that, notwithstanding the forgoing proviso, if a Pre-Closing Buyer Return has to be filed prior to the resolution by the Firm, such Pre-Closing Buyer Return shall be filed as prepared by Buyer (and subject to any comments from the Representative to which Buyer agrees) and then, to the extent necessary upon resolution of such matter by the Firm, such Pre-Closing Buyer Return shall be amended and refiled consistent with such resolution by the Firm. The Representative and Buyer shall cooperate to timely file the Pre-Closing Buyer Returns but, for the avoidance of doubt, Buyer shall sign and file any Pre-Closing Buyer Return.

(b)    Excluding any Pre-Closing Buyer Returns, Buyer shall prepare or cause to be prepared all Tax Returns of the Group Companies and of Blocker for periods ending on or before the Closing Date and for any Straddle Period, in each case, the due date of which (taking into account extensions of time to file) is after the Closing Date. Buyer shall submit each such Tax Return that is a Pass-Through

41

Income Tax Return of any Group Company (a "Buyer Return") to the Representative along with all workpapers, at least 30 days prior to the due date (taking into account any extensions) for review and approval, which approval shall not be unreasonably withheld, conditioned or delayed (it being understood that any approval rights with respect to any Buyer Return shall not apply with respect to any matter previously determined with respect to such Buyer Return by the Firm in accordance with Section 9.01(c)(iii)); provided that if Buyer and the Representative are not able to resolve any comments of the Representative with respect to any such Buyer Return, then such items of disagreement shall be promptly submitted to and resolved by the Firm in accordance with standards for preparation of such Tax Returns set forth in this ARTICLE IX, including Section 9.01(c); provided, further, that, notwithstanding the forgoing proviso, if the Buyer Return has to be filed prior to the resolution by the Firm, such Buyer Return shall be filed in a manner consistent with the past procedures and practices and accounting methods of the Group Companies (except as otherwise agreed to by the Representative, in its sole discretion or, at the election of the Buyer, consistent with a Pre-Closing Buyer Return) and then, to the extent necessary upon resolution of such matter by the Firm, such Buyer Return shall be amended and refiled consistent with such resolution by the Firm. The Representative and Buyer shall cooperate to timely file the Buyer Returns but, for the avoidance of doubt, Buyer shall sign and file, or cause to be signed and filed, any Buyer Return.

(c)    All Pre-Closing Buyer Returns and Buyer Returns shall be prepared and filed in a manner consistent with the past procedures and practices and accounting methods of Blocker and the Group Companies and this ARTICLE IX; provided that (i) with respect to the preparation and filing of such Tax Returns, such Tax Returns shall reflect all applicable Transaction Tax Deductions in the Pre-Closing Tax Period so long as such Transaction Tax Deductions are "more likely than not" deductible (or deductible at a higher confidence level) in the Pre-Closing Tax Period (and, for that purpose, the safe-harbor election of Rev. Proc. 2011-29 (or corresponding state or local election) shall be made on the applicable Tax Return for any success-based fees), (ii) for the Tax year beginning prior to the Closing Date and ending on or after the Closing Date shall reflect an election under Section 754 of the Code (solely with respect to the Company's Income Tax Return) to the extent that such an election is not already in effect and (iii) if, in connection with preparing any Pre-Closing Buyer Return or any Buyer Return, Buyer believes that it is affirmatively required under applicable Law to prepare or file any Pre-Closing Buyer Return or Buyer Return in a manner inconsistent with past practices, procedures and accounting methods of the Group Companies, then Buyer shall promptly deliver written notice of such belief to the Representative, together with sufficient information setting forth the legal basis for determining that such action is so affirmatively required, and the Representative shall have a reasonable period to notify Buyer if it agrees or disagrees with such conclusion and the legal basis therefor. If the Representative does not agree with Buyer's conclusion, then such disagreement shall be promptly submitted to and resolved by the Firm (with the fees and expenses of the Firm borne by Buyer unless the Firm agrees with Buyer's position, in which event they would be borne by the Representative); provided that if the Firm determines that applicable law affirmatively requires the preparation and filing of a Pre-Closing Buyer Return or a Buyer Return to be prepared in a manner inconsistent with the past practices, procedures and accounting methods, then Buyer shall have the right to prepare such Pre-Closing Buyer Return or Buyer Return consistent with such decision in providing such Pre-Closing Buyer Return or Buyer Return to the Representative for its review and approval in accordance with Section 9.01(a) or Section 9.01(b), as applicable.

(d)    All matters submitted to the Firm for resolution pursuant to this ARTICLE IX shall be resolved pursuant to the procedures set forth in Section 3.03(b)(ii) of this Agreement for resolution as if such dispute were an Objection Dispute. The determination by the Firm shall be final and binding on the Parties.

9.02 Pre-Closing Tax Matters. After the Closing, Buyer shall not, and Buyer shall cause its Affiliates (including Blocker and the Group Companies) not to, take any of the following actions if such action is with respect to a Pass-Through Income Tax Return or Pass-Through Income Tax Matter, would

42

result in an increase in the Blocker Tax Liability Amount, the Tax Liability Amount, or would change any component of the Closing Cash Payment or otherwise affect any amounts payable by the Unitholders or their direct or indirect equityholders or members: (a) other than Tax Returns that are filed pursuant to Section 9.01, file or amend or otherwise modify any Tax Return relating to a Pre-Closing Tax Period, (b) after the date any Pre-Closing Buyer Return or Buyer Return is filed, amend or otherwise modify any such Tax Return, (c) make or change any Tax election or accounting method or practice with respect to, or that has retroactive effect to, any Pre-Closing Tax Period or (d) except for filing of any Tax Return pursuant to the procedures set forth in Section 9.03, extend or waive, or cause to be extended or waived, any statute of limitations or other period for the assessment of any Tax or deficiency related to a Pre-Closing Tax Period, or (e) except pursuant to the procedures set forth in Section 9.01, make or initiate any voluntary contact with a Taxing Authority (including any voluntary disclosure agreement or similar process) regarding any Pre-Closing Tax Period.

9.03 Tax Proceedings. Notwithstanding any other provision of this Agreement, the Representative shall have the sole right in its discretion to elect to represent the interests of the Group Companies and, in each case, their direct and indirect owners in any claim, audit, examination, or administrative or court proceeding relating to any audits or assessments or other disputes (including any settlement or disposition thereof) regarding any Taxes or any Tax Return filed by the Group Companies with respect to Pre-Closing Tax Periods for any Pass-Through Income Tax Matter (a "PT-Tax Proceeding")ending on or before the Closing Date or for which any Designated Unitholder could be liable pursuant to Section 2.09(c); provided that Buyer shall have the right to participate in the defense thereof and to employ counsel, at its own expense, separate from the counsel employed by the Representative; provided, further,that (x) the Representative shall not consent to the entry of any judgment, or settle, compromise or discharge any such claim, audit, examination, or administrative or court proceeding without the prior written consent of Buyer (which shall not be unreasonably withheld, conditioned or delayed) if such action would have the effect of increasing the present or future Tax Liability of the Company, and (y) a "push out" election shall be made under Section 6226 of the Code and the applicable regulations promulgated thereunder to the extent permitted with respect to a PT-Tax Proceeding. The Representative and Buyer shall jointly control any PT-Tax Proceeding with respect to any Straddle Period; provided, that (x) neither the Representative nor Buyer shall consent to the entry of any judgment, or settle, compromise or discharge any such claim, audit, examination, or administrative or court proceeding without the prior written consent of the other party (which shall not be unreasonably withheld, conditioned or delayed), and (y) a "push out" election shall be made under Section 6226 of the Code and the applicable regulations promulgated thereunder to the extent permitted with respect to a PT-Tax Proceeding. After the Closing, the Company and Buyer shall promptly notify the Representative, as applicable, in writing upon receiving notice from any Taxing Authority of the commencement of any such PT-Tax Proceeding, and Buyer shall take all action reasonably necessary (including providing a power of attorney) to enable the Representative, as applicable, to exercise its control rights as set forth in this Section 9.03.

9.04 Cooperation. Buyer, the Group Companies and Blocker and the Representative shall cooperate fully, as and to the extent reasonably requested by any other Party, in connection with the preparation and filing of Tax Returns pursuant to Section 9.01 and any audit, litigation or other proceeding with respect to Taxes and the computation and verification of any amounts paid or payable under Section 9.01 (including any supporting work papers, schedules and documents). Such cooperation shall include the retention and (upon the other Party's request) the provision of records and information which are reasonably relevant to any such audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. The Company shall, and shall cause its Subsidiaries to, retain all books and records with respect to Tax matters pertinent to the Group Companies relating to any Tax periods and shall abide by all record retention agreements entered into with any Taxing Authority, and shall give the Representative reasonable written notice prior to transferring, destroying or discarding any such books and records prior to the expiration of

43

the applicable statute of limitations for that Tax period, and if the Representative so requests, the Company shall, and shall cause its Subsidiaries to, allow the Representative to take possession of such books and records rather than destroying or discarding such books and records.

9.05 No Code Section 338 or Section 336 Election. Buyer shall not, and shall cause its Affiliates (including Blocker and the Group Companies) not to, make any election under Section 338 or 336 of the Code (or any similar provision under state, local or foreign Law) with respect to the acquisition of Blocker pursuant to this Agreement.

9.06 Straddle Period. To the extent it is necessary for purposes of this Agreement to determine the allocation of Taxes among a Straddle Period, Taxes of the Group Companies and Blocker, as applicable, based on or measured by income, gross or net sales, or payments or receipts shall be allocated between the Pre-Closing Tax Period and the Post-Closing Tax Period based on an interim closing of the books as of the close of business on the Closing Date and any other Taxes shall be allocated between the Pre-Closing Tax Period and the Post-Closing Tax Period on a per diem basis.

9.07 Closing of Tax Period.

(a)    The Parties shall, to the extent permitted or required under applicable Law, treat the Closing Date as the last day of the taxable period of the Group Companies for all Tax purposes; provided that the Parties agree that the Transactions result in a continuation of the Company and applicable Subsidiaries and not a termination within the meaning of Code Section 708(b) and no Party shall take a position inconsistent therewith for any Tax purpose.

(b)    With respect to the preparation of any Income Tax Return for any Straddle Period, the Parties agree (i) the Company shall use the "interim closing method" (and the "calendar day convention") pursuant to Code Section 706 (and any similar provision of state, local or non-U.S. law) to account for any varying interests in the Company such that any income, gain, loss and deduction (and any other items) for the portion of such Straddle Period ending on and including the Closing Date shall be allocated solely to the members of the Company with respect to the Pre-Closing Tax Period, (ii) all deductions of the Group Companies attributable to the Transactions (including any deductions attributable to the Transaction Tax Deductions) shall be taken into account in the Pre-Closing Tax Period (and allocated solely to the members of the Company with respect to the Pre-Closing Tax Period) to the extent "more likely than not" deductible (or deductible at a higher level of confidence) in the Pre-Closing Tax Period, determined as if the tax year ended on and included the Closing Date, and applying the seventy percent safe harbor election under Revenue Procedure 2011-29 to any "success based fees" to the extent applicable, (iii) any financing or refinancing arrangements entered into at any time by or at the direction of Buyer or its Affiliates or any other transactions entered into by or at the direction of Buyer or its Affiliates in connection with the Transactions shall not be taken into account in the Pre-Closing Tax Period, and (iv) any items of income, gain, loss and deduction attributable to transactions outside the Ordinary Course of business on the Closing Date after the time of the Closing shall not be taken into account in the Pre-Closing Tax Period.

(c)    If Buyer is a U.S. corporation, Buyer shall cause Blocker to join Buyer's "consolidated group" (as defined in Treasury Regulation Section 1.1502-76(h)) effective on the day after the Closing Date. In such event, the Parties agree that Buyer and its Affiliates and the Group Companies (i) shall not make an election under Treasury Regulation Section 1.1502-76(b)(2)(ii)(D) to ratably allocate items (or any make any similar election or ratably allocate items under any corresponding provision of state, local or foreign Law) and (ii) shall not apply the "next day" rule of Treasury Regulation Section 1.1502-76(b)(1)(ii)(B) with respect to any of the Transaction Tax Deductions.

44

9.08 Allocation of the Closing Cash Payment. For U.S. federal and applicable state income tax purposes, Buyer and the Representative shall allocate the Transaction Consideration (other than the Blocker Purchase Price) plus a ratable share of the applicable Liabilities of the Group Companies and any other relevant Tax items in accordance with the allocation principles set forth on the Allocation Schedule attached hereto as Exhibit H for purposes of determining the portion of the gain or loss recognized upon the sale of the Common Units and Incentive Units pursuant to the Merger that is attributable to the Company's "unrealized receivables," "inventory items" (as such terms are defined in Section 751 of the Code), and other items. Neither Buyer nor the Representative shall, and Buyer shall cause its Affiliates not to, take any position in any audits, tax returns or otherwise which is inconsistent with such allocation unless required to do so by applicable Law or good faith resolution of a tax contest.

9.09 Tax Treatment of Payments. Any adjustment payments pursuant to Section 3.03 will be deemed adjustments to the Closing Cash Payment, unless otherwise required by Law.

9.10 Merger Tax Liability. Notwithstanding anything to the contrary in this Agreement, Blocker Seller shall not be liable for any Taxes of Blocker attributable to any and all transactions that occur following the sale of the Blocker Shares, including any and all Taxes incurred as a result of the Merger.

ARTICLE X

CONDITIONS TO THE OBLIGATIONS OF BUYER AND MERGER SUB

The obligations of Buyer and Merger Sub to consummate the Transactions are subject to the satisfaction of the following conditions as of the Closing Date, any or all of which may be waived in whole or in part by Buyer:

10.01 Accuracy of Representations and Warranties. The Seller Fundamental Representations shall be true and correct in all respects (other than de minimis exceptions) as of the Closing Date as though such representations and warranties had been made on and as of the Closing Date (except that any such representations and warranties that are made as of a specified date shall be true and correct only as of such date). The representations and warranties set forth in ARTICLE V and ARTICLE VI) (other than the Seller Fundamental Representations) shall be true and correct (disregarding all qualifications or limitations as to "materiality," "in all material respects" or "Material Adverse Effect" set forth therein) as of the Closing Date as though such representations and warranties had been made on and as of the Closing Date (except that any such representations and warranties that are made as of a specified date shall be true and correct only as of such date), except where the failure of such representations and warranties to be true and correct has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

10.02 Compliance with Covenants. Each of the Company and Blocker Seller shall have performed in all material respects all of the covenants and agreements required to be performed by it under this Agreement prior to the Closing.

10.03 No Adverse Proceeding. No Proceeding by any Governmental Authority shall be pending against the Company or Blocker Seller wherein an unfavorable judgment, decree or order would reasonably be expected to prevent the performance of this Agreement or the consummation of any of the Transactions, declare unlawful the Transactions or cause such Transactions to be rescinded.

10.04 Termination of HSR Waiting Period. The waiting period under the Hart-Scott-Rodino Act shall have expired or been terminated.

45

10.05 German Merger Control Clearance. The merger control approval required under s.35 et seq. of the German Act against Restraints of Competition (Gesetz gegen Wettbewerbsbeschränkugen, GWB) (the "German Anti-Trust Law") shall have been obtained or, if applicable, shall have been deemed to have been obtained as a result of the expiry of the applicable waiting periods or jurisdiction having been declined.

10.06 No Material Adverse Effect. Since the date of this Agreement, there shall not have been, individually or in the aggregate, a Material Adverse Effect.

10.07 Dissenting Interests. Holders of not more than 10% of the issued and outstanding Common Units and Vested Incentive Units shall have properly demanded appraisal of, or dissenters' rights with respect to, such interests pursuant to Section 18-210 of the DLLCA.

10.08 Unitholder Consent. The Unitholder Consent shall remain in effect.

10.09 Closing Deliverables. Blocker Seller and the Company shall have delivered the items required to be delivered by them pursuant to Section 3.02.

ARTICLE XI

CONDITIONS TO THE OBLIGATIONS OF THE COMPANY AND BLOCKER SELLER

The obligation of the Company and Blocker Seller to consummate the Transactions is subject to the satisfaction of the following conditions as of the Closing Date, any or all of which may be waived in whole or in part by the Company, Blocker Seller and the Representative:

11.01 Accuracy of Representations and Warranties. The Buyer Fundamental Representations shall be true and correct in all respects (other than de minimis exceptions) as of the date of this Agreement and as of the Closing Date as though such representations and warranties had been made on and as of the Closing Date (except that any such representations and warranties that are made as of a specified date shall be true and correct only as of such date). The representations and warranties set forth in ARTICLE IV (other than the Buyer Fundamental Representations) shall be true and correct as of the date of this Agreement and as of the Closing Date, as though such representations and warranties had been made on and as of the Closing Date (except that any such representations and warranties that are made as of a specified date shall be true and correct only as of such date), except where the failure of such representations and warranties to be true and correct, individually or in the aggregate has not, or would not, individually or in the aggregate, reasonably be expected to have a Buyer Material Adverse Effect.

11.02 Compliance with Covenants. Each of Buyer and Merger Sub shall have performed in all material respects all of the covenants and agreements required to be performed by it under this Agreement at or prior to the Closing.

11.03 No Adverse Proceeding. No Proceeding by any Governmental Authority shall be pending wherein an unfavorable judgment, decree or order would reasonably be expected to prevent the performance of this Agreement or the consummation of any of the Transactions, declare unlawful the Transactions or cause such transactions to be rescinded.

11.04 Termination of HSR Waiting Period. The waiting period under the Hart-Scott-Rodino Act shall have expired or been terminated.

46

11.05 German Merger Control Clearance. The merger control approval required under the German Anti-Trust Law shall have been obtained or, if applicable, shall have been deemed to have been obtained as a result of the expiry of the applicable waiting periods or jurisdiction having been declined.

11.06 Closing Deliverables. Buyer shall have delivered the items required to be delivered by it pursuant to Section 3.02(b).

ARTICLE XII
DEFINITIONS

12.01 Defined Terms. As used herein, the following terms shall have the following meanings:

"280G Approval" has the meaning set forth in Section 7.11.

"401(k) Plan" has the meaning set forth in Section 7.10.

"Acquisition Proposal" means any proposal or offer from any Person (other than Buyer, Merger Sub and their respective accountants, attorneys, consultants, advisors, investment bankers, or other representatives) relating to any merger or recapitalization involving any of the Group Companies, any sale of a majority of the equity securities of any of the Group Companies, any sale of all or substantially all of the assets of any of the Group Companies or other similar transaction involving any of the Group Companies (excluding, for the avoidance of doubt, sales of inventory in the Ordinary Course).

"Adjustment Escrow Amount" means $6,000,000.

"Adjustment Escrow Fund" means, as of any date, the amount of funds then held by the Escrow Agent pursuant to the Escrow Agreement.

"Adjustment Time" means 12:01 a.m. prevailing Eastern Time on the Closing Date.

"Affiliate" of any particular Person means any other Person controlling, controlled by or under common control with such particular Person, where "control" means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, contract or otherwise.

"Agreement" has the meaning forth in the Preamble.

"Anti-Corruption Laws" means all applicable Laws relating to the prevention of corruption and bribery, including the U.S. Foreign Corrupt Practices Act of 1977.

"Antitrust Conditions" has the meaning set forth in Section 7.02(b).

"Authorized Action" has the meaning set forth in Section 14.17(d).

"Bankruptcy and Equity Exceptions" has the meaning set forth in Section 4.03."Base Amount" means $750,000,000.

"Blocker" has the meaning set forth in the Recitals.

"Blocker Adjustment Payment" has the meaning set forth in Section 3.03(b)(iv).

47

"Blocker Closing" has the meaning set forth in Section 1.03.

"Blocker Closing Payment" has the meaning set forth in Section 1.02(a).

"Blocker Company Units" has the meaning set forth in the Recitals.

"Blocker Fundamental Representations" means the representations and warranties set forth in Sections 5.01, 5.02, 5.03, 5.05, 5.06 and 5.10.

"Blocker Purchase" has the meaning set forth in the Recitals.
"Blocker Purchase Price" has the meaning set forth in Section 1.02.

"Blocker Seller" has the meaning set forth in the Preamble.
"Blocker Shares" has the meaning set forth in the Recitals.

"Blocker Tax Liability Amount" means an amount, which may be a positive or negative number, equal to the sum of the amounts separately calculated pursuant to this definition with respect to each jurisdiction in which the Blocker is currently filing Tax Returns and, with respect to each such jurisdiction, the amount calculated shall be the amount equal to (a) the liability of Blocker for Income Taxes owing and unpaid as of the Closing Date (which, for the avoidance of doubt, shall be reflected as a positive number) or (b) the overpayment by Blocker of Income Taxes as of the Closing Date (which, for the avoidance of doubt, shall be reflected as a negative number), in each case, with respect to such jurisdiction computed for the taxable period (or portion thereof) ending on and including the Closing Date; provided that such amounts shall be calculated (i) in accordance with the past practice (including reporting positions, elections and accounting methods) of Blocker in preparing Tax Returns for Income Taxes, (ii) by excluding all deferred Tax Liabilities and deferred Tax assets, in each case, established for purposes of United States generally accepted accounting principles, (iii) by treating the Closing Date as the final day of the taxable year of Blocker (but not for purposes of treating any "deferred revenue" as having accelerated into the Pre-Closing Tax Period for U.S. federal and applicable state and local tax purposes), (iv) by including unpaid Taxes imposed by application of Section 965 of the Code (including any Taxes deferred by an election under Section 965(h) of the Code), (v) by allocating to the Pre-Closing Tax Period all deductions with respect to any Transaction Tax Deductions that are "more likely than not" deductible (or deductible with a higher confidence level) in a Pre-Closing Tax Period and applying the seventy percent safe-harbor election under Revenue Procedure 2011-29 to any "success based fees," (vi) by excluding any amounts taken into account in calculating any of Cash Amount, Funded Debt or Transaction Expenses, (vii) by excluding any liabilities for accruals or reserves established or required to be established under United States generally accepted accounting principles methodologies that require the accrual for contingent Income Taxes as defined by IFRS or with respect to uncertain Tax positions as defined by GAAP or other similar accounting methodologies and any liabilities arising from any change in any accounting method of any of the Group Companies made following the Closing, and (viii) by treating any overpayments of Income Taxes with respect to the tax year ending on December 31, 2018 as a payment of Taxes by the Blocker in the tax period (or portion thereof) ending on the Closing Date for purposes of determining the liability of Blocker for Income Taxes or the overpayment by Blocker of Income Taxes, as applicable, for the tax period (or portion thereof) ending on the Closing Date.

"Business Day" means any day, excluding Saturday, Sunday and any other day on which commercial banks in New York, New York or Chicago, Illinois are authorized or required by law to close.

"Buyer" has the meaning set forth in the Preamble.

48

"Buyer Fundamental Representations" means the representations and warranties set forth in Sections 4.01, 4.02, 4.03 and 4.05.

"Buyer Material Adverse Effect" means a material adverse effect on the ability of Buyer or Merger Sub to consummate the Transactions and perform all of their respective obligations hereunder and under the other Transaction Documents to which they are party in a timely manner.

"Buyer Parties" has the meaning set forth in Section 8.07."Buyer Returns" has the meaning set forth in Section 9.01(b)."Buyer's 401(k) Plan" has the meaning set forth in Section 8.06.

"Cash Amount" means, expressed in United States dollars, (a) all cash and cash equivalents that are convertible into cash within 30 days or less (including marketable securities, checks, bank deposits and short term investments and the value of any in-the-money currency and interest rate swaps less the value of any out-of-the-money currency and interest rate swaps to the extent not included as Funded Debt) of Blocker and the Group Companies, less (b) issued but uncleared checks, bank overdrafts and negative cash balances in other accounts, plus (c) checks, other wire transfers and drafts which have been received by Blocker and the Group Companies but not yet cleared, in each case, as of as of the Adjustment Time; provided, that the Cash Amount shall be reduced by the use of any cash or cash equivalents of the Group Companies between the Adjustment Time and the Closing to make distributions to any Unitholder, to repay Funded Debt or to pay Transaction Expenses. For the avoidance of doubt, Restricted Cash shall not be included in the Cash Amount.

"Certificate of Merger" has the meaning set forth in Section 2.02."Closing" has the meaning set forth in Section 3.01.

"Closing Cash Payment" means the amount equal to (a) the Base Amount, plus (b) the Cash Amount, minus (c) the outstanding amount of all Funded Debt as of the Adjustment Time, minus (d) the Transaction Expenses, minus (e) the Adjustment Escrow Amount, minus (f) the Representative Holdback, minus (g) the Tax Liability Amount and the Blocker Tax Liability Amount, minus (h) the Working Capital Deficit, if any, plus (i) the Working Capital Surplus, if any.

"Closing Date" has the meaning set forth in Section 3.01.

"Closing Statement" has the meaning set forth in Section 3.03(b)(i).

"Code" means the Internal Revenue Code of 1986.

"Common Unit" means a Unit (as defined in the Operating Agreement) of the Company that is not an Incentive Unit.

"Company" has the meaning set forth in the Preamble.

"Company Fundamental Representations" means the representations and warranties set forth in Sections 6.01, 6.02, 6.03, 6.04 and 6.24.

"Company Intellectual Property" means the Company-Owned Intellectual Property together with the Intellectual Property used or held for use by the Group Companies that is owned by a third party.

49

"Company Products" has the meaning set forth in Section 6.21(a).

"Company-Owned Intellectual Property" means the Intellectual Property owned or purported to be owned by the Group Companies.

"Company's Knowledge" means the actual knowledge, after due inquiry of Rich Sorota, Steve Weinberger, Gijsbert Dezaire, Michael Bregenzer, Maureen Bryan, Mark McCumby and Julie Nass.

"Confidentiality Agreement" has the meaning set forth in Section 7.06."Continuing Employees" has the meaning set forth on Section 8.06.

"Contract" means any contract, lease, deed, mortgage, license, instrument, note, commitment, undertaking, indenture, joint venture and any other agreement, legally binding arrangement, commitment or other legally binding agreement (whether written or oral).

"Cyber Threat" means any malicious intrusion or program routine, device, code or instructions or other undisclosed feature, including any virus, software lock, self-destruction, drop-device, malicious logic, ransomware, banking malware, worm, Trojan horse, trap door, "disabling," lock out," "metering" device, undocumented code, or any malicious code, that is capable of, in an unauthorized manner, accessing, modifying, deleting, damaging, disabling, corrupting, deactivating, interfering with or otherwise harming the Group Companies' IT Systems.

"D&O Tail" has the meaning set forth in Section 8.02(b).

"Designated Courts" has the meaning set forth in Section 14.11(a)."Designated Unitholder" means each Unitholder other than Blocker.

"Distribution Principles" means the principles of distribution set forth in Section 9.5(b) of the Operating Agreement (i.e., the principles of distribution if all of the assets and properties of the Group Companies were sold and the resulting proceeds were distributed among the members of the Company pursuant to Section 9.5(b) of the Operating Agreement) taking into account the principles of Section 6.4 of the Operating Agreement; provided that the Distribution Principles shall be applied such that (a) the Blocker Tax Liability Amount and any Funded Debt or Transaction Expenses of Blocker reduce or increase, as applicable, only the proceeds payable with respect to the Blocker Company Units and (b) any Cash Amount of the Blocker increases only the proceeds payable with respect to the Blocker Company Units.

"DLLCA" has the meaning set forth in the Recitals.

"Effect" has the meaning set forth in the definition of Material Adverse Effect.

"Effective Time" has the meaning set forth in Section 2.02.

"End Date" means the date that is 240 days after the date of this Agreement.

"Environmental Laws" means all applicable Laws enacted and in effect on or prior to the Closing Date concerning pollution or protection of public health, the environment, natural resources and worker health and safety, including all those relating to the presence, use, production, generation, handling, transportation, treatment, recycling, storage, disposal, distribution, labeling, testing, registration, processing, discharge, Release, control, investigation or cleanup of or exposure to any Hazardous Materials.

50

"Environmental Permit" means any federal, state, local, provincial, or foreign permits, licenses, approvals, registrations, waivers, consents or authorizations required by any Governmental Authority under or in connection with any Environmental Law (including any and all orders, consent orders or binding agreements issued by or entered into with a Governmental Authority under any applicable Environmental Law) for the Group Companies to own, operate or occupy their businesses or properties.

"ERISA" means the Employee Retirement Income Security Act of 1974. "Escrow Agent" means Acquiom Clearinghouse, LLC.

"Escrow Agreement" means an Escrow Agreement in the form of Exhibit I attached hereto, to be dated as of the Closing Date, by and among the Escrow Agent, the Representative, US Buyer and Irish Buyer.

"Estimated Closing Cash Payment" has the meaning set forth in Section 3.03(a)(i)."Estimated Closing Statement" has the meaning set forth in Section 3.03(a)(i)."FDA" means the Food and Drug Administration of the United States of America. "FDA Ethics Policy" has the meaning set forth in Section 6.21(d).

"Financial Statements" has the meaning set forth in Section 6.06(a).

"Firm" has the meaning set forth in Section 3.03(b)(ii).

"Funded Debt" means, as of the time of determination, without duplication: (a) the amount of all indebtedness for borrowed money by Blocker or the Group Companies; (b) long or short-term obligations of Blocker or the Group Companies evidenced by bonds, debentures, notes or other similar instruments or debt securities; (c) any obligation of Blocker or the Group Companies evidenced by any surety bonds, letters of credit or bankers' acceptances or similar facilities, in each case, solely to the extent drawn upon; (d) Liabilities of Blocker or the Group Companies under leases that have been classified as capitalized leases on the Latest Balance Sheet and, if applicable, additional leases that are entered into between the date of the Latest Balance Sheet and the Adjustment Time that are classified as capital leases in accordance with GAAP, applied consistently with the Group Companies' past practices; (e) obligations under any interest rate, currency swap or other hedging agreement or arrangement; (f) obligations for the deferred purchase price of property, business, assets, securities or services in respect of which Blocker or any of the Group Companies are liable, contingently or otherwise (including the maximum value of any "earn-outs" and "seller notes" payable); (g) any declared but unpaid dividends owed to any Unitholder; (h) any outstanding obligations for the lease buyout associated with the German manufacturing facility closure (including any corresponding severance payment obligations) and (i) guarantees by Blocker or any of the Group Companies of any of the obligations referred to in the foregoing clauses (a) through (h) (but only to the extent called upon or drawn) and (i) any unpaid principal, premium, accrued and unpaid interest, prepayment or termination penalties, breakage costs, related expenses, commitment and other fees, reimbursements and all other amounts payable in connection with any amounts covered by clauses (a) through (h) above (including, as applicable, as a result of the prepayment of such obligations); provided that Funded Debt shall not include (A) any amounts included in Transaction Expenses or Working Capital,

(B) any Liabilities or obligations related to inter-company debt between or among the Group Companies or

(C) obligations for leases classified as operating leases in the Financial Statements, (D) any undrawn surety bonds, letters of credit or bankers' acceptances or similar facilities or (E) the benefit of any unamortized debt issuance costs.

51

"Future Distribution Amount" means any amounts to be distributed to the Unitholders or Blocker Seller pursuant to the Escrow Agreement, Section 3.03(b), Section 8.08 or Section 14.17(c).

"GAAP" means United States generally accepted accounting principles as applicable to private companies.

"Government Official" means any officer or employee of a Governmental Authority, including state-owned entities, or of a public organization or any Person acting in an official capacity for or on behalf of any Governmental Authority or public organization.

"Governmental Authority" means any United States or non-United States, federal, state, provincial or local governmental or regulatory commission, arbitrator, arbitral forum, board, bureau, agency, court or regulatory or administrative body.

"Group Companies" means the Company and each of its Subsidiaries.

"Group Companies' IT Systems" has the meaning set forth in Section 6.25(c).

"Hart-Scott-Rodino Act" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

"Hazardous Materials" means petroleum, petroleum hydrocarbons or petroleum products, petroleum by-products, radioactive materials, asbestos or asbestos-containing materials, gasoline, diesel fuel, pesticides, radon, urea formaldehyde, mold, lead or lead-containing materials, polychlorinated biphenyls and any other chemicals, materials, substances or wastes in any amount or concentration that are regulated under or for which Liability can be imposed under any Environmental Law due to their hazardous, toxic, dangerous or deleterious properties or characteristics.

"Health Care Law" has the meaning set forth in Section 6.13(i).

"IFRS" means the International Financial Reporting Standards issued by the International Accounting Standards Board as of the date of this Agreement.

"Inbound License" means each license, sublicense, agreement, or other permission entered into by the Group Companies granting the Group Companies a license to use or hold for use any Intellectual Property owned by a third party.

"Incentive Unit" means an Incentive Unit (as defined in the Operating Agreement) of the Company.

"Income Tax Return" means all Tax Returns filed or required to be filed with any Taxing Authority with respect to Income Taxes including with respect to any Pass-Through Income Tax Matter.

"Income Taxes" means Taxes imposed on, or determined by reference to, net income, or franchise taxes imposed in lieu of Taxes on net income.

"Insurance Policies" has the meaning set forth in Section 6.15.

"Insurance Receivables" means insurance proceeds due to the Company or the Group Companies pursuant to claim number KY18K2533201 under policy number EON G29519547 001.

"Intellectual Property" means all intellectual property and proprietary rights throughout the world, including (a) inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereon, and all patents, patent applications and patent disclosures, together with all

52

provisionals, reissues, continuations, continuations-in-part, divisions, renewals, extensions and reexaminations thereof, (b) all design patents, design rights and industrial designs, including product and product packaging designs, together with all registrations and applications therefor, (c) all trademarks, service marks, trade dress, product designs, product packaging designs, logos, slogans, trade names, domain names, URLs, brand names, corporate names, user names, screen names, social media identifiers (including social media names, "tags," and "handles" as well as accounts with Twitter, Facebook and other social media companies) or other designations of source or origin, together with all goodwill associated with and symbolized by any of the foregoing, whether or not applied for or registered and all applications, registrations and renewals in connection therewith, (d) all copyrights and copyrightable works, including, product packaging designs, artwork and images, documentation, advertising copy, marketing materials, product descriptions, inserts, website content, translations, specifications, mask works, drawings, graphics, designs, databases, recordings and other works of authorship and derivative works thereof, and all applications, registrations and renewals in connection therewith, (e) all trade secrets and confidential information, know-how, formulas, compositions, manufacturing and production processes and techniques, methods, schematics, product road maps, technical data, designs, drawings, flowcharts, block diagrams and specifications, (f) all computer software (including data and related documentation) and databases, and any and all software implementations of algorithms, specifications, models and methodologies, whether in source code or object code, design documents, flow-charts, user manuals and training materials relating thereto, (g) all copies and tangible embodiments of any and all of the foregoing, and (h) all causes of action resulting from past, current and future infringement of any and all of the foregoing, including all rights to and claims for damages and injunctive relief for infringement, or other violation, with the right but no obligation to sue for such legal and equitable relief.

"Interim Financial Statements" has the meaning set forth in Section 6.06(a).

"Interim Period" has the meaning set forth in Section 7.03.

"IRS" means the Internal Revenue Services of the United States of America.

"Key Customer" has the meaning set forth in Section 6.20(a).

"Key Supplier" has the meaning set forth in Section 6.20(b).

"Latest Balance Sheet" has the meaning set forth in Section 6.06(a).

"Law" means any federal, state, local, municipal, foreign, order, constitution, law (including common law), ordinance, code, rule, judgment, decree, regulation, statute or treaty.

"Leased Real Property" has the meaning set forth in Section 6.10(b)."Letter of Transmittal" has the meaning set forth in Section 2.08(b)."Liabilities" has the meaning set forth in Section 6.06(b).

"Lien" means any lien (statutory or otherwise), mortgage, deed of trust, pledge, security interest, charge, claim, encroachment, right of first refusal, easement or other restriction of any kind, but excluding restrictions on transfer generally arising under federal and state securities Laws.

"Material Adverse Effect" means any state of facts, event, effect, occurrence, condition, violation, breach, default, failure to comply, change in circumstance, loss or development (each, an "Effect"), or combination thereof, that has had, or could reasonably be expected to have, individually or in the aggregate,

53

a material adverse effect upon (a) the condition (financial or otherwise), business or operating results of the Group Companies, taken as a whole, or (b) the ability of Blocker Seller and the Company to perform their respective obligations under this Agreement; provided that none of the following (or the results thereof) will constitute, either alone or in combination, or be taken into account in determining whether there has been or will be, a Material Adverse Effect: (i) general economic or geopolitical conditions affecting generally the industries or markets in which the Group Companies operate; (ii) Effects attributable to acts of terrorism, sabotage, cyber-attack, military action, declaration of a national emergency or war (regardless of whether declared) or any escalation or worsening thereof; (iii) conditions generally affecting the United States or worldwide economy or credit, financial, banking, securities or capital markets; (iv) any earthquake, hurricane, tsunami, tornado, flood, mudslide or other natural disaster, weather condition, explosion or fire or other act of God; (v) changes or prospective changes in United States generally accepted accounting principles; (vi) changes or prospective changes in Laws or the enforcement or interpretation thereof or any action required to be taken under any Law by which the Company or its Subsidiaries (or any of their respective assets or properties) is bound; (vii) (w) the taking of any action permitted or required by this Agreement or taken at the written request of Buyer or its Affiliates, (x) the failure to take any action if such action is prohibited by this Agreement, (y) Buyer's failure to consent to any of the actions prohibited by Section 7.03 or (z) the negotiation or execution of this Agreement or any other Transaction Document or announcement, pendency or consummation of this Agreement or the Transactions or the identity, nature or ownership of Buyer, including the impact thereof on the relationships, contractual or otherwise, of the Company or any of its Subsidiaries with any of its or their business relations or employees; (viii) any failure, in and of itself, to meet any budgets, projections, forecasts, predictions, revenue, earnings or performance metrics or operating statistics (but, for the avoidance of doubt, not the underlying causes of any such failure to the extent such underlying cause is not otherwise excluded from the definition of Material Adverse Effect); (ix) the matters expressly set forth on, and solely to the extent expressly described on, the Schedules; and (x) any action taken by Buyer or its Affiliates with respect to the Transactions, except, in the case of clauses (i) through (vi), to the extent such Effect has a disproportionate impact on the Group Companies, taken as a whole, as compared to other participants engaged in the industries and geographies in which the Group Companies operate.

"Material Contracts" has the meaning set forth in Section 6.18(a).

"Merger" has the meaning set forth in the Recitals.

"Merger Sub" has the meaning set forth in the Preamble.

"New Plans" has the meaning set forth in Section 8.06.

"Objection Disputes" has the meaning set forth in Section 3.03(b)(i).

"Objection Statement" has the meaning set forth in Section 3.03(b)(i).

"Off-the-Shelf License" means each license, sublicense, Contract, or other permission for commercially available computer software programs licensed on a non-exclusive basis under "shrink wrap" or other standard form licenses that, in each case, has incurred license fees on an annual basis of less than $250,000.

"Operating Agreement" means that Fifth Amended and Restated Limited Liability Company Agreement of the Company, dated November 9, 2012, as amended.

"Ordinary Course" means the ordinary course of business of Blocker or the Group Companies, as applicable, consistent with past practice (including with respect to quantity and frequency).

54

"Outbound License" means each license, sublicense, Contract or other permission entered into by the Group Companies that grants to any Person a license of any Company Intellectual Property.

"Overpayment Credits" means any overpayment of Taxes from a Pre-Closing Tax Period or any prepayment of Taxes in a Pre-Closing Tax Period applied to reduce Taxes in a tax period beginning after the Closing Date.

"Owned Real Property" has the meaning set forth in Section 6.10(c)."Party" or "Parties" has the meaning set forth in the Preamble.

"Pass-Through Income Tax Matter" means any matter relating to the determination of (A) any U.S. state non-resident withholding taxes with respect to the Group Companies or (B) any income taxes with respect to the operations of the business of the Company and/or any of its Subsidiaries if any of the Unitholders (or their direct and indirect owners) would be liable as a matter of Law for such income taxes (e.g., the income tax Liability for items of income, gain, loss, deduction and credit passed-through to owners with respect to a partnership for U.S. federal or applicable state and local income tax purposes).

"Pass-Through Income Tax Return" means any Tax Return with respect to income taxes of the Company and/or any of its Subsidiaries if any of the Unitholders (or their direct and indirect owners) would be liable as a matter of Law for such income taxes.

"Paying Agent" has the meaning set forth in Section 2.08(a).

"Paying Agent Agreement" has the meaning set forth in Section 2.08(a).

"Payoff Letters" has the meaning set forth in Section 3.02(c).

"Permits" has the meaning set forth in Section 6.16.

"Permitted Liens" means (i) Liens for Taxes not yet delinquent or for Taxes being contested in good faith through appropriate proceedings that are reserved for on the Financial Statements in accordance with GAAP, (ii) purchase money Liens, (iii) customary Liens of lessors, lessees, sublessors, sublessees, licensors or licensees arising under lease arrangements of license arrangements, (iv) Liens relating to Funded Debt included in the calculation of the Closing Cash Payment pursuant to this Agreement that will be eligible for release pursuant to the Payoff Letters, (v) Liens arising in the Ordinary Course of business and not incurred in connection with the borrowing of money, none of which materially impacts the current use or value of the affected property, (vi) mechanics Liens and similar Liens for labor, materials, or supplies arising in the Ordinary Course of business for amounts not yet overdue, (vii) zoning, building codes, and other land use Laws regulating the use or occupancy of real property or the activities conducted thereon that are imposed by any Governmental Authority having jurisdiction over such real property and which are not violated in any material respect by the current use and operation of such real property by the Group Companies, (viii) easements, servitudes, covenants, conditions, restrictions, and other similar non-monetary matters affecting title to any assets of the Group Companies and other title defects that do not materially impair the use or occupancy of such assets in the operation of the business of the Group Company in question, (ix) with respect to the Leased Real Property, all Liens which are suffered or incurred by the fee owner, any superior lessor, sublessors or licensor, or any inferior lessee, sublessee or licensee, that do not materially impair the use or occupancy of such assets in the operation of the businesses of the Group Companies, (x) non-monetary Liens in respect of all matters set forth on title policies or surveys made available by the Company to Buyer prior to the date of this Agreement that do not materially impair the use or occupancy of such assets in the operation of the businesses of the Group Companies taken as a whole,

55

(xi) non-exclusive licenses of Intellectual Property granted in the Ordinary Course and (xii) Liens set forth on Schedule 12.01.

"Person" means an individual, partnership, corporation, limited liability company, business trust, joint stock corporation, estate, trust, unincorporated association, joint venture, Governmental Authority or other entity, of whatever nature.

"Personal Data" means any information (including a person's name, street address, telephone number, e-mail address, photograph, social security number, tax identification number, driver's license number, passport number, payment card number, bank account information and other financial information, customer or account numbers, account access codes and passwords, medical records, internet protocol address, geographic location, health or diet information, family members, political beliefs, group memberships, internet browsing history, persistent or unique identifier, order and purchase histories, amounts spent, platform behavior, conduct, preferences, demographic data and any other data and information, including, for the avoidance of doubt, any information regarded as "personal data" pursuant to any applicable Law) which, whether alone or in combination with other information, identifies or is associated with an identified or identifiable natural person.

"Plan" means each "employee benefit plan" (within the meaning of Section 3(3) of ERISA), whether or not subject to ERISA, and each other employment, consulting, severance, change in control, retention, bonus, pension, profit sharing, executive compensation, deferred compensation, incentive compensation, stock compensation, stock purchase, stock option, stock appreciation, phantom stock option, health or other medical, dental, life, disability, vacation, tuition reimbursement, cafeteria, fringe benefit or any other employee benefit or compensation plan, program, policy, agreement or arrangement (whether for the benefit of one individual or more than one individual) (i) that is sponsored, maintained or contributed to or required to be contributed to by any of the Group Companies, or (ii) with respect to which any of the Group Companies has any material Liability, in each case, other than any plan, program, policy, agreement or arrangement that is required to be maintained or contributed to by applicable Law (other than the Healthcare Law).

"Pre-Closing Buyer Returns" has the meaning set forth in Section 9.01(a).

"Post-Closing Tax Period" means any taxable period or portion of a taxable period that is not a Pre-Closing Tax Period.

"Pre-Closing Tax Period" means any taxable periods ending on or before the Closing Date and, for any Straddle Period, the portion through the end of the Closing Date.

"Privacy Agreement" has the meaning set forth in Section 6.25(b).

"Proceeding" means any litigation, suits, arbitration, administrative actions, Governmental Authority investigations, audits or inspections or similar proceedings.

"PT-Tax Proceeding" has the meaning set forth in Section 9.03.

"R&W Policy" means the buyer-side representations and warranties insurance policy purchased by, and issued to, Buyer by AIG Specialty Insurance Company.

"Recall" has the meaning set forth in Section 6.21(c).

56

"Registered Company-Owned Intellectual Property" means all Company-Owned Intellectual Property that is: (i) a pending or issued patent; (ii) a trademark application or registration; (iii) a copyright application or registration; and (iv) a domain name.

"Registered Intellectual Property" means all Company-Owned Intellectual Property as well as Intellectual Property owned by a third party but exclusively licensed to the Group Companies that is the subject of: (i) a pending or issued patent; (ii) a trademark application or registration; (iii) a copyright application or registration; and (iv) any other registrations that have been issued to or applied for by the Group Companies, or the applicable third party licensor (including any domain names and social media accounts/handles).

"Reimbursement Conditions" means (i) with respect to the amount described in clause (A)(x) of Section 2.09(c), the Company actually pays such amount to the Internal Revenue Service and provides timely written notice of such payment to the applicable Designated Unitholder promptly upon making any such withholding as required under and in accordance with Code Section 1446 and the applicable Treasury Regulations thereunder; and (ii) with respect to the amount described in clause (A)(y) of Section 2.09(c),either (A) a Pass-Through Income Tax Return prepared pursuant to and in accordance with the procedures of Section 9.01 shows an amount due or (B) the Company received notice of an applicable PT-Tax Proceeding from the applicable U.S. state or local Taxing Authority within three years after the Closing Date (or March 15, 2023, if later) and, in either case, (A) the Company actually pays such amount to the applicable U.S. state or local Taxing Authority in connection with such pass-Through Income Tax Return or upon resolution of the applicable PT-Tax Proceeding pursuant to and in accordance with the procedures set forth in Section 9.03 and (B) promptly provides each Designated Unitholder the original or a certified copy of a receipt issued by the Taxing Authority evidencing such payment or a copy of the Tax Return reporting such payment, as applicable.

"Related Party" means, with respect to Blocker or any of the Group Companies: (i) Blocker Seller; (ii) the Unitholders (other than Blocker); (iii) each individual who is an officer, director or manager of Blocker Seller, Blocker, or any of the Group Companies; (iv) each member of the immediate family of each of the individuals referred to in clauses (ii) and (iii) above; (v) each equity holder of any Unitholder; (vi) any trust or other Person that any one of the individuals referred to in the immediately preceding clauses (i) through (v) controls (or in which more than one of such individuals collectively control); and (vii) any Affiliate of any of the foregoing.

"Release" means any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, migrating, leaching, dumping, or disposing into the indoor or outdoor environment.

"Reports" has the meaning set forth in Section 6.21(e).

"Representative" has the meaning set forth in Section 14.17(a)."Representative Holdback" means $1,000,000.

"Restricted Cash" means any cash that is pledged as collateral for letters of credit, held in trust for the benefit of a third party pursuant to a contractual trust agreement, held in escrow pursuant to a contractual arrangement or pledged to a Person to secure a letter of credit or surety or performance bond.

"RGHSR" has the meaning set forth in the Preamble.
"Schedules" means the disclosure schedules to this Agreement.

57

"Securities Act" means the Securities and Exchange Act of 1933.

"Seller Fundamental Representations" means the Blocker Fundamental Representations and the Company Fundamental Representations, collectively.

"Site" means any Owned Real Property, Leased Real Property and any other real property currently or previously owned, leased, occupied or operated by (i) any of the Group Companies, (ii) any predecessors of the Group Companies, or (iii) any entities previously owned by any of the Group Companies, in each case, including all soil, subsoil, surface waters and groundwater thereat.

"Specified Award Agreement" has the meaning set forth in Section 7.13.

"Straddle Period" means any taxable period that begins before and ends after the Closing Date.

"Subsidiary" or "Subsidiaries" of any Person means any corporation, partnership, limited liability company or other legal entity in which such Person (either alone or through or together with any other Subsidiary), owns, directly or indirectly, fifty percent or more of the stock or other equity or ownership interests, the holder of which is generally entitled to elect a majority of the board of directors or other governing body of such legal entity.

"Surviving Company" has the meaning set forth in Section 2.01."Tax Accrual Amounts" has the meaning set forth in Section 6.14(h).

"Tax Liability Amount" means an amount, which may be a positive or negative number, equal to the sum of the amounts separately calculated pursuant to this definition with respect to each jurisdiction in which the Group Companies are currently filing Tax Returns for Income Taxes, and with respect to each such jurisdiction, the amount calculated shall be the amount equal to (a) the liability of the Group Companies for Income Taxes owing and unpaid as of the Closing Date (which, for the avoidance of doubt, shall be reflected as a positive number) or (b) the overpayment by the Group Companies of Income Taxes as of the Closing Date (including any overpayments of tax withheld from any Designated Unitholder under Code Section 1446(a)) (which, for the avoidance of doubt, shall be reflected as a negative number), in each case, with respect to such jurisdiction computed for the taxable period (or portion thereof) ending on and including the Closing Date; provided that such amounts shall be calculated (i) in accordance with the past practice (including reporting positions, elections and accounting methods) of the Group Companies in preparing Tax Returns for Income Taxes, (ii) by excluding all deferred Tax Liabilities and deferred Tax assets, in each case, established for GAAP purposes, (iii) by treating the Closing Date as the final day of the taxable year of each of the Group Companies (but not for purposes of treating any "deferred revenue" as having accelerated into the Pre-Closing Tax Period for U.S. federal and applicable state and local tax purposes), (iv) by including unpaid Taxes imposed by application of Section 965 of the Code (including any Taxes deferred by an election under Section 965(h) of the Code), (v) by allocating to the Pre-Closing Tax Period all deductions with respect to any Transaction Tax Deductions that are "more likely than not" deductible (or deductible with a higher confidence level) in a Pre-Closing Tax Period and applying the seventy percent safe-harbor election under Revenue Procedure 2011-29 to any "success based fees," (vi) by excluding any amounts taken into account in calculating any of Cash Amount, Funded Debt or Transaction Expenses, (vii) by excluding any liabilities for accruals or reserves established or required to be established under GAAP methodologies that require the accrual for contingent Income Taxes as defined by IFRS or with respect to uncertain Tax positions as defined by GAAP or other similar accounting methodologies and any liabilities arising from any change in any accounting method of any of the Group Companies made following the Closing, and (viii) by treating any overpayments of Income Taxes with respect to the tax year ending on December 31, 2018 (including any overpayments of tax withheld from any Designated Unitholder under Code Section 1446(a) for the tax year ending

58

December 31, 2018) as a payment of Taxes by the Group Companies in the tax period (or portion thereof) ending on the Closing Date for purposes of determining the liability of the Group Companies for Income Taxes or the overpayment by the Group Companies of Income Taxes, as applicable, for the tax period (or portion thereof) ending on the Closing Date.

"Tax Return" means any return, claim for refund, report, statement or information return relating to Taxes, including any schedule or attachment thereto, and including any amendments thereof.

"Taxes" means all federal, provincial, territorial, state, municipal, local, domestic, foreign or other taxes, imposts, and assessments including ad valorem, capital, capital stock, customs and import duties, disability, documentary stamp, employment, excise, franchise, gains, goods and services, gross income, gross receipts, income, intangible, inventory, license, mortgage recording, net income, occupation, payroll, personal property, production, profits, property, real property, recording, rent, sales, social security, stamp, transfer, transfer gains, unemployment, use, value added, consumption, escheat, unclaimed property, windfall profits, and withholding, together with any interest, additions, fines or penalties with respect thereto and any interest in respect of such additions, fines or penalties.

"Taxing Authority" means the Internal Revenue Service and any other Governmental Authority that has the right to impose Taxes on any of the Group Companies.

"Transaction Consideration" means the sum of the Estimated Closing Cash Payment, plus the aggregate of all Future Distribution Amounts.

"Transaction Documents" has the meaning set forth in Section 14.03.

"Transaction Expenses" means, to the extent not paid by a Group Company or Blocker prior to the Adjustment Time, the aggregate amount of (i) all fees, costs and expenses (including legal, accounting, investment banking, broker's, finder's and other professional or advisory fees and expenses) incurred by or on behalf of, or to be paid by, a Group Company or Blocker in connection with the negotiation and execution of this Agreement and the other Transaction Documents or the consummation of the Transactions, (ii) without duplication of amounts included in Funded Debt, any fees and expenses payable to the Group Companies' existing lenders' counsel in connection with repayment of the Funded Debt pursuant to the Payoff Letters, (iii) all bonus, incentive and similar change in control, discretionary or retention or other compensatory payments payable to any employees, officers, directors, consultants, or managers of a Group Company or Blocker that become payable solely as a result of the consummation of the Transactions, together with the employer's share of any payroll, social security, unemployment or similar taxes thereon, (iv) the cost of the D&O Tail, (v) any amounts payable by a Group Company in respect of phantom equity awards that become payable in connection with the consummation of the Transactions (including, for the avoidance of doubt, all amounts in respect of phantom equity awards that vested prior but will be paid in connection with the consummation of the Transactions), together with the employer's share of any payroll, social security, unemployment or similar taxes thereon, (vi) 50% of the fees due to the Escrow Agent pursuant to the Escrow Agreement, (vii) 50% of the fees due to the Paying Agent pursuant to the Paying Agent Agreement and (viii) 50% of any indirect Transfer Tax imposed by China, Germany or India as set forth in Section 8.05(a).

"Transaction Tax Deductions" means any deductions that would result from or be attributable to the Transactions (including the write-off of deferred financing fees, costs and expenses, the payment of any transaction related fees, costs or expenses and/or bonuses (or similar amounts), and the payment of Funded Debt that is outstanding as of the Adjustment Time or the Transaction Expenses) and, for such purpose, the Parties agree to apply the safe harbor election set forth in Internal Revenue Service Revenue Procedure

59

2011-29 to determine the amount of deductions attributable to the payment of any success based fees within the scope of such revenue procedure, to the extent applicable.

"Transactions" means the transactions contemplated by this Agreement and the other Transaction Documents, including the Blocker Purchase and the Merger.

"Transfer Taxes" has the meaning set forth in Section 8.05(a).

"Unitholder" means each holder of record of Common Units or Incentive Units.

"Unitholder Consent" has the meaning set forth in the Recitals.

"Unitholder Percentage" means, with respect to each Designated Unitholder or Blocker Seller, a percentage equal to the aggregate dollar amount of Transaction Consideration actually received by such Designated Unitholder or Blocker Seller, divided by the aggregate amount of Transaction Consideration.

"Vested Incentive Unit" means an Incentive Unit that, as of the Effective Time, has vested in accordance with the terms of the agreement pursuant to which such Incentive Unit was granted to the holder thereof.

"Waived 280G Benefit" has the meaning set forth in Section 7.11.

"WARN Act" means the Worker Adjustment and Retraining Notification Act or any similar foreign, state or local Law and the rules and regulations promulgated thereunder from time to time.

"Working Capital" means, as of the Adjustment Time, (a) the current assets of the Group Companies set forth on Exhibit J attached hereto, minus (b) the current liabilities of the Group Companies set forth on Exhibit J attached hereto, in each case, calculated on a consolidated basis, after eliminating any intercompany amounts; provided that (i) Working Capital shall exclude the Cash Amount, Restricted Cash, any Funded Debt, any Transaction Expenses, the Tax Liability Amount, unamortized debt issuance costs, any current or deferred Income Tax assets or liabilities and any Insurance Receivables, (ii) Working Capital shall, except as set forth on Exhibit J attached hereto under the heading "Exceptions to Past Practice," which principles shall be applied in calculating Working Capital, be calculated in accordance with, and on a basis consistent with, the same accounting methodologies, principles, practices, estimation techniques and procedures used in preparing the Latest Balance Sheet (including calculating reserves in accordance with the same methodologies used to calculate such reserves in preparing the Latest Balance Sheet) and (iii) Working Capital shall (x) not include any purchase accounting or other adjustment arising out of the consummation of the Transactions; and (y) be based on facts and circumstances as they exist prior to the Closing and shall exclude the effect of any act, decision or event occurring on or after the Closing. For the avoidance of doubt, only the line items included on Exhibit J attached hereto shall be included in Working Capital.

"Working Capital Deficit" means the amount (if any) by which Working Capital is less than $65,262,238.

"Working Capital Surplus" means the amount (if any) by which Working Capital is greater than $65,262,238.

"Year-End Financial Statements" has the meaning set forth in Section 6.06(a).12.02 Other Definitional Provisions.

60

(a)    All terms defined in this Agreement shall have such defined meanings when used in any certificates, reports or other documents made or delivered pursuant hereto or thereto, unless the context otherwise requires or as otherwise indicated therein.

(b)    Terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa.

(c)    All references to "$" in this Agreement shall be deemed references to United States dollars.

(d)    Accounting terms which are not otherwise defined in this Agreement have the meanings given to them under GAAP. To the extent that the definition of an accounting term defined in this Agreement is inconsistent with the meaning of such term under GAAP, the definition set forth in this Agreement will control.

ARTICLE XIII
TERMINATION

13.01 Termination. This Agreement may be terminated at any time prior to the Closing:

(a)    by mutual written consent of Buyer and the Company;

(b)    by Buyer, if:

(i)    there has been a material breach by the Company or Blocker Seller of any covenant, representation or warranty contained in this Agreement that has prevented or would prevent the satisfaction of any condition set forth in ARTICLE X and (A) Buyer has provided written notice to the Company and the Representative (and, if such breach is by Blocker Seller, to Blocker Seller) of such material breach and its intent to terminate this Agreement pursuant to this Section 13.01(b)(i); and (B) the Company or Blocker Seller, as applicable, has not cured such material breach within 20 Business Days (or by the End Date, if sooner) after receiving written notice thereof from Buyer; provided that Buyer shall not be entitled to terminate this Agreement pursuant to this Section 13.01(b)(i) if there has been a material breach by Buyer or Merger Sub of any covenant, representation or warranty contained in this Agreement that has prevented or would prevent satisfaction of any condition set forth in ARTICLE XI; or

(ii)    the Transactions have not been consummated by the End Date; provided that Buyer shall not be entitled to terminate this Agreement pursuant to this Section 13.01(b)(ii) if Buyer's or Merger Sub's breach of this Agreement has substantially contributed to the failure of the Transactions to occur by the End Date, or has prevented the consummation of Transactions;

(c)    by the Company, if:

(i)    there has been a material breach by Buyer or Merger Sub of any covenant, representation or warranty contained in this Agreement that has prevented or would prevent the satisfaction of any condition set forth in ARTICLE XI and (A) the Company has provided written notice to Buyer of such material breach and its intent to terminate this Agreement pursuant to this Section 13.01(c)(i); and (B) Buyer or Merger Sub, as applicable, has not cured such material breach within 20 Business Days (or by the End Date, if sooner) after receiving written notice thereof from the Company; provided that the Company shall not be entitled to terminate this Agreement pursuant to this Section 13.01(c)(i) if there has been a material breach by the Company or Blocker Seller that has prevented or would prevent satisfaction of any condition set forth in ARTICLE X; or

61

(ii)    the Transactions have not been consummated by the End Date; provided that the Company shall not be entitled to terminate this Agreement pursuant to this Section 13.01(c)(ii) if the Company's or Blocker Seller's breach of this Agreement has substantially contributed to the failure of the Transactions to occur by the End Date, or has prevented the consummation of Transactions;

(d)    by either Buyer or the Company, if any Governmental Authority shall have enacted, promulgated, issued, entered or enforced any injunction, judgment, order or ruling permanently enjoining, restraining or prohibiting the Transactions, which injunction, judgment, order or ruling shall have become final and non-appealable; provided that the right to terminate this Agreement under this Section 13.01(d) shall not be available to any Party whose failure to fulfill any obligation or condition under this Agreement has been the cause of, or resulted in, such injunction, judgment, order or ruling.

13.02 Effect of Termination. If any Party validly terminates this Agreement pursuant to Section 13.01, all rights and obligations of the Parties hereunder shall terminate without any Liability of any Party to any other Party, except that the provisions of this ARTICLE XIII and ARTICLE XIV (other than Section 14.12) shall survive the termination of this Agreement; provided that no termination of this Agreement shall in any way limit any claim by a Party that another Party willfully and intentionally breached the terms of this Agreement prior to or in connection with such termination, nor shall such termination limit the right of such non-breaching Party to seek all other remedies available to it at law or equity.

ARTICLE XIV

GENERAL PROVISIONS

14.01 Survival. Each of the representations and warranties, and each of the covenants and agreements that contemplate or require performance prior to the Closing, in each case, set forth in this Agreement or any other Transaction Document, or in any certificate delivered hereunder or thereunder, shall terminate at and as of the Closing. Without limiting the foregoing, the sole and exclusive recourse of Buyer and Merger Sub for any breach of any such representations and warranties shall be against the R&W Policy. Each covenant and agreement set forth in this Agreement or any other Transaction Document, or in any certificate delivered hereunder or thereunder that contemplates or requires performance at or after the Closing shall expressly survive the Closing in accordance with its terms.

14.02 Notices. All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given when personally delivered, one day after deposit with Federal Express or similar overnight courier service, upon the date sent if by electronic mail with confirmation of transmission prior to 5:00 pm, prevailing Eastern Time, and, if not, the next Business Day after successful transmission or three days after being mailed by first class mail, return receipt requested. Notices, demands and communications to Buyer, the Representative, Blocker Seller and the Company shall, unless another address is specified in writing, be sent to the addresses indicated below:

(a) if to Buyer, Merger Sub and/or the Surviving Company (after the Effective Time) to:

Perrigo Company
515 Eastern Avenue
Allegan, MI 49010
Attention: Legal Department

62

with a copy (which notice shall not constitute notice) to:

Morgan, Lewis & Bockius LLP

101 Park Avenue

New York, NY 10178-0060

Attention: Sheryl Orr

(b)    if to the Company (prior to the Effective Time) to:

Ranir Global Holdings, LLC

4701 East Paris Avenue SE

Grand Rapids, MI 49512

Attention: Michael Bregenzer, General Counsel

with a copy (which notice shall not constitute notice) to:

Kirkland & Ellis LLP

300 North LaSalle Street

Chicago, IL 60654

Attention: Robert A. Wilson, P.C.

if to Blocker Seller to:

Camden Partners III SPV, L.P.

500 East Pratt Street, Suite 1200

Baltimore, Maryland 21202

Attention: J. Todd Sherman

David Warnock

with a copy (which notice shall not constitute notice) to:

Duane Morris LLP

111 S. Calvert Street, Suite 21202
Baltimore, Maryland 21202

Attention: Michael C. Hardy, Esquire Email: MCHardy@duanemorris.com

(c)    if to the Representative to:

900 N. Michigan Avenue

Ste. 1600

Chicago, IL 60611

Attention: Christopher Capps

with a copy (which notice shall not constitute notice) to:

63

RM Partners Law LLC

305 N. Peoria Street

Suite 200

Chicago, IL 60607

Attention: Michael S. Roberts

14.03 Entire Agreement. This Agreement (including the Exhibits and Schedules attached to this Agreement), the Certificate of Merger, the Escrow Agreement, the Paying Agent Agreement, the Letters of Transmittal and the certificates of the Parties delivered pursuant to Section 3.02 (collectively, the "Transaction Documents") contain the entire understanding of the Parties in respect of their subject matter and supersede all prior agreements and understandings (oral or written) between the Parties with respect to such subject matter, other than the Confidentiality Agreement, which shall survive in full force and effect in accordance with its terms. The Exhibits and Schedules constitute a part of this Agreement as though set forth in full above.

14.04 Expenses. Except as otherwise provided in this Agreement, each Party shall pay its own fees and expenses, including its own counsel fees, incurred in connection with this Agreement; provided that Blocker Seller shall pay all fees and expenses of Blocker incurred in connection with this Agreement to the extent not otherwise treated as a Transaction Expense.

14.05 Amendment; Waiver. This Agreement may not be modified, amended, supplemented, canceled or discharged, except by written instrument executed by Buyer, the Company, the Representative and Blocker Seller; provided that waivers to this Agreement shall be deemed effective upon the execution by the Party against whom enforcement is sought. No failure to exercise, and no delay in exercising, any right, power or privilege under this Agreement shall operate as a waiver, nor shall any single or partial exercise of any right, power or privilege hereunder preclude the exercise of any other right, power or privilege. No waiver of any breach of any provision shall be deemed to be a waiver of any preceding or succeeding breach of the same or any other provision, nor shall any waiver be implied from any course of dealing between the Parties. No extension of time for performance of any obligations or other acts hereunder or under any other Transaction Document shall be deemed to be an extension of the time for performance of any other obligations or any other acts.

14.06 Binding Effect; Assignment. The rights and obligations of this Agreement shall bind and inure to the benefit of the Parties and their respective successors and assigns. Nothing expressed or implied in this Agreement shall be construed to give any other Person any legal or equitable rights hereunder, except that (a) the former and current officers, directors, employees and agents of Blocker and the Group Companies are express third party beneficiaries of Section 8.02 and (b) the Unitholders and Blocker Seller are express third party beneficiaries of Section 8.05. Except as expressly provided herein, the rights and obligations of this Agreement may not be assigned by any Party without the prior written consent of each other Party. Buyer and Merger Sub may, without the consent of any other Party, assign their rights hereunder for collateral security purposes to any lender providing financing to Buyer.

14.07 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by electronic mail transmission of a ".pdf" or other similar data file shall be effective as delivery of a manually executed counterpart to this Agreement.

14.08 Interpretation. When a reference is made in this Agreement to an article, section, paragraph, clause, schedule or exhibit, such reference shall be deemed to be to an article, section, paragraph, clause, schedule or exhibit of this Agreement unless otherwise indicated. Whenever the words "include," "includes"

64

or "including" are used in this Agreement, they shall be deemed to be followed by the words "without limitation." Words of one gender shall be held to include the other genders. The word "or" shall not be exclusive. Unless otherwise indicated, the words "herein," "hereof," "hereunder" or "hereby" and similar terms are to be deemed to refer to this Agreement as a whole and not to any specific section. The words "day" and "days" shall be held to refer to calendar day(s). The words "year" and "years" shall be held to refer to calendar year(s), unless otherwise indicated. The headings contained herein and on the Schedules are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Unless otherwise specified herein, references to any statute, listing rule, rule, standard, regulation or other law include a reference to the corresponding rules and regulations and each of them as amended, modified, supplemented, consolidated, replaced or rewritten from time to time. References to any section of any statute, listing rule, rule, standard, regulation or other law include any successor to such section. References to any Contract (including this Agreement) or organizational document are to the Contract or organizational document as amended, modified, supplemented or replaced from time to time, unless otherwise stated.

14.09 Schedules. Any information set forth in one section of the Schedules will be deemed to apply to other sections of the Schedules to the extent its relevance to such other section is reasonably apparent from the face of such disclosure (notwithstanding the omission of a reference or cross-reference thereto). The specification of any dollar amount in the representations and warranties contained in this Agreement or the inclusion of any specific item in the Schedules hereto is not intended to imply that such amounts, or higher or lower amounts, or the items so included, or other items not included, are or are not required to be disclosed, and no Party shall use the fact of the setting of such amounts or the fact of the inclusion of any such item in any dispute or controversy with any Party as to whether any obligation, item or matter not described herein or included in a Schedule is or is not required to be disclosed (including whether such amounts or items are required to be disclosed as material) or that the amounts, or higher or lower amounts, or the items so included, or other items not included, are within or outside the Ordinary Course. The information contained in the Schedules is disclosed solely for the purposes of this Agreement, and no information contained therein shall be deemed to be an admission by any Party to any third party of any matter whatsoever, including of any violation of Law or breach of any agreement.

14.10 Governing Law; Interpretation. This Agreement shall be governed by and interpreted and construed in accordance with the internal laws of the State of Delaware. Any and all claims, controversies, causes of action and Proceedings arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the internal laws of the State of Delaware, without giving effect to any conflict-of-laws or other rule that would result in the application of the laws of a different jurisdiction.

14.11 Forum Selection; Consent to Jurisdiction; Waiver of Jury Trial.

(a)    Any Proceeding against Buyer, Merger Sub, the Company, any of the Unitholders,
Blocker Seller, the Surviving Company or the Representative arising out of, relating to, or with respect to, this Agreement or the Transactions shall be brought exclusively in the state or federal courts located in New Castle County in the State of Delaware (the "Designated Courts"), and the Parties hereto accept the exclusive jurisdiction of the Designated Courts for the purpose of any such Proceeding. Each Party hereby irrevocably waives, to the fullest extent permitted by Law, any objection which it may now or hereafter have to the laying of venue of any such Proceeding in any Designated Court and hereby further irrevocably waives any claim that any such Proceeding brought in the Designated Courts has been brought in an inconvenient forum. Each Party agrees that service of any process, summons, notice or document sent in accordance with Section 14.02 shall be effective service of process in any such Proceeding.

(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE OUT OF, OR WITH RESPECT TO, THIS AGREEMENT OR

65

THE TRANSACTIONS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, DIRECTLY OR INDIRECTLY, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OR ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS OF THIS SECTION 14.11(b).EITHER PARTY MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

14.12 Specific Performance. Each of the Parties agrees that this Agreement is intended to be legally binding and specifically enforceable pursuant to its terms and that Buyer, the Company, Blocker Seller and the Designated Unitholders would be irreparably harmed if any of the provisions of this Agreement are not performed in accordance with their specific terms and that monetary damages would not provide adequate remedy in such event. Accordingly, in addition to any other remedy to which a Party may be entitled at Law, a Party shall be entitled to injunctive relief without the posting of any bond to prevent breaches of this Agreement and to specifically enforce the terms and provisions hereof. Each Party further waives any defense that a remedy at Law would be adequate in any action or Proceeding for specific performance or injunctive relief hereunder.

14.13 Arm's Length Negotiations; Drafting. Each Party expressly represents and warrants to the other Parties that before executing this Agreement, such Party has fully informed itself of the terms, contents, conditions and effects of this Agreement, such Party has relied solely and completely upon its own judgment in executing this Agreement and such Party has had the opportunity to seek and has obtained the advice of counsel before executing this Agreement, which is the result of arm's length negotiations conducted by and among the Parties and their respective counsel. This Agreement shall be deemed drafted jointly by the Parties and nothing shall be construed against one Party or another as the drafting Party.

14.14 Time. With regard to all dates and time periods set forth or referred to in this Agreement, time is of the essence.

14.15 Made Available. The phrase "made available to Buyer" or similar phrases as used in this Agreement shall mean that the subject documents were either posted to the virtual data room maintained by the Company or its representatives or delivered by electronic mail to Buyer or its accountants or attorneys, in each case, at least one day prior to the date of this Agreement.

14.16 Confidentiality; Public Announcements.

(a) Except as may be required by Law, or as otherwise permitted or expressly

contemplated herein, no Party shall, and each Party shall cause its respective Affiliates, employees, agents and representatives not to, disclose to any third party the existence of this Agreement or the subject matter or terms hereof, without the prior consent of Buyer, the Company and Representative; provided that the Parties and their respective Affiliates, employees, agents and representatives shall be permitted to (a) disclose any such information to their attorneys, advisors and representatives and (b) disclose and use such

66

information in connection with enforcing their rights and fulfilling their obligations under this Agreement or any other Transaction Document.

(b)    The Parties agree that no public release, public filing or public announcement concerning this Agreement or the other Transaction Documents or the Transactions shall be issued by any Party or any of their Affiliates without the prior written consent of Buyer and the Representative (which consent shall not be unreasonably withheld, conditioned or delayed), except as such release or announcement may be required by applicable Law or the rules or regulations of any securities exchange, in which case the applicable Party shall allow the other Parties reasonable time to comment on, and shall consider in good faith any comments received by such other Parties to, such release or announcement in advance of such issuance.

(c)    Prior to the Closing, Buyer, the Company and the Representative shall mutually agree upon a press release announcing the consummation of the Transactions and Buyer and the Company may issue such press release following the Closing without the consent of any other Party. In connection with the preparation of any Securities Exchange Commission filing required to be made by Buyer in connection with the Transactions, each Party shall use commercially reasonable efforts upon the request of Buyer to furnish Buyer with all reasonable information concerning such Party as may be reasonably necessary in connection with such filing, to the extent such information is then reasonably available to such Party.

14.17 Designation of the Representative.

(a)    Designation. RGHSR is hereby designated to serve as the representative of the Unitholders and Blocker Seller (the "Representative") with respect to the matters expressly set forth in this Agreement and the other Transaction Documents to be performed by the Representative.

(b)    Authority. By executing a Letter of Transmittal (or, in the case of Blocker Seller, this Agreement), each Designated Unitholder and Blocker Seller hereby irrevocably appoints the Representative as such Person's agent, proxy and attorney-in-fact for all purposes of this Agreement, the Escrow Agreement, the Paying Agent Agreement and any other agreement entered into in connection herewith (including the full power and authority on such Person's behalf) (i) to consummate the Transactions, (ii) to pay expenses incurred by or on behalf of such Person or the Representative in connection with the Transactions, including the negotiation and performance of the Transaction Documents (whether incurred on or after the date of this Agreement), (iii) to calculate any amounts payable to such Person pursuant to any Transaction Document, (iv) to execute such further agreements or instruments of assignment in accordance with this Agreement, or as Buyer shall reasonably request, or which the Representative shall consider necessary or proper to effectuate the Transactions, all of which shall have the effect of binding such Person as if such Person had personally executed such agreement or instrument, (v) to resolve any adjustments or issues relating to any component of the Closing Cash Payment or Future Distribution Amounts, (vi) to receive notices and other deliverables hereunder on behalf of such Person, (vii) to execute and deliver on behalf of such Person any amendment or waiver to any Transaction Document, (viii) to take all other actions to be taken by or on behalf of such Person in connection with the Transactions, (ix) to dispute, compromise, settle and pay any claims made in connection with this Agreement or the Transactions and (x) to do each and every act and exercise any and all rights which such Person is permitted or required to do or exercise under the Transaction Documents. Such agency, proxy and attorney-in-fact and all authority granted hereunder are coupled with an interest, are therefore irrevocable without the consent of the Representative and shall survive the death, incapacity, bankruptcy, dissolution or liquidation of such Person. If, after the execution of this Agreement, any Designated Unitholder or Blocker Seller dies, dissolves or liquidates or becomes incapacitated or incompetent, then the Representative is nevertheless authorized, empowered and directed to act in accordance with this Agreement as if that death, dissolution, liquidation, incapacity or incompetency had not occurred

67

and regardless of notice thereof. All decisions and actions by the Representative shall be binding upon all of the Designated Unitholders and Blocker Seller and neither Blocker Seller nor any Designated Unitholder shall have the right to object, dissent, protest or otherwise contest the same.

(c)    Representative Holdback. The Representative Holdback shall be withheld and paid directly to an account maintained by the Representative as a fund for the fees and expenses of the Representative incurred in its capacity as such, with any balance of the Representative Holdback not utilized for such purposes to be returned to Blocker Seller and the Designated Unitholders in accordance with their Designated Unitholder Percentages. In the event that the Representative Holdback is insufficient to satisfy the fees and expenses of the Representative incurred in its capacity as such, the Representative shall be entitled to recover any such expenses from any portion of the Adjustment Escrow Fund to be distributed to Blocker Seller and the Designated Unitholders. The Representative shall also be entitled to recover any remaining expenses directly from Blocker Seller and the Designated Unitholders severally in accordance with their respective Unitholder Percentage (and not jointly or jointly and severally), and the Representative shall not have any obligation to personally advance funds in connection with the performance of any duties under this Agreement.

(d)    Authority; Indemnification. Buyer shall be entitled to rely on any action taken by the Representative, pursuant to Section 14.17(b) (each, an "Authorized Action"), and each Authorized Action shall be binding on Blocker Seller and each Designated Unitholder as fully as if such Person had taken such Authorized Action. Buyer agrees that the Representative, as the Representative, shall have no Liability to Buyer for any Authorized Action, except to the extent that such Authorized Action is found by a final order of a court of competent jurisdiction to have constituted actual fraud; provided that the foregoing shall not limit any Liability that Blocker Seller or the Designated Unitholders may have to Buyer with respect to such Authorized Action. Blocker Seller and each Designated Unitholder, severally in accordance to its Unitholder Percentage, and not jointly or jointly and severally, will indemnify, reimburse and hold harmless the Representative against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by the Representative in connection with any Proceeding to which the Representative is made a party by reason of the fact that the Representative is or was acting as the Representative pursuant to the terms of this Agreement.

(e)    Duties of the Representative. The Representative shall have only the duties expressly stated in the Transaction Documents, and shall have no other duty, express or implied. The Representative is not, by virtue of serving as Representative, a fiduciary of Blocker Seller, any Designated Unitholders or any other Person. The Representative, in its capacity as such, has no personal responsibility or Liability for any representation, warranty or covenant of the Company or any other Person. The Representative shall not be required to make any inquiry concerning either the performance or observance of any of the terms, provisions or conditions of this Agreement.

(f)    Exculpation. The Representative shall not be liable to Blocker Seller or any Designated Unitholder for any action taken or omitted by it or any agent employed by it under any Transaction Document, except to the extent that such action or omission is found by a final order of a court of competent jurisdiction to have constituted actual fraud. The Representative shall not be liable to Blocker Seller or any Designated Unitholder for any apportionment or distribution of the Transaction Consideration except to the extent that such apportionment or distribution is found by a final order of a court of competent jurisdiction to have constituted actual fraud. Neither the Representative nor any agent employed by it shall incur any Liability to Blocker Seller or any Designated Unitholder relating to the performance of its other duties hereunder, except to the extent that the Representative is found by a final order of a court of competent jurisdiction to have committed actual fraud in connection therewith.

68

14.18 Company Representation. Buyer, for itself and on behalf of its respective Subsidiaries (including Merger Sub) and their respective directors, equityholders, members, partners, officers, employees and Affiliates, hereby agrees that, in the event that a dispute arises after the Closing between Buyer, the Surviving Company and/or its Subsidiaries, on the one hand, and the Representative, Blocker Seller or any Designated Unitholder, on the other hand, Kirkland & Ellis LLP may represent the Representative, Blocker Seller or such Designated Unitholder in such dispute, even though the interests of the Representative, Blocker Seller or such Designated Unitholder may be directly adverse to Buyer, the Surviving Company and/or its Subsidiaries and even though Kirkland & Ellis LLP may have represented the Company and/or its Subsidiaries in the Transactions. Buyer and Merger Sub further agree that, as to all communications among Kirkland & Ellis LLP, the Representative, the Company, and of its Subsidiaries and any of their respective Affiliates that relate in any way to the Transactions, the attorney-client privilege and the expectation of client confidence belongs to the Representative and shall not pass to or be claimed by Buyer, the Surviving Company or any of their Subsidiaries. Notwithstanding the foregoing, in the event that a dispute arises between Buyer, the Surviving Company or any of their Subsidiaries and a third party (other than a party to any Transaction Document or any Affiliate of any such party) after the Closing, the Surviving Company and its Subsidiaries may assert the attorney-client privilege to prevent disclosure of confidential communications by Kirkland & Ellis LLP to such third party; provided that neither the Surviving Company nor its Subsidiaries may waive such privilege without the prior written consent of the Representative. In addition, all of the client files and records in the possession of Kirkland & Ellis LLP related to the Transactions will be property of (and be controlled by) the Representative and neither the Company nor any of its Subsidiaries shall be entitled to retain copies of, or have access to, any such records.

14.19 Acknowledgements. The representations and warranties of the Company expressly set forth in ARTICLE VI and the representations and warranties of Blocker Seller expressly set forth in ARTICLE V constitute the sole and exclusive representations and warranties made to Buyer and its Affiliates or any other Person with respect to the Group Companies, the Unitholders, Blocker Seller, Blocker and their respective Affiliates in connection with the Transactions, and Buyer, on its own behalf and on behalf of its Affiliates, acknowledges and agrees that any other representations and warranties of any kind or nature, express or implied, are specifically disclaimed by the Group Companies, the Unitholders, Blocker, Blocker Seller and their respective Affiliates and shall not form the basis of any claim against the Group Companies, the Unitholders, Blocker, Blocker Seller, any of their respective Affiliates or any other Person. Without limiting the foregoing, Buyer, on its own behalf and on behalf of its Affiliates, acknowledges and agrees that Buyer and its Affiliates have not relied on any representations or warranties whatsoever, whether express or implied, other than the representations and warranties of the Company expressly set forth in ARTICLE VI and the representations and warranties of Blocker Seller expressly set forth in ARTICLE V. In furtherance of the foregoing, Buyer, on its own behalf and on behalf of its Affiliates, acknowledges that Buyer and its Affiliates have conducted, to their satisfaction, an independent investigation of the financial condition and position, results of operations, assets, liabilities, properties and projected operations of Blocker and the Group Companies prior to making their determination to proceed with the Transactions and have completed such investigations of Blocker and the Group Companies as they deem necessary and appropriate, and have received all of the information that they have requested from the Company and its Subsidiaries and Blocker in connection with the execution and delivery of this Agreement and the other Transaction Documents and the consummation of the Transactions. In connection with Buyer's and its Affiliates' investigation of Blocker and the Group Companies, Buyer and its Affiliates have received certain projections, including projected statements of operating revenues and income from operations of the Group Companies, and certain business plan information. Buyer, on its own behalf and on behalf of its Affiliates, acknowledges that there are uncertainties inherent in attempting to make such estimates, projections and other forecasts and plans, that Buyer and its Affiliates are familiar with such uncertainties and that Buyer and its Affiliates are taking full responsibility for making their own evaluation of the adequacy and accuracy of all estimates, projections and other forecasts and plans so furnished to it, including the reasonableness of the assumptions underlying such estimates, projections and forecasts.

69

14.20 Guaranty.

(a)    The Guarantor, intending to be legally bound, hereby irrevocably, unconditionally and absolutely guarantees to Blocker Seller and the Company the full and punctual payment by US Buyer and Irish Buyer of all of US Buyer's and Irish Buyer's respective obligations arising (i) at or prior to the Closing pursuant to this Agreement and the transactions contemplated hereby, including US Buyer's and Irish Buyer's payment obligations set forth in Section 3.02(b)(i) and 3.02(b)(ii), or (ii) pursuant to Section 13.02 upon termination of this Agreement (collectively, the "Guaranteed Obligations"). The Guarantor acknowledges and agrees that the obligation of the Guarantor under this Section 14.20 is one of payment, not collection, and a separate action or actions may be brought and prosecuted against the Guarantor to enforce this Section 14.20, irrespective of whether any action is brought against US Buyer or Irish Buyer or whether US Buyer or Irish Buyer is joined in any such action or actions. The Guarantor further acknowledges and agrees that the obligations of the Guarantor under this Section 14.20 shall be unconditional and absolute and no release or extinguishments of US Buyer or Irish Buyer obligations or liabilities, whether by decree in any bankruptcy proceeding or otherwise, shall affect the continuing validity and enforceability of this guarantee; provided, however, that the Guarantor shall be entitled to assert as a defense to any claim for payment or performance of the Guaranteed Obligations any and all of the rights, defenses, counterclaims, exculpations, set-offs, indemnities and limitations on liability to which US Buyer or Irish Buyer may be entitled to assert under this Agreement, including that (i) such Guaranteed Obligations are not currently due under the terms of this Agreement, or (ii) that such Guaranteed Obligations have previously been paid or performed in full. The foregoing guarantee shall remain in full force and effect until the date on which each Guaranteed Obligation has been completely performed and/or paid in full, as applicable. The Guarantor agrees that it will reimburse Blocker Seller and the Company for all reasonable and documented out-of-pocket expenses (including reasonable counsel fees and expenses) that are incurred by Blocker Seller and the Company in connection with any action pursuant to which this Section 14.20 is enforced against the Guarantor pursuant to a final non-appealable order.

(b)    The Guarantor hereby represents and warrants to Blocker Seller and the Company, as of the date hereof and as of the Closing Date, that:

(i)    The Guarantor is a Ireland public limited company duly organized, validly existing and in good standing under the laws of Ireland and has all requisite power and authority to enter into and perform its obligations under this Agreement.

(ii)    This Agreement has been duly authorized, executed and delivered by the Guarantor, and this Agreement is the legal, valid and binding obligation of the Guarantor, enforceable against the Guarantor in accordance with its terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar Laws affecting the enforcement of creditors' rights generally. All necessary consents, approvals and authorizations have been provided by the applicable governing body and equityholders of the Guarantor in connection with this Agreement.

(iii)    Neither the execution and delivery of this Agreement nor the consummation of the Transactions will (A) violate, conflict with or result in a breach of or constitute a default under any provision of the Guarantor's organizational documents, (B) violate, conflict with or result in a breach of or constitute a default under any judgment, order, decree, rule or regulation of any court or Governmental Authority to which the Guarantor is subject or (C) violate, conflict with or result in a breach of any Law.

70

(iv)    The Guarantor has, as of the date of this Agreement, and will have for so long as

any Guaranteed Obligations remain outstanding, access to sufficient funds to guarantee, in cash, the payment by US Buyer and Irish Buyer of the Guaranteed Obligations.

[SIGNATURES APPEAR ON THE FOLLOWING PAGE]

71

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.

COMPANY:
RANIR GLOBAL HOLDINGS, LLC
By:	/s/ Richard Sorota
Name:	Richard Sorota
Title:	President and Chief Executive Officer

Signature Page to Stock Purchase Agreement and Agreement and Plan of Merger

GUARANTOR:
PERRIGO COMPANY, PLC
By:	/s/ Murray Kessler
Name:	Murray Kessler
Title:	President & CEO

Signature Page to Stock Purchase Agreement and Agreement and Plan of Merger

US BUYER:
PERRIGO ORAL HEALTH CARE HOLDINGS, INC.
By:	/s/ Jeffrey Needham
Name:	Jeffrey Needham
Title:	President

Signature Page to Stock Purchase Agreement and Agreement and Plan of Merger

IRISH BUYER:
PERRIGO IRELAND 6 DAC
By:	/s/ Louis Cherico
Name:	Louis Cherico
Title:	Director

Signature Page to Stock Purchase Agreement and Agreement and Plan of Merger

MERGER SUB:
BIG MOUTH MERGER SUB, LLC
By:	/s/ Jeffrey Needham
Name:	Jeffrey Needham
Title:	President

Signature Page to Stock Purchase Agreement and Agreement and Plan of Merger

BLOCKER SELLER:
CAMDEN PARTNERS III SPV, L.P.
By:	CAMDEN PARTNERS III SPV, L.P.
Its:	General Partners
By:	/s/ J. Todd Sherman
Name:	J. Todd Sherman
Title:	Member and Manager

Signature Page to Stock Purchase Agreement and Agreement and Plan of Merger

REPRESENTATIVE:
RGH SELLER REP, LLC
By:	/s/ Christopher W. Capps
Name:	Christopher W. Capps
Title:	Manager

Signature Page to Stock Purchase Agreement and Agreement and Plan of Merger

EX-10.4

Exhibit 10.4

July 1, 2019

PERSONAL AND CONFIDENTIAL

Mr. Ronald Winowiecki

RE: Employment Separation and Severance Perrigo Company Confidential Supplemental Wavier and Release Agreement 2

Dear Ron:

This Supplemental Waiver and Release Agreement 2 (“Agreement 2”) is entered into by and between Perrigo Company plc (“Perrigo” or “the Company”), and Ronald Winowiecki (“you” or “Employee” or “Executive”) on the date written above. It is made in connection with that certain Waiver and Release Agreement 1 (“Agreement 1”) entered into by the parties as of April 11, 2019.

Pursuant to Agreement 1, you agreed (among other things) to execute and deliver this Agreement 2 to the Company, and the Company agreed (among other things) to pay you the severance pay and benefits described in Agreement 1.

Accordingly, you agree as follows:

1.General Release by Executive.Employee voluntarily and knowingly releases and discharges the Company, its parents, subsidiaries and Affiliates, and their respective officers, directors, shareholders, employees, subsidiaries, divisions, parent companies, employee benefit plans and fiduciaries, both past and present (the “Released Parties”),from any and all claims, debts, suits or causes of action, known or unknown, based upon any fact, circumstance, or event occurring or existing at or prior to the Eligible Employee’s execution of this Supplemental Waiver and Release Agreement, including, but not limited to, any claims or actions arising out of or during the Eligible Employee’s employment with the Company and/or separation of employment, including any claim under the Age Discrimination in Employment Act, 29 U.S.C. § 621 etseq., as amended Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e etseq., as amended, the Americans with Disabilities Act, 42 U.S.C. § 12101 etseq., the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 301 etseq., as amended, the Older Workers Benefit Protection Act, 29 U.S.C. § 621 etseq., the Family and Medical Leave Act, 29 U.S.C. § 2601 etseq., the Civil Rights Act and any and all other federal, state or local laws, and any contract, tort, or common law claims now or hereafter recognized, including, without limitation, any claim of breach of contract, promissory estoppel, detrimental reliance, wrongful discharge, false imprisonment, assault, battery, intentional infliction of emotional distress, defamation, slander, libel, fraud, invasion of privacy, breach of the covenant of good faith and fair dealing, breach of fiduciary duty, conversion, and tortious interference with any type of third-party relationship, as well as any and all damages that may arise out of any such claims, including, without limitation, claims for economic loss, lost profits, loss of capital, lost wages, lost earning capacity, emotional distress, mental anguish, personal injuries, punitive damages, or any future damages, and claims of retaliation of any nature, including, but not limited to, the anti-retaliatory provisions of the statutes identified in this

Initials /s/ RW

Section . “Affiliate” means any member of the group of corporations, trades or businesses or other organizations compromising the “controlled group” with the Company.

2.Exclusions from General Release. Excluded from the General Release above are any claims or rights which cannot be waived by law, including Employee’s right, if any, to workers’ compensation benefits (although Employee represents that Employee has reported all work-related injuries or illnesses, if any, that Employee suffered or sustained during employment with the Company), unemployment insurance benefits, or vested rights under any retirement plan. This Agreement also does not release Employee’s right to execute and receive the benefits described in attached Agreement B as detailed herein. Employee understands that also excluded from the General Release is the right to file an administrative charge of discrimination (or similar charge) or to participate in any other type of state or federal investigation. However, by signing this Agreement Employee agrees that Employee is waiving any right to monetary or injunctive relief, recovery or reinstatement in connection with any such charge or investigation.

3.General Release by the Company. In consideration of the agreements of Executive set forth in this Agreement, the Company, on behalf of itself and its Affiliates, voluntarily and knowingly releases and discharges Executive, his heirs, executors and parties in interest with him, from any and all claims, debts, suits or causes of action, known or unknown, based upon any fact, circumstance, or event occurring or existing at or prior to the Company’s execution of this Waiver and Release Agreement.

4.Acknowledgements.    In signing this Agreement, Employee acknowledges that:

(a)The Company has not provided Employee with any tax advice, and Employee is solely responsible for the tax consequences of compensation provided under this Agreement or under any Company benefit plan;

(b)Employee has signed this Agreement voluntarily and knowingly in exchange for the consideration described in Agreement 1 and the Policy, which Employee acknowledges as adequate and satisfactory and beyond that to which Employee is otherwise entitled;

(c)Employee is advised by the Company to consult with an attorney before signing this Agreement;

(d)Employee has been advised to consult an attorney before signing this Agreement and that he has at least forty-five (45) days in which to consider the Agreement and that Employee has signed on the date indicated below after concluding that this Agreement is satisfactory;

(e)Employee is advised by the Company that this Agreement shall not become effective or enforceable until seven (7) days after Employee’s execution of this Agreement, provided that the Agreement is not timely revoked in accordance with this paragraph. Employee also understands that Employee may revoke this Agreement during the seven (7) day period. To be effective, Employee’s revocation must be in writing and delivered to Bryan Rojek, Vice President, Global Total Rewards, Human Resources Department, 515 Eastern Ave., Allegan, Michigan 49010 within the seven (7) day revocation period. Employee understands that seven (7) days after Employee’s execution of this Agreement, this Agreement will become effective and enforceable without any further affirmative action by either Employee or the Company;

5.Please contact Todd Kingma, EVP, General Counsel at 269-686-1941 if you have any questions. On behalf of Perrigo, I thank you for your service and wish you the best in your future endeavors.

Initials /s/ RW

Sincerely,

PERRIGO COMPANY, PLC
By:	/s/ Bryan J. Rojek
	Bryan J. Rojek
Its:	Vice President, Global Total Rewards

I have read this Perrigo Company Confidential Supplemental Waiver and Release Agreement 2 and I understand all of its terms. I enter into and sign this Perrigo Company Confidential Supplemental Waiver and Release Agreement knowingly and voluntarily with full knowledge of what it means.

Date:	July 1, 2019	/s/ Ronald Winowiecki
		Ronald Winowiecki

PLEASE RETURN TO:

Bryan Rojek

Vice President of Global Total Rewards

Human Resources Department

Perrigo Company plc

515 Eastern Avenue

Allegan, MI 49010

bryan.rojek@perrigo.com

Initials /s/ RW

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Murray S. Kessler, certify that:

1. I have reviewed this report on Form 10-Q of Perrigo Company plc;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2019

/s/ Murray S. Kessler

Murray S. Kessler

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Raymond P. Silcock, certify that:

1. I have reviewed this report on Form 10-Q of Perrigo Company plc;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2019

/s/ Raymond P. Silcock

Raymond P. Silcock

Chief Financial Officer

EX-32

Exhibit 32

The following statement is being made to the Securities and Exchange Commission solely for the purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.

Securities and Exchange Commission

450 Fifth Street NW

Washington, D.C. 20549

Re: Perrigo Company plc

Ladies and Gentlemen:

In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), each of the undersigned hereby certifies that:

(i) this Quarterly Report on Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(ii) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Perrigo Company plc.

Date:	August 8, 2019	/s/ Murray S. Kessler
		Murray S. Kessler
		Chief Executive Officer and President
Date:	August 8, 2019	/s/ Raymond P. Silcock
		Raymond P. Silcock
		Chief Financial Officer

XML

Cover Page - shares	6 Months Ended
	Jun. 29, 2019	Aug. 02, 2019
Cover page.
Document type	10-Q
Document Quarterly Report	true
Document period end date	Jun. 29, 2019
Document Transition Report	false
Entity registrant name	Perrigo Company plc
Entity Incorporation, State or Country Code	L2
Entity Address, Address Line One	The Sharp Building,
Entity Address, Address Line Two	Hogan Place,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 TY74
Country Region	353
City Area Code	1
Local Phone Number	7094000
Title of 12(b) Security	Ordinary shares
Trading Symbol	PRGO
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity central index key	0001585364
Entity Interactive Data Current	Yes
Current calendar year end date	--12-31
Entity filer category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
Entity Shell Company	false
Entity common stock, shares outstanding		136,054,652
Entity File Number	001-36353
Document calendar year focus	2019
Document calendar period focus	Q2
Amendment flag	false

XML

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Income Statement [Abstract]
Net sales	[1]	$ 1,149.0	$ 1,186.4	$ 2,323.5	$ 2,403.4
Cost of sales		718.2	715.4	1,443.9	1,439.7
Gross profit		430.8	471.0	879.6	963.7
Operating expenses
Distribution		23.7	23.8	47.1	48.5
Research and development		43.9	91.9	84.0	130.3
Selling		140.1	155.2	288.7	316.5
Administration		127.2	96.8	252.3	204.5
Impairment charges		27.8	1.7	31.9	1.7
Restructuring		12.2	3.7	21.5	5.2
Other operating expense (income)		0.9	3.2	(3.2)	6.1
Total operating expenses		375.8	376.3	722.3	712.8
Operating income		55.0	94.7	157.3	250.9
Change in financial assets		(5.5)	(0.6)	(15.9)	9.0
Interest expense, net		31.2	32.1	59.8	63.5
Other (income) expense, net		2.3	7.9	5.5	12.1
Loss on extinguishment of debt		0.0	0.0	0.0	0.5
Income before income taxes		27.0	55.3	107.9	165.8
Income tax expense		18.0	19.1	35.0	48.8
Net income		$ 9.0	$ 36.2	$ 72.9	$ 117.0
Earnings per share
Basic (in dollars per share)		$ 0.07	$ 0.26	$ 0.54	$ 0.84
Diluted (in dollars per share)		$ 0.07	$ 0.26	$ 0.54	$ 0.84
Weighted-average shares outstanding
Basic (in shares)		136.0	138.1	136.0	139.5
Diluted (in shares)		136.5	138.7	136.3	140.0

[1] Derived from the location of the entity that sells to a third party.

XML

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 9.0	$ 36.2	$ 72.9	$ 117.0
Other comprehensive income (loss):
Foreign currency translation adjustments	27.8	(165.6)	11.0	(92.6)
Change in fair value of derivative financial instruments, net of tax	2.7	(3.5)	4.4	(4.1)
Change in post-retirement and pension liability, net of tax	0.0	(0.2)	(0.5)	(0.4)
Other comprehensive income (loss), net of tax	30.5	(169.3)	14.9	(97.1)
Comprehensive income (loss)	$ 39.5	$ (133.1)	$ 87.8	$ 19.9

XML

Condensed Consolidated Balance Sheets - USD ($) shares in Millions, $ in Millions	Jun. 29, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 1,055.7	$ 551.1
Accounts receivable, net of allowance for doubtful accounts of $6.3 and $6.4, respectively	1,117.1	1,073.1
Inventories	940.5	878.0
Prepaid expenses and other current assets	322.1	400.0
Total current assets	3,435.4	2,902.2
Property, plant and equipment, net	824.3	829.1
Operating lease assets	135.4	0.0
Goodwill and indefinite-lived intangible assets	3,967.8	4,029.1
Definite-lived intangible assets, net	2,675.2	2,858.9
Deferred income taxes	6.8	1.2
Other non-current assets	383.8	362.9
Total non-current assets	7,993.3	8,081.2
Total assets	11,428.7	10,983.4
Liabilities and Shareholders’ Equity
Accounts payable	513.7	474.9
Payroll and related taxes	126.3	132.1
Accrued customer programs	385.2	442.4
Accrued liabilities	262.7	201.3
Accrued income taxes	104.1	96.5
Current indebtedness	398.8	190.2
Total current liabilities	1,790.8	1,537.4
Long-term debt, less current portion	3,084.4	3,052.2
Deferred income taxes	280.2	282.3
Other non-current liabilities	546.9	443.4
Total non-current liabilities	3,911.5	3,777.9
Total liabilities	5,702.3	5,315.3
Commitments and contingencies - Refer to Note 15
Controlling interests:
Preferred shares, $0.0001 par value per share, 10 shares authorized	0.0	0.0
Ordinary shares, €0.001 par value per share, 10,000 shares authorized	7,395.5	7,421.7
Accumulated other comprehensive income	99.5	84.6
Retained earnings (accumulated deficit)	(1,768.8)	(1,838.3)
Total controlling interest	5,726.2	5,668.0
Noncontrolling interest	0.2	0.1
Total shareholders’ equity	5,726.4	5,668.1
Total liabilities and shareholders' equity	$ 11,428.7	$ 10,983.4
Supplemental Disclosures of Balance Sheet Information
Ordinary shares, issued and outstanding (in shares)	136.0	135.9

XML

Condensed Consolidated Balance Sheets (Parenthetical) $ in Millions	Jun. 29, 2019 USD ($) $ / shares shares	Jun. 29, 2019 € / shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2018 € / shares
Statement of Financial Position [Abstract]
Allowance for doubtful accounts | $	$ 6.3		$ 6.4
Stockholders' Equity:
Preferred shares, par value (in dollars per share) | $ / shares	$ 0.0001		$ 0.0001
Preferred shares, authorized	10,000,000		10,000,000
Ordinary shares, par value (in EUR per share) | € / shares		€ 0.001		€ 0.001
Ordinary shares, authorized	10,000,000,000		10,000,000,000

XML

Condensed Consolidated Statements of Shareholders' Equity Statement - USD ($) shares in Millions, $ in Millions	Total	Ordinary Shares Issued	Accumulated Other Comprehensive Income	Retained Earnings (Accumulated Deficit)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of new accounting standards | Adoption of new accounting standards	$ 5.3		$ (1.0)	$ 6.3
Beginning balance (shares) at Dec. 31, 2017		140.8
Balance, beginning at Dec. 31, 2017	6,170.5	$ 7,892.9	253.1	(1,975.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	80.8			80.8
Other comprehensive income (loss)	72.2		72.2
Stock options exercised	0.2	$ 0.2
Restricted stock plan (shares)		0.2
Compensation for stock options	2.7	$ 2.7
Compensation for restricted stock	10.0	10.0
Cash dividends, $0.19 per share	(26.7)	(26.7)
Shares withheld for payment of employees' withholding tax liability	(1.5)	$ (1.5)
Repurchases of ordinary shares (shares)		(1.3)
Repurchases of ordinary shares	(108.1)	$ (108.1)
Ending balance (shares) at Mar. 31, 2018		139.7
Balance, ending at Mar. 31, 2018	6,205.4	$ 7,769.5	324.3	(1,888.4)
Beginning balance (shares) at Dec. 31, 2017		140.8
Balance, beginning at Dec. 31, 2017	6,170.5	$ 7,892.9	253.1	(1,975.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	117.0
Other comprehensive income (loss)	(97.1)
Repurchases of ordinary shares (shares)		(3.3)
Ending balance (shares) at Jun. 30, 2018		137.7
Balance, ending at Jun. 30, 2018	5,897.1	$ 7,594.3	155.0	(1,852.2)
Beginning balance (shares) at Mar. 31, 2018		139.7
Balance, beginning at Mar. 31, 2018	6,205.4	$ 7,769.5	324.3	(1,888.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	36.2			36.2
Other comprehensive income (loss)	(169.3)		(169.3)
Stock options exercised	0.1	$ 0.1
Restricted stock plan (shares)		0.1
Compensation for stock options	2.7	$ 2.7
Compensation for restricted stock	6.9	6.9
Cash dividends, $0.19 per share	(26.1)	$ (26.1)
Shares withheld for payment of employees' withholding tax liability (shares)		(0.1)
Shares withheld for payment of employees' withholding tax liability	(1.9)	$ (1.9)
Repurchases of ordinary shares (shares)		(2.0)
Repurchases of ordinary shares	(156.9)	$ (156.9)
Ending balance (shares) at Jun. 30, 2018		137.7
Balance, ending at Jun. 30, 2018	5,897.1	$ 7,594.3	155.0	(1,852.2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of new accounting standards | Adoption of new accounting standards	(3.4)			(3.4)
Beginning balance (shares) at Dec. 31, 2018		135.9
Balance, beginning at Dec. 31, 2018	5,668.0	$ 7,421.7	84.6	(1,838.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	63.9			63.9
Other comprehensive income (loss)	(15.6)		(15.6)
Restricted stock plan (shares)		0.2
Compensation for stock options	1.8	$ 1.8
Compensation for restricted stock	14.2	14.2
Cash dividends, $0.19 per share	(25.9)	$ (25.9)
Shares withheld for payment of employees' withholding tax liability (shares)		(0.1)
Shares withheld for payment of employees' withholding tax liability	(2.4)	$ (2.4)
Ending balance (shares) at Mar. 30, 2019		136.0
Balance, ending at Mar. 30, 2019	5,700.6	$ 7,409.4	69.0	(1,777.8)
Beginning balance (shares) at Dec. 31, 2018		135.9
Balance, beginning at Dec. 31, 2018	5,668.0	$ 7,421.7	84.6	(1,838.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	72.9
Other comprehensive income (loss)	$ 14.9		14.9
Repurchases of ordinary shares (shares)	0.0
Ending balance (shares) at Jun. 29, 2019		136.0
Balance, ending at Jun. 29, 2019	$ 5,726.2	$ 7,395.5	99.5	(1,768.8)
Beginning balance (shares) at Mar. 30, 2019		136.0
Balance, beginning at Mar. 30, 2019	5,700.6	$ 7,409.4	69.0	(1,777.8)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	9.0			9.0
Other comprehensive income (loss)	30.5		30.5
Stock options exercised	0.3	0.3
Compensation for stock options	1.3	1.3
Compensation for restricted stock	14.2	14.2
Cash dividends, $0.19 per share	(28.9)	(28.9)
Shares withheld for payment of employees' withholding tax liability	$ (0.8)	$ (0.8)
Repurchases of ordinary shares (shares)	0.0
Ending balance (shares) at Jun. 29, 2019		136.0
Balance, ending at Jun. 29, 2019	$ 5,726.2	$ 7,395.5	$ 99.5	$ (1,768.8)

XML

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Jun. 29, 2019	Mar. 30, 2019	Jun. 30, 2018	Mar. 31, 2018
Statement of Stockholders' Equity [Abstract]
Dividends paid (in dollars per share)	$ 0.21	$ 0.19	$ 0.19	$ 0.19

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Cash Flows From (For) Operating Activities
Net income	$ 72.9	$ 117.0
Adjustments to derive cash flows:
Depreciation and amortization	191.5	217.8
Share-based compensation	28.0	22.3
Impairment charges	31.9	1.7
Change in financial assets	(15.9)	9.0
Loss on extinguishment of debt	0.0	0.5
Restructuring charges	21.5	5.2
Deferred income taxes	9.2	(14.2)
Amortization of debt premium	(3.0)	(3.7)
Other non-cash adjustments, net	26.4	5.1
Subtotal	362.5	360.7
Increase (decrease) in cash due to:
Accounts receivable	(55.3)	(24.3)
Inventories	(78.3)	(99.3)
Accounts payable	41.2	89.2
Payroll and related taxes	(23.0)	(48.4)
Accrued customer programs	(52.8)	33.9
Accrued liabilities	(19.2)	(30.4)
Accrued income taxes	(36.7)	(20.8)
Other, net	19.9	(5.9)
Subtotal	(204.2)	(106.0)
Net cash from (for) operating activities	158.3	254.7
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	1.7	10.3
Purchase of investment securities		(7.5)
Royalty Pharma contingent milestone payment	250.0
Asset acquisitions	(35.0)
Additions to property, plant and equipment	(54.7)	(33.3)
Net proceeds from sale of business and other assets		1.3
Net cash from (for) investing activities	162.0	(29.2)
Cash Flows From (For) Financing Activities
Issuances of long-term debt		431.0
Payments on long-term debt	(158.9)	(457.3)
Borrowings (repayments) of revolving credit agreements and other financing, net	397.5	(8.2)
Deferred financing fees		(2.4)
Issuance of ordinary shares	0.3
Repurchase of ordinary shares		(265.0)
Cash dividends	(54.8)	(52.8)
Other financing, net	(5.9)	(7.5)
Net cash from (for) financing activities	178.2	(362.2)
Effect of exchange rate changes on cash and cash equivalents	6.1	(15.5)
Net increase (decrease) in cash and cash equivalents	504.6	(152.2)
Cash and cash equivalents, beginning of period	551.1	678.7
Cash and cash equivalents, end of period	$ 1,055.7	$ 526.5

XML

Summary of Significant Accounting Policies

6 Months Ended

Jun. 29, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

The Company

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

We are dedicated to making lives better by bringing “Quality, Affordable Self-Care Products™” that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. We are also a leading producer of generic prescription pharmaceutical topical products such as creams, lotions, gels, and nasal sprays.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Segment Reporting Change

               During the three months ended March 30, 2019, we changed the composition of our operating and reporting segments. We moved our Israeli diagnostic business from the Consumer Self-Care International segment to the Prescription Pharmaceuticals segment and we made certain adjustments to our allocations between segments. These changes were made to reflect changes in the way in which management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in Note 2 and Note 17.

Our new reporting and operating segments are as follows:

• Consumer Self-Care Americas ("CSCA"), formerly Consumer Healthcare Americas, comprises our consumer self-care business (OTC, contract manufacturing, infant formula and animal health categories) in the U.S., Mexico and Canada.

• Consumer Self-Care International ("CSCI"), formerly Consumer Healthcare International, comprises our branded consumer self-care business primarily in Europe, our consumer-focused business in the United Kingdom and Australia, and our liquid licensed products business in the United Kingdom.

• Prescription Pharmaceuticals ("RX") comprises our Prescription Pharmaceuticals business in the U.S. and our diagnostic business in Israel, which was previously in our CSCI segment.

Recent Accounting Standard Pronouncements

Below are recent Accounting Standard Updates ("ASU") that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Recently Issued Accounting Standards Not Yet Adopted
Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
ASU 2018-15: Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract	This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.	January 1, 2020	We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.
ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement	This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.	January 1, 2020	We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.
ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ASU 2018-19: Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments ASU 2019-05: Financial Instruments-Credit Losses: Targeted Transition Relief	This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.	January 1, 2020	We are in the process of completing our evaluation. Upon adoption, we are not expecting a material impact on the financial statements.
ASU 2018-18: Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606	This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.	January 1, 2020	We are in the process of completing our evaluation. Upon adoption, we are not expecting a material impact on the financial statements.
ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans	This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans.	December 31, 2020	We are currently evaluating the implications of adoption on our Consolidated Financial Statements.

XML

Revenue Recognition

6 Months Ended

Jun. 29, 2019

Revenue from Contract with Customer [Abstract]

Revenue Recognition

REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations⁽¹⁾ (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
U.S.	$	768.6	$	772.3	$	1,537.4	$	1,558.7
Europe(2)	315.8		344.3		656.7		706.2
All other countries(3)	64.6		69.8		129.4		138.5
	$	1,149.0	$	1,186.4	$	2,323.5	$	2,403.4

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $6.9 million and $12.1 million for the three and six months ended June 29, 2019, respectively, and $5.0 million and $10.4 million for the three and six months ended June 30, 2018, respectively.

(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

The following is a summary of our net sales by category (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
CSCA(1)
Cough/cold/allergy/sinus	$	120.9	$	109.3	$	253.5	$	250.8
Gastrointestinal	106.2		103.0		206.5		195.2
Infant nutritionals	85.5		109.2		181.5		212.6
Analgesics	88.2		92.2		177.0		185.9
Smoking cessation	77.0		71.2		143.8		137.1
Animal health	22.4		31.9		42.0		58.2
Vitamins, minerals and dietary supplements	3.9		4.3		7.3		7.3
Other CSCA(2)	78.0		75.8		152.3		151.4
Total CSCA	582.1		596.9		1,163.9		1,198.5
CSCI
Cough/cold/allergy/sinus	74.1		84.7		169.8		183.4
Lifestyle	81.2		86.1		162.7		175.8
Personal care and derma-therapeutics	69.2		79.7		135.2		155.3
Natural health and vitamins, minerals and dietary supplements	25.6		27.9		55.4		61.1
Anti-parasites	26.0		30.4		52.7		58.5
Other CSCI(3)	51.4		49.1		102.5		101.6
Total CSCI	327.5		357.9		678.3		735.7
Total RX	239.4		231.6		481.3		469.2
Total net sales	$	1,149.0	$	1,186.4	$	2,323.5	$	2,403.4

(1)    Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $65.8 million and $133.1 million for the three and six months ended June 29, 2019, respectively, and $77.1 million and $146.5 million for the three and six months ended June 30, 2018, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	June 29, 2019		December 31, 2018
Short-term contract assets	Prepaid expenses and other current assets	$	16.6	$	25.5

XML

Acquisitions

6 Months Ended

Jun. 29, 2019

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

Acquisitions Completed During the Six Months Ended June 29, 2019

Generic Product Acquisition

On May 17, 2019, we purchased the Abbreviated New Drug Application ("ANDA") for a generic product used to relieve pain from osteoarthritis, for $15.7 million in cash, which we capitalized as a developed product technology intangible asset. We plan to launch the product during the third quarter of 2019 and begin amortizing it over a 20-year useful life. Operating results attributable to the product are included within our RX segment.

Budesonide Nasal Spray and Triamcinolone Nasal Spray

On April 1, 2019, we purchased product ANDAs and other records and registrations of Budesonide Nasal Spray, a generic equivalent of Rhinocort Allergy^®, and Triamcinolone Nasal Spray, a generic equivalent of Nasacort Allergy^®, from Barr Laboratories, Inc. ("Barr"), a subsidiary of Teva Pharmaceuticals, for $14.0 million in cash. We previously developed and marketed the products in collaboration with Barr under a development, marketing and commercialization agreement that originated in August 2003. Under this prior agreement, we paid Barr a percentage of net income from products sold by Perrigo in the U.S. By purchasing the assets from Barr and terminating the original development, marketing and commercialization agreement, we are now entitled to 100% of the income from sales of the product. Operating results attributable to these products are included within our CSCA segment. The intangible assets acquired are classified as developed product technology with a 10-year useful life.

Acquisitions Completed During the Year Ended December 31, 2018

Nasonex-branded products

On May 29, 2018, we entered into a license agreement with Merck Sharp & Dohme Corp. ("Merck"), which allows us to develop and commercialize an OTC version of Nasonex-branded products containing the compound, mometasone furoate monohydrate. The acquisition was accounted for as an asset acquisition based on our assessment that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset to be used for R&D. In accordance with Accounting Standards Codification Topic 730 Research and Development, the non-refundable upfront license fee of $50.0 million was recorded in R&D expense in our CHCA segment because the intangible research and development asset acquired has no alternative use. The agreement requires us to make contingent payments if we obtain regulatory approval and achieve certain sales milestones. We will also be obligated to make royalty payments on potential future sales. The contingent consideration will be included in the measurement of the cost of the asset when the contingency is resolved and the consideration is paid or becomes payable. Consideration paid after U.S. Food and Drug Administration approval will be capitalized and amortized to cost of goods sold over the economic life of each product.

XML

Goodwill and Intangible Assets

6 Months Ended

Jun. 29, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):

	December 31, 2018		Transfer to assets held-for-sale			Currency Translation Adjustments			June 29, 2019
CSCA(1)	$	1,713.7	$	(42.2	)	$	2.1		$	1,673.6
CSCI(2)	1,151.3		—			(9.2		)	1,142.1
RX	1,114.8		—			4.8			1,119.6
Total goodwill	$	3,979.8	$	(42.2	)	$	(2.3	)	$	3,935.3

(1) We had accumulated impairments of $24.5 million and $161.2 million as of June 30, 2018 and June 29, 2019, respectively.

(2) We had accumulated impairments of $868.4 million as of June 30, 2018 and June 29, 2019.

  During the three months ended June 29, 2019, our RX U.S. reporting unit had an indication of potential impairment which was driven by a combination of industry and market factors and uncertainty related to the timing

and associated cash flows of the projected ProAir launch. Goodwill remaining in this reporting unit was $1,119.6 million as of June 29, 2019. We prepared an impairment test as of June 29, 2019 and determined that the fair value of the RX U.S. reporting unit continued to exceed net book value by approximately 10%. The excess was lower than our annual impairment test as of October 1, 2018, in which fair value exceeded carrying value by more than 25%. While no impairment was recorded as of June 29, 2019, future developments such as deterioration in business performance or market multiples could reduce the fair value of this reporting unit and lead to impairment in a future period. 

In conjunction with the test performed during the three months ended June 29, 2019, we early adopted ASU 2017-04 which removes the Step 2 requirement in instances when the carrying value of a reporting unit exceeds its fair value. Prospectively, if a reporting unit’s carrying value exceeds its fair value, we will record an impairment charge in the amount of the difference, limited to the amount of goodwill attributed to that reporting unit.

Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):

	June 29, 2019				December 31, 2018
	Gross		Accumulated Amortization		Gross		Accumulated Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands	$	18.0	$	—	$	18.1	$	—
In-process research and development	14.5		—		31.2		—
Total indefinite-lived intangibles	$	32.5	$	—	$	49.3	$	—
Definite-lived intangibles:
Distribution and license agreements and supply agreements	$	173.7	$	105.2	$	178.6	$	99.0
Developed product technology, formulations, and product rights	1,321.0		706.1		1,318.8		654.6
Customer relationships and distribution networks	1,558.5		613.9		1,586.6		566.5
Trademarks, trade names, and brands	1,266.0		219.5		1,282.4		188.5
Non-compete agreements	8.3		7.6		12.9		11.8
Total definite-lived intangibles	$	4,327.5	$	1,652.3	$	4,379.3	$	1,520.4
Total intangible assets	$	4,360.0	$	1,652.3	$	4,428.6	$	1,520.4

We recorded amortization expense of $73.6 million and $149.0 million for the three and six months ended June 29, 2019, respectively, and $85.3 million and $172.4 million for the three and six months ended June 30, 2018, respectively.

During the three months ended June 29, 2019, we identified impairment indicators for a certain definite-lived asset related to changes in pricing and competition in the market, which lowered the projected cash flows we expect to generate from the asset. We determined the asset was impaired by $27.8 million in our RX segment.

We recorded an impairment charge of $4.1 million on an in process R&D asset in the CSCA segment during the three months ended March 30, 2019 due to changes in projected development and regulatory timelines.

XML

Inventories

6 Months Ended

Jun. 29, 2019

Inventory Disclosure [Abstract]

Inventories

INVENTORIES

Major components of inventory were as follows (in millions):

 

	June 29, 2019		December 31, 2018
Finished goods	$	501.2	$	444.9
Work in process	192.8		197.5
Raw materials	246.5		235.6
Total inventories	$	940.5	$	878.0

XML

Fair Value Measurements

6 Months Ended

Jun. 29, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):

	June 29, 2019						December 31, 2018
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Measured at fair value on a recurring basis:
Assets:
Investment securities	$	2.8	$	—	$	—	$	9.4	$	—	$	—
Foreign currency forward contracts	—		4.0		—		—		3.8		—
Funds associated with Israeli severance liability	—		14.0		—		—		13.0		—
Royalty Pharma contingent milestone payments	—		—		89.1		—		—		323.2
Total assets	$	2.8	$	18.0	$	89.1	$	9.4	$	16.8	$	323.2
Liabilities:
Foreign currency forward contracts	$	—	$	3.6	$	—	$	—	$	9.2	$	—
Contingent consideration	—		—		12.1		—		—		15.3
Total liabilities	$	—	$	3.6	$	12.1	$	—	$	9.2	$	15.3
Measured at fair value on a non-recurring basis:
Assets:
Goodwill(1)	$	—	$	—	$	—	$	—	$	—	$	42.2
Indefinite-lived intangible assets(2)	—		—		—		—		—		10.5
Definite-lived intangible assets(3)	—		—		—		—		—		22.4
Total assets	$	—	$	—	$	—	$	—	$	—	$	75.1

(1) As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million.

(2) As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million.

(3) As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million.

There were no transfers among Level 1, 2, and 3 during the three and six months ended June 29, 2019 or the year ended December 31, 2018.

Royalty Pharma Contingent Milestone Payments

The table below summarizes the change in fair value of the Royalty Pharma contingent milestone payments (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019			June 30, 2018
Beginning balance	$	83.6	$	124.9	$	323.2		$	134.5
Payments received	—		—		(250.0		)	—
Change in fair value	5.5		0.6		15.9			(9.0		)
Ending balance	$	89.1	$	125.5	$	89.1		$	125.5

We value our contingent milestone payments from Royalty Pharma using a modified Black-Scholes Option Pricing Model ("BSOPM"). Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri^® that are received by Royalty Pharma until the contingent milestones are resolved. Volatility and the estimated fair value of the milestones have a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. We assess volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. The table below represents the volatility and rate of return:

	Three Months Ended
	June 29, 2019		June 30, 2018
Volatility	30.0	%	30.0	%
Rate of return	7.99	%	8.09	%

The fair value of the Royalty Pharma contingent milestone payment increased by $5.5 million and $15.9 million during the three and six months ended June 29, 2019, respectively. These adjustments were driven by higher projected global net sales of Tysabri^® and the estimated probability of achieving the earn-out. The fair value of the Royalty Pharma contingent milestone payments increased by $0.6 million during the three months ended June 30, 2018. This increase included a $2.9 million decrease in the fair value of the 2018 contingent milestone payment, more than offset by a $3.5 million increase in the fair value of the 2020 contingent milestone payment. During the six months ended June 30, 2018, the fair value of the Royalty Pharma contingent milestone payments decreased $9.0 million. The net changes in the fair value of the contingent milestone payments were due to the fluctuation of the projected global net sales of Tysabri^®_, which were impacted by competition, namely the launch of Ocrevus^® in the U.S. and European markets.

In order for us to receive the 2020 milestone payment of $400.0 million, Royalty Pharma contingent payments for Tysabri^® sales in 2020 must exceed $351.0 million. In 2018, the Royalty Pharma contingent payments for Tysabri^® were $337.5 million, which exceeded the threshold. If Royalty Pharma contingent payments for Tysabri^® sales do not meet the prescribed threshold in 2020, we will write off the $89.1 million asset as an expense. If the prescribed threshold is exceeded, we will increase the asset to $400.0 million and recognize income of $310.9 million in Change in financial assets on the Condensed Consolidated Statements of Operations.

Contingent Consideration

The table below summarizes the change in fair value of contingent consideration (in millions):

	Three Months Ended						Six Months Ended
	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Beginning balance	$	12.4		$	18.1		$	15.3		$	22.0
Changes in value	0.9			(1.8		)	(2.0		)	(1.4		)
Currency translation adjustments	—			(0.1		)	—			—
Settlements and other adjustments	(1.2		)	—			(1.2		)	(4.4		)
Ending balance	$	12.1		$	16.2		$	12.1		$	16.2

Goodwill and Intangible Assets

Animal Health

When determining the fair value of our animal health reporting unit for the year ended December 31, 2018, we utilized a combination of comparable company market and discounted cash flow techniques. In our comparable company market approach, we considered observable market information and transactions for companies that we deemed to be of a comparable nature, scope, and size of animal health (Level 2 inputs). Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products, plus gross margin, advertising and promotion, and other operating expenses based on the growth plans (Level 3 inputs). In our discounted cash flow analysis, we utilized projected sales growth rate and discount rate assumptions of 2.5% and 9.8%, respectively. The discount rate correlates with the required investment return and risk that we believe market participants would apply to the projected growth rate. In addition, we burdened projected free cash flows with the capital spending deemed necessary to support the cash flows and applied the jurisdictional tax rate of 22.8%. We weighted indications of fair value resulting from the market approach and present value techniques, considering the reasonableness of the range of measurements and the point within the range that we determined was most representative of fair market conditions.

When assessing our animal health indefinite-lived intangible asset for the year ended December 31, 2018, we utilized a multi-period excess earnings method ("MPEEM") to determine the fair value of the intangible asset. Our cash flow projections included revenue assumptions related to new products, product line extensions, and existing products. We utilized long-term growth rate and discount rate assumptions of (0.3)% and 9.8%, respectively, and we applied a jurisdictional tax rate of 22.8%.

When assessing our animal health definite-lived assets for impairment for the year ended December 31, 2018, we utilized a combination of MPEEM and relief from royalty methods to determine the fair values of definite-lived assets within the asset group. The projected financial information, inputs, and assumptions utilized were consistent with those utilized in the goodwill discounted cash flow analysis described above.

Generic product

When measuring the impairment of a certain definite-lived asset during the three months ended June 29, 2019, we utilized a discounted cash flow technique to estimate the fair value of the asset. Significant valuation inputs and assumptions relate to our projected future cash flows, including the total market size, our estimated market share, and our average selling price.

Fixed Rate Long-term Debt    

Our fixed rate long-term debt consisted of the following (in millions):

	June 29, 2019				December 31, 2018
	Level 1		Level 2		Level 1		Level 2
Public Bonds
Carrying Value (excluding discount)	$	2,600.0			$	2,600.0
Fair value	$	2,533.0			$	2,316.6
Retail bond and private placement note
Carrying value (excluding premium)			$	153.5			$	292.5
Fair value			$	167.8			$	307.9

The fair values of our public bonds for all periods were based on quoted market prices. The fair value of our private placement note for all periods was based on interest rates offered for borrowings of a similar nature and remaining maturities. The fair value of our retail bond for the year ended December 31, 2018 was based on interest rates offered for borrowings of a similar nature and remaining maturities. On May 23, 2019, we repaid the retail bond in full (refer to Note 11).

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt, revolving credit agreements, and variable rate long-term debt, approximate their fair value.

XML

Investments

6 Months Ended

Jun. 29, 2019

Investments [Abstract]

Investments

INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):

Measurement Category	Balance Sheet Location	June 29, 2019		December 31, 2018
Fair value method	Prepaid expenses and other current assets	$	2.8	$	9.4
Fair value method(1)	Other non-current assets	$	2.8	$	4.4
Equity method	Other non-current assets	$	16.8	$	15.1

(1) Measured at fair value using the Net Asset Value practical expedient.

The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):

		Three Months Ended						Six Months Ended
Measurement Category	Income Statement Location	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Fair value method	Other (income) expense, net	$	1.8		$	6.3		$	7.9		$	10.6
Equity method	Other (income) expense, net	$	(1.0	)	$	(0.9	)	$	(1.7	)	$	(0.7	)

During the three months ended June 30, 2018, Perrigo Asia Holding Company Limited increased its investment in Zibo Xinhua - Perrigo Pharmaceutical Company Limited by $7.5 million.

XML

Assets held for sale

6 Months Ended

Jun. 29, 2019

Discontinued Operations and Disposal Groups [Abstract]

Assets Held for Sale

ASSETS HELD FOR SALE

We classify assets as "held for sale" when, among other factors, management approves and commits to a formal plan of sale with the expectation the sale will be completed within one year. The net assets of the business held for sale are then recorded at the lower of their current carrying value and the fair market value, less costs to sell.

During the three months ended June 29, 2019, management committed to a plan to sell our animal health business; as a result, such assets were classified as held-for-sale. On July 8, 2019, we completed the sale of our animal health business (refer to Note 18). The assets associated with our animal health business were reported in our CSCA segment.

The assets held-for-sale were reported within Prepaid expenses and other current assets and liabilities held-for-sale were reported in Accrued liabilities. The amounts consisted of the following (in millions):

	June 29, 2019
Assets held for sale
Current assets	$	29.3
Property, plant and equipment, net	10.8
Goodwill and indefinite-lived intangible assets	42.2
Definite-lived intangible assets, net	36.4
Other assets	25.7
Total assets held for sale	$	144.4
Liabilities held for sale
Current liabilities	$	11.3
Other liabilities	38.3
Total liabilities held for sale	$	49.6

XML

Derivative Instruments and Hedging Activities

6 Months Ended

Jun. 29, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

On January 1, 2019, we adopted Accounting Standards Update No. 2017-12 Targeted Improvements to Accounting for Hedge Activities ("ASU 2017-12") using a modified retrospective approach. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three and six months ended June 30, 2018 below conform to the disclosure requirements prior to the adoption of ASU 2017-12.

Prior to the adoption of ASU 2017-12, we were required to separately measure and reflect the amount by which the hedging instrument did not offset the changes in the fair value or cash flows of hedged items, which was referred to as the ineffective amount. We assessed hedge effectiveness on a quarterly basis and recorded the gain or loss related to the ineffective portion of derivative instruments, if any, in Other (income) expense, net on the Condensed Consolidated Statements of Operations. Pursuant to the provisions of ASU 2017-12, we are no longer required to separately measure and recognize hedge ineffectiveness. Therefore, we no longer recognize hedge ineffectiveness separately on our Condensed Consolidated Statements of Income, but instead recognize the entire change in the fair value of:

• Cash flow hedges included in the assessment of hedge effectiveness in OCI. The amounts recorded in OCI will subsequently be reclassified to earnings in the same line item on the Condensed Consolidated Statements of Operations as impacted by the hedged item when the hedged item affects earnings; and

• Fair value hedges included in the assessment of hedge effectiveness in the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item.

Prior to the adoption of ASU 2017-12, we excluded option premiums and forward points (excluded components) from our assessment of hedge effectiveness for our foreign exchange cash flow hedges. We

recognized all changes in fair value of the excluded components in Other (income) expense, net, on the Condensed Consolidated Statements of Operations. The amendments in ASU 2017-12 continue to allow those components to be excluded from the assessment of hedge effectiveness and add cross-currency basis spread as an allowable excluded component. The provisions of ASU 2017-12 allow a policy election to either continue to recognize changes in the fair value of the excluded components currently in earnings or to recognize the initial value of the excluded component using an amortization approach. We have elected to recognize the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. The cumulative effect adjustment between Accumulated Other Comprehensive Income ("AOCI") and Retained earnings (accumulated deficit) from applying this policy on existing hedges at the date of adoption was immaterial.

We record derivative instruments on the balance sheet on a gross basis as either an asset or liability measured at fair value (refer to Note 6). Additionally, changes in a derivative's fair value, which are measured at the end of each period, are recognized in earnings unless a derivative can be designated in a qualifying hedging relationship.

Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. We have elected to recognize the fair value of the excluded component in OCI and amortize on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. All of our designated derivatives are assessed for hedge effectiveness quarterly. All of our designated derivatives were classified as cash flow hedges as of June 29, 2019 and December 31, 2018.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.

We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "Aa3" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of our forward currency exchange contracts is 18 months.

We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.

All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.

Interest Rate Swaps

Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense. There were no active designated or non-designated interest rate swaps as of June 29, 2019 and December 31, 2018.

Foreign Currency Derivatives

Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows (in millions):

	Notional Amount
	June 29, 2019		December 31, 2018
Israeli Shekel (ILS)	$	340.6	$	232.6
British Pound (GBP)	111.0		90.2
European Euro (EUR)	108.0		134.2
Swedish (SEK)	42.2		38.7
Danish Krone (DKK)	58.2		56.5
United States Dollar (USD)	46.2		39.3
Canadian Dollar (CAD)	41.9		31.7
Polish Zloty (PLZ)	33.5		18.2
Chinese Yuan (CNY)	20.0		—
Norwegian Krone (NOK)	6.8		6.2
Romanian New Leu (RON)	5.9		4.4
Mexican Peso (MPX)	4.2		25.9
Other	12.6		8.7
Total	$	831.1	$	686.6

Effects of Derivatives on the Financial Statements

The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects.

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):

		Asset Derivatives
		Fair Value
	Balance Sheet Location	June 29, 2019		December 31, 2018
Designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	1.0	$	2.0
Non-designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	3.0	$	1.8

		Liability Derivatives
		Fair Value
	Balance Sheet Location	June 29, 2019		December 31, 2018
Designated derivatives:
Foreign currency forward contracts	Accrued liabilities	$	2.6	$	6.4
Non-designated derivatives:
Foreign currency forward contracts	Accrued liabilities	$	1.0	$	2.8

The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments in AOCI (in millions):

	Three Months Ended
	June 29, 2019
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings			Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements			Interest expense, net	$	(0.4	)	Interest expense, net	$	—
Foreign currency forward contracts	$	1.1	Net sales	0.1			Net sales	0.1
			Cost of sales	(0.2		)	Cost of sales	(1.1		)
				$	(0.5	)		$	(1.0	)

	Six Months Ended
	June 29, 2019
Instrument	Amount of Gain/(Loss) Recorded in OCI(1)		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings			Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements			Interest expense, net	$	(1.0	)	Interest expense, net	$	—
Foreign currency forward contracts	$	—	Net sales	0.3			Net sales	—
			Cost of sales	(1.4		)	Cost of sales	(2.2		)
				$	(2.1	)		$	(2.2	)

(1) Net loss of $1.6 million is expected to be reclassified out of AOCI into earnings during the next 12 months.

	Three Months Ended
	June 30, 2018
	Effective Portion
Instrument	Amount of Gain/(Loss) Recorded in OCI			Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements				Interest expense, net	$	(0.4	)
Foreign currency forward contracts	$	(4.3	)	Net sales	—
				Cost of sales	1.6
				Interest expense, net	(1.1		)
				Other (income) expense, net	(0.1		)
					$	—

	Six Months Ended
	June 30, 2018
	Effective Portion
Instrument	Amount of Gain/(Loss) Recorded in OCI			Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements				Interest expense, net	$	(0.9	)
Foreign currency forward contracts	$	(4.3	)	Net sales	—
				Cost of sales	3.9
				Interest expense, net	(2.0		)
				Other (income) expense, net	(0.5		)
					$	0.5

The amounts of gain/(loss) recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):

		Three Months Ended					Six Months Ended
Non-Designated Derivatives	Income Statement Location	June 29, 2019			June 30, 2018		June 29, 2019			June 30, 2018
Foreign currency forward contracts	Other (income) expense, net	$	(4.3	)	$	11.8	$	(13.1	)	$	8.6
	Interest expense, net	1.4			0.2		1.8			(0.7		)
Total		$	(2.9	)	$	12.0	$	(11.3	)	$	7.9

The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Condensed Consolidated Statements of Operations in Other (income) expense, net for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar-translated amounts of each Income Statement account in current and/or future periods.

The classification and amount of gain/(loss) recognized in earnings on fair value and cash flow hedging relationships are as follows (in millions):

	Three Months Ended
	June 29, 2019
	Net Sales		Cost of Sales			Interest Expense, net			Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,149.0	$	718.2		$	31.2		$	2.3
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	0.1	$	(0.2	)	$	—		$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	0.1	$	(1.1	)	$	—		$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—		$	(0.4	)	$	—

	Six Months Ended
	June 29, 2019
	Net Sales		Cost of Sales			Interest Expense, net			Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	2,323.5	$	1,443.9		$	59.8		$	5.5
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	0.3	$	(1.4	)	$	—		$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	(2.2	)	$	—		$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—		$	(1.0	)	$	—

XML

Leases

6 Months Ended

Jun. 29, 2019

Leases [Abstract]

Leases

LEASES

We adopted ASU 2016-02, Leases, as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification.

Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately $166.5 million and $164.0 million, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.

We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.

We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.

Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The balance sheet location of our lease assets and liabilities were as follows (in millions):

Assets	Balance Sheet Location	June 29, 2019
Operating	Operating lease assets	$	135.4
Finance	Other non-current assets	17.1
Total		$	152.5

Liabilities	Balance Sheet Location	June 29, 2019
Current
Operating	Accrued liabilities	$	32.9
Finance	Current indebtedness	1.9
Non-Current
Operating	Other non-current liabilities	107.4
Finance	Long-term debt, less current portion	11.8
Total		$	154.0

The below table shows our lease assets and liabilities by reporting segment (in millions):

	Assets				Liabilities
	Operating		Financing		Operating		Financing
	June 29, 2019		June 29, 2019		June 29, 2019		June 29, 2019
CSCA	$	22.7	$	8.9	$	22.9	$	8.4
CSCI	42.0		6.1		42.9		3.2
RX	37.5		0.3		38.9		0.3
Unallocated	33.2		1.8		35.6		1.8
Total	$	135.4	$	17.1	$	140.3	$	13.7

Lease expense was as follows (in millions):

	Three Months Ended		Six Months Ended
	June 29, 2019		June 29, 2019
Operating leases(a)	$	11.2	$	23.2
Finance leases
Amortization	$	0.7	$	1.3
Interest	0.1		0.2
Total finance leases	$	0.8	$	1.5

(a) Includes short-term leases and variable lease costs, which are immaterial.

Total operating lease expense for the three and six months ended June 30, 2018 was $14.2 million and $26.1 million, respectively.

The annual future maturities of our leases as of June 29, 2019 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2019	$	19.4	$	1.2	$	20.6
2020	34.6		2.3		36.9
2021	24.9		3.6		28.5
2022	18.3		1.2		19.5
2023	14.0		1.0		15.0
After 2023	51.7		7.8		59.5
Total lease payments	162.9		17.1		180.0
Less: Interest	22.6		3.4		26.0
Present value of lease liabilities	$	140.3	$	13.7	$	154.0

`

Our weighted average lease terms and discount rates are as follows:

	June 29, 2019
Weighted-average remaining lease term (in years)
Operating leases	6.59
Finance leases	9.43
Weighted-average discount rate
Operating leases	4.19	%
Finance leases	4.35	%

Our lease cash flow classifications are as follows (in millions):

	Six Months Ended
	June 29, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	23.0
Operating cash flows for finance leases	$	0.2
Financing cash flows for finance leases	$	1.4
Leased assets obtained in exchange for new finance lease liabilities	$	7.8
Leased assets obtained in exchange for new operating lease liabilities	$	12.8

Leases

LEASES

We adopted ASU 2016-02, Leases, as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification.

Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately $166.5 million and $164.0 million, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.

We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.

We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.

Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The balance sheet location of our lease assets and liabilities were as follows (in millions):

Assets	Balance Sheet Location	June 29, 2019
Operating	Operating lease assets	$	135.4
Finance	Other non-current assets	17.1
Total		$	152.5

Liabilities	Balance Sheet Location	June 29, 2019
Current
Operating	Accrued liabilities	$	32.9
Finance	Current indebtedness	1.9
Non-Current
Operating	Other non-current liabilities	107.4
Finance	Long-term debt, less current portion	11.8
Total		$	154.0

The below table shows our lease assets and liabilities by reporting segment (in millions):

	Assets				Liabilities
	Operating		Financing		Operating		Financing
	June 29, 2019		June 29, 2019		June 29, 2019		June 29, 2019
CSCA	$	22.7	$	8.9	$	22.9	$	8.4
CSCI	42.0		6.1		42.9		3.2
RX	37.5		0.3		38.9		0.3
Unallocated	33.2		1.8		35.6		1.8
Total	$	135.4	$	17.1	$	140.3	$	13.7

Lease expense was as follows (in millions):

	Three Months Ended		Six Months Ended
	June 29, 2019		June 29, 2019
Operating leases(a)	$	11.2	$	23.2
Finance leases
Amortization	$	0.7	$	1.3
Interest	0.1		0.2
Total finance leases	$	0.8	$	1.5

(a) Includes short-term leases and variable lease costs, which are immaterial.

Total operating lease expense for the three and six months ended June 30, 2018 was $14.2 million and $26.1 million, respectively.

The annual future maturities of our leases as of June 29, 2019 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2019	$	19.4	$	1.2	$	20.6
2020	34.6		2.3		36.9
2021	24.9		3.6		28.5
2022	18.3		1.2		19.5
2023	14.0		1.0		15.0
After 2023	51.7		7.8		59.5
Total lease payments	162.9		17.1		180.0
Less: Interest	22.6		3.4		26.0
Present value of lease liabilities	$	140.3	$	13.7	$	154.0

`

Our weighted average lease terms and discount rates are as follows:

	June 29, 2019
Weighted-average remaining lease term (in years)
Operating leases	6.59
Finance leases	9.43
Weighted-average discount rate
Operating leases	4.19	%
Finance leases	4.35	%

Our lease cash flow classifications are as follows (in millions):

	Six Months Ended
	June 29, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	23.0
Operating cash flows for finance leases	$	0.2
Financing cash flows for finance leases	$	1.4
Leased assets obtained in exchange for new finance lease liabilities	$	7.8
Leased assets obtained in exchange for new operating lease liabilities	$	12.8

XML

Indebtedness

6 Months Ended

Jun. 29, 2019

Debt Disclosure [Abstract]

Indebtedness

INDEBTEDNESS

Total borrowings outstanding are summarized as follows (in millions):

			June 29, 2019			December 31, 2018
Revolving Credit Agreement
	2018 Revolver due March 8, 2023		$	325.0		$	—
Term loan
	2018 Term loan due March 8, 2020(1)		323.4			351.3
Notes and Bonds
	Coupon	Due
	5.000%	May 23, 2019	—			137.6
	3.500%	March 15, 2021	280.4			280.4
	3.500%	December 15, 2021	309.6			309.6
	5.105%	July 28, 2023(1)	153.5			154.9
	4.000%	November 15, 2023	215.6			215.6
	3.900%	December 15, 2024	700.0			700.0
	4.375%	March 15, 2026	700.0			700.0
	5.300%	November 15, 2043	90.5			90.5
	4.900%	December 15, 2044	303.9			303.9
	Total notes and bonds		2,753.5			2,892.5
Other financing			87.2			2.8
Unamortized premium (discount), net			8.9			12.2
Deferred financing fees			(14.8		)	(16.4		)
Total borrowings outstanding			3,483.2			3,242.4
	Current indebtedness		(398.8		)	(190.2		)
Total long-term debt less current portion			$	3,084.4		$	3,052.2

(1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

We are in compliance with all covenants under our debt agreements as of June 29, 2019.

Revolving Credit Agreements

On March 8, 2018, we terminated the revolving credit agreement entered into on December 5, 2014 and entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2018 Revolver"). During the three months ended June 29, 2019, in anticipation of the Ranir Global Holdings, LLC (“Ranir”) acquisition (refer to Note 18), we borrowed $375.0 million under this facility. There were $325.0 million of borrowings outstanding under the 2018 Revolver as of June 29, 2019. There were no borrowings outstanding under the 2018 Revolver as of December 31, 2018.

Term Loans

On December 5, 2014, Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ($614.3 million) tranche, maturing on December 5, 2019. On March 8, 2018, we refinanced the €350.0 million outstanding under the term loan with the proceeds of a new €350.0 million ($431.0 million) term loan, maturing on March 8, 2020 (the "2018 Term Loan"). In addition, as a result of the refinancing during the three months ended March 31, 2018, we recorded a loss of $0.5 million, consisting of the write-off of deferred financing fees in Loss on extinguishment of debt on the Condensed Consolidated Statements of Operations. During the six months ended June 29, 2019, we made $24.7 million in scheduled principal payments on the 2018 Term Loan.

Notes and Bonds

In connection with the Omega acquisition, on March 30, 2015, we assumed a 5.000% retail bond due in 2019 in the amount of €120.0 million ($130.7 million). On May 23, 2019 we repaid the bond in full.

Other Financing

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". The balance outstanding under the facilities was $73.9 million at June 29, 2019. There were no borrowings outstanding under the facilities as of December 31, 2018.

We have financing leases that are reported in the above table under "Other financing" (refer to Note 10).

XML

Earnings Per Share and Shareholders' Equity

6 Months Ended

Jun. 29, 2019

Earnings Per Share [Abstract]

Earnings Per Share and Shareholders' Equity

EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
Numerator:
Net income	$	9.0	$	36.2	$	72.9	$	117.0
Denominator:
Weighted average shares outstanding for basic EPS	136.0		138.1		136.0		139.5
Dilutive effect of share-based awards	0.5		0.6		0.3		0.5
Weighted average shares outstanding for diluted EPS	136.5		138.7		136.3		140.0
Anti-dilutive share-based awards excluded from computation of diluted EPS	1.7		1.7		1.8		0.9

Shareholders' Equity

Share Repurchases

Following the expiration of our 2015 share repurchase plan authorization, in October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program. We did not repurchase any shares during the three and six months ended June 29, 2019. During the three and six months ended June 30, 2018, we repurchased 2.0 million and 3.3 million ordinary shares

at an average repurchase price of $79.42 and $80.42 per share, for a total of $156.9 million and $265.0 million, respectively.

XML

Accumulated Other Comprehensive Income (Loss)

6 Months Ended

Jun. 29, 2019

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Accumulated Other Comprehensive Income (Loss)

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):

	Fair Value of Derivative Financial Instruments, net of tax			Foreign Currency Translation Adjustments		Post-Retirement and Pension Liability Adjustments, net of tax			Total AOCI
Balance at December 31, 2018	$	(15.5	)	$	104.5	$	(4.4	)	$	84.6
OCI before reclassifications	0.2			11.0		—			11.2
Amounts reclassified from AOCI	4.2			—		(0.5		)	3.7
Other comprehensive loss	$	4.4		$	11.0	$	(0.5	)	$	14.9
Balance at June 29, 2019	$	(11.1	)	$	115.5	$	(4.9	)	$	99.5

XML

Income Taxes

6 Months Ended

Jun. 29, 2019

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The effective tax rates were as follows:

Three Months Ended				Six Months Ended
June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
66.6	%	34.5	%	32.5	%	29.4	%

The effective tax rate for the three months ended June 29, 2019 increased compared to the prior year period due primarily to changes in the jurisdictional mix of pre-tax book income and a $27.8 million reduction in pre-tax income due to an impairment charge related to a definite-lived intangible asset.

The effective tax rate for the six months ended June 29, 2019 increased compared to the prior year period due primarily to changes in the jurisdictional mix of pre-tax book income.

On October 31, 2018, we received an audit finding letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the years ended December 31, 2012 and December 31, 2013. The audit finding letter relates to the tax treatment of the 2013 sale of the Tysabri^® intellectual property and other assets related to Tysabri^® to Biogen Idec from Elan Pharma. The consideration paid by Biogen to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Irish Revenue issued a Notice of Amended Assessment (“NoA”) on November 29, 2018 which assesses an Irish corporation tax liability against Elan Pharma in the amount of €1,636 million, not including interest or any applicable penalties. We disagree with this assessment and believe that the NoA is without merit and incorrect as a matter of law. We filed an appeal of the NoA on December 27, 2018 and will pursue all available administrative and judicial avenues as may be necessary or appropriate. As part of this strategy to pursue all available administrative and judicial avenues, Elan Pharma was, on February 25, 2019, granted leave by the Irish High Court to seek judicial review of the issuance of the NoA by Irish Revenue. The judicial review filing is based on our belief that Elan Pharma's legitimate expectations as a taxpayer have been breached, not on the merits of the NoA itself. The High Court has scheduled a hearing in this judicial review proceeding in April 2020, and we would expect a decision in this matter in the second half of 2020. If we are ultimately successful in the judicial review proceedings the NoA will be invalidated and Irish Revenue will not be able to re-issue the NoA. The proceedings before the Tax Appeals Commission have been stayed until a decision on the judicial review application has been made.

On August 15, 2017, we filed a complaint in the United States District Court for the Western District of Michigan to recover $163.6 million of Federal income tax, penalties, and interest assessed and collected by the IRS, plus statutory interest thereon from the dates of payment, for the fiscal years ended June 27, 2009, June 26, 2010, June 25, 2011, and June 30, 2012 (the “2009 tax year,” “2010 tax year,” “2011 tax year,” and “2012 tax year,” respectively). The IRS audits of those years culminated in the issuances of two statutory notices of deficiency: (1) on August 27, 2014 for the 2009 and 2010 tax years and (2) on April 20, 2017 for the 2011 and 2012 tax years. The statutory notices of deficiency both included un-agreed income adjustments related principally to transfer pricing adjustments regarding the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the

United States. In addition, the statutory notice of deficiency for the 2011 and 2012 tax years included the capitalization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits. We fully paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and filed timely claims for refund on June 11, 2015 and June 7, 2017 for the 2009-2010 tax years and 2011-2012 tax years, respectively. Our claims for refund were disallowed by certified letters dated August 18, 2015 and July 11, 2017, for the 2009-2010 tax years and 2011-2012 tax years, respectively. The complaint was timely, based upon the refund claim denials, and seeks refunds of tax, interest, and penalties of $37.2 million for the 2009 tax year, $61.5 million for the 2010 tax year, $40.2 million for the 2011 tax year, and $24.7 million for the 2012 tax year. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017. The cumulative deferred charge as recorded on the balance sheet is $29.7 million lower than the amounts reflected above due to overpayments credited to succeeding years, such that the actual refund the company is seeking to receive will be reduced by that amount. In addition, we recently conceded a royalty due to Perrigo U.S. on all omeprazole sales that equates to a 24% of our refund claims and any omeprazole adjustments that may be asserted by the IRS for future years.

On July 11, 2017, we received a draft Notice of Proposed Adjustment (“NOPA”) associated with transfer pricing positions for the IRS audit of Athena Neurosciences, Inc. (“Athena”), a subsidiary of Elan acquired in 1996, for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Athena was the originator of the patents associated with Tysabri^® prior to the acquisition of Athena by Elan in 1996. The draft NOPA asserted that when Elan took over the future funding of Athena’s in-process R&D in 1996, after it acquired Athena in 1996, it should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. In response to the draft NOPA, we provided the IRS with substantial additional documentation supporting our position. On April 26, 2019, we received a revised NOPA from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, 2012 and 2013. The NOPA carries forward the theory from a 2017 draft NOPA. The revised NOPA proposes a payment of $843.0 million, which represents additional tax and a 40.0% penalty. This amount excludes consideration of offsetting tax attributes and potentially material interest. We strongly disagree with the IRS position and will pursue all available administrative and judicial remedies, including potentially those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. No payment of the additional amounts is required until the matter is resolved administratively, judicially, or through treaty negotiation.

On December 22, 2016, we received a notice of proposed adjustment for the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. Perrigo acquired Elan in December 2013. This proposed adjustment relates to the deductibility of litigation costs. We disagree with the IRS’s position asserted in the notice of proposed adjustment and intend to contest it.

We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. These jurisdictions include, but are not limited to, the United States, Ireland and other jurisdictions in Europe. In addition to the matters discussed above, the IRS is currently auditing our fiscal years ended June 29, 2013, June 28, 2014, and June 27, 2015 (which covers the period of the Elan transaction). The Israel Tax Authority's audit of our fiscal years ended June 29, 2013 and June 28, 2014 concluded with no material impact to the financial statements and the Israel Tax Authority is now auditing our fiscal years ended December 31, 2015, December 31, 2016 and December 31, 2017.

XML

Contingencies

6 Months Ended

Jun. 29, 2019

Commitments and Contingencies Disclosure [Abstract]

Contingencies

CONTINGENCIES

In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of June 29, 2019, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to, individually or in the aggregate, have a material adverse effect on our financial condition, results of operations, or cash flows. 

Price-Fixing Lawsuits

We have been named as a co-defendant with certain other generic pharmaceutical manufacturers in a number of class actions alleging that we and other manufacturers of the same product engaged in anti-competitive behavior to fix or raise the prices of certain drugs and/or allocate customers starting, in some instances, as early as June 2013. The class actions were filed on behalf of putative classes of (a) direct purchasers, (b) end payors, and (c) indirect resellers. The products in question are Clobetasol gel, Desonide, and Econazole. The same class plaintiffs have filed complaints naming us as a co-defendant, along with 27 other manufacturers, alleging an overarching conspiracy to fix or raise the prices of 15 generic prescription pharmaceutical products starting in 2011. Perrigo manufactures only two of the products at issue, Nystatin cream and Nystatin ointment.

We have also been named a co-defendant along with 35 other manufacturers in a complaint filed by three supermarket chains alleging that defendants conspired to fix prices of 31 generic prescription pharmaceutical products starting in 2013. The only allegations specific to us relate to Clobetasol, Desonide, Econazole, Nystatin cream, and Nystatin ointment.

On August 3, 2018, a large managed care organization filed a complaint against us alleging price-fixing and customer allocation concerning 17 different products among 27 manufacturers including Perrigo. The only allegations specific to us concern Clobetasol gel, Desonide, Econazole, Nystatin cream, and Nystatin ointment.

Most recently, on January 16, 2019, a similar suit was brought by a health insurance carrier in the U.S. District Court for the District of Minnesota alleging a conspiracy to fix prices of 30 products among 30 defendants. The only allegations specific to us concern Clobetasol gel, Desonide, Econazole, Nystatin cream, and Nystatin ointment.

Certain complaints listed above were amended in December 2017, January 2018, and April 2019. All of the above complaints have been consolidated for pretrial proceedings, along with complaints filed against other companies alleging price fixing with respect to more than two dozen other drugs, as part of a case captioned In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724 in the U.S. District Court for the Eastern District of Pennsylvania.

Pursuant to the court’s schedule staging various cases in phases, we moved to dismiss the complaints relating to Clobetasol and Econazole. The court issued a decision denying the motions in part in October 2018 and issued a second decision in February 2019 dismissing various state law claims, but allowing other state law claims to proceed. We filed answers to the Clobetasol gel complaints on December 31, 2018. We filed answers to the Desonide and Econazole complaints on March 15, 2019.

Motions to dismiss certain other complaints listed above were filed on February 21, 2019. Plaintiffs’ oppositions were due on May 2, 2019 and defendants’ replies were filed on June 13, 2019. Certain deposition discovery is allowed to proceed as of the court’s July 15, 2019 order in all cases and documentary discovery is also proceeding. At this stage, we cannot reasonably predict the outcome of the liability, if any, associated with these claims.

Securities Litigation

In the United States (cases related to events in 2015-2017)

On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (Roofers’ Pension Fund v. Papa, et al.). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (Wilson v. Papa, et al.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated the Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.

On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. In the amended complaint, the lead plaintiffs seek to represent three classes of shareholders - shareholders who purchased shares during the period April 21, 2015 through May 3, 2017 on the U.S. exchanges; shareholders who purchased shares during the same period on the Tel Aviv exchange; and shareholders who owned shares on November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (the final day of the Mylan tender offer) regardless of whether the shareholders tendered their shares. The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company and at Omega, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri^® royalty stream. The amended complaint does not include an estimate of damages. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions to dismiss in part and denying the motions to dismiss in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims arising from the Tysabri^® accounting issue described above and claims alleging incorrect disclosure of organic growth described above. The defendants who were not dismissed are Perrigo Company plc, Joe Papa, and Judy Brown. The claims (described above) that were not dismissed relate to the integration issues regarding the Omega acquisition and the alleged price fixing activities with respect to six generic prescription pharmaceuticals. The defendants who remain in the case (the Company, Mr. Papa, and Ms. Brown) have filed answers denying liability, and the discovery stage of litigation has begun. We intend to defend the lawsuit vigorously.

On November 1, 2017, Carmignac Gestion, S.A., filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Carmignac Gestion, S.A. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through April 2016. Plaintiff contends that the defendants provided

inadequate disclosure throughout the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. On July 31, 2019, the court granted the motion to dismiss in part and denied it in part. The case is now in the discovery phase. We intend to defend the lawsuit vigorously.

On January 16, 2018, Manning & Napier Advisors, LLC filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled Manning & Napier Advisors, LLC v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5) and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. On July 31, 2019, the court granted the motion to dismiss in part and denied it in part. The case is now in the discovery phase. We intend to defend the lawsuit vigorously.

On January 26, 2018, two different plaintiff groups (the Mason Capital group and the Pentwater group) each filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (Roofers’ Pension Fund case). The same law firm represents these two plaintiff groups, and the two complaints are substantially similar. These two cases are not securities class actions. One case is styled Mason Capital L.P., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The other case is styled Pentwater Equity Opportunities Master Fund Ltd., et al.  v. Perrigo Company plc, et al., and also was filed in the U.S. District Court for the District of New Jersey. Both cases are assigned to the same federal judge that is hearing the class action case and the other individual cases described above (Carmignac and Manning & Napier). Each complaint asserts claims under Securities Exchange Act sections 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the factual allegations in these two cases overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above and the allegations in the Carmignac case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to these cases conferred about how these cases should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in these cases. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuits vigorously.

On February 13, 2018, a group of plaintiff investors affiliated with Harel Insurance Investments & Financial Services, Ltd. filed a lawsuit against us and the same individuals who are defendants in the amended complaint in the securities class action case described above (Roofers’ Pension Fund case). This lawsuit is not a securities class action. The new complaint is substantially similar to the amended complaint in the Roofers' Pension Fund case. The relevant period in the new complaint stretches from February 2014 to May 2, 2017. The complaint adds as defendants two individuals who served on our Board prior to 2016. The case is styled Harel Insurance Company, Ltd., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action cases and the four other individual cases described above (Carmignac, Manning & Napier, Mason Capital, and Pentwater). The Harel Insurance Company complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule 10b‑5) and section 14(e) (related to tender offer disclosures) against all defendants as well as 20(a) control person liability against the individual defendants. The complaint also asserts claims based on Israeli securities laws. In general, the plaintiffs' allegations describe events during the period from February 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset from February 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above and the allegations in the four opt out cases also described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously.

On February 16, 2018, First Manhattan Company filed a securities lawsuit against us and three individuals (former Chairman and CEO Joseph Papa, former CFO Judy Brown, and former Executive Vice President and Board member Marc Coucke). This lawsuit is not a securities class action. The case is styled First Manhattan Co. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the five other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), 14(e), and 18 against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiff’s allegations focus on events during the period from April 2015 through May 2017. Plaintiff contends that the defendants provided inadequate disclosure at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. This lawsuit was filed by the same law firm that filed the Manning & Napier Advisors case and the Carmignac case described above and generally makes the same factual assertions as in the Manning & Napier Advisors case. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. On April 20, 2018, the plaintiff filed an amended complaint that did not materially change the factual allegations of the original complaint. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. Because this plaintiff made some factual allegations that were not asserted in the Roofers’ Pension Fund case, the parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case and the remaining defendants filed a motion to dismiss addressing the additional allegations in this case. On July 31, 2019, the court granted the motion to dismiss in part and denied it in part. The case is now in the discovery phase. We intend to defend the lawsuit vigorously.

On April 20, 2018, a group of plaintiff investors affiliated with TIAA-CREF filed a lawsuit against us and the same individuals who are the defendants in the Harel Insurance case complaint. This lawsuit is not a securities class action. The law firm representing the plaintiffs in the Harel Insurance case also represents the TIAA-CREF plaintiff entities in this case, and the new complaint is substantially similar to the Harel Insurance complaint. The relevant period in the new complaint is August 14, 2014 to May 2, 2017 inclusive. The case is styled TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey and is assigned to the same federal judge that is hearing the class action case and the six other individual cases described above (Carmignac, Manning & Napier, Mason Capital, Pentwater, Harel Insurance,

and First Manhattan). The TIAA-CREF Investment Management complaint asserts claims under Securities Exchange Act section 10(b) (and related SEC Rule l0b-5), section 14(e) (related to tender offer disclosures) against all defendants as well as section 20(a) control person liability against the individual defendants. In general, plaintiffs' allegations describe events during the period from August 2014 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer events in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset from August 2014 until the withdrawal of past financial statements in April 2017. Many of the factual allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiffs do not provide an estimate of damages. After the court issued its July 2018 opinion in the Roofers’ Pension Fund case (described above) the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to this case and the remaining defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the litigation has begun. We intend to defend the lawsuit vigorously.

On October 29, 2018, Nationwide Mutual Funds and Nationwide Variable Insurance Trust (both on behalf of several fund series) filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the seven other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b-5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs' allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the First Manhattan case, the Manning & Napier Advisors case, and the Carmignac case described above and generally makes the same factual assertions as in the Manning & Napier case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case described above. The plaintiff does not provide an estimate of damages. The defendants (the Company, Mr. Papa, and Ms. Brown) filed a motion to dismiss addressing the additional allegations in this case. On July 31, 2019, the court granted the motion to dismiss in part and denied it in part. The case is now in the discovery phase. We intend to defend the lawsuit vigorously.

On November 15, 2018, a group of plaintiff investors affiliated with Westchester Capital Funds filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the Mason Capital L.P. case and the Pentwater Equity Opportunities Master Fund Ltd. case (described above) represents the affiliates of the Westchester Funds in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the Mason Capital and in the Pentwater cases described above. The case is styled WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al., and is filed in the U.S. District Court for the District of New Jersey. The WCM case is assigned to the same federal judge that is hearing the Roofer’s Fund class action case and the eight other individual cases described above. The complaint asserts claims under Securities Exchange Act sections 10(b) (and SEC Rule 10b‑5) and 14(e) against all defendants as well as 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 as well us up through May 3, 2017. Plaintiffs identify disclosures concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case. The defendants (the Company, Mr.

Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.

On November 15, 2018, a group of plaintiff investors affiliated with Hudson Bay Capital Management LP filed a lawsuit against us, our former Chairman and CEO Joseph Papa and our former CFO Judy Brown. This lawsuit is not a securities class action. The same law firm that represents the plaintiffs in the Mason Capital L.P., the Pentwater Equity Opportunities Master Fund Ltd., and the WCM cases (described above) represents the affiliates of Hudson Bay Capital Management in this lawsuit. The factual allegations of the complaint are substantially similar to the factual allegations of the complaints in the Mason Capital, in the Pentwater, and in the WCM cases described above. The case is styled Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al., and is filed in the U.S. District Court for the District of New Jersey. The Hudson Bay Fund case is assigned to the same federal judge that is hearing the Roofer’s Fund class action case and the nine other individual cases described above. The complaint asserts claims under Securities Exchange Act section 14(e) against all defendants and section 20(a) control person claims against the individual defendants. In general, the plaintiffs’ allegations describe events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the factual allegations in this complaint overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case described above. The plaintiffs do not provide an estimate of damages. In view of the court’s July 2018 opinion in the Roofers’ Pension Fund case (described above), the parties to this case conferred about how this case should proceed. The parties agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in this case. The defendants (the Company, Mr. Papa, and Ms. Brown) filed answers denying liability, and the discovery stage of the cases has begun. We intend to defend the lawsuit vigorously.

On January 31, 2019, Schwab Capital Trust and a variety of other Schwab entities filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Schwab Capital Trust, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the ten other opt out cases. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by us during that period, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the Carmignac case, the Manning & Napier case, the First Manhattan case, and the Nationwide Mutual Funds case described above and generally makes the same factual assertions as in the Nationwide Mutual Funds case. The complaint does not include factual allegations that the court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The plaintiff does not provide an estimate of damages. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending in the Carmignac, Manning & Napier, First Manhattan, and Nationwide Mutual cases described above. On July 31, 2019, the court granted in part and denied in part the motion to dismiss in the Carmignac and related cases; therefore this case has now also moved into the discovery phase. We intend to defend the lawsuit vigorously.

On February 6, 2019, OZ Master Fund, Ltd. and a related entity filed a securities lawsuit against us and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the eleven other opt out cases described above. The complaint asserts claims under Securities Exchange Act sections 10(b) (and SEC Rule 10b‑5), and 14(e) against all defendants as well as 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of

Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri^® asset. Many of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The plaintiff does not provide an estimate of damages. The parties agreed that the court's rulings in July 2018 in the Roofer's case (discussed above) and in July 2019 in the Carmignac and other cases (discussed above) will apply to this case as well.The parties agreed to a proposed schedule, which the court approved in July 2019, by which the plaintiffs are participating in the discovery proceedings in the Roofer's Pension Fund case described above and the various individual cases also described above. We intend to defend the lawsuit vigorously.

On February 14, 2019, Highfields Capital I LP and related entities filed a securities lawsuit against the Company and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Highfields Capital I LP, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of Massachusetts. The complaint asserts claims under Securities Exchange Act sections 14(e) and 18 against all defendants, as well as 20(a) control person liability against the individual defendants. The complaint also asserts Massachusetts state law claims under Massachusetts Unfair Business Methods Law (chapter 93A § 11), and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged improper accounting for the Tysabri^® asset. Some of the allegations in this case overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above and with allegations in one or more of the opt out cases described above. Plaintiffs do not provide a clear calculation of how they estimated damages and seek treble damages, punitive damages, and attorney's fees. On May 7, 2019, defendants filed a motion to transfer this case to the U.S. District Court for the District of New Jersey so that the proceedings in this case can be coordinated with the other cases (discussed above) pending in that court. The transfer motion has been fully briefed. We intend to defend the lawsuit vigorously.

On February 22, 2019, Aberdeen Canada Funds -- Global Equity Funds (and 30 other entities, some unrelated to Aberdeen) filed a securities lawsuit against the Company and two individuals (former Chairman and CEO Joseph Papa and former CFO Judy Brown). This lawsuit is not a securities class action. The case is styled Aberdeen Canada Funds -- Global Equity Fund, et al. v. Perrigo Company plc, et al., and was filed in the U.S. District Court for the District of New Jersey. The case was assigned to the same judge hearing the class action case and the twelve other opt-out cases pending in that Court. The complaint asserts claims under Securities Exchange Act sections 10(b) (and Rule 10b‑5) against all defendants and 20(a) control person liability against the individual defendants. In general, the plaintiffs’ allegations focus on events during the period from April 2015 through May 2017 (including the period of the Mylan tender offer). Plaintiffs contend that the defendants provided inadequate disclosure at various times during the period concerning the valuation and integration of Omega, the financial guidance provided by the Company during that period, and alleged undisclosed pricing pressure for generic prescription pharmaceuticals, and alleged price fixing activities with respect to six generic prescription pharmaceuticals. This lawsuit was filed by the same law firm that filed the Carmignac case, the Manning & Napier case, the First Manhattan case, the Nationwide Mutual Funds case, and the Schwab Capital Trust case described above, and generally makes the same factual assertions as in the Nationwide Mutual Funds case. The complaint does not include factual allegations that the Court dismissed in the July 2018 ruling in the Roofer’s Pension Fund case also described above. Many of the allegations in this case also overlap with the allegations of the June 2017 amended complaint in the Roofer’s Pension Fund case described above. The parties have agreed that the defendants will not have to respond to the complaint until 45 days after the court decides the motion to dismiss pending the Carmignac, Manning & Napier, First Manhattan, and Nationwide Mutual Funds cases described above. The plaintiff does not provide an estimate of damages. On July 31, 2019, the court granted in part and denied in part the motion to dismiss in the Carmignac and related cases; therefore this case has now also moved into the discovery phase. We intend to defend the lawsuit vigorously.

In Israel (cases related to events in 2015-2017)

Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are potentially subject to securities litigation in Israel. Three cases were filed; one was voluntarily dismissed in each of 2017 and 2018 and one was stayed in 2018. We are consulting Israeli counsel about our response to these allegations and we intend to defend this case vigorously.

On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. The lead plaintiff seeks to represent a class of shareholders who purchased Perrigo stock on the Tel Aviv exchange during the period April 24, 2015 through May 3, 2017 and also a claim for those that owned shares on the final day of the Mylan tender offer (November 13, 2015). The amended complaint names as defendants the Company, Ernst & Young LLP (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri^® royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of 2.7 billion NIS (approximately $760.0 million at 1 NIS = 0.28 cents). After the other two cases filed in Israel were voluntarily dismissed, the plaintiff in this case agreed to stay this case pending the outcome of the Roofers’ Pension Fund case in the U.S. (described above). The Israeli court approved the stay, and this case is now stayed. We intend to defend the lawsuit vigorously.

In the United States (cases related to Irish Tax events)

On January 3, 2019, a shareholder filed a complaint against the Company, our CEO Murray Kessler, and our former CFO Ronald Winowiecki in the U.S. District Court for the Southern District of New York (Masih v. Perrigo Company, et al.). Plaintiff purports to represent a class of shareholders for the period November 8, 2018 through December 20, 2018, inclusive. The complaint alleges violations of Securities Exchange Act section 10(b) (and Rule 10b‑5) against all defendants and section 20(a) control person liability against the individual defendants. In general the allegations contend that the Company, in its Form 10‑Q filed November 8, 2018, disclosed information about an October 31, 2018 audit finding letter received from Irish tax authorities but failed to disclose enough material information about that letter until December 20, 2018, when we filed a current report on Form 8‑K about Irish tax matters. The plaintiff does not provide an estimate of class damages. The Court selected lead plaintiffs and changed the name of the case to In re Perrigo Company plc Sec. Litig. The lead plaintiffs filed an amended complaint on April 12, 2019, which named the same defendants, asserted the same class period, and invoked the same Exchange Act sections. The amended complaint generally repeated the allegations of the original complaint with a few additional details and adds that the defendants also failed to timely disclose the Irish tax authorities’ Notice of Amended Assessment received on November 29, 2018. Defendants filed a motion to dismiss on May 3, 2019. On May 31, 2019, the plaintiffs filed a second amended complaint, which asserted a longer class period (March 1, 2018 through December 20, 2018) and added one additional individual defendant, former CEO Uwe Roehrhoff. In general, the second amended complaint contends that Perrigo’s disclosures about the Irish tax audit were inadequate beginning with Perrigo’s 10-K filed on March 1, 2018 through December 20, 2018 and repeats many of the allegations of the April 2019 amended complaint. The second amended complaint alleges violations of Securities Exchange Act section 10(b) (and SEC Rule 10b-5) against all defendants and section 20(a) control person liability against the three individual defendants. All defendants filed a joint motion to dismiss, and the plaintiffs filed an opposition. The defendants' reply is due in mid-August 2019. At some time thereafter the court will decide the motion. We intend to defend the lawsuit vigorously.

In Israel (cases related to Irish Tax events)

On December 31, 2018, a shareholder filed an action against the Company, our CEO Murray Kessler, and our former CFO Ronald Winowiecki in Tel Aviv District Court (Baton v. Perrigo Company plc, et. al.). The case is a securities class action brought in Israel making similar factual allegations for the same period as those asserted in the In re Perrigo Company plc Sec. Litig case in New York federal court. This case alleges that persons who invested through the Tel Aviv stock exchange can assert claims under Israeli securities law that will follow the liability principles of Sections 10(b) and 20(a) of the U.S. Securities Exchange Act. The plaintiff does not provide an estimate of class damages. We filed a request for a stay, the plaintiff agreed in part, and the court approved a stay and required the parties to update the court about the U.S. proceedings by September 1, 2019. We intend to defend the lawsuit vigorously.

Claim Arising from the Omega Acquisition

On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV (together the "Sellers") in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo has asserted a counterclaim for monetary damages contending that we breached a warranty in the SPA and breached the duty of good faith in performing the SPA. Alychlo has recently filed papers seeking permission to introduce an additional counterclaim theory of recovery related to the Irish tax issue recently disclosed by the Company such that if the position of the Irish tax authorities prevails, Alychlo would have a further basis for its counterclaim against Perrigo. The proposed additional counterclaim theory does not appear to increase any damages sought. In June 2019, the Tribunal denied permission for Alychlo to introduce the additional counterclaim and dismissed certain aspects of the original Alychlo counterclaim. There can be no assurance that our Claim will be successful, and the Sellers deny liability for the Claim. To the extent that aspects of Alychlo’s counterclaim survived the Tribunal’s ruling in June 2019, we deny that Alychlo is entitled to any relief (including monetary relief). The arbitration proceedings are confidential as required by the SPA and the rules of the CEPANI.

Other Matters

Our Board of Directors received a shareholder demand letter dated October 30, 2018 relating to the allegations in the securities cases and price fixing lawsuits described above. The letter demands that the Board of Directors initiate an action against certain current and former executives and Board members to recover damages allegedly caused to the Company. In response, the Company reminded the shareholder that any derivative claim can only proceed in accordance with Irish law, the law that governs the Company’s internal affairs. The shareholder has responded that he intends to file a lawsuit asserting derivative claims but has not yet filed a lawsuit.

XML

Restructuring Charges

6 Months Ended

Jun. 29, 2019

Restructuring Charges [Abstract]

Restructuring Charges

RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, and asset impairments. The following reflects our restructuring activity (in millions):

	Three Months Ended						Six Months Ended
	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Beginning balance	$	20.5		$	12.4		$	24.0		$	21.4
Additional charges	12.2			3.7			18.1			5.2
Payments	(9.0		)	(3.1		)	(18.0		)	(13.8		)
Non-cash adjustments	0.3			(0.3		)	(0.1		)	(0.1		)
Ending balance	$	24.0		$	12.7		$	24.0		$	12.7

The charges incurred during the three and six months ended June 29, 2019 were primarily associated with the reorganization of our executive management team and other actions taken to streamline the organization. Of the amount recorded during the six months ended June 29, 2019, $9.8 million related to the CSCI segment due primarily to the sales force reorganization in France. The charges incurred during the six months ended June 30, 2018 were primarily associated with continued costs from actions we took to streamline our organization as announced on February 21, 2017, as well as additional lease exit costs. All charges are recorded in Restructuring expense on the Condensed Consolidated Financial Statements. The remaining $24.0 million liability for employee severance benefits is expected to be paid within the next year.

XML

Segment Information

6 Months Ended

Jun. 29, 2019

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company.

The below tables show select financial measures by reporting segment (in millions):

	Total Assets
	June 29, 2019		December 31, 2018
CSCA	$	4,041.9	$	3,571.7
CSCI	4,593.5		4,613.0
RX	2,793.3		2,798.7
Total	$	11,428.7	$	10,983.4

	Three Months Ended
	June 29, 2019							June 30, 2018
	Net Sales		Operating Income (Loss)			Intangible Asset Amortization		Net Sales		Operating Income (Loss)			Intangible Asset Amortization
CSCA	$	582.1	$	107.8		$	9.3	$	596.9	$	64.6		$	15.3
CSCI	327.5		(2.9		)	43.0		357.9		4.0			49.2
RX	239.4		14.7			21.3		231.6		53.6			20.8
Unallocated	—		(64.6		)	—		—		(27.5		)	—
Total	$	1,149.0	$	55.0		$	73.6	$	1,186.4	$	94.7		$	85.3

	Six Months Ended
	June 29, 2019							June 30, 2018
	Net Sales		Operating Income (Loss)			Intangible Asset Amortization		Net Sales		Operating Income (Loss)			Intangible Asset Amortization
CSCA	$	1,163.9	$	202.0		$	19.3	$	1,198.5	$	183.2		$	30.5
CSCI	678.3		5.1			87.1		735.7		16.3			100.3
RX	481.3		75.3			42.6		469.2		114.8			41.6
Unallocated	—		(125.1		)	—		—		(63.4		)	—
Total	$	2,323.5	$	157.3		$	149.0	$	2,403.4	$	250.9		$	172.4

XML

Subsequent Events

6 Months Ended

Jun. 29, 2019

Subsequent Events [Abstract]

Subsequent Events

SUBSEQUENT EVENTS

Animal health business

On July 8, 2019, we completed the sale of our animal health business to PetIQ for base consideration of$185.0 million, which we estimate will result in a pre-tax gain of $80.0 million to $90.0 million. The final purchase price and gain is subject to customary post-closing adjustments for changes to working capital compared to the target working capital on the closing date and is expected to be finalized by the fourth quarter of 2019.

Generic product acquisition

On July 2, 2019, we purchased the ANDA for a generic gel product used for the treatment of Hemophilus vaginitis for $49.0 million in cash, which we capitalized as a developed product technology intangible asset. We plan to launch the product during the three months ended September 28, 2019 and begin amortizing it over a 20-year useful life. Operating results attributable to the product will be included within our RX segment.

Ranir Global Holdings, LLC

On July 1, 2019, we acquired 100% of the outstanding equity interest in Ranir, a privately-held company, for total base consideration of $750.0 million in a debt-free, cash-free transaction. We funded the transaction with cash on hand and borrowings under the 2018 Revolver (refer to Note 11).

Ranir is headquartered in Grand Rapids, Michigan, and is a leading global supplier of private label and branded oral care products. This transaction advances our transformation to a consumer-focused, self-care company while enhancing our position as a global leader in consumer self-care solutions. Ranir operations will be reported in our CSCA segment.

During the three and six months ended June 29, 2019, in connection with the acquisition, we incurred $2.2 million of general transaction costs (legal, banking and other professional fees). The amounts were recorded in Administration expenses and were not allocated to the CSCA segment.

We are in the process of gathering significant relevant information needed to complete the valuation for the assets acquired and liabilities assumed. As a result, the initial accounting for the acquisition accounting is incomplete. The provisional acquisition amounts recognized for assets acquired and liabilities assumed and the supplemental pro-forma information will be included in our quarterly Report on Form 10-Q for the third quarter of 2019.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 29, 2019

Accounting Policies [Abstract]

Basis of presentation

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2018.

Principles of consolidation

all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Recently Issued Accounting Standards

Recent Accounting Standard Pronouncements

Below are recent Accounting Standard Updates ("ASU") that we are still assessing to determine the effect on our Condensed Consolidated Financial Statements. We do not believe that any other recently issued accounting standards could have a material effect on our Condensed Consolidated Financial Statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Recently Issued Accounting Standards Not Yet Adopted
Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
ASU 2018-15: Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract	This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.	January 1, 2020	We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.
ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement	This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.	January 1, 2020	We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.
ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ASU 2018-19: Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments ASU 2019-05: Financial Instruments-Credit Losses: Targeted Transition Relief	This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.	January 1, 2020	We are in the process of completing our evaluation. Upon adoption, we are not expecting a material impact on the financial statements.
ASU 2018-18: Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606	This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.	January 1, 2020	We are in the process of completing our evaluation. Upon adoption, we are not expecting a material impact on the financial statements.
ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans	This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans.	December 31, 2020	We are currently evaluating the implications of adoption on our Consolidated Financial Statements.

Derivatives instruments and hedging

On January 1, 2019, we adopted Accounting Standards Update No. 2017-12 Targeted Improvements to Accounting for Hedge Activities ("ASU 2017-12") using a modified retrospective approach. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three and six months ended June 30, 2018 below conform to the disclosure requirements prior to the adoption of ASU 2017-12.

Prior to the adoption of ASU 2017-12, we were required to separately measure and reflect the amount by which the hedging instrument did not offset the changes in the fair value or cash flows of hedged items, which was referred to as the ineffective amount. We assessed hedge effectiveness on a quarterly basis and recorded the gain or loss related to the ineffective portion of derivative instruments, if any, in Other (income) expense, net on the Condensed Consolidated Statements of Operations. Pursuant to the provisions of ASU 2017-12, we are no longer required to separately measure and recognize hedge ineffectiveness. Therefore, we no longer recognize hedge ineffectiveness separately on our Condensed Consolidated Statements of Income, but instead recognize the entire change in the fair value of:

• Cash flow hedges included in the assessment of hedge effectiveness in OCI. The amounts recorded in OCI will subsequently be reclassified to earnings in the same line item on the Condensed Consolidated Statements of Operations as impacted by the hedged item when the hedged item affects earnings; and

• Fair value hedges included in the assessment of hedge effectiveness in the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item.

Prior to the adoption of ASU 2017-12, we excluded option premiums and forward points (excluded components) from our assessment of hedge effectiveness for our foreign exchange cash flow hedges. We

recognized all changes in fair value of the excluded components in Other (income) expense, net, on the Condensed Consolidated Statements of Operations. The amendments in ASU 2017-12 continue to allow those components to be excluded from the assessment of hedge effectiveness and add cross-currency basis spread as an allowable excluded component. The provisions of ASU 2017-12 allow a policy election to either continue to recognize changes in the fair value of the excluded components currently in earnings or to recognize the initial value of the excluded component using an amortization approach. We have elected to recognize the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. The cumulative effect adjustment between Accumulated Other Comprehensive Income ("AOCI") and Retained earnings (accumulated deficit) from applying this policy on existing hedges at the date of adoption was immaterial.

We record derivative instruments on the balance sheet on a gross basis as either an asset or liability measured at fair value (refer to Note 6). Additionally, changes in a derivative's fair value, which are measured at the end of each period, are recognized in earnings unless a derivative can be designated in a qualifying hedging relationship.

Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. We have elected to recognize the fair value of the excluded component in OCI and amortize on a straight-line basis over the life of the derivative instrument, within the same line item on the Condensed Consolidated Statements of Operations that is used to present the earnings effect of the hedged item. All of our designated derivatives are assessed for hedge effectiveness quarterly. All of our designated derivatives were classified as cash flow hedges as of June 29, 2019 and December 31, 2018.

We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.

We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "Aa3" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of our forward currency exchange contracts is 18 months.

We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows:

Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing.

Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses.

All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes.

Leases

We adopted ASU 2016-02, Leases, as of January 1, 2019, using the modified retrospective transition approach, with a cumulative-effect adjustment to the opening balance of retained earnings as of the effective date. The financial results reported in periods prior to 2019 are unchanged. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification.

Adoption of the new standard resulted in additional operating lease liabilities and lease assets, including  the transition of existing capital lease liabilities and lease assets to finance classification, of approximately $166.5 million and $164.0 million, respectively, as of January 1, 2019. Upon adoption, the difference between the lease assets and lease liabilities partially related to existing deferred lease liabilities reclassified to lease assets and the transition of capital lease assets and liabilities at their carrying values. In addition, historical build-to-suit assets and liabilities were removed on transition and recorded as an adjustment to retained earnings, net of deferred tax impact. The standard did not materially impact our consolidated net income or cash flow classification.

We lease certain office buildings, warehouse facilities, vehicles, and plant, office, and computer equipment. Lease assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.

We evaluate arrangements at inception to determine if lease components are included. An arrangement includes a lease component if it identifies an asset and we have control over the asset. For new leases beginning January 1, 2019 or later, we have elected for all asset classes not to separate lease components from the non-lease components included in an arrangement when measuring the leased asset and leased liability.

Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We recognize lease expense for leases on a straight-line basis over the lease term. We apply the portfolio approach to certain groups of computer equipment and vehicle leases when the term, classification, and asset type are identical. The discount rate selected is the incremental borrowing rate we would obtain for a secured financing of the lease asset over a similar term.

Many of our leases include one or more options to extend the lease term. Certain leases also include options to terminate early or purchase the leased property, all of which are executed at our sole discretion. Optional periods may be included in the lease term and measured as part of the lease asset and lease liability if we are reasonably certain to exercise our right to use the leased asset during the optional periods. We generally consider renewal options to be reasonably certain of execution and included in the lease term when significant leasehold improvements have been made by us to the leased assets. The depreciable lives of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain of our lease agreements include contingent rental payments based on per unit usage over contractual levels (e.g., miles driven or machine hours used) and others include rental payments adjusted periodically for market reviews or inflationary indexes. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

XML

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 29, 2019

Accounting Policies [Abstract]

Schedule of New Accounting Pronouncements

As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Recently Issued Accounting Standards Not Yet Adopted
Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
ASU 2018-15: Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract	This guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize as assets or expense as incurred.	January 1, 2020	We currently plan to adopt the standard prospectively on the effective date. Upon adoption, no impact is currently expected, however, future hosting arrangements treated as service contracts will need to be evaluated for capitalizable costs during implementation. The Consolidated Financial Statement impact will align with the presentation of the underlying hosting contracts, which will be included within Operating expenses.
ASU 2018-13: Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement	This guidance amends ASC 820 to add, remove, and modify certain disclosure requirements for fair value measurements.	January 1, 2020	We currently plan to adopt the standard on the effective date. Upon adoption, we will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurement. We will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy.
ASU 2016-13: Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ASU 2018-19: Codification Improvements for Topic 326: Measurement of Credit Losses on Financial Instruments ASU 2019-05: Financial Instruments-Credit Losses: Targeted Transition Relief	This guidance changes the impairment model for most financial assets and certain other instruments, replacing the current "incurred loss" approach with an "expected loss" credit impairment model, which will apply to most financial assets measured at amortized cost, and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and off-balance sheet credit exposures such as letters of credit.	January 1, 2020	We are in the process of completing our evaluation. Upon adoption, we are not expecting a material impact on the financial statements.
ASU 2018-18: Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606	This guidance amends ASC 808 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The proposed guidance would be applied retrospectively to the date of initial adoption of Topic 606.	January 1, 2020	We are in the process of completing our evaluation. Upon adoption, we are not expecting a material impact on the financial statements.
ASU 2018-14: Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans	This guidance amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other post-retirement plans.	December 31, 2020	We are currently evaluating the implications of adoption on our Consolidated Financial Statements.

XML

Revenue Recognition (Tables)

6 Months Ended

Jun. 29, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

We generated net sales in the following geographic locations⁽¹⁾ (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
U.S.	$	768.6	$	772.3	$	1,537.4	$	1,558.7
Europe(2)	315.8		344.3		656.7		706.2
All other countries(3)	64.6		69.8		129.4		138.5
	$	1,149.0	$	1,186.4	$	2,323.5	$	2,403.4

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $6.9 million and $12.1 million for the three and six months ended June 29, 2019, respectively, and $5.0 million and $10.4 million for the three and six months ended June 30, 2018, respectively.

(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

The following is a summary of our net sales by category (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
CSCA(1)
Cough/cold/allergy/sinus	$	120.9	$	109.3	$	253.5	$	250.8
Gastrointestinal	106.2		103.0		206.5		195.2
Infant nutritionals	85.5		109.2		181.5		212.6
Analgesics	88.2		92.2		177.0		185.9
Smoking cessation	77.0		71.2		143.8		137.1
Animal health	22.4		31.9		42.0		58.2
Vitamins, minerals and dietary supplements	3.9		4.3		7.3		7.3
Other CSCA(2)	78.0		75.8		152.3		151.4
Total CSCA	582.1		596.9		1,163.9		1,198.5
CSCI
Cough/cold/allergy/sinus	74.1		84.7		169.8		183.4
Lifestyle	81.2		86.1		162.7		175.8
Personal care and derma-therapeutics	69.2		79.7		135.2		155.3
Natural health and vitamins, minerals and dietary supplements	25.6		27.9		55.4		61.1
Anti-parasites	26.0		30.4		52.7		58.5
Other CSCI(3)	51.4		49.1		102.5		101.6
Total CSCI	327.5		357.9		678.3		735.7
Total RX	239.4		231.6		481.3		469.2
Total net sales	$	1,149.0	$	1,186.4	$	2,323.5	$	2,403.4

(1)    Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3)

Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

Contract with Customer Balances

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	June 29, 2019		December 31, 2018
Short-term contract assets	Prepaid expenses and other current assets	$	16.6	$	25.5

XML

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 29, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):

	December 31, 2018		Transfer to assets held-for-sale			Currency Translation Adjustments			June 29, 2019
CSCA(1)	$	1,713.7	$	(42.2	)	$	2.1		$	1,673.6
CSCI(2)	1,151.3		—			(9.2		)	1,142.1
RX	1,114.8		—			4.8			1,119.6
Total goodwill	$	3,979.8	$	(42.2	)	$	(2.3	)	$	3,935.3

(1) We had accumulated impairments of $24.5 million and $161.2 million as of June 30, 2018 and June 29, 2019, respectively.

(2)

We had accumulated impairments of $868.4 million as of June 30, 2018 and June 29, 2019.

Schedule of finite and indefinite-lived intangible assets

Intangible assets and related accumulated amortization consisted of the following (in millions):

	June 29, 2019				December 31, 2018
	Gross		Accumulated Amortization		Gross		Accumulated Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands	$	18.0	$	—	$	18.1	$	—
In-process research and development	14.5		—		31.2		—
Total indefinite-lived intangibles	$	32.5	$	—	$	49.3	$	—
Definite-lived intangibles:
Distribution and license agreements and supply agreements	$	173.7	$	105.2	$	178.6	$	99.0
Developed product technology, formulations, and product rights	1,321.0		706.1		1,318.8		654.6
Customer relationships and distribution networks	1,558.5		613.9		1,586.6		566.5
Trademarks, trade names, and brands	1,266.0		219.5		1,282.4		188.5
Non-compete agreements	8.3		7.6		12.9		11.8
Total definite-lived intangibles	$	4,327.5	$	1,652.3	$	4,379.3	$	1,520.4
Total intangible assets	$	4,360.0	$	1,652.3	$	4,428.6	$	1,520.4

XML

Inventories (Tables)

6 Months Ended

Jun. 29, 2019

Inventory Disclosure [Abstract]

Schedule of inventory, current

Major components of inventory were as follows (in millions):

 

	June 29, 2019		December 31, 2018
Finished goods	$	501.2	$	444.9
Work in process	192.8		197.5
Raw materials	246.5		235.6
Total inventories	$	940.5	$	878.0

XML

Fair Value Measurements (Tables)

6 Months Ended

Jun. 29, 2019

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring and Nonrecurring Basis

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):

	June 29, 2019						December 31, 2018
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Measured at fair value on a recurring basis:
Assets:
Investment securities	$	2.8	$	—	$	—	$	9.4	$	—	$	—
Foreign currency forward contracts	—		4.0		—		—		3.8		—
Funds associated with Israeli severance liability	—		14.0		—		—		13.0		—
Royalty Pharma contingent milestone payments	—		—		89.1		—		—		323.2
Total assets	$	2.8	$	18.0	$	89.1	$	9.4	$	16.8	$	323.2
Liabilities:
Foreign currency forward contracts	$	—	$	3.6	$	—	$	—	$	9.2	$	—
Contingent consideration	—		—		12.1		—		—		15.3
Total liabilities	$	—	$	3.6	$	12.1	$	—	$	9.2	$	15.3
Measured at fair value on a non-recurring basis:
Assets:
Goodwill(1)	$	—	$	—	$	—	$	—	$	—	$	42.2
Indefinite-lived intangible assets(2)	—		—		—		—		—		10.5
Definite-lived intangible assets(3)	—		—		—		—		—		22.4
Total assets	$	—	$	—	$	—	$	—	$	—	$	75.1

(1) As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million.

(2) As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million.

(3)

As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million.

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The table below summarizes the change in fair value of the Royalty Pharma contingent milestone payments (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019			June 30, 2018
Beginning balance	$	83.6	$	124.9	$	323.2		$	134.5
Payments received	—		—		(250.0		)	—
Change in fair value	5.5		0.6		15.9			(9.0		)
Ending balance	$	89.1	$	125.5	$	89.1		$	125.5

Schedule of Fair Value Assumptions

The table below represents the volatility and rate of return:

	Three Months Ended
	June 29, 2019		June 30, 2018
Volatility	30.0	%	30.0	%
Rate of return	7.99	%	8.09	%

Reconciliation of Level 3 Liabilities

The table below summarizes the change in fair value of contingent consideration (in millions):

	Three Months Ended						Six Months Ended
	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Beginning balance	$	12.4		$	18.1		$	15.3		$	22.0
Changes in value	0.9			(1.8		)	(2.0		)	(1.4		)
Currency translation adjustments	—			(0.1		)	—			—
Settlements and other adjustments	(1.2		)	—			(1.2		)	(4.4		)
Ending balance	$	12.1		$	16.2		$	12.1		$	16.2

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments

Our fixed rate long-term debt consisted of the following (in millions):

	June 29, 2019				December 31, 2018
	Level 1		Level 2		Level 1		Level 2
Public Bonds
Carrying Value (excluding discount)	$	2,600.0			$	2,600.0
Fair value	$	2,533.0			$	2,316.6
Retail bond and private placement note
Carrying value (excluding premium)			$	153.5			$	292.5
Fair value			$	167.8			$	307.9

XML

Investments (Tables)

6 Months Ended

Jun. 29, 2019

Investments [Abstract]

Equity securities

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):

Measurement Category	Balance Sheet Location	June 29, 2019		December 31, 2018
Fair value method	Prepaid expenses and other current assets	$	2.8	$	9.4
Fair value method(1)	Other non-current assets	$	2.8	$	4.4
Equity method	Other non-current assets	$	16.8	$	15.1

(1) Measured at fair value using the Net Asset Value practical expedient.

Equity security expense (income)

The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):

		Three Months Ended						Six Months Ended
Measurement Category	Income Statement Location	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Fair value method	Other (income) expense, net	$	1.8		$	6.3		$	7.9		$	10.6
Equity method	Other (income) expense, net	$	(1.0	)	$	(0.9	)	$	(1.7	)	$	(0.7	)

XML

Assets Held for Sale (Tables)

6 Months Ended

Jun. 29, 2019

Discontinued Operations and Disposal Groups [Abstract]

Assets and liabilities held for sale

The amounts consisted of the following (in millions):

	June 29, 2019
Assets held for sale
Current assets	$	29.3
Property, plant and equipment, net	10.8
Goodwill and indefinite-lived intangible assets	42.2
Definite-lived intangible assets, net	36.4
Other assets	25.7
Total assets held for sale	$	144.4
Liabilities held for sale
Current liabilities	$	11.3
Other liabilities	38.3
Total liabilities held for sale	$	49.6

XML

Derivative Instruments and Hedging Activities (Tables)

6 Months Ended

Jun. 29, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Foreign Currency Forward Contracts

Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows (in millions):

	Notional Amount
	June 29, 2019		December 31, 2018
Israeli Shekel (ILS)	$	340.6	$	232.6
British Pound (GBP)	111.0		90.2
European Euro (EUR)	108.0		134.2
Swedish (SEK)	42.2		38.7
Danish Krone (DKK)	58.2		56.5
United States Dollar (USD)	46.2		39.3
Canadian Dollar (CAD)	41.9		31.7
Polish Zloty (PLZ)	33.5		18.2
Chinese Yuan (CNY)	20.0		—
Norwegian Krone (NOK)	6.8		6.2
Romanian New Leu (RON)	5.9		4.4
Mexican Peso (MPX)	4.2		25.9
Other	12.6		8.7
Total	$	831.1	$	686.6

Schedule of derivative instruments in statement of financial position, fair value

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):

		Asset Derivatives
		Fair Value
	Balance Sheet Location	June 29, 2019		December 31, 2018
Designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	1.0	$	2.0
Non-designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	3.0	$	1.8

		Liability Derivatives
		Fair Value
	Balance Sheet Location	June 29, 2019		December 31, 2018
Designated derivatives:
Foreign currency forward contracts	Accrued liabilities	$	2.6	$	6.4
Non-designated derivatives:
Foreign currency forward contracts	Accrued liabilities	$	1.0	$	2.8

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)

The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments in AOCI (in millions):

	Three Months Ended
	June 29, 2019
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings			Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements			Interest expense, net	$	(0.4	)	Interest expense, net	$	—
Foreign currency forward contracts	$	1.1	Net sales	0.1			Net sales	0.1
			Cost of sales	(0.2		)	Cost of sales	(1.1		)
				$	(0.5	)		$	(1.0	)

	Six Months Ended
	June 29, 2019
Instrument	Amount of Gain/(Loss) Recorded in OCI(1)		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings			Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Interest rate swap agreements			Interest expense, net	$	(1.0	)	Interest expense, net	$	—
Foreign currency forward contracts	$	—	Net sales	0.3			Net sales	—
			Cost of sales	(1.4		)	Cost of sales	(2.2		)
				$	(2.1	)		$	(2.2	)

(1) Net loss of $1.6 million is expected to be reclassified out of AOCI into earnings during the next 12 months.

Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)

	Three Months Ended
	June 30, 2018
	Effective Portion
Instrument	Amount of Gain/(Loss) Recorded in OCI			Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements				Interest expense, net	$	(0.4	)
Foreign currency forward contracts	$	(4.3	)	Net sales	—
				Cost of sales	1.6
				Interest expense, net	(1.1		)
				Other (income) expense, net	(0.1		)
					$	—

	Six Months Ended
	June 30, 2018
	Effective Portion
Instrument	Amount of Gain/(Loss) Recorded in OCI			Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings
Interest rate swap agreements				Interest expense, net	$	(0.9	)
Foreign currency forward contracts	$	(4.3	)	Net sales	—
				Cost of sales	3.9
				Interest expense, net	(2.0		)
				Other (income) expense, net	(0.5		)
					$	0.5

Amount of Gain/(Loss) Recognized against Earnings

The amounts of gain/(loss) recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):

		Three Months Ended					Six Months Ended
Non-Designated Derivatives	Income Statement Location	June 29, 2019			June 30, 2018		June 29, 2019			June 30, 2018
Foreign currency forward contracts	Other (income) expense, net	$	(4.3	)	$	11.8	$	(13.1	)	$	8.6
	Interest expense, net	1.4			0.2		1.8			(0.7		)
Total		$	(2.9	)	$	12.0	$	(11.3	)	$	7.9

Classification of Gain (Loss) Recognized in Earnings on Fair Value and Cash Flow Hedging Relationships

The classification and amount of gain/(loss) recognized in earnings on fair value and cash flow hedging relationships are as follows (in millions):

	Three Months Ended
	June 29, 2019
	Net Sales		Cost of Sales			Interest Expense, net			Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,149.0	$	718.2		$	31.2		$	2.3
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	0.1	$	(0.2	)	$	—		$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	0.1	$	(1.1	)	$	—		$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—		$	(0.4	)	$	—

	Six Months Ended
	June 29, 2019
	Net Sales		Cost of Sales			Interest Expense, net			Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	2,323.5	$	1,443.9		$	59.8		$	5.5
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	0.3	$	(1.4	)	$	—		$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	(2.2	)	$	—		$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—		$	(1.0	)	$	—

XML

Leases (Tables)

6 Months Ended

Jun. 29, 2019

Leases [Abstract]

Balance Sheet Location of Lease Assets and Liabilities

The balance sheet location of our lease assets and liabilities were as follows (in millions):

Assets	Balance Sheet Location	June 29, 2019
Operating	Operating lease assets	$	135.4
Finance	Other non-current assets	17.1
Total		$	152.5

Liabilities	Balance Sheet Location	June 29, 2019
Current
Operating	Accrued liabilities	$	32.9
Finance	Current indebtedness	1.9
Non-Current
Operating	Other non-current liabilities	107.4
Finance	Long-term debt, less current portion	11.8
Total		$	154.0

The below table shows our lease assets and liabilities by reporting segment (in millions):

	Assets				Liabilities
	Operating		Financing		Operating		Financing
	June 29, 2019		June 29, 2019		June 29, 2019		June 29, 2019
CSCA	$	22.7	$	8.9	$	22.9	$	8.4
CSCI	42.0		6.1		42.9		3.2
RX	37.5		0.3		38.9		0.3
Unallocated	33.2		1.8		35.6		1.8
Total	$	135.4	$	17.1	$	140.3	$	13.7

Finance Lease Maturity

The annual future maturities of our leases as of June 29, 2019 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2019	$	19.4	$	1.2	$	20.6
2020	34.6		2.3		36.9
2021	24.9		3.6		28.5
2022	18.3		1.2		19.5
2023	14.0		1.0		15.0
After 2023	51.7		7.8		59.5
Total lease payments	162.9		17.1		180.0
Less: Interest	22.6		3.4		26.0
Present value of lease liabilities	$	140.3	$	13.7	$	154.0

Operating Lease Liability Maturity

The annual future maturities of our leases as of June 29, 2019 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2019	$	19.4	$	1.2	$	20.6
2020	34.6		2.3		36.9
2021	24.9		3.6		28.5
2022	18.3		1.2		19.5
2023	14.0		1.0		15.0
After 2023	51.7		7.8		59.5
Total lease payments	162.9		17.1		180.0
Less: Interest	22.6		3.4		26.0
Present value of lease liabilities	$	140.3	$	13.7	$	154.0

Lease Expense

Lease expense was as follows (in millions):

	Three Months Ended		Six Months Ended
	June 29, 2019		June 29, 2019
Operating leases(a)	$	11.2	$	23.2
Finance leases
Amortization	$	0.7	$	1.3
Interest	0.1		0.2
Total finance leases	$	0.8	$	1.5

(a) Includes short-term leases and variable lease costs, which are immaterial.

Weighted Average Lease Terms and Discount Rates

Our weighted average lease terms and discount rates are as follows:

	June 29, 2019
Weighted-average remaining lease term (in years)
Operating leases	6.59
Finance leases	9.43
Weighted-average discount rate
Operating leases	4.19	%
Finance leases	4.35	%

Leease Cash Flow Classifications

Our lease cash flow classifications are as follows (in millions):

	Six Months Ended
	June 29, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	23.0
Operating cash flows for finance leases	$	0.2
Financing cash flows for finance leases	$	1.4
Leased assets obtained in exchange for new finance lease liabilities	$	7.8
Leased assets obtained in exchange for new operating lease liabilities	$	12.8

XML

Indebtedness (Tables)

6 Months Ended

Jun. 29, 2019

Debt Disclosure [Abstract]

Schedule of debt

Total borrowings outstanding are summarized as follows (in millions):

			June 29, 2019			December 31, 2018
Revolving Credit Agreement
	2018 Revolver due March 8, 2023		$	325.0		$	—
Term loan
	2018 Term loan due March 8, 2020(1)		323.4			351.3
Notes and Bonds
	Coupon	Due
	5.000%	May 23, 2019	—			137.6
	3.500%	March 15, 2021	280.4			280.4
	3.500%	December 15, 2021	309.6			309.6
	5.105%	July 28, 2023(1)	153.5			154.9
	4.000%	November 15, 2023	215.6			215.6
	3.900%	December 15, 2024	700.0			700.0
	4.375%	March 15, 2026	700.0			700.0
	5.300%	November 15, 2043	90.5			90.5
	4.900%	December 15, 2044	303.9			303.9
	Total notes and bonds		2,753.5			2,892.5
Other financing			87.2			2.8
Unamortized premium (discount), net			8.9			12.2
Deferred financing fees			(14.8		)	(16.4		)
Total borrowings outstanding			3,483.2			3,242.4
	Current indebtedness		(398.8		)	(190.2		)
Total long-term debt less current portion			$	3,084.4		$	3,052.2

(1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

XML

Earnings Per Share and Shareholders' Equity (Tables)

6 Months Ended

Jun. 29, 2019

Earnings Per Share [Abstract]

Schedule of earnings per share, basic and diluted

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):

	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
Numerator:
Net income	$	9.0	$	36.2	$	72.9	$	117.0
Denominator:
Weighted average shares outstanding for basic EPS	136.0		138.1		136.0		139.5
Dilutive effect of share-based awards	0.5		0.6		0.3		0.5
Weighted average shares outstanding for diluted EPS	136.5		138.7		136.3		140.0
Anti-dilutive share-based awards excluded from computation of diluted EPS	1.7		1.7		1.8		0.9

XML

Accumulated Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Jun. 29, 2019

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of accumulated other comprehensive income (loss)

Changes in our AOCI balances, net of tax were as follows (in millions):

	Fair Value of Derivative Financial Instruments, net of tax			Foreign Currency Translation Adjustments		Post-Retirement and Pension Liability Adjustments, net of tax			Total AOCI
Balance at December 31, 2018	$	(15.5	)	$	104.5	$	(4.4	)	$	84.6
OCI before reclassifications	0.2			11.0		—			11.2
Amounts reclassified from AOCI	4.2			—		(0.5		)	3.7
Other comprehensive loss	$	4.4		$	11.0	$	(0.5	)	$	14.9
Balance at June 29, 2019	$	(11.1	)	$	115.5	$	(4.9	)	$	99.5

XML

Income Taxes Income Taxes (Tables)

6 Months Ended

Jun. 29, 2019

Income Tax Disclosure [Abstract]

Schedule of effective income tax rate reconciliation

The effective tax rates were as follows:

Three Months Ended				Six Months Ended
June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
66.6	%	34.5	%	32.5	%	29.4	%

XML

Restructuring Charges (Tables)

6 Months Ended

Jun. 29, 2019

Restructuring Charges [Abstract]

Restructuring and related costs

The following reflects our restructuring activity (in millions):

	Three Months Ended						Six Months Ended
	June 29, 2019			June 30, 2018			June 29, 2019			June 30, 2018
Beginning balance	$	20.5		$	12.4		$	24.0		$	21.4
Additional charges	12.2			3.7			18.1			5.2
Payments	(9.0		)	(3.1		)	(18.0		)	(13.8		)
Non-cash adjustments	0.3			(0.3		)	(0.1		)	(0.1		)
Ending balance	$	24.0		$	12.7		$	24.0		$	12.7

XML

Segment Information (Tables)

6 Months Ended

Jun. 29, 2019

Segment Reporting [Abstract]

Schedule of segment reporting information, by segment

The below tables show select financial measures by reporting segment (in millions):

	Total Assets
	June 29, 2019		December 31, 2018
CSCA	$	4,041.9	$	3,571.7
CSCI	4,593.5		4,613.0
RX	2,793.3		2,798.7
Total	$	11,428.7	$	10,983.4

	Three Months Ended
	June 29, 2019							June 30, 2018
	Net Sales		Operating Income (Loss)			Intangible Asset Amortization		Net Sales		Operating Income (Loss)			Intangible Asset Amortization
CSCA	$	582.1	$	107.8		$	9.3	$	596.9	$	64.6		$	15.3
CSCI	327.5		(2.9		)	43.0		357.9		4.0			49.2
RX	239.4		14.7			21.3		231.6		53.6			20.8
Unallocated	—		(64.6		)	—		—		(27.5		)	—
Total	$	1,149.0	$	55.0		$	73.6	$	1,186.4	$	94.7		$	85.3

	Six Months Ended
	June 29, 2019							June 30, 2018
	Net Sales		Operating Income (Loss)			Intangible Asset Amortization		Net Sales		Operating Income (Loss)			Intangible Asset Amortization
CSCA	$	1,163.9	$	202.0		$	19.3	$	1,198.5	$	183.2		$	30.5
CSCI	678.3		5.1			87.1		735.7		16.3			100.3
RX	481.3		75.3			42.6		469.2		114.8			41.6
Unallocated	—		(125.1		)	—		—		(63.4		)	—
Total	$	2,323.5	$	157.3		$	149.0	$	2,403.4	$	250.9		$	172.4

XML

Revenue Recognition - Schedule of Revenue by Geographic Location (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,149.0	$ 1,186.4	$ 2,323.5	$ 2,403.4
U.S.
Disaggregation of Revenue [Line Items]
Net sales	[1]	768.6	772.3	1,537.4	1,558.7
Europe
Disaggregation of Revenue [Line Items]
Net sales	[1],[2]	315.8	344.3	656.7	706.2
All other countries
Disaggregation of Revenue [Line Items]
Net sales	[1],[3]	64.6	69.8	129.4	138.5
Ireland
Disaggregation of Revenue [Line Items]
Net sales		$ 6.9	$ 5.0	$ 12.1	$ 10.4

[1] Derived from the location of the entity that sells to a third party.

[2] Includes Ireland net sales of $6.9 million and $12.1 million for the three and six months ended June 29, 2019, respectively, and $5.0 million and $10.4 million for the three and six months ended June 30, 2018, respectively.

[3] Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

XML

Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,149.0	$ 1,186.4	$ 2,323.5	$ 2,403.4
CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2]	582.1	596.9	1,163.9	1,198.5
CSCA | Cough/Cold/Allergy/Sinus
Disaggregation of Revenue [Line Items]
Net sales	[2]	120.9	109.3	253.5	250.8
CSCA | Gastrointestinal
Disaggregation of Revenue [Line Items]
Net sales	[2]	106.2	103.0	206.5	195.2
CSCA | Infant nutritionals
Disaggregation of Revenue [Line Items]
Net sales	[2]	85.5	109.2	181.5	212.6
CSCA | Analgesics
Disaggregation of Revenue [Line Items]
Net sales	[2]	88.2	92.2	177.0	185.9
CSCA | Smoking cessation
Disaggregation of Revenue [Line Items]
Net sales	[2]	77.0	71.2	143.8	137.1
CSCA | Animal health
Disaggregation of Revenue [Line Items]
Net sales	[2]	22.4	31.9	42.0	58.2
CSCA | Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales	[2]	3.9	4.3	7.3	7.3
CSCA | Other CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2],[3]	78.0	75.8	152.3	151.4
CSCI
Disaggregation of Revenue [Line Items]
Net sales		327.5	357.9	678.3	735.7
CSCI | Cough, Cold, and Allergy
Disaggregation of Revenue [Line Items]
Net sales		74.1	84.7	169.8	183.4
CSCI | Lifestyle
Disaggregation of Revenue [Line Items]
Net sales		81.2	86.1	162.7	175.8
CSCI | Personal care and derma-therapeutics
Disaggregation of Revenue [Line Items]
Net sales		69.2	79.7	135.2	155.3
CSCI | Natural Health and Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales		25.6	27.9	55.4	61.1
CSCI | Anti-Parasite
Disaggregation of Revenue [Line Items]
Net sales		26.0	30.4	52.7	58.5
CSCI | Other CSCI
Disaggregation of Revenue [Line Items]
Net sales	[4]	51.4	49.1	102.5	101.6
RX
Disaggregation of Revenue [Line Items]
Net sales		$ 239.4	$ 231.6	$ 481.3	$ 469.2

[1] Derived from the location of the entity that sells to a third party.

[2] Includes net sales from our OTC contract manufacturing business.

[3] Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[4] Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

XML

Revenue Recognition - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,149.0	$ 1,186.4	$ 2,323.5	$ 2,403.4
Contract manufacturing
Disaggregation of Revenue [Line Items]
Net sales		$ 65.8	$ 77.1	$ 133.1	$ 146.5

[1] Derived from the location of the entity that sells to a third party.

XML

Revenue Recognition - Schedule of Contract Balances (Details) - USD ($) $ in Millions	Jun. 29, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Short-term contract assets	$ 16.6	$ 25.5

XML

Acquisitions (Details) - USD ($) $ in Millions				3 Months Ended		6 Months Ended
	May 17, 2019	Apr. 01, 2019	May 29, 2018	Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Business Acquisition [Line Items]
Research and Development Expense				$ 43.9	$ 91.9	$ 84.0	$ 130.3
Consumer Healthcare Americas | Merck Sharp & Dohme License Agreement
Business Acquisition [Line Items]
Research and Development Expense			$ 50.0
Developed Product Technology | Generic Product Acquisition
Business Acquisition [Line Items]
Payments to acquire the ANDA	$ 15.7
Useful life of intangible assets	20 years
Developed Product Technology | Budesonide Nasal Spray and Triamcinolone Nasal Spray
Business Acquisition [Line Items]
Payments to acquire the ANDA		$ 14.0
Income from sales owned by company (percent)		100.00%
Useful life of intangible assets		10 years

XML

Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Goodwill [Roll Forward]
December 31, 2018	$ 3,979.8
Transfer to assets held-for-sale	(42.2)
Currency Translation Adjustments	(2.3)
June 29, 2019	3,935.3
CSCA
Goodwill [Roll Forward]
December 31, 2018	1,713.7
Transfer to assets held-for-sale	(42.2)
Currency Translation Adjustments	2.1
June 29, 2019	1,673.6
Accumulated impairments	(161.2)	$ (24.5)
CSCI
Goodwill [Roll Forward]
December 31, 2018	1,151.3
Currency Translation Adjustments	(9.2)
June 29, 2019	1,142.1
Accumulated impairments	(868.4)	$ (868.4)
RX
Goodwill [Roll Forward]
December 31, 2018	1,114.8
Currency Translation Adjustments	4.8
June 29, 2019	$ 1,119.6

XML

Goodwill and Intangible Assets - Intangible categories (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 29, 2019	Mar. 30, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018	Dec. 31, 2018	Oct. 01, 2018
Finite And Indefinite Lived Assets By Major Class [Line Items]
Goodwill	$ 3,935.3			$ 3,935.3		$ 3,979.8
Indefinite-lived intangibles:	32.5			32.5		49.3
Gross	4,327.5			4,327.5		4,379.3
Accumulated Amortization	1,652.3			1,652.3		1,520.4
Total other intangible assets	4,360.0			4,360.0		4,428.6
Intangible assets amortization expense	73.6		$ 85.3	149.0	$ 172.4
Impairment of Diclo 3% product	27.8		1.7	31.9	1.7
Trademarks, trade names, and brands
Finite And Indefinite Lived Assets By Major Class [Line Items]
Indefinite-lived intangibles:	18.0			18.0		18.1
In-process research and development
Finite And Indefinite Lived Assets By Major Class [Line Items]
Indefinite-lived intangibles:	14.5			14.5		31.2
Impairment of indefinite lived intangible assets		$ 4.1
Distribution and license agreements and supply agreements
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	173.7			173.7		178.6
Accumulated Amortization	105.2			105.2		99.0
Developed product technology, formulations, and product rights
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	1,321.0			1,321.0		1,318.8
Accumulated Amortization	706.1			706.1		654.6
Customer relationships and distribution networks
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	1,558.5			1,558.5		1,586.6
Accumulated Amortization	613.9			613.9		566.5
Trademarks and Trade Names
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	1,266.0			1,266.0		1,282.4
Accumulated Amortization	219.5			219.5		188.5
Non-compete agreements
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	8.3			8.3		12.9
Accumulated Amortization	7.6			7.6		11.8
RX
Finite And Indefinite Lived Assets By Major Class [Line Items]
Goodwill	1,119.6			1,119.6		$ 1,114.8
Intangible assets amortization expense	$ 21.3		$ 20.8	$ 42.6	$ 41.6
Fair value in excess of book value (percent)	10.00%			10.00%			25.00%
RX | Generic Product Acquisition
Finite And Indefinite Lived Assets By Major Class [Line Items]
Impairment of Diclo 3% product	$ 27.8

XML

Inventories (Details) - USD ($) $ in Millions	Jun. 29, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Finished goods	$ 501.2	$ 444.9
Work in process	192.8	197.5
Raw materials	246.5	235.6
Total inventories	$ 940.5	$ 878.0

XML

Fair Value Measurements - Financial Instruments at Fair Value (Details) - USD ($) $ in Millions	Jun. 29, 2019	Dec. 31, 2018
Measured at fair value on a non-recurring basis:
Goodwill carrying amount	$ 3,935.3	$ 3,979.8
Indefinite-lived intangible assets carrying value	32.5	49.3
Definite-lived intangible assets carrying value	2,675.2	2,858.9
Measured at fair value on a recurring basis | Level 1
Assets:
Investment securities	2.8	9.4
Foreign currency forward contracts	0.0	0.0
Funds associated with Israeli severance liability	0.0	0.0
Royalty Pharma contingent milestone payments	0.0	0.0
Total assets	2.8	9.4
Liabilities:
Foreign currency forward contracts	0.0	0.0
Contingent consideration	0.0	0.0
Total liabilities	0.0	0.0
Measured at fair value on a recurring basis | Level 2
Assets:
Investment securities	0.0	0.0
Foreign currency forward contracts	4.0	3.8
Funds associated with Israeli severance liability	14.0	13.0
Royalty Pharma contingent milestone payments	0.0	0.0
Total assets	18.0	16.8
Liabilities:
Foreign currency forward contracts	3.6	9.2
Contingent consideration	0.0	0.0
Total liabilities	3.6	9.2
Measured at fair value on a recurring basis | Level 3
Assets:
Investment securities	0.0	0.0
Foreign currency forward contracts	0.0	0.0
Funds associated with Israeli severance liability	0.0	0.0
Royalty Pharma contingent milestone payments	89.1	323.2
Total assets	89.1	323.2
Liabilities:
Foreign currency forward contracts	0.0	0.0
Contingent consideration	12.1	15.3
Total liabilities	12.1	15.3
Measured at fair value on a non-recurring basis
Measured at fair value on a non-recurring basis:
Indefinite-lived intangible assets carrying value		46.9
Definite-lived intangible assets carrying value		72.0
Measured at fair value on a non-recurring basis | Level 1
Assets:
Total assets	0.0	0.0
Measured at fair value on a non-recurring basis:
Goodwill	0.0	0.0
Indefinite-lived intangible assets	0.0	0.0
Definite-lived intangible assets	0.0	0.0
Measured at fair value on a non-recurring basis | Level 2
Assets:
Total assets	0.0	0.0
Measured at fair value on a non-recurring basis:
Goodwill	0.0	0.0
Indefinite-lived intangible assets	0.0	0.0
Definite-lived intangible assets	0.0	0.0
Measured at fair value on a non-recurring basis | Level 3
Assets:
Total assets	0.0	75.1
Measured at fair value on a non-recurring basis:
Goodwill	0.0	42.2	[1]
Indefinite-lived intangible assets	0.0	10.5	[2]
Definite-lived intangible assets	0.0	22.4	[3]
CSCA
Measured at fair value on a non-recurring basis:
Goodwill carrying amount	$ 1,673.6	1,713.7
CSCA | Measured at fair value on a non-recurring basis
Measured at fair value on a non-recurring basis:
Goodwill carrying amount		$ 178.9

[1] (1) As of December 31, 2018, goodwill with a carrying amount of $178.9 million was written down to a fair value of $42.2 million.

[2] (2) As of December 31, 2018, indefinite-lived intangible assets with a carrying amount of $46.9 million were written down to a fair value of $10.5 million.

[3] (3) As of December 31, 2018, definite-lived intangible assets with a carrying amount of $72.0 million were written down to a fair value of $22.4 million.

XML

Fair Value Measurements - Additional Information (Details) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 29, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 29, 2019 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 USD ($)	Mar. 30, 2019 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfers among level 1, 2, and 3	$ 0.0			$ 0.0
Income recognized from change is asset	5.5	$ 0.6	$ 15.9	(9.0)
Measured on a recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Potential contingent milestone payments	89.1		89.1			$ 323.2
Royalty Pharma Contingent Milestone Payments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net sales included in calculation for milestone payment						337.5
Royalty Pharma Contingent Milestone Payments | Measured on a recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of milestone payment	5.5	0.6	15.9	(9.0)
Estimated fair valued contingent milestone payment	$ 89.1	125.5	$ 89.1	$ 125.5		$ 323.2	$ 83.6	$ 124.9	$ 134.5
Royalty Pharma 2018 Contingent Milestone Payments | Measured on a recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of milestone payment		(2.9)
Royalty Pharma 2020 Contingent Milestone Payments [Member] | Measured on a recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of milestone payment		$ 3.5
Royalty Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Rate of return			7.99%	8.09%
Measurement Input, Price Volatility | Royalty Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Volatility	0.300	0.300	0.300	0.300
Measurement Input, Long-term Revenue Growth Rate | CSCA
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reporting Unit, Discounted Cash Flow, Measurement Input						0.025
Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input						(0.003)
Measurement Input, Discount Rate | CSCA
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reporting Unit, Discounted Cash Flow, Measurement Input						0.098
Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input						0.098
Measurement Input, Tax Rate | CSCA
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reporting Unit, Discounted Cash Flow, Measurement Input						0.228
Indefinite-lived Intangible Assets (Excluding Goodwill), Measurement Input						0.228
Scenario, Forecast
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty Pharma contingent payment sales threshold					$ 400.0
Scenario, Forecast | Royalty Pharma Contingent Milestone Payments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net sales threshold to trigger milestone payment					351.0
Write-off of contingent milestone payment if sales threshold is not met					89.1
Royalty Pharma contingent payment sales threshold					400.0
Income recognized from change is asset					$ 310.9

XML

Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) - Measured on a recurring basis - Level 3 - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018	Dec. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	$ 12.1		$ 12.1		$ 15.3
Contingent Consideration
Beginning balance	12.4	$ 18.1	15.3	$ 22.0
Changes in value	0.9	(1.8)	(2.0)	(1.4)
Currency translation adjustments	0.0	(0.1)	0.0	0.0
Settlements and other adjustments	(1.2)	0.0	(1.2)	(4.4)
Ending balance	12.1	16.2	12.1	16.2
Royalty Pharma Contingent Milestone Payments
Royalty Pharma Contingent Milestone Payments
Beginning balance	83.6	124.9	323.2	134.5
Payments received	0.0	0.0	(250.0)	0.0
Change in fair value	5.5	0.6	15.9	(9.0)
Ending balance	$ 89.1	$ 125.5	$ 89.1	$ 125.5

XML

Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details) - USD ($) $ in Millions	Jun. 29, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	$ 2,753.5	$ 2,892.5
Public bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	2,533.0	2,316.6
Retail Bonds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Retail bond and private placement note	167.8	307.9
Reported Value Measurement | Public bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	2,600.0	2,600.0
Reported Value Measurement | Retail Bonds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Retail bond and private placement note	$ 153.5	$ 292.5

XML

Investments (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018	Dec. 31, 2018
Other (income) expense, net
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method, other expense (income)		$ 1.8	$ 6.3	$ 7.9	$ 10.6
Equity securities, equity method, other expense (income)		(1.0)	(0.9)	(1.7)	$ (0.7)
Prepaid expenses and other current assets
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method		2.8		2.8		$ 9.4
Other non-current assets
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method	[1]	2.8		2.8		4.4
Equity securities, equity method, other non-current assets		$ 16.8		$ 16.8		$ 15.1
Zibo Xinhua
Schedule of Equity Method Investments [Line Items]
Increase in investment in Zibo Xinhua			$ 7.5

[1] (1) Measured at fair value using the Net Asset Value practical expedient.

XML

Assets Held for Sale (Details) $ in Millions	Jun. 29, 2019 USD ($)
Prepaid expenses and other current assets
Assets held for sale
Current assets	$ 29.3
Property, plant and equipment	10.8
Goodwill and indefinite-lived intangible assets	42.2
Definite-lived intangible assets, net	36.4
Other assets	25.7
Total assets held for sale	144.4
Accrued liabilities
Liabilities held for sale
Current liabilities	11.3
Other liabilities	38.3
Total liabilities held for sale	$ 49.6

XML

Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details) - Foreign currency forward contracts - USD ($) $ in Millions	Jun. 29, 2019	Dec. 31, 2018
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	$ 831.1	$ 686.6
Israeli Shekel (ILS)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	340.6	232.6
British Pound (GBP)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	111.0	90.2
European Euro (EUR)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	108.0	134.2
Swedish (SEK)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	42.2	38.7
Danish Krone (DKK)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	58.2	56.5
United States Dollar (USD)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	46.2	39.3
Canadian Dollar (CAD)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	41.9	31.7
Polish Zloty (PLZ)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	33.5	18.2
Chinese Yuan (CNY)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	20.0	0.0
Norwegian Krone (NOK)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	6.8	6.2
Romanian New Leu (RON)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	5.9	4.4
Mexican Peso (MPX)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	4.2	25.9
Other
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	$ 12.6	$ 8.7

XML

Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) - Foreign currency forward contracts - USD ($) $ in Millions	Jun. 29, 2019	Dec. 31, 2018
Designated derivatives: | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 1.0	$ 2.0
Designated derivatives: | Accrued liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	2.6	6.4
Non-designated derivatives: | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	3.0	1.8
Non-designated derivatives: | Accrued liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 1.0	$ 2.8

XML

Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 29, 2019 USD ($)	Jun. 29, 2019 USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings	$ (0.5)	$ (2.1)
Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net	(1.0)	(2.2)
Net gain expected to be reclassified out of AOCI into earnings in the next 12 months	(1.6)	(1.6)
Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements	(0.4)	(1.0)
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	0.0	0.0
Gain (Loss) on Components Excluded from Assessment of Interest Rate Cash Flow Hedge Effectiveness	0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.0	0.0
Net Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements		0.0
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	0.1	0.3
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.1	0.0
Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements		0.0
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	(0.2)	(1.4)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	(1.1)	(2.2)
Foreign currency forward contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI	$ 1.1	$ 0.0

XML

Derivative Instruments and Hedging Activities - Other Comprehensive Income Movement (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Foreign currency forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]
Amount of Gain/(Loss) Recorded in OCI (Effective Portion)	$ (4.3)	$ (4.3)
Designated derivatives:
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0.0	0.5
Designated derivatives: | Interest expense, net | Interest Rate Swap
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	(0.4)	(0.9)
Designated derivatives: | Interest expense, net | Foreign currency forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	(1.1)	(2.0)
Designated derivatives: | Cost of sales | Foreign currency forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	1.6	3.9
Designated derivatives: | Other (income) expense, net | Foreign currency forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	(0.1)	$ (0.5)
Designated derivatives: | Sales [Member] | Foreign currency forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income on (Loss) Derivatives [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	$ 0.0

XML

Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) - Non-designated derivatives: - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized against Earnings	$ (2.9)	$ 12.0	$ (11.3)	$ 7.9
Foreign currency forward contracts | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized against Earnings	(4.3)	11.8	(13.1)	8.6
Foreign currency forward contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized against Earnings	$ 1.4	$ 0.2	$ 1.8	$ (0.7)

XML

Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Net sales	[1]	$ 1,149.0	$ 1,186.4	$ 2,323.5	$ 2,403.4
Cost of sales		718.2	715.4	1,443.9	1,439.7
Interest expense, net		31.2	32.1	59.8	63.5
Other (income) expense, net		2.3	$ 7.9	5.5	$ 12.1
Net Sales
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings		0.1		0.3
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		0.1		0.0
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings				0.0
Cost of sales
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings		(0.2)		(1.4)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		(1.1)		(2.2)
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings				0.0
Interest expense, net
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings		0.0		0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		0.0		0.0
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings		(0.4)		(1.0)
Other (income) expense, net
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings		0.0		0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		0.0		0.0
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings		$ 0.0		$ 0.0

[1] Derived from the location of the entity that sells to a third party.

XML

Leases (Details) - USD ($) $ in Millions	Jun. 29, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Lease liabilities	$ 140.3	$ 166.5
Lease assets	$ 135.4	$ 164.0	$ 0.0

XML

Leases - Balance Sheet Location of Assets and Liabilities (Details) - USD ($) $ in Millions	Jun. 29, 2019	Jan. 01, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Operating lease assets	$ 135.4	$ 164.0	$ 0.0
Finance leases	17.1
Right-of-Use Asset	152.5
Present value of lease liabilities	154.0
Total operating lease liabilities	140.3	$ 166.5
Total finance lease liabilities	13.7
Operating lease assets
Lessee, Lease, Description [Line Items]
Operating lease assets	135.4
Other non-current assets
Lessee, Lease, Description [Line Items]
Finance leases	17.1
Accrued liabilities
Lessee, Lease, Description [Line Items]
Operating lease liability, current	32.9
Current indebtedness
Lessee, Lease, Description [Line Items]
Finance lease liability, current	1.9
Other noncurrent liabilities
Lessee, Lease, Description [Line Items]
Operating lease liability, noncurrent	107.4
Long-term debt, less current portion
Lessee, Lease, Description [Line Items]
Finance lease liability, noncurrent	11.8
CSCA
Lessee, Lease, Description [Line Items]
Operating lease assets	22.7
Finance leases	8.9
Total operating lease liabilities	22.9
Total finance lease liabilities	8.4
CSCI
Lessee, Lease, Description [Line Items]
Operating lease assets	42.0
Finance leases	6.1
Total operating lease liabilities	42.9
Total finance lease liabilities	3.2
RX
Lessee, Lease, Description [Line Items]
Operating lease assets	37.5
Finance leases	0.3
Total operating lease liabilities	38.9
Total finance lease liabilities	0.3
Unallocated
Lessee, Lease, Description [Line Items]
Operating lease assets	33.2
Finance leases	1.8
Total operating lease liabilities	35.6
Total finance lease liabilities	$ 1.8

XML

Leases - Lease Expense (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Leases [Abstract]
Operating leases	[1]	$ 11.2		$ 23.2
Finance leases
Amortization		0.7		1.3
Interest		0.1		0.2
Total finance leases		$ 0.8		$ 1.5
Operating lease expense			$ 14.2		$ 26.1

[1] (a) Includes short-term leases and variable lease costs, which are immaterial.

XML

Leases - Annual Future Maturities of Leases (Details) - USD ($) $ in Millions	Jun. 29, 2019	Jan. 01, 2019
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2019	$ 19.4
2020	34.6
2021	24.9
2022	18.3
2023	14.0
After 2023	51.7
Total lease payments	162.9
Less: Interest	22.6
Present value of lease liabilities	140.3	$ 166.5
Finance Lease, Liability, Payment, Due [Abstract]
2019	1.2
2020	2.3
2021	3.6
2022	1.2
2023	1.0
After 2023	7.8
Total lease payments	17.1
Less: Interest	3.4
Present value of lease liabilities	13.7
Lease Liabilities, Payments, Due [Abstract]
2019	20.6
2020	36.9
2021	28.5
2022	19.5
2023	15.0
After 2023	59.5
Total lease payments	180.0
Less: Interest	26.0
Present value of lease liabilities	$ 154.0

XML

Leases - Weighted Average Lease Terms and Discount Rates (Details)	Jun. 29, 2019
Leases [Abstract]
Weighted-average remaining lease term - Operating leases	6 years 7 months 2 days
Weighted-average lease term - Finance leases	9 years 5 months 4 days
Weighted-average discount rate - Operating lease (percent)	4.19%
Weighted-average discount rate - Finance lease (percent)	4.35%

XML

Leases - Lease Cash Flow Classifications (Details) $ in Millions	6 Months Ended
	Jun. 29, 2019 USD ($)
Leases [Abstract]
Operating cash flows for operating leases	$ 23.0
Operating cash flows for finance leases	0.2
Financing cash flows for finance leases	1.4
Leased assets obtained in exchange for new finance lease liabilities	7.8
Leased assets obtained in exchange for new operating lease liabilities	$ 12.8

XML

Indebtedness - Schedule of Borrowings Outstanding (Details) - USD ($) $ in Millions		6 Months Ended
		Jun. 29, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Notes and Bonds		$ 2,753.5	$ 2,892.5
Other financing		87.2	2.8
Unamortized premium (discount), net		8.9	12.2
Deferred financing fees		(14.8)	(16.4)
Total borrowings outstanding		3,483.2	3,242.4
Current indebtedness		(398.8)	(190.2)
Long-term debt, less current portion		3,084.4	3,052.2
2018 Revolver
Debt Instrument [Line Items]
Long-term Line of Credit		$ 325.0	0.0
2018 Euro-Denominated Term Loan due March 8, 2020
Debt Instrument [Line Items]
Series	[1]	2018 Term loan due March 8, 2020
Term loans		$ 323.4	351.3
5.000% Unsecured Senior notes due May 23, 2019
Debt Instrument [Line Items]
Series		May 23, 2019
Interest rate, stated percentage		5.00%
Notes and Bonds		$ 0.0	137.6
3.500% Unsecured Senior notes due March 15, 2021
Debt Instrument [Line Items]
Series		Mar. 15, 2021
Interest rate, stated percentage		3.50%
Notes and Bonds		$ 280.4	280.4
3.5% Senior note due December 15, 2021
Debt Instrument [Line Items]
Series		Dec. 15, 2021
Interest rate, stated percentage		3.50%
Notes and Bonds		$ 309.6	309.6
5.105% Senior note due July 28, 2023
Debt Instrument [Line Items]
Series	[1]	July 28, 2023
Interest rate, stated percentage		5.105%
Notes and Bonds		$ 153.5	154.9
4.00% unsecured senior notes due November 15, 2023
Debt Instrument [Line Items]
Series		Nov. 15, 2023
Interest rate, stated percentage		4.00%
Notes and Bonds		$ 215.6	215.6
3.9% senior note due December 15, 2024
Debt Instrument [Line Items]
Series		Dec. 15, 2024
Interest rate, stated percentage		3.90%
Notes and Bonds		$ 700.0	700.0
4.375% senior note due March 15, 2026
Debt Instrument [Line Items]
Series		Mar. 15, 2026
Interest rate, stated percentage		4.375%
Notes and Bonds		$ 700.0	700.0
5.30% unsecured senior notes due November 15, 2043
Debt Instrument [Line Items]
Series		Nov. 15, 2043
Interest rate, stated percentage		5.30%
Notes and Bonds		$ 90.5	90.5
4.9% senior notes due December 15, 2044
Debt Instrument [Line Items]
Series		Dec. 15, 2044
Interest rate, stated percentage		4.90%
Notes and Bonds		$ 303.9	$ 303.9

[1] Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

XML

Indebtedness - Additional Information (Details) $ in Millions				3 Months Ended		6 Months Ended
	May 23, 2019 USD ($)	May 23, 2019 EUR (€)	Dec. 05, 2014 USD ($)	Jun. 29, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 29, 2019 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	Mar. 08, 2018 USD ($)	Mar. 08, 2018 EUR (€)	Dec. 05, 2014 EUR (€)
Debt Instrument [Line Items]
Debt instrument, issuance date			Dec. 05, 2014
Loss on extinguishment of debt				$ 0.0	$ 0.0	$ 0.0	$ 0.5
Repayments of debt						24.7
Outstanding balance				73.9		73.9		$ 0.0
2018 Revolver
Debt Instrument [Line Items]
Face amount of debt									$ 1,000.0
Amount borrowed on line of credit				375.0
Borrowings outstanding				$ 325.0		$ 325.0		$ 0.0
2014 Term loan due December 5, 2019
Debt Instrument [Line Items]
Face amount of debt			$ 614.3							€ 350,000,000.0	€ 500,000,000.0
Loss on extinguishment of debt					$ 0.5
2018 Euro-Denominated Term Loan due March 8, 2020
Debt Instrument [Line Items]
Face amount of debt									$ 431.0	€ 350,000,000.0
Retail Bond
Debt Instrument [Line Items]
Interest rate, stated percentage	5.00%	5.00%
Retail bond repayed in full	$ 130.7	€ 120,000,000.0

XML

Earnings Per Share and Shareholders' Equity (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended				6 Months Ended
	Jun. 29, 2019	Mar. 30, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 29, 2019	Jun. 30, 2018	Oct. 31, 2018
Numerator:
Net income	$ 9.0	$ 63.9	$ 36.2	$ 80.8	$ 72.9	$ 117.0
Denominator:
Weighted average shares outstanding for basic EPS	136.0		138.1		136.0	139.5
Dilutive effect of share-based awards (in shares)	0.5		0.6		0.3	0.5
Weighted average shares outstanding for diluted EPS	136.5		138.7		136.3	140.0
Anti-dilutive share-based awards excluded from computation of diluted EPS (shares)	1.7		1.7		1.8	0.9
Stock repurchase program, authorized amount							$ 1,000.0
Repurchases of ordinary shares (shares)	0.0				0.0
Share price (in dollars per share)			$ 79.42			$ 80.42
Repurchase of equity amount			$ 156.9			$ 265.0
Ordinary Shares Issued
Denominator:
Repurchases of ordinary shares (shares)			2.0	1.3		3.3

XML

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 29, 2019	Mar. 30, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 29, 2019	Jun. 30, 2018
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	$ 5,700.6	$ 5,668.0	$ 6,205.4	$ 6,170.5	$ 5,668.0	$ 6,170.5
Other comprehensive income (loss), net of tax	30.5	(15.6)	(169.3)	72.2	14.9	(97.1)
Balance, ending	5,726.2	5,700.6	5,897.1	6,205.4	5,726.2	5,897.1
Fair value of derivative financial instruments, net of tax
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning		(15.5)			(15.5)
OCI before reclassifications					0.2
Amounts reclassified from AOCI					4.2
Other comprehensive income (loss), net of tax					4.4
Balance, ending	(11.1)				(11.1)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning		104.5			104.5
OCI before reclassifications					11.0
Amounts reclassified from AOCI					0.0
Other comprehensive income (loss), net of tax					11.0
Balance, ending	115.5				115.5
Post-Retirement and Pension Liability Adjustments, net of tax
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning		(4.4)			(4.4)
OCI before reclassifications					0.0
Amounts reclassified from AOCI					(0.5)
Other comprehensive income (loss), net of tax					(0.5)
Balance, ending	(4.9)				(4.9)
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	69.0	84.6	324.3	253.1	84.6	253.1
OCI before reclassifications					11.2
Amounts reclassified from AOCI					3.7
Other comprehensive income (loss), net of tax	30.5	(15.6)	(169.3)	72.2	14.9
Balance, ending	$ 99.5	$ 69.0	$ 155.0	$ 324.3	$ 99.5	$ 155.0

XML

Income Taxes (Details) € in Millions, $ in Millions		3 Months Ended		6 Months Ended		12 Months Ended
	Aug. 15, 2017 USD ($)	Jun. 29, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 29, 2019 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Apr. 26, 2019 USD ($)	Nov. 29, 2018 EUR (€)
Income Tax Contingency [Line Items]
Asset Impairment Charges		$ 27.8	$ 1.7	$ 31.9	$ 1.7
Effective income tax rate reconciliation, percent		66.60%	34.50%	32.50%	29.40%
Income tax examination, penalties and interest expense	$ 163.6					$ 24.7	$ 40.2	$ 61.5	$ 37.2
Income tax overpayments applied to succeeding years		$ 29.7		$ 29.7
Royalty conceded on all omeprazole sales as a percent of refund claims (percent)				24.00%
IRS notice of proposed adjustment amount from 2011,2012 and 2013 audit of Athena, including penalty										$ 843.0
IRS notice of proposed adjustment, penalty (percent)										40.00%
Revenue Commissioners, Ireland
Income Tax Contingency [Line Items]
Unsettled audit assessment from income tax examination | €											€ 1,636

XML

Contingencies (Details) $ in Millions, ₪ in Billions					12 Months Ended
	May 31, 2019 plaintiff	Jan. 16, 2019 product defendant	Jun. 28, 2017 USD ($) product defendant	Jun. 28, 2017 ILS (₪) product defendant	Dec. 31, 2018 case	Jun. 29, 2019 dozens $ / ₪	Feb. 22, 2019 product plaintiff case defendant	Feb. 14, 2019 defendant	Feb. 06, 2019 product case defendant	Jan. 31, 2019 product case defendant	Nov. 15, 2018 product case	Oct. 29, 2018 product case defendant	Aug. 03, 2018 product manufacturer	Apr. 20, 2018 product case	Feb. 16, 2018 case defendant	Feb. 13, 2018 product case defendant	Jan. 26, 2018 product complaint plaintiff case	Jan. 16, 2018 product defendant	Dec. 31, 2017 case	Nov. 01, 2017 defendant	Jun. 21, 2017 product individual	Dec. 28, 2013 product supermarket manufacturer	Dec. 31, 2011 product manufacturer
Loss Contingencies [Line Items]
Number of manufacturers | manufacturer																							27
Number of generic prescription pharmaceuticals | product																	6				6		15
Number of products manufactured by the Company | product																							2
Number of dozens of other drugs | dozens						2
Number of individuals | individual																					11
Number of plaintiff groups | plaintiff																	2
Number of complaints | complaint																	2
Number of cases																	2
Number of overlapped cases																	2
Price-Fixing Lawsuit, Supermarket Chains
Loss Contingencies [Line Items]
Number of manufacturers | manufacturer																						35
Number of supermarket chains | supermarket																						3
Number of generic prescription pharmaceuticals | product																						31
Price-fixing Lawsuit, Managed Care Organization
Loss Contingencies [Line Items]
Number of manufacturers | manufacturer													27
Number of generic prescription pharmaceuticals | product													17
Price-fixing Lawsuit, Health Insurance Carrier
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product		30
Number of defendants | defendant		30
Carmignac Gestion, S.A. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of co-defendants | defendant																				3
Manning & Napier Advisors, LLC v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product																		6
Number of co-defendants | defendant																		3
Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product																6
Number of co-defendants | defendant																2
Number of opt out cases																4
First Manhattan Co. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals															6
Number of co-defendants | defendant															3
Number of opt out cases															5
TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product														6
Number of opt out cases														6
Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product												6
Number of co-defendants | defendant												2
Number of opt out cases												7
WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product											6
Number of opt out cases											8
Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals											6
Number of opt out cases											9
Schwab Capital Trust, et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product										6
Number of co-defendants | defendant										2
Number of opt out cases										10
OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product									6
Number of co-defendants | defendant									2
Number of opt out cases									11
Highfields Capital I LP, et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of co-defendants | defendant								2
Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product							6
Number of co-defendants | defendant							2
Number of additional plaintiffs | plaintiff							30
Number of opt out cases							12
Cases Filed in Israel
Loss Contingencies [Line Items]
Number of cases																			3
Number of cases dismissed					1
Number of cases stayed					1
Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product			6	6
Number of current or former directors and officers | defendant			11	11
Damages sought by plaintiff			$ 760.0	₪ 2.7
Foreign currency exchange rate, remeasurement | $ / ₪						0.28
In re Perrigo Company plc Sec. Litig. [Member]
Loss Contingencies [Line Items]
Loss Contingency, Number of Defendants Added | plaintiff	1

XML

Restructuring Charges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018
Restructuring Reserve [Roll Forward]
Beginning balance	$ 20.5	$ 12.4	$ 24.0	$ 21.4
Additional charges	12.2	3.7	18.1	5.2
Payments	(9.0)	(3.1)	(18.0)	(13.8)
Non-cash adjustments	0.3	(0.3)	(0.1)	(0.1)
Ending balance	$ 24.0	$ 12.7	24.0	$ 12.7
CSCI
Restructuring Reserve [Roll Forward]
Additional charges			$ 9.8

XML

Segment Information (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2019	Jun. 30, 2018	Jun. 29, 2019	Jun. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Total Assets		$ 11,428.7		$ 11,428.7		$ 10,983.4
Net sales	[1]	1,149.0	$ 1,186.4	2,323.5	$ 2,403.4
Operating Income (Loss)		55.0	94.7	157.3	250.9
Intangible Asset Amortization		73.6	85.3	149.0	172.4
CSCA
Segment Reporting Information [Line Items]
Total Assets		4,041.9		4,041.9		3,571.7
Net sales	[2]	582.1	596.9	1,163.9	1,198.5
Operating Income (Loss)		107.8	64.6	202.0	183.2
Intangible Asset Amortization		9.3	15.3	19.3	30.5
CSCI
Segment Reporting Information [Line Items]
Total Assets		4,593.5		4,593.5		4,613.0
Net sales		327.5	357.9	678.3	735.7
Operating Income (Loss)		(2.9)	4.0	5.1	16.3
Intangible Asset Amortization		43.0	49.2	87.1	100.3
RX
Segment Reporting Information [Line Items]
Total Assets		2,793.3		2,793.3		$ 2,798.7
Net sales		239.4	231.6	481.3	469.2
Operating Income (Loss)		14.7	53.6	75.3	114.8
Intangible Asset Amortization		21.3	20.8	42.6	41.6
Unallocated
Segment Reporting Information [Line Items]
Net sales		0.0	0.0	0.0	0.0
Operating Income (Loss)		(64.6)	(27.5)	(125.1)	(63.4)
Intangible Asset Amortization		$ 0.0	$ 0.0	$ 0.0	$ 0.0

[1] Derived from the location of the entity that sells to a third party.

[2] Includes net sales from our OTC contract manufacturing business.

XML

Subsequent Events (Details) - USD ($) $ in Millions					6 Months Ended
	Jul. 08, 2019	Jul. 02, 2019	Jul. 01, 2019	May 17, 2019	Jun. 29, 2019	Jun. 30, 2018
Subsequent Event [Line Items]
Net proceeds from sale of business and other assets						$ 1.3
Subsequent Event
Subsequent Event [Line Items]
Net proceeds from sale of business and other assets	$ 185.0
Ranir Global Holdings, LLC
Subsequent Event [Line Items]
General transaction costs					$ 2.2
Ranir Global Holdings, LLC | Subsequent Event
Subsequent Event [Line Items]
Outstanding equity interest acquired (percent)			100.00%
Total base consideration			$ 750.0
Minimum | Subsequent Event
Subsequent Event [Line Items]
Pre-tax gain on sale of business	80.0
Maximum | Subsequent Event
Subsequent Event [Line Items]
Pre-tax gain on sale of business	$ 90.0
Developed Product Technology | Generic Product Acquisition
Subsequent Event [Line Items]
Payments to acquire the ANDA				$ 15.7
Useful life of intangible assets				20 years
Developed Product Technology | Generic Product Acquisition | Subsequent Event
Subsequent Event [Line Items]
Payments to acquire the ANDA		$ 49.0
Useful life of intangible assets		20 years